


**CUMULATIVE  
SUPPLEMENT 8  
AUGUST 2021**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41st EDITION**

**Department of Health and Human Services**

Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**2021**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41<sup>th</sup> EDITION**

**Cumulative Supplement 8  
August 2021**

**CONTENTS**

	<i>PAGE</i>
<b>Contents</b>	
1.0 INTRODUCTION.....	v
1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2 CUMULATIVE SUPPLEMENT CONTENT .....	vi
1.3 APPLICANT NAME CHANGES .....	vii
1.4 LEVOTHYROXINE SODIUM .....	viii
1.5 AVAILABILITY OF THE EDITION.....	ix
1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7 CUMULATIVE SUPPLEMENT LEGEND.....	xi
 <b>DRUG PRODUCT LISTS</b>	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate <i>in vivo</i> Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
 <b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**41<sup>st</sup> EDITION**

**CUMULATIVE SUPPLEMENT 8  
AUGUST 2021**

## **1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## **1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## **1.2 CUMULATIVE SUPPLEMENT CONTENT**

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOB/PRA) of any changes or corrections. The DOB/PRA can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### **1.3 APPLICANT NAME CHANGES**

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME (NEW ABBREVIATED NAME)</u>
AKORN INC (AKORN)	AKORN OPERATING CO LLC (AKORN)
AKORN INC (AKORN INC)	AKORN OPERATING CO LLC (AKORN)
PADDOCK LABORATORIES LLC (PADDOCK LABS LLC)	PADAGIS US LLC (PADAGIS US)

PADDOCK LABORATORIES LLC (PADDOCK LLC)	PADAGIS US LLC (PADAGIS US)
PERRIGO CO OF TENNESSEE INC (PERRIGO CO)	PADAGIS US LLC (PADAGIS US)
PERRIGO CO TENNESSEE INC (PERRIGO CO TENNESSEE)	PADAGIS US LLC (PADAGIS US)
PERRIGO NEW YORK INC (PERRIGO NEW YORK)	PADAGIS US LLC (PADAGIS US)
PERRIGO PHARMA INTERNATIONAL DAC (PERRIGO PHARMA INTL)	PADAGIS US LLC (PADAGIS US)
PERRIGO UK FINCO LTD PARTNERSHIP (PERRIGO UK FINCO)	PADAGIS ISRAEL PHARMACEUTICALS LTD (PADAGIS ISRAEL)
PERRIGO ISRAEL PHARMACEUTICALS LTD (PERRIGO ISRAEL)	PADAGIS ISRAEL PHARMACEUTICALS LTD (PADAGIS ISRAEL)
WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD (WEST-WARD PHARMS INT)	HIKMA PHARMACEUTICALS USA INC (HIKMA PHARMS)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4) .
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN GROUP HOLDINGS 4 LLC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable

---

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).

Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at

<http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,

<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## **1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST**

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts,

esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST  
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2020</u>	<u>MAR 2021</u>	<u>JUN 2021</u>	<u>SEP 2021</u>	<u>DEC 2021</u>
DRUG PRODUCTS	20478	20726	20916		
LISTED SINGLE SOURCE	2659 (13.0%)	2671 (12.9%)	2675 (12.8%)		
MULTISOURCE	17819 (87.0%)	18055 (87.1%)	18241 (87.2%)		
THERAPEUTICALLY EQUIVALENT	17746 (86.7%)	17990 (86.8%)	18175 (86.9%)		
NOT THERAPEUTICALLY EQUIVALENT	73 (0.4%)	65 (0.3%)	66 (0.3%)		
EXCEPTIONS <sup>4</sup>	54 (0.3%)	54 (0.3%)	54 (0.3%)		
NEW MOLECULAR ENTITIES APPROVED	22	29	33		
NUMBER OF APPLICANTS	1185	1184	1182		

#### 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

---

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABIRATERONE ACETATE

TABLET; ORAL						
ABIRATERONE ACETATE						
AB	AMNEAL PHARMS	500MG	A208327	002	Dec 23, 2020	Apr NEWA
AB	QILU	500MG	A212462	002	Jun 25, 2021	Jun NEWA

ACARBOSE

TABLET; ORAL						
ACARBOSE						
AB	EMCURE PHARMS LTD	25MG	A202271	001	Feb 07, 2012	Apr CMFD
AB		50MG	A202271	002	Feb 07, 2012	Apr CMFD
AB		100MG	A202271	003	Feb 07, 2012	Apr CMFD
>D> AB	HANGZHOU ZHONGMEI	25MG	A213821	001	Aug 18, 2020	Aug DISC
>A>	@	25MG	A213821	001	Aug 18, 2020	Aug DISC
>D> AB		50MG	A213821	002	Aug 18, 2020	Aug DISC
>A>	@	50MG	A213821	002	Aug 18, 2020	Aug DISC
>D> AB		100MG	A213821	003	Aug 18, 2020	Aug DISC
>A>	@	100MG	A213821	003	Aug 18, 2020	Aug DISC

ACETAMINOPHEN

POWDER; INTRAVENOUS						
ACETAMINOPHEN						
+ @	MYLAN LABS LTD	1GM/VIAL	N206610	001	Jan 15, 2021	Jan NEWA
SOLUTION; INTRAVENOUS						
ACETAMINOPHEN						
+!	B BRAUN MEDICAL INC	500MG/50ML (10MG/ML)	N204957	001	Feb 18, 2021	Feb NEWA
+!		1GM/100ML (10MG/ML)	N204957	002	Feb 18, 2021	Feb NEWA

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL						
CODEINE, ASPIRIN, APAP FORMULA NO. 2						
>D>	@ SCHERER LABS	150MG;180MG;15MG	A085640	001		Aug CRLD
>A>	+ @	150MG;180MG;15MG	A085640	001		Aug CRLD
CODEINE, ASPIRIN, APAP FORMULA NO. 3						
>D>	@ SCHERER LABS	150MG;180MG;30MG	A085639	001		Aug CRLD
>A>	+ @	150MG;180MG;30MG	A085639	001		Aug CRLD

ACETAMINOPHEN; BUTALBITAL

TABLET; ORAL						
BUTALBITAL AND ACETAMINOPHEN						
AA	ALVOGEN	300MG;50MG	A207635	001	Jun 05, 2017	Jun CAHN
AA		325MG;50MG	A205120	001	Oct 30, 2015	Jun CAHN
>D>	@ WATSON LABS	325MG;50MG	A087550	001	Oct 19, 1984	Aug CRLD
>A>	+ @	325MG;50MG	A087550	001	Oct 19, 1984	Aug CRLD
PHRENILIN						
>D>	@ VALEANT	325MG;50MG	A087811	001	Jun 19, 1985	Aug CRLD
>A>	+ @	325MG;50MG	A087811	001	Jun 19, 1985	Aug CRLD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
>D>	@ GILBERT LABS	325MG;50MG;40MG	A088825	001	Dec 05, 1984	Aug CRLD
>A>	+ @	325MG;50MG;40MG	A088825	001	Dec 05, 1984	Aug CRLD
>A> AA	SENORES PHARMS	300MG;50MG;40MG	A214087	001	Aug 13, 2021	Aug CAHN

>A> AA		325MG;50MG;40MG	A214087	002	Aug 13, 2021	Aug CAHN
AA	XSPIRE PHARMA	300MG;50MG;40MG	A206615	001	Aug 04, 2017	Feb CAHN
TABLET; ORAL						
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE						
>D> AA	ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Aug CRLD
>A> AA	+	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Aug CRLD
AA	ALVOGEN	325MG;50MG;40MG	A204984	001	Jan 10, 2017	Jun CAHN
	@ GRANULES	325MG;50MG;40MG	A040864	001	Dec 01, 2008	Apr CAHN

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL						
BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE						
AB	NOSTRUM LABS INC	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	Jan CAHN

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL

TREZIX

XSPIRE PHARMA

320.5MG;30MG;16MG

A204785 001 Nov 26, 2014 Jul CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

>D>	@ ACTAVIS MID ATLANTIC	120MG/5ML;12MG/5ML	A085861	001	Aug CRLD
>A>	+ @	120MG/5ML;12MG/5ML	A085861	001	Aug CRLD
	TYLENOL W/ CODEINE				
>D>	@ ORTHO MCNEIL PHARM	120MG/5ML;12MG/5ML	A085057	001	Aug CRLD
>A>	+ @	120MG/5ML;12MG/5ML	A085057	001	Aug CRLD
	TABLET;ORAL				
	ACETAMINOPHEN AND CODEINE PHOSPHATE				
>A> AA	NOSTRUM LABS INC	300MG;15MG	A088629	002	Mar 06, 1985 Aug CMS1
>A> AA		300MG;30MG	A088629	003	Mar 06, 1985 Aug CMS1
>D> AA	!	300MG;60MG	A088629	001	Mar 06, 1985 Aug CRLD
>A> AA	+!	300MG;60MG	A088629	001	Mar 06, 1985 Aug CRLD
>D>	@ PUREPAC PHARM	300MG;30MG	A086681	001	Aug CRLD
>A>	+ @	300MG;30MG	A086681	001	Aug CRLD
>D>	@ SANDOZ	300MG;15MG	A087433	001	Aug CRLD
>A>	+ @	300MG;15MG	A087433	001	Aug CRLD
>D>	@	300MG;30MG	A085917	001	Aug CRLD
>A>	+ @	300MG;30MG	A085917	001	Aug CRLD
	@ VINTAGE	300MG;15MG	A089990	001	Sep 30, 1988 Apr DISC
	@	300MG;30MG	A089805	001	Sep 30, 1988 Apr DISC
	@	300MG;60MG	A089828	001	Sep 30, 1988 Apr DISC
AA		300MG;60MG	A089828	001	Sep 30, 1988 Apr CAHN
	TYLENOL W/ CODEINE NO. 2				
>D>	@ JANSSEN PHARMS	300MG;15MG	A085055	002	Aug CRLD
>A>	+ @	300MG;15MG	A085055	002	Aug CRLD
	TYLENOL W/ CODEINE NO. 3				
>D>	@ JANSSEN PHARMS	300MG;30MG	A085055	003	Aug CRLD
>A>	+ @	300MG;30MG	A085055	003	Aug CRLD
	TYLENOL W/ CODEINE NO. 4				
>D>	@ JANSSEN PHARMS	300MG;60MG	A085055	004	Aug CRLD
>A>	+ @	300MG;60MG	A085055	004	Aug CRLD

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL

ANEXSIA 5/325

AA	! SPECGX LLC	325MG;5MG	A040409	001	Oct 20, 2000 Apr CHRS
	ANEXSIA 7.5/325				
AA	! SPECGX LLC	325MG;7.5MG	A040405	001	Sep 08, 2000 Apr CHRS
	HYDROCODONE BITARTRATE AND ACETAMINOPHEN				
>A>	@ ALVOGEN	300MG;5MG	A208540	001	Nov 08, 2018 Aug CAHN
>A>	@	300MG;7.5MG	A208540	002	Nov 08, 2018 Aug CAHN
>A>	@	300MG;10MG	A208540	003	Nov 08, 2018 Aug CAHN
>A>	@	325MG;2.5MG	A209958	001	Oct 24, 2018 Aug CAHN
>A>	@	325MG;5MG	A209958	002	Oct 24, 2018 Aug CAHN
>A>	@	325MG;7.5MG	A209958	003	Oct 24, 2018 Aug CAHN
>A>	@	325MG;10MG	A209958	004	Oct 24, 2018 Aug CAHN
>D>	@ ALVOGEN PINE BROOK	300MG;5MG	A208540	001	Nov 08, 2018 Aug CAHN
>D>	@	300MG;7.5MG	A208540	002	Nov 08, 2018 Aug CAHN
>D>	@	300MG;10MG	A208540	003	Nov 08, 2018 Aug CAHN
>D>	@	325MG;2.5MG	A209958	001	Oct 24, 2018 Aug CAHN
>D>	@	325MG;5MG	A209958	002	Oct 24, 2018 Aug CAHN
>D>	@	325MG;7.5MG	A209958	003	Oct 24, 2018 Aug CAHN
>D>	@	325MG;10MG	A209958	004	Oct 24, 2018 Aug CAHN
AA	! SPECGX LLC	325MG;10MG	A040400	001	Jul 26, 2000 Apr CHRS
	NORCO				
	@ APIL	325MG;2.5MG	A040148	004	Jul 07, 2014 Apr DISC
	@	325MG;5MG	A040099	001	Jun 25, 1997 Apr DISC
	@	325MG;5MG	A040148	005	Jul 07, 2014 Apr DISC
	@	325MG;7.5MG	A040148	003	Sep 12, 2000 Apr DISC
	@	325MG;10MG	A040148	001	Feb 14, 1997 Apr DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## SOLUTION;ORAL

## OXYCODONE AND ACETAMINOPHEN

>D>	! ABHAI LLC	325MG/5ML;5MG/5ML	A 211499	001	Dec 31, 2018	Aug CTEC
>A> AA	!	325MG/5ML;5MG/5ML	A 211499	001	Dec 31, 2018	Aug CTEC
>A> AA	NOSTRUM LABS INC	325MG/5ML;5MG/5ML	A 201448	001	Aug 26, 2021	Aug NEWA
TABLET;ORAL						
OXYCODONE 5/APAP 500						
>D>	@ BRISTOL MYERS SQUIBB	500MG;5MG	A 085911	001		Aug CRLD
>A>	+ @	500MG;5MG	A 085911	001		Aug CRLD
OXYCODONE AND ACETAMINOPHEN						
AA	CHARTWELL	325MG;5MG	A 207834	001	Aug 15, 2019	Jan CAHN
AA		325MG;7.5MG	A 207834	002	Aug 15, 2019	Jan CAHN
AA		325MG;10MG	A 207834	003	Aug 15, 2019	Jan CAHN
PERCOSET						
>D>	@ VINTAGE PHARMS LLC	325MG;5MG	A 085106	002		Aug CRLD
>A>	+ @	325MG;5MG	A 085106	002		Aug CRLD
ROXICET						
>D>	@ HIKMA PHARMS	325MG;5MG	A 087003	001		Aug CRLD
>A>	+ @	325MG;5MG	A 087003	001		Aug CRLD
>A>	@	325MG;5MG	A 087003	001		Jan DISC

ACETAZOLAMIDE

## CAPSULE, EXTENDED RELEASE;ORAL

## ACETAZOLAMIDE

AB	ACCORD HLTHCARE	500MG	A 207659	001	Oct 18, 2018	Apr CMFD
AB	! INDICUS PHARMA	500MG	A 090779	001	Jul 14, 2011	Jun CAHN
TABLET;ORAL						
ACETAZOLAMIDE						
AB	APPSCO	125MG	A 211372	001	Feb 22, 2021	Feb NEWA
AB		250MG	A 211372	002	Feb 22, 2021	Feb NEWA
>A> AB	RUBICON	125MG	A 215101	001	Aug 19, 2021	Aug NEWA
>A> AB		250MG	A 215101	002	Aug 19, 2021	Aug NEWA

ACETIC ACID, GLACIAL; ALUMINUM ACETATE

## SOLUTION/DROPS;OTIC

## DOMEBORO

>D>	@ BAYER PHARMS	2%;0.79%	A 084476	001		Aug CRLD
>A>	+ @	2%;0.79%	A 084476	001		Aug CRLD

ACETYLCYSTEINE

## INJECTABLE; INTRAVENOUS

## ACETYLCYSTEINE

AP	EXELA PHARMA	6GM/30ML (200MG/ML)	A 204797	001	Apr 15, 2021	Apr NEWA
----	--------------	---------------------	----------	-----	--------------	----------

ACLIDINIUM BROMIDE

## POWDER, METERED; INHALATION

## TUDORZA PRESSAIR

+!	ASTRAZENECA	0.4MG/INH	N 202450	001	Jul 23, 2012	Feb CAHN
----	-------------	-----------	----------	-----	--------------	----------

ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE

## POWDER, METERED; INHALATION

## DUAKLIR PRESSAIR

+!	ASTRAZENECA	0.4MG/INH;0.012MG/INH	N 210595	001	Mar 29, 2019	Jun CHRS
+		0.4MG/INH;0.012MG/INH	N 210595	001	Mar 29, 2019	Jun CRLD
		0.4MG/INH;0.012MG/INH	N 210595	001	Mar 29, 2019	Feb CAHN

ACYCLOVIR

## OINTMENT;TOPICAL

## ACYCLOVIR

AB	@ ANDA REPOSITORY	5%	A 206437	001	Jul 31, 2017	Jun DISC
	MACLEODS PHARMS LTD	5%	A 212444	001	May 19, 2021	May NEWA
SUSPENSION;ORAL						
ACYCLOVIR						
>A>	@ VISTAPHARM	200MG/5ML	A 213951	001	Jan 11, 2021	Jul DISC
AB		200MG/5ML	A 213951	001	Jan 11, 2021	Jan NEWA

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ACYCLOVIR SODIUM

AP	NAMIGEN LLC	EQ 50MG BASE/ML	A207919	001	Jun 17, 2020	Jun CAHN
AP	ZYDUS PHARMS	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CHRS
AP	!	EQ 50MG BASE/ML	A206535	001	Aug 31, 2018	Jan CPOT

ADAPALENE; BENZOYL PEROXIDE

GEL; TOPICAL

EPIDUO FORTE

+! GALDERMA LABS

0.3%; 2.5%

N207917 001 Jul 15, 2015 Feb CTEC

ADENOSINE

SOLUTION; INTRAVENOUS

ADENOSINE

AP	EMCURE PHARMS LTD	60MG/20ML (3MG/ML)	A202313	001	Sep 15, 2014	Feb CMFD
AP		90MG/30ML (3MG/ML)	A202313	002	Sep 15, 2014	Feb CMFD

AIR POLYMER-TYPE A

FOAM; INTRAUTERINE

EXEM FOAM KIT

>D>	+! GISKIT	10ML	N212279	001	Nov 07, 2019	Aug CAHN
>A>	+!	10ML	N212279	001	Nov 07, 2019	Aug CAHN

ALBENDAZOLE

TABLET; ORAL

ALBENDAZOLE

AB	DR REDDYS	200MG	A211034	001	Jan 26, 2021	Jan NEWA
	@ LUPIN LTD	200MG	A211636	001	Jun 10, 2020	Jan DISC
AB	MSN	200MG	A213435	001	Jan 21, 2021	Jan NEWA

ALBUTEROL SULFATE

AEROSOL, METERED; INHALATION

ALBUTEROL SULFATE

AB1	@ PADAGIS US	EQ 0.09MG BASE/INH	A203760	001	Feb 24, 2020	Jul CAHN
	SANDOZ INC	EQ 0.09MG BASE/INH	A207085	001	Jun 01, 2021	May NEWA

SOLUTION; INHALATION

ALBUTEROL SULFATE

>D>	@ AUROBINDO PHARMA LTD	EQ 0.021% BASE	A211888	001	Apr 20, 2020	Aug CAHN
>D>	@	EQ 0.042% BASE	A211888	002	Apr 20, 2020	Aug CAHN
>D> AN		EQ 0.083% BASE	A206224	001	Oct 17, 2017	Aug CAHN
>A>	@ LUOXIN AUROVITAS	EQ 0.021% BASE	A211888	001	Apr 20, 2020	Aug CAHN
>A>	@	EQ 0.042% BASE	A211888	002	Apr 20, 2020	Aug CAHN
>A> AN		EQ 0.083% BASE	A206224	001	Oct 17, 2017	Aug CAHN

TABLET; ORAL

ALBUTEROL SULFATE

AB	AIZANT	EQ 2MG BASE	A210948	001	Mar 15, 2019	Feb CMFD
AB		EQ 4MG BASE	A210948	002	Mar 15, 2019	Feb CMFD
	@ EYWA	EQ 2MG BASE	A213524	001	Oct 08, 2020	Apr DISC
	@	EQ 4MG BASE	A213524	002	Oct 08, 2020	Apr DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE

>D>	@ AUROBINDO PHARMA LTD	EQ 0.083% BASE; 0.017%	A206532	001	Jul 08, 2020	Aug CAHN
>D>	@	EQ 0.083% BASE; 0.017%	A206532	001	Jul 08, 2020	Jan DISC
>A>	@ LUOXIN AUROVITAS	EQ 0.083% BASE; 0.017%	A206532	001	Jul 08, 2020	Aug CAHN

ALENDRONATE SODIUM

TABLET; ORAL

ALENDRONATE SODIUM

	@ JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun DISC
	@	EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun DISC
	@	EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun DISC
	@	EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun DISC
	@ US ANTIBIOTICS	EQ 5MG BASE	A079049	003	Aug 04, 2008	May CAHN
	@	EQ 10MG BASE	A079049	004	Aug 04, 2008	May CAHN
	@	EQ 35MG BASE	A079049	001	Aug 04, 2008	May CAHN
	@	EQ 70MG BASE	A079049	002	Aug 04, 2008	May CAHN

ALENDRONATE SODIUM; CHOLECALCIFEROL

TABLET;ORAL

FOSAMAX PLUS D

+ ORGANON

+!

EQ 70MG BASE;2,800 IU

EQ 70MG BASE;5,600 IU

N021762 001 Apr 07, 2005

Jun CAHN

N021762 002 Apr 26, 2007

Jun CAHN

ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

TEKTURNA HCT

+ @ NODEN PHARMA

+ @

EQ 150MG BASE;12.5MG

EQ 150MG BASE;25MG

N022107 001 Jan 18, 2008

May DISC

N022107 002 Jan 18, 2008

May DISC

ALLOPURINOL

TABLET;ORAL

ALLOPURINOL

AB CHARTWELL

100MG

AB 300MG

A077353 001 Sep 08, 2005

Jun CAHN

A077353 002 Sep 08, 2005

Jun CAHN

ALPRAZOLAM

TABLET;ORAL

ALPRAZOLAM

@ MYLAN

0.25MG

A074215 001 Jan 27, 1994

Jun DISC

@

0.5MG

A074215 002 Jan 27, 1994

Jun DISC

@

1MG

A074215 003 Jan 27, 1994

Jun DISC

@

2MG

A074215 004 Jan 27, 1994

Jun DISC

AB NOVITIUM PHARMA

0.25MG

A074174 001 Oct 19, 1993

Apr CMFD

AB 0.5MG

A074174 002 Oct 19, 1993

Apr CMFD

AB 1MG

A074174 003 Oct 19, 1993

Apr CMFD

AB 2MG

A074174 004 Oct 19, 1993

Apr CMFD

ALPROSTADIL

INJECTABLE;INJECTION

CAVERJECT

+ @ PFIZER

0.005MG/VIAL

N020379 003 Jun 27, 1996

Jan CAHN

AP + 0.01MG/VIAL

N020379 001 Jul 06, 1995

Jan CAHN

AP +! 0.02MG/VIAL

N020379 002 Jul 06, 1995

Jan CAHN

AP +! 0.04MG/VIAL

N020379 004 May 19, 1997

Jan CAHN

CAVERJECT IMPULSE

PFIZER

0.01MG/VIAL

N021212 001 Jun 11, 2002

Jan CAHN

0.02MG/VIAL

N021212 002 Jun 11, 2002

Jan CAHN

PROSTIN VR PEDIATRIC

AP +! PFIZER 0.5MG/ML

N018484 001

Jan CAHN

AMANTADINE HYDROCHLORIDE

SYRUP;ORAL

AMANTADINE HYDROCHLORIDE

&gt;A&gt; AA INVATECH 50MG/5ML

A214178 001 Aug 20, 2021

Aug NEWA

@ WOCKHARDT BIO AG 50MG/5ML

A075060 001 Dec 24, 1998

Jan DISC

TABLET;ORAL

AMANTADINE HYDROCHLORIDE

@ INVAGEN PHARMS 100MG

A207571 001 Jan 31, 2017

Jan DISC

TABLET, EXTENDED RELEASE;ORAL

OSMOLEX ER

+ ADAMAS PHARMA EQ 129MG BASE

N209410 001 Feb 16, 2018

Jan CAHN

+ @ EQ 161MG BASE

N209410 004 Apr 22, 2020

Jan CAHN

+ EQ 193MG BASE

N209410 002 Feb 16, 2018

Jan CAHN

+ @ EQ 258MG BASE

N209410 003 Feb 16, 2018

May DISC

+! EQ 258MG BASE

N209410 003 Feb 16, 2018

Jan CAHN

+ ADAMAS PHARMS EQ 129MG BASE

N209410 001 Feb 16, 2018

Jan CAHN

+ @ EQ 161MG BASE

N209410 004 Apr 22, 2020

Jan CAHN

+ EQ 193MG BASE

N209410 002 Feb 16, 2018

Jan CAHN

+! EQ 258MG BASE

N209410 003 Feb 16, 2018

Jan CAHN

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

&gt;A&gt; @ CHARTWELL RX EQ 5MG ANHYDROUS;50MG

A073357 001 Nov 27, 1991

Aug CAHN

&gt;D&gt; @ YAOPHARMA CO LTD EQ 5MG ANHYDROUS;50MG

A073357 001 Nov 27, 1991

Aug CAHN

AMINOCAPROIC ACID

## SOLUTION;ORAL

## AMICAR

AA	+!	AKORN	0.25GM/ML	N015230	002	Feb	CPOT
AA	+!		1.25GM/5ML	N015230	002	Feb	CDFR
		AMINOCAPROIC ACID					
AA		AIRIS PHARMA PVT LTD	0.25GM/ML	A213825	001	Apr 08,	2021
AA		AMNEAL	0.25GM/ML	A212780	001	Aug 23,	2019
AA			1.25GM/5ML	A212780	001	Aug 23,	2019
AA		BELCHER	0.25GM/ML	A213825	001	Apr 08,	2021
AA		LEADING PHARMA LLC	0.25GM/ML	A214140	001	Jan 26,	2021
AA			1.25GM/5ML	A214140	001	Jan 26,	2021
AA		TULEX PHARMS INC	0.25GM/ML	A212494	001	Aug 11,	2020
AA			1.25GM/5ML	A212494	001	Aug 11,	2020
AA		VISTAPHARM	0.25GM/ML	A212814	001	Feb 26,	2020
AA			1.25GM/5ML	A212814	001	Feb 26,	2020
		SYRUP;ORAL					
		AMINOCAPROIC ACID					
AA		LEADING PHARMA LLC	1.25GM/5ML	A214140	001	Jan 26,	2021
		TABLET;ORAL					
		AMINOCAPROIC ACID					
AB		EDENBRIDGE PHARMS	500MG	A212110	001	Jun 14,	2021
AB		LEADING PHARMA LLC	500MG	A213928	001	Feb 12,	2021
AB			1GM	A213928	002	Feb 12,	2021

AMINOPHYLLINE

## INJECTABLE;INJECTION

## AMINOPHYLLIN

>D>	@	GD SEARLE LLC	25MG/ML	A087243	001	May 24,	1982	Aug CRLD
>A>	+	@	25MG/ML	A087243	001	May 24,	1982	Aug CRLD
>D>	@		25MG/ML	A087621	001	May 24,	1982	Aug CRLD
>A>	+	@	25MG/ML	A087621	001	May 24,	1982	Aug CRLD

AMIODARONE HYDROCHLORIDE

## INJECTABLE;INJECTION

## AMIODARONE HYDROCHLORIDE

>A> AP		ACELLA	50MG/ML	A077610	001	Oct 30,	2008	Aug CAHN
>A> AP			50MG/ML	A077834	001	Oct 30,	2008	Aug CAHN
>D> AP		WOCKHARDT	50MG/ML	A077610	001	Oct 30,	2008	Aug CAHN
>D> AP			50MG/ML	A077834	001	Oct 30,	2008	Aug CAHN

## TABLET;ORAL

## AMIODARONE HYDROCHLORIDE

AB		RUBICON	100MG	A078578	002	Feb 26,	2021	Feb NEWA
AB			400MG	A078578	003	Feb 26,	2021	Feb NEWA

AMITRIPTYLINE HYDROCHLORIDE

## TABLET;ORAL

## AMITRIPTYLINE HYDROCHLORIDE

AB		MANKIND PHARMA	10MG	A213999	001	Feb 19,	2021	Feb NEWA
AB			25MG	A213999	002	Feb 19,	2021	Feb NEWA
AB			50MG	A213999	003	Feb 19,	2021	Feb NEWA
AB			75MG	A213999	004	Feb 19,	2021	Feb NEWA
AB			100MG	A213999	005	Feb 19,	2021	Feb NEWA
AB			150MG	A213999	006	Feb 19,	2021	Feb NEWA
		@ MYLAN	10MG	A086009	002			Jun DISC
		@	25MG	A086009	003			Jun DISC
		@	50MG	A086009	001			Jun DISC
		@	75MG	A086009	004			Jun DISC
		@	100MG	A086009	005			Jun DISC
		@	150MG	A086009	006			Jun DISC
>D> AB		SANDOZ	10MG	A085968	004			Aug CRLD
>A> AB	+		10MG	A085968	004			Aug CRLD
>D> AB			50MG	A085968	001			Aug CRLD
>A> AB	+		50MG	A085968	001			Aug CRLD
>D> AB			75MG	A085968	006			Aug CRLD
>A> AB	+		75MG	A085968	006			Aug CRLD
>D> AB			100MG	A085968	003			Aug CRLD
>A> AB	+		100MG	A085968	003			Aug CRLD
>D> AB			150MG	A085968	005			Aug CRLD
>A> AB	+		150MG	A085968	005			Aug CRLD
AB		UNICHEM	10MG	A214548	001	May 19,	2021	May NEWA
AB			25MG	A214548	002	May 19,	2021	May NEWA

TABLET;ORAL

## AMITRIPTYLINE HYDROCHLORIDE

AB	50MG	A214548	003	May 19, 2021	May NEWA
AB	75MG	A214548	004	May 19, 2021	May NEWA
AB	100MG	A214548	005	May 19, 2021	May NEWA
AB	150MG	A214548	006	May 19, 2021	May NEWA

AMLODIPINE BESYLATETABLET;ORAL

## AMLODIPINE BESYLATE

@ WOCKHARDT	EQ 2.5MG BASE	A078500	001	Sep 06, 2007	Jan DISC
@	EQ 5MG BASE	A078500	002	Sep 06, 2007	Jan DISC
@	EQ 10MG BASE	A078500	003	Sep 06, 2007	Jan DISC

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMILTABLET;ORAL

## AMLODIPINE AND OLMESARTAN MEDOXOMIL

@ JUBILANT GENERICS	EQ 5MG BASE;20MG	A207450	001	May 15, 2017	Jun DISC
@	EQ 5MG BASE;40MG	A207450	002	May 15, 2017	Jun DISC
@	EQ 10MG BASE;20MG	A207450	003	May 15, 2017	Jun DISC
@	EQ 10MG BASE;40MG	A207450	004	May 15, 2017	Jun DISC

AMMONIA N-13INJECTABLE;INTRAVENOUS

## AMMONIA N 13

AP	METHODIST	3.75mCi-260mCi/ML	A215083	001	Jul 09, 2021	Jul NEWA
AP	NUKEMED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Jan CAHN

AMOXICILLINCAPSULE;ORAL

## AMOXICILLIN

AB	CHARTWELL	250MG	A062058	001		Jun CAHN
AB		500MG	A062058	002		Jun CAHN

## AMOXIL

AB	US ANTIBIOTICS	250MG	A062216	001		May CAHN
AB		500MG	A062216	004		May CAHN

FOR SUSPENSION;ORAL

## AMOXIL

AB	US ANTIBIOTICS	50MG/ML	A062226	005		May CAHN
AB		125MG/5ML	A062226	001		May CAHN

+ @

200MG/5ML

N050760 001 Apr 15, 1999

AB		250MG/5ML	A062226	002		May CAHN
AB	+ @	400MG/5ML	N050760	002	Apr 15, 1999	May CAHN

## LAROTID

AB	US ANTIBIOTICS	125MG/5ML	A062226	003		May CAHN
AB		250MG/5ML	A062226	004		May CAHN

TABLET;ORAL

## AMOXIL

+ @ US ANTIBIOTICS	500MG	N050754	002	Jul 10, 1998	May CAHN
+ @	875MG	N050754	001	Jul 10, 1998	May CAHN

TABLET, CHEWABLE;ORAL

## AMOXIL

+ @ US ANTIBIOTICS	125MG	N050542	002		May CAHN
@	200MG	N050761	001	Apr 15, 1999	May CAHN

+ @

250MG

N050542 001

@

400MG

N050761 002 Apr 15, 1999

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLECAPSULE, TABLET, CAPSULE, DELAYED REL PELETS;ORAL

## LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED)

@ ANI PHARMS	500MG;500MG;30MG	A200218	001	Aug 30, 2013	Jul CTNA	
@	500MG;500MG;30MG	A200218	001	Aug 30, 2013	Jul CPOT	
@	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A200218	001	Aug 30, 2013	Jul CDFR	
AB	! RISING	500MG;500MG;30MG	A206006	001	Oct 07, 2016	Jul CTNA
AB	!	500MG;500MG;30MG	A206006	001	Oct 07, 2016	Jul CPOT
AB	!	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A206006	001	Oct 07, 2016	Jul CDFR
AB	SANDOZ INC	500MG;500MG;30MG	A202588	001	Mar 04, 2014	Jul CTNA
AB		500MG;500MG;30MG	A202588	001	Mar 04, 2014	Jul CPOT
AB		500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/A,30MG	A202588	001	Mar 04, 2014	Jul CDFR

CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL  
PREVPAC (COPACKAGED)

+ @ TAKEDA PHARMS USA	500MG;500MG;30MG	N 050757	001	Dec 02, 1997	Jul CTNA
+ @	500MG;500MG;30MG	N 050757	001	Dec 02, 1997	Jul CPOT
+ @	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ A,30MG	N 050757	001	Dec 02, 1997	Jul CDFR

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL  
OMEПRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+ @ CUMBERLAND PHARMS	500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ A,20MG	N 050824	001	Feb 08, 2011	May DISC
-----------------------	--	----------	-----	--------------	----------

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL

AMOXICILLIN AND CLAVULANATE POTASSIUM

AB MICRO LABS LTD INDIA	200MG/5ML;EQ 28.5MG BASE/5ML	A 205187	001	May 21, 2021	May NEWA
AB AUGMENTIN '125'	400MG/5ML;EQ 57MG BASE/5ML	A 205187	002	May 21, 2021	May NEWA
AB + US ANTIBIOTICS AUGMENTIN '200'	125MG/5ML;EQ 31.25MG BASE/5ML	N 050575	001	Aug 06, 1984	May CAHN
+ @ US ANTIBIOTICS AUGMENTIN '250'	200MG/5ML;EQ 28.5MG BASE/5ML	N 050725	001	May 31, 1996	May CAHN
AB +! US ANTIBIOTICS AUGMENTIN '400'	250MG/5ML;EQ 62.5MG BASE/5ML	N 050575	002	Aug 06, 1984	May CAHN
+ @ US ANTIBIOTICS AUGMENTIN ES-600	400MG/5ML;EQ 57MG BASE/5ML	N 050725	002	May 31, 1996	May CAHN
AB + US ANTIBIOTICS TABLET;ORAL AUGMENTIN '250'	600MG/5ML;EQ 42.9MG BASE/5ML	N 050755	001	Jun 22, 2001	May CAHN
+ @ US ANTIBIOTICS AUGMENTIN '500'	250MG;EQ 125MG BASE	N 050564	001	Aug 06, 1984	May CAHN
+ @ US ANTIBIOTICS AUGMENTIN '875'	500MG;EQ 125MG BASE	N 050564	002	Aug 06, 1984	May CAHN
AB + US ANTIBIOTICS TABLET, CHEWABLE;ORAL AUGMENTIN '125'	875MG;EQ 125MG BASE	N 050720	001	Feb 13, 1996	May CAHN
+ @ US ANTIBIOTICS AUGMENTIN '200'	125MG;EQ 31.25MG BASE	N 050597	001	Jul 22, 1985	May CAHN
+ @ US ANTIBIOTICS AUGMENTIN '250'	200MG;EQ 28.5MG BASE	N 050726	001	May 31, 1996	May CAHN
+ @ US ANTIBIOTICS AUGMENTIN '400'	250MG;EQ 62.5MG BASE	N 050597	002	Jul 22, 1985	May CAHN
+ @ US ANTIBIOTICS AUGMENTIN XR	400MG;EQ 57MG BASE	N 050726	002	May 31, 1996	May CAHN
TABLET, EXTENDED RELEASE;ORAL AUGMENTIN XR	1GM;EQ 62.5MG BASE	N 050785	001	Sep 25, 2002	May CAHN

AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB RHODES PHARMS	2.5MG;2.5MG;2.5MG;2.5MG	A 213111	003	Jan 13, 2021	Jan NEWA
AB	3.75MG;3.75MG;3.75MG;3.75MG	A 213111	005	Jan 13, 2021	Jan NEWA
AB	5MG;5MG;5MG;5MG	A 213111	006	Jan 13, 2021	Jan NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB ASCENT PHARMS INC	1.25MG;1.25MG;1.25MG;1.25MG	A 213709	001	Apr 22, 2021	Apr NEWA
AB	1.875MG;1.875MG;1.875MG;1.875MG	A 213709	002	Apr 22, 2021	Apr NEWA
AB	2.5MG;2.5MG;2.5MG;2.5MG	A 213709	003	Apr 22, 2021	Apr NEWA
AB	3.125MG;3.125MG;3.125MG;3.125MG	A 213709	004	Apr 22, 2021	Apr NEWA
AB	3.75MG;3.75MG;3.75MG;3.75MG	A 213709	005	Apr 22, 2021	Apr NEWA
AB	5MG;5MG;5MG;5MG	A 213709	006	Apr 22, 2021	Apr NEWA
AB	7.5MG;7.5MG;7.5MG;7.5MG	A 213709	007	Apr 22, 2021	Apr NEWA
>A> AB LIBERTY PHARMA INC	1.25MG;1.25MG;1.25MG;1.25MG	A 210293	001	Apr 03, 2020	Aug CAHN
>A> AB	1.875MG;1.875MG;1.875MG;1.875MG	A 210293	002	Apr 03, 2020	Aug CAHN
>A> AB	2.5MG;2.5MG;2.5MG;2.5MG	A 210293	003	Apr 03, 2020	Aug CAHN
>A> AB	3.75MG;3.75MG;3.75MG;3.75MG	A 210293	004	Apr 03, 2020	Aug CAHN
>A> AB	5MG;5MG;5MG;5MG	A 210293	005	Apr 03, 2020	Aug CAHN
>A> AB	7.5MG;7.5MG;7.5MG;7.5MG	A 210293	006	Apr 03, 2020	Aug CAHN
>D> AB MYLAN	1.25MG;1.25MG;1.25MG;1.25MG	A 206721	001	Nov 10, 2015	Aug CAHN

## TABLET; ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

>A>	@	1.25MG;1.25MG;1.25MG;1.25MG	A206721	001	Nov 10, 2015	Aug CAHN
>D> AB		1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015	Aug CAHN
>A>	@	1.875MG;1.875MG;1.875MG;1.875MG	A206721	002	Nov 10, 2015	Aug CAHN
>D> AB		2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015	Aug CAHN
>A>	@	2.5MG;2.5MG;2.5MG;2.5MG	A206721	003	Nov 10, 2015	Aug CAHN
>D> AB		3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015	Aug CAHN
>A>	@	3.125MG;3.125MG;3.125MG;3.125MG	A206721	004	Nov 10, 2015	Aug CAHN
>D> AB		3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015	Aug CAHN
>A>	@	3.75MG;3.75MG;3.75MG;3.75MG	A206721	005	Nov 10, 2015	Aug CAHN
>D> AB		5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015	Aug CAHN
>A>	@	5MG;5MG;5MG;5MG	A206721	006	Nov 10, 2015	Aug CAHN
>D> AB		7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015	Aug CAHN
>A>	@	7.5MG;7.5MG;7.5MG;7.5MG	A206721	007	Nov 10, 2015	Aug CAHN
AB	RHODES PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A213111	001	Jan 13, 2021	Jan NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A213111	002	Jan 13, 2021	Jan NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A213111	004	Jan 13, 2021	Jan NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A213111	007	Jan 13, 2021	Jan NEWA
>D> AB	USPHARMA	1.25MG;1.25MG;1.25MG;1.25MG	A210293	001	Apr 03, 2020	Aug CAHN
>D> AB		1.875MG;1.875MG;1.875MG;1.875MG	A210293	002	Apr 03, 2020	Aug CAHN
>D> AB		2.5MG;2.5MG;2.5MG;2.5MG	A210293	003	Apr 03, 2020	Aug CAHN
>D> AB		3.75MG;3.75MG;3.75MG;3.75MG	A210293	004	Apr 03, 2020	Aug CAHN
>D> AB		5MG;5MG;5MG;5MG	A210293	005	Apr 03, 2020	Aug CAHN
>D> AB		7.5MG;7.5MG;7.5MG;7.5MG	A210293	006	Apr 03, 2020	Aug CAHN

AMPHETAMINE SULFATE

## TABLET; ORAL

## AMPHETAMINE SULFATE

AA	@ GLENMARK PHARMS LTD	5MG	A212186	001	Jan 27, 2021	Jun DISC
	@	5MG	A212186	001	Jan 27, 2021	Jan NEWA
AA	@	10MG	A212186	002	Jan 27, 2021	Jun DISC
		10MG	A212186	002	Jan 27, 2021	Jan NEWA
>D> AA	HAVIX	5MG	A212901	001	May 22, 2020	Aug CAHN
>D> AA		10MG	A212901	002	May 22, 2020	Aug CAHN
>D>	@ LANNETT	5MG	A083901	001	Aug 31, 1984	Aug CRLD
>A>	+ @	5MG	A083901	001	Aug 31, 1984	Aug CRLD
>D>	@	10MG	A083901	002	Aug 31, 1984	Aug CRLD
>A>	+ @	10MG	A083901	002	Aug 31, 1984	Aug CRLD
	@ MAYNE PHARMA	5MG	A213898	001	Jul 14, 2020	Jan DISC
	@	10MG	A213898	002	Jul 14, 2020	Jan DISC
	@ NOVAST LABS	5MG	A213763	001	Aug 24, 2020	Mar DISC
	@	10MG	A213763	002	Aug 24, 2020	Mar DISC
>A> AA	RHODES PHARMS	5MG	A213852	001	Sep 07, 2021	Aug NEWA
>A> AA		10MG	A213852	002	Sep 07, 2021	Aug NEWA
>A> AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Aug CAHN
>A> AA		10MG	A212901	002	May 22, 2020	Aug CAHN
AA	SPECGX LLC	5MG	A213583	001	Jan 22, 2021	Jan NEWA
AA		10MG	A213583	002	Jan 22, 2021	Jan NEWA
AA	SUN PHARM IND'S INC	5MG	A214574	001	Jan 27, 2021	Jan NEWA
AA		10MG	A214574	002	Jan 27, 2021	Jan NEWA
TABLET, ORALLY DISINTEGRATING; ORAL						
EVEKEO ODT						
+ @ ARBOR PHARMS LLC		2.5MG	N209905	005	Apr 16, 2021	Jul DISC
+ @		2.5MG	N209905	005	Apr 16, 2021	Apr NEWA
+ !		20MG	N209905	004	Jan 30, 2019	Apr CHRS

AMPICILLIN SODIUM

## INJECTABLE; INJECTION

## AMPICILLIN SODIUM

AP	@ HQ SPECLT PHARMA	EQ 125MG BASE/VIAL	A062772	005	Apr 15, 1993	Mar CAHN
AP		EQ 250MG BASE/VIAL	A062772	006	Apr 15, 1993	Mar CAHN
AP		EQ 500MG BASE/VIAL	A062772	007	Apr 15, 1993	Mar CAHN
AP	@	EQ 500MG BASE/VIAL	A062772	008	Apr 15, 1993	Mar CAHN
AP		EQ 1GM BASE/VIAL	A062772	001	Apr 15, 1993	Mar CAHN
AP	@	EQ 1GM BASE/VIAL	A062772	002	Apr 15, 1993	Mar CAHN
AP		EQ 2GM BASE/VIAL	A062772	003	Apr 15, 1993	Mar CAHN
AP	@	EQ 2GM BASE/VIAL	A062772	004	Apr 15, 1993	Mar CAHN
AP		EQ 10GM BASE/VIAL	A063142	001	Apr 15, 1993	Mar CAHN

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

AMPICILLIN AND SULBACTAM

AP	HQ SPECLT PHARMA	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A065176	001	Nov 30, 2005	Mar CAHN
AP		EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A065176	002	Nov 30, 2005	Mar CAHN
AP		EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A065188	001	Nov 25, 2005	Mar CAHN

ANAGRELIDE HYDROCHLORIDE

CAPSULE; ORAL

ANAGRELIDE HYDROCHLORIDE

>A>	@ CHARTWELL RX	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Aug CAHN
>A>	@	EQ 1MG BASE	A076683	002	Apr 18, 2005	Aug CAHN
>D>	@ UPSHER SMITH LABS	EQ 0.5MG BASE	A076683	001	Apr 18, 2005	Aug CAHN
>D>	@	EQ 1MG BASE	A076683	002	Apr 18, 2005	Aug CAHN

ANASTROZOLE

TABLET; ORAL

ANASTROZOLE

>D> AB	FRESENIUS KABI USA	1MG	A090088	001	Jun 28, 2010	Aug DISC
>A>	@	1MG	A090088	001	Jun 28, 2010	Aug DISC
	@ US ANTIBIOTICS	1MG	A090732	001	Jun 28, 2010	May CAHN

ANIDULAFUNGIN

POWDER; INTRAVENOUS

ERAXIS

+! VICURON HOLDINGS	50MG/VIAL	N021632	001	Feb 17, 2006	Jul CAHN
+!	100MG/VIAL	N021632	002	Nov 14, 2006	Jul CAHN

APIXABAN

TABLET; ORAL

APIXABAN

AB	BRECKENRIDGE	2.5MG	A209845	001	Jul 26, 2021	Jul NEWA
AB		5MG	A209845	002	Jul 26, 2021	Jul NEWA

APREMILAST

TABLET; ORAL

APREMILAST

AB	AMNEAL	10MG	A211782	001	Jun 30, 2021	Jun NEWA
AB		20MG	A211782	002	Jun 30, 2021	Jun NEWA
AB		30MG	A211782	003	Jun 30, 2021	Jun NEWA
>D> AB	UNICHEM	10MG	A211819	001	Feb 17, 2021	Aug DISC
>A>	@	10MG	A211819	001	Feb 17, 2021	Aug DISC
	AB	10MG	A211819	001	Feb 17, 2021	Feb NFTG
>D> AB		20MG	A211819	002	Feb 17, 2021	Aug DISC
>A>	@	20MG	A211819	002	Feb 17, 2021	Aug DISC
	AB	20MG	A211819	002	Feb 17, 2021	Feb NFTG
>D> AB		30MG	A211819	003	Feb 17, 2021	Aug DISC
>A>	@	30MG	A211819	003	Feb 17, 2021	Aug DISC
	AB	30MG	A211819	003	Feb 17, 2021	Feb NFTG

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION

ARFORMOTEROL TARTRATE

AN	AXAR PHARMS INC	EQ 0.015MG BASE/2ML	A213762	001	Jun 22, 2021	Jun NFTG
AN	CIPPLA	EQ 0.015MG BASE/2ML	A207306	001	Jun 22, 2021	Jun NFTG
AN	GLENMARK PHARMS LTD	EQ 0.015MG BASE/2ML	A213132	001	Jun 22, 2021	Jun NFTG

ARGATROBAN

INJECTABLE; INJECTION

ARGATROBAN

AP	CAPLIN	50MG/50ML (1MG/ML)	A214235	001	Jan 21, 2021	Jan NFTG
	INJECTABLE; INTRAVENOUS					
	ARGATROBAN IN SODIUM CHLORIDE					
+ @ EAGLE PHARMS		50MG/50ML (1MG/ML)	N022434	001	Jun 29, 2011	May DISC
	SOLUTION; INTRAVENOUS					
	ARGATROBAN IN SODIUM CHLORIDE					
+! ACCORD HLTHCARE		50MG/50ML (1MG/ML)	N212035	001	Jun 07, 2021	Jun NEWA

ARSENIC TRIOXIDE

## INJECTABLE; INJECTION

## ARSENIC TRIOXIDE

>D>	@ AMNEAL	1MG/ML	A210739	001	Jan 25, 2021	Aug CMFD
>A> AP		1MG/ML	A210739	001	Jan 25, 2021	Aug CMFD
AP	@	1MG/ML	A210739	001	Jan 25, 2021	May DISC
		1MG/ML	A210739	001	Jan 25, 2021	Jan NEWA
>A> AP		2MG/ML	A210739	002	Aug 19, 2021	Aug NEWA
AP	@ INGENUS PHARMS LLC	2MG/ML	A209315	002	Jan 14, 2021	Feb DISC
		2MG/ML	A209315	002	Jan 14, 2021	Jan NEWA

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

## INJECTABLE; INTRAVENOUS

## INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE)

+!	SANDOZ CANADA INC	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N021265	002	Jan 29, 2004	Feb CAIN
----	-------------------	---	---------	-----	--------------	----------

ASENAPINE MALEATE

## TABLET; SUBLINGUAL

## ASENAPINE MALEATE

AB	ALEMBIC PHARMS LTD	EQ 2.5MG BASE	A206098	003	Jul 19, 2021	Jul NEWA
AB	BRECKENRIDGE	EQ 5MG BASE	A205960	003	Mar 08, 2021	Feb NEWA

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

## TABLET; ORAL

## NORGESIC

+ @ BAUSCH		385MG;30MG;25MG	N013416	003	Oct 27, 1982	May CAHN
+ @ BAUSCH		770MG;60MG;50MG	N013416	004	Oct 27, 1982	May CAHN

ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE

## CAPSULE; ORAL

## PROPOXYPHENE COMPOUND 65

>D>	@ SANDOZ	389MG;32.4MG;65MG	A080044	002	Sep 16, 1983	Aug CRLD
>A>	+ @	389MG;32.4MG;65MG	A080044	002	Sep 16, 1983	Aug CRLD

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

## TABLET; ORAL

## CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

!	INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jul CHRS
		325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jul CTEC
	@ SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jul DISC

ASPIRIN; DIPYRIDAMOLE

## CAPSULE, EXTENDED RELEASE; ORAL

## ASPIRIN AND DIPYRIDAMOLE

AB	@ LANNETT CO INC	25MG;200MG	A204552	001	Mar 20, 2019	Apr DISC
	MICRO LABS	25MG;200MG	A209929	001	Aug 11, 2021	Jul NEWA
>D> AB	SUN PHARM	25MG;200MG	A208572	001	Aug 21, 2018	Aug DISC
>A>	@	25MG;200MG	A208572	001	Aug 21, 2018	Aug DISC

ASPIRIN; HYDROCODONE BITARTRATE

## TABLET; ORAL

## HYDROCODONE BITARTRATE AND ASPIRIN

## LGM PHARMA 500MG;5MG

A205479 001 May 28, 2021 May NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE

## TABLET; ORAL

## OXYCODONE AND ASPIRIN

## @ MAYNE PHARMA INC 325MG;4.8355MG

A091670 001 Mar 16, 2011 Jul DISC

ATAZANAVIR SULFATE

## CAPSULE; ORAL

## ATAZANAVIR SULFATE

AB	LAURUS LABS LTD	EQ 150MG BASE	A212579	001	Apr 30, 2021	Apr NEWA
AB		EQ 200MG BASE	A212579	002	Apr 30, 2021	Apr NEWA
AB		EQ 300MG BASE	A212579	003	Apr 30, 2021	Apr NEWA

ATOMOXETINE HYDROCHLORIDE

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB	HETERO LABS LTD V	10MG	A202682	001	Mar 11, 2021	Mar NEWA
AB		18MG	A202682	002	Mar 11, 2021	Mar NEWA
AB		25MG	A202682	003	Mar 11, 2021	Mar NEWA
AB		40MG	A202682	004	Mar 11, 2021	Mar NEWA
AB		60MG	A202682	005	Mar 11, 2021	Mar NEWA
AB		80MG	A202682	006	Mar 11, 2021	Mar NEWA
AB		100MG	A202682	007	Mar 11, 2021	Mar NEWA
	@ MYLAN	10MG	A079021	001	Feb 18, 2021	Feb DISC
AB		10MG	A079021	001	Feb 18, 2021	Feb NEWA
	@	18MG	A079021	002	Feb 18, 2021	Feb DISC
AB		18MG	A079021	002	Feb 18, 2021	Feb NEWA
	@	25MG	A079021	003	Feb 18, 2021	Feb DISC
AB		25MG	A079021	003	Feb 18, 2021	Feb NEWA
	@	40MG	A079021	004	Feb 18, 2021	Feb DISC
AB		40MG	A079021	004	Feb 18, 2021	Feb NEWA
	@	60MG	A079021	005	Feb 18, 2021	Feb DISC
AB		60MG	A079021	005	Feb 18, 2021	Feb NEWA
	@	80MG	A079021	006	Feb 18, 2021	Feb DISC
AB		80MG	A079021	006	Feb 18, 2021	Feb NEWA
	@	100MG	A079021	007	Feb 18, 2021	Feb DISC
AB		100MG	A079021	007	Feb 18, 2021	Feb NEWA

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ALKEM LABS LTD	EQ 10MG BASE	A209288	001	Dec 21, 2018	Jan CAHN
AB		EQ 20MG BASE	A209288	002	Dec 21, 2018	Jan CAHN
AB		EQ 40MG BASE	A209288	003	Dec 21, 2018	Jan CAHN
AB		EQ 80MG BASE	A209288	004	Dec 21, 2018	Jan CAHN
>A> AB	AUGUST	EQ 10MG BASE	A214969	001	Sep 02, 2021	Aug NEWA
>A> AB		EQ 20MG BASE	A214969	002	Sep 02, 2021	Aug NEWA
>A> AB		EQ 40MG BASE	A214969	003	Sep 02, 2021	Aug NEWA
>A> AB		EQ 80MG BASE	A214969	004	Sep 02, 2021	Aug NEWA
AB	DR REDDYS LABS LTD	EQ 10MG BASE	A214659	001	Jul 14, 2021	Jul NEWA
AB		EQ 20MG BASE	A214659	002	Jul 14, 2021	Jul NEWA
AB		EQ 40MG BASE	A214659	003	Jul 14, 2021	Jul NEWA
AB		EQ 80MG BASE	A214659	004	Jul 14, 2021	Jul NEWA

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

EZETIMIBE AND ATORVASTATIN CALCIUM

@ SCOV3	EQ 10MG BASE;10MG	A206084	001	Apr 26, 2017	Jul CAHN	
@	EQ 20MG BASE;10MG	A206084	002	Apr 26, 2017	Jul CAHN	
@	EQ 40MG BASE;10MG	A206084	003	Apr 26, 2017	Jul CAHN	
@	EQ 80MG BASE;10MG	A206084	004	Apr 26, 2017	Jul CAHN	
LIPTRUZET						
+ @ ORGANON	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	Feb CAHN	
+ @	EQ 20MG BASE;10MG	N200153	002	May 03, 2013	Feb CAHN	
+ @	EQ 40MG BASE;10MG	N200153	003	May 03, 2013	Feb CAHN	
+ @	EQ 80MG BASE;10MG	N200153	004	May 03, 2013	Feb CAHN	

ATOVAQUONE

SUSPENSION;ORAL

ATOVAQUONE

AB	BIONPHARMA INC	750MG/5ML	A212918	001	Mar 30, 2021	Mar NEWA
----	----------------	-----------	---------	-----	--------------	----------

ATROPINE SULFATE

SOLUTION;INTRAVENOUS

ATROPINE SULFATE

AP	ACCORD HLTHCARE	0.25MG/5ML (0.05MG/ML)	A212868	001	Jul 26, 2021	Jul NFTG
AP		0.5MG/5ML (0.1MG/ML)	A212868	002	Jul 26, 2021	Jul NFTG
AP		1MG/10ML (0.1MG/ML)	A212868	003	Jul 26, 2021	Jul NEWA
AP	+! HOSPIRA	1MG/10ML (0.1MG/ML)	N021146	003	Jul 09, 2001	Jul CTEC
AP	+!	1MG/10ML (0.1MG/ML)	N021146	005	Aug 17, 2017	Mar CTEC
AP	INTL MEDICATION SYS	1MG/10ML (0.1MG/ML)	A212461	001	Oct 05, 2020	Mar CTEC
SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL						
ATROPINE SULFATE						
AP	ACCORD HLTHCARE	8MG/20ML (0.4MG/ML)	A213424	001	Mar 19, 2021	Mar NFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

AA WINDER LABS LLC 0.025MG;2.5MG A211362 001 Jan 27, 2021 Jan NEWA

ATROPINE SULFATE; EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION

ENLON-PLUS

+ @ MYLAN 0.14MG/ML;10MG/ML N019678 001 Nov 06, 1991 Jan CAHN

AVAPRITINIB

TABLET; ORAL

AYVAKIT

+ BLUEPRINT MEDICINES 25MG N212608 004 Jun 16, 2021 Jun NEWA  
+ 50MG N212608 005 Jun 16, 2021 Jun NEWAAVIBACTAM SODIUM; CEFTAZIDIME

POWDER; INTRAVENOUS

AVYCAZ

+! ALLERGAN EQ 0.5GM BASE;2GM/VIAL N206494 001 Feb 25, 2015 Jan CDFR

AZELASTINE HYDROCHLORIDE

SPRAY, METERED; NASAL

ASTELIN

>D> AB	+! MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N020114	001	Nov 01, 1996	Aug CPOT
>A> AB	+!	0.137MG/SPRAY	N020114	001	Nov 01, 1996	Aug CPOT
	ASTEPRO					
>D>	@ MYLAN SPECIALITY LP	EQ 0.125MG BASE/SPRAY	N022203	001	Oct 15, 2008	Aug CPOT
>A>	@	0.137MG/SPRAY	N022203	001	Oct 15, 2008	Aug CPOT
	+ @	0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Jul DISC
AB	+!	0.2055MG/SPRAY	N022203	002	Aug 31, 2009	Jul CPOT
	AZELASTINE HYDROCHLORIDE					
>D> AB	AKORN	EQ 0.125MG BASE/SPRAY	A207610	001	May 17, 2019	Aug CPOT
>A> AB		0.137MG/SPRAY	A207610	001	May 17, 2019	Aug CPOT
>D> AB		EQ 0.1876MG BASE/SPRAY	A210032	001	Aug 23, 2019	Aug CPOT
>A> AB		0.2055MG/SPRAY	A210032	001	Aug 23, 2019	Aug CPOT
>D> AB	ALKEM LABS LTD	EQ 0.125MG BASE/SPRAY	A208156	001	Aug 18, 2017	Aug CPOT
>A> AB		0.137MG/SPRAY	A208156	001	Aug 18, 2017	Aug CPOT
>D> AB	AMNEAL	EQ 0.125MG BASE/SPRAY	A204660	001	Aug 28, 2017	Aug CPOT
>A> AB		0.137MG/SPRAY	A204660	001	Aug 28, 2017	Aug CPOT
>D> AB		EQ 0.1876MG BASE/SPRAY	A208199	001	Dec 15, 2017	Aug CPOT
>A> AB		0.2055MG/SPRAY	A208199	001	Dec 15, 2017	Aug CPOT
>D> AB	APOTEX INC	EQ 0.125MG BASE/SPRAY	A077954	001	Apr 30, 2009	Aug CPOT
>A> AB		0.137MG/SPRAY	A077954	001	Apr 30, 2009	Aug CPOT
>D> AB		EQ 0.1876MG BASE/SPRAY	A201846	001	Aug 31, 2012	Aug CPOT
>A> AB		0.2055MG/SPRAY	A201846	001	Aug 31, 2012	Aug CPOT
>D> AB	AUROBINDO PHARMA LTD	EQ 0.125MG BASE/SPRAY	A212289	001	May 08, 2020	Aug CPOT
>A> AB		0.137MG/SPRAY	A212289	001	May 08, 2020	Aug CPOT
>D> AB		EQ 0.1876MG BASE/SPRAY	A212775	001	Nov 12, 2020	Aug CPOT
>A> AB		0.2055MG/SPRAY	A212775	001	Nov 12, 2020	Aug CPOT
>A> AB	BRECKENRIDGE	0.137MG/SPRAY	A090176	001	Jul 28, 2015	Aug CPOT
>D> AB		EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Aug CPOT
>D> AB	HIKMA	EQ 0.125MG BASE/SPRAY	A091444	001	Oct 24, 2014	Aug CPOT
>D> AB		EQ 0.1876MG BASE/SPRAY	A207243	001	Sep 22, 2017	Aug CPOT
>A> AB	HIKMA PHARMS	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Aug CPOT
>A> AB		0.2055MG/SPRAY	A207243	001	Sep 22, 2017	Aug CPOT
>D> AB	SUN PHARM	EQ 0.125MG BASE/SPRAY	A090423	001	May 23, 2012	Aug CPOT
>A> AB		0.137MG/SPRAY	A090423	001	May 23, 2012	Aug CPOT
>A> AB	UPSHER SMITH LABS	0.137MG/SPRAY	A202609	001	Mar 17, 2017	Aug CPOT
>D> AB		EQ 0.125MG BASE/SPRAY	A202609	001	Mar 17, 2017	Aug CPOT
>D> AB	ZYDUS PHARMS	EQ 0.125MG BASE/SPRAY	A091409	001	Aug 14, 2017	Aug CPOT
>A> AB		0.137MG/SPRAY	A091409	001	Aug 14, 2017	Aug CPOT

AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE

>A> AB	APOTEX	0.137MG/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017	Aug CPOT
>D> AB		EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A207712	001	Apr 28, 2017	Aug CPOT
>D> AB	PADAGIS ISRAEL	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A208111	001	Feb 18, 2021	Aug CPOT
>A> AB		0.137MG/SPRAY;0.05MG/SPRAY	A208111	001	Feb 18, 2021	Aug CPOT
AB	PERRIGO UK FINCO	EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY	A208111	001	Feb 18, 2021	Feb NEWA

SPRAY, METERED;NASAL  
DYMISTA

>D> AB +! MYLAN SPECIALITY LP EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY N202236 001 May 01, 2012 Aug CPOT  
>A> AB +! 0.137MG/SPRAY;0.05MG/SPRAY N202236 001 May 01, 2012 Aug CPOT

AZITHROMYCIN

FOR SUSPENSION;ORAL  
AZITHROMYCIN

AB TARO	EQ 200MG BASE/5ML	A211521	001	Dec 11, 2019	Feb CMFD
INJECTABLE; INJECTION					
AZITHROMYCIN					
@ MYLAN ASI	EQ 500MG BASE/VIAL	A065506	001	Mar 24, 2009	Feb DISC
TABLET;ORAL					
AZITHROMYCIN					
AB ALEMBIC PHARMS LTD	EQ 600MG BASE	A211793	001	Jan 27, 2020	Jul CMFD
AB YUNG SHIN PHARM	EQ 500MG BASE	A211318	001	Mar 17, 2021	Mar NEWA
	EQ 600MG BASE	A211068	001	May 08, 2020	Feb CMFD

BACITRACIN

INJECTABLE; INJECTION  
BACITRACIN  
@ XELLIA PHARMS APS 50,000 UNITS/VIAL

A203177 001 Aug 25, 2014 Jun DISC

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;TOPICAL  
CORTISPORIN  
+ @ MONARCH PHARMS 400 UNITS/GM;1%;EQ 3.5MG  
BASE/GM;5,000 UNITS/GM

N050168 002 May 04, 1984 Jul DISC

BACLOFEN

INJECTABLE;INTRATHECAL  
BACLOFEN

AP MAIA PHARMS INC	0.05MG/ML	A210777	001	Jan 15, 2021	Jan NEWA
>D> @	0.5MG/ML	A210048	001	Sep 11, 2019	Aug CMFD
>A> AP	0.5MG/ML	A210048	001	Sep 11, 2019	Aug CMFD
>D> @	2MG/ML	A210048	002	Sep 11, 2019	Aug CMFD
>A> AP	2MG/ML	A210048	002	Sep 11, 2019	Aug CMFD

## GABLOFEN

AP +! PIRAMAL CRITICAL	0.05MG/ML	N022462	001	Nov 19, 2010	Mar CHRS
AP +	0.05MG/ML	N022462	001	Nov 19, 2010	Mar CRLD
AP +!	0.5MG/ML	N022462	002	Nov 19, 2010	Mar CHRS
AP +	0.5MG/ML	N022462	002	Nov 19, 2010	Mar CRLD
AP +!	2MG/ML	N022462	003	Nov 19, 2010	Mar CHRS
AP +	2MG/ML	N022462	003	Nov 19, 2010	Mar CRLD

TABLET;ORAL  
BACLOFEN

AB AUROBINDO PHARMA LTD	10MG	A214099	001	Jul 13, 2021	Jul NEWA
AB	20MG	A214099	002	Jul 13, 2021	Jul NEWA
AB BEXIMCO PHARMS USA	10MG	A214114	001	Jul 16, 2021	Jul NEWA
AB	20MG	A214114	002	Jul 16, 2021	Jul NEWA
AB IMPAX	5MG	A077971	003	Jul 07, 2021	Jun NEWA
AB	10MG	A077971	001	Oct 26, 2007	Jun CAHN
AB	20MG	A077971	002	Oct 26, 2007	Jun CAHN
AB INNOGENIX	5MG	A212378	003	Apr 30, 2021	Apr NEWA
AB KARTHA	5MG	A214374	001	Mar 05, 2021	Feb NEWA
AB	10MG	A214374	002	Mar 05, 2021	Feb NEWA
AB	20MG	A214374	003	Mar 05, 2021	Feb NEWA

TABLET, ORALLY DISINTEGRATING;ORAL  
KEMSTRO

+ @ UCB INC	10MG	N021589	001	Oct 30, 2003	May CRLD
+ @	20MG	N021589	002	Oct 30, 2003	May CRLD

BALOXAVIR MARBOXIL

TABLET;ORAL  
XOFLUZA  
+ GENENTECH INC 80MG

N210854 003 Mar 18, 2021 Mar NEWA

BELUMOSUDIL MESYLATE

TABLET;ORAL  
REZUROCK  
+! KADMON PHARMS LLC EQ 200MG BASE

N214783 001 Jul 16, 2021 Jul NEWA

>A> **BELZUTIFAN**

>A> TABLET;ORAL  
>A> WELIREG  
>A> +! MERCK SHARP DOHME 40MG

N215383 001 Aug 13, 2021 Aug NEWA

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL  
BENAZEPRIL HYDROCHLORIDE

>A> AB CADILA 5MG	A078848 001 May 23, 2008 Aug CAHN
>A> AB 10MG	A078848 002 May 23, 2008 Aug CAHN
>A> AB 20MG	A078848 003 May 23, 2008 Aug CAHN
>A> AB 40MG	A078848 004 May 23, 2008 Aug CAHN
>D> AB ZYDUS PHARMS USA 5MG	A078848 001 May 23, 2008 Aug CAHN
>D> AB 10MG	A078848 002 May 23, 2008 Aug CAHN
>D> AB 20MG	A078848 003 May 23, 2008 Aug CAHN
>D> AB 40MG	A078848 004 May 23, 2008 Aug CAHN
LOTENSIN	
AB + VALIDUS PHARMS 5MG	N019851 001 Jun 25, 1991 Feb CAHN
AB + 10MG	N019851 002 Jun 25, 1991 Feb CAHN
AB + 20MG	N019851 003 Jun 25, 1991 Feb CAHN
AB +! 40MG	N019851 004 Jun 25, 1991 Feb CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLORTIAZIDE

TABLET;ORAL  
BENAZEPRIL HYDROCHLORIDE AND HYDROCHLORTIAZIDE

@ MYLAN 5MG;6.25MG	A076688 001 Feb 11, 2004 Jul DISC
@ 10MG;12.5MG	A076688 002 Feb 11, 2004 Jul DISC
@ 20MG;12.5MG	A076688 003 Feb 11, 2004 Jul DISC
@ 20MG;25MG	A076688 004 Feb 11, 2004 Jul DISC
SANDOZ 5MG;6.25MG	A076631 001 Feb 11, 2004 Jul CTEC
LOTENSIN HCT	
+ @ VALIDUS PHARMS 5MG;6.25MG	N020033 001 May 19, 1992 Feb CAHN
AB + 10MG;12.5MG	N020033 002 May 19, 1992 Feb CAHN
AB + 20MG;12.5MG	N020033 004 May 19, 1992 Feb CAHN
AB +! 20MG;25MG	N020033 003 May 19, 1992 Feb CAHN

BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM

SOLUTION/DROPS;OPHTHALMIC  
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE  
+! BAUSCH LOMB IRELAND 0.4%;0.3%

N211039 001 Mar 09, 2020 May CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL  
CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE  
AB ENCUBE 5%;1.2%  
DUAC  
AB + STIEFEL 5%;1.2%

A212433 001 Apr 28, 2021 Apr NEWA  
N050741 001 Aug 26, 2002 Jan CHRS

BENZOYL PEROXIDE; TRETINOIN

CREAM;TOPICAL  
TWYNEO  
+! SOL-GEL TECHNOLOGIES 3%;0.1%

N214902 001 Jul 26, 2021 Jul NEWA

BEPOTASTINE BESILATE

SOLUTION/DROPS;OPHTHALMIC  
BEPOTASTINE BESILATE

AT APOTEX 1.5%	A206066 001 Mar 05, 2019 May CMFD
AT MYLAN 1.5%	A206220 001 Mar 18, 2019 May CMFD
BEPREVE	
AT +! BAUSCH AND LOMB INC 1.5%	N022288 001 Sep 08, 2009 May CTEC

BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

CELESTONE SOLUSPAN

>D>	AB	+!	MERCK SHARP DOHME	3MG/ML; EQ 3MG BASE/ML	N014602	001	Aug CAHN
>A>	AB	+!	ORGANON	3MG/ML; EQ 3MG BASE/ML	N014602	001	Aug CAHN

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

@ PHARMGEN EQ 0.05% BASE A070274 001 Aug 12, 1985 May CAHN

SPRAY; TOPICAL

SERNIVO

+! PRIMUS PHARMS

EQ 0.05% BASE/SPRAY N208079 001 Feb 05, 2016 Mar CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	!	TARO	EQ 0.05% BASE; 1%	A076493	001	Jul 28, 2004	Feb CHRS
	+	@ MERCK SHARP DOHME	EQ 0.05% BASE; 1%	N020010	001	Dec 08, 2000	Feb DISC

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

>A>	AT	ACELLA	EQ 0.5% BASE	A078694	001	Nov 16, 2009	Aug CAHN
>D>	AT	WOCKHARDT	EQ 0.5% BASE	A078694	001	Nov 16, 2009	Aug CAHN

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

@ WOCKHARDT 5MG A040532 001 Sep 29, 2003 Jan DISC

@ 50MG A040518 001 Sep 29, 2003 Jan DISC

URECHOLINE

>D>	@ ODYSSEY PHARMS	10MG	A088440	001	May 29, 1984	Aug CRLD
>A>	+ @	10MG	A088440	001	May 29, 1984	Aug CRLD
>D>	@	25MG	A088441	001	May 29, 1984	Aug CRLD
>A>	+ @	25MG	A088441	001	May 29, 1984	Aug CRLD

BEXAROTENE

CAPSULE; ORAL

BEXAROTENE

AB	TEVA PHARMS USA	75MG	A209931	001	Jan 14, 2021	Jan NEWA
----	-----------------	------	---------	-----	--------------	----------

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

BIMATOPROST

AT	!	AKORN	0.03%	A203299	001	Nov 08, 2018	Feb CAHN
AT	!	ALEMBIC PHARMS LTD	0.03%	A210263	001	Apr 12, 2019	Jan CHRS
AT	!	LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Jan CHRS

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	UNICHEM	5MG	A078635	001	Aug 18, 2009	Apr CAHN
AB	!	10MG	A078635	002	Aug 18, 2009	Apr CAHN

BIVALIRUDIN

INJECTABLE; INTRAVENOUS

BIVALIRUDIN

AP	HAINAN POLY PHARM	250MG/VIAL	A213078	001	May 28, 2021	May NEWA
----	-------------------	------------	---------	-----	--------------	----------

BLEOMYCIN SULFATE

INJECTABLE; INJECTION

BLEOMYCIN SULFATE

>D>	AP	CIPILA	EQ 15 UNITS BASE/VIAL	A209439	001	Mar 11, 2019	Aug DISC
>A>		@	EQ 15 UNITS BASE/VIAL	A209439	001	Mar 11, 2019	Aug DISC

BORTEZOMIB

INJECTABLE; INTRAVENOUS, SUBCUTANEOUS  
VELCADE  
+! TAKEDA PHARMS USA 3.5MG/VIAL

N021602 001 May 13, 2003 May CAHN

BOSENTAN

TABLET; ORAL  
BOSENTAN

>D> AB	ALEMBIC PHARMS LTD	62.5MG	A211461	001	Jan 23, 2020	Aug DISC
>A>	@	62.5MG	A211461	001	Jan 23, 2020	Aug DISC
AB		62.5MG	A211461	001	Jan 23, 2020	May CMFD
>D> AB		125MG	A211461	002	Jan 23, 2020	Aug DISC
>A>	@	125MG	A211461	002	Jan 23, 2020	Aug DISC
AB		125MG	A211461	002	Jan 23, 2020	May CMFD
TRACLEER						
AB	+ ACTELION	62.5MG	N021290	001	Nov 20, 2001	Feb CAHN
AB	+!	125MG	N021290	002	Nov 20, 2001	Feb CAHN
TABLET, FOR SUSPENSION; ORAL						
TRACLEER						
+! ACTELION		32MG	N209279	001	Sep 05, 2017	Feb CAHN

BRIGATINIB

TABLET; ORAL  
ALUNBRIG

+ TAKEDA PHARMS USA	30MG	N208772	001	Apr 28, 2017	May CAHN
+	90MG	N208772	002	Apr 28, 2017	May CAHN
+!	180MG	N208772	003	Oct 02, 2017	May CAHN

BRINCIDOFUVIR

SUSPENSION; ORAL

TEMBEXA						
+! CHIMERIX	10MG/ML	N214460	001	Jun 04, 2021	Jun NEWA	
TABLET; ORAL						
TEMBEXA						
+! CHIMERIX	100MG	N214461	001	Jun 04, 2021	Jun NEWA	

BRINZOLAMIDE

SUSPENSION/DROPS; OPHTHALMIC  
BRINZOLAMIDE

>A> AB	BAUSCH	1%	A204884	001	Aug 18, 2021	Aug NEWA
--------	--------	----	---------	-----	--------------	----------

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL  
PARLODEL

AB	+ VALIDUS PHARMS	EQ 5MG BASE	N017962	002	Mar 01, 1982	Feb CAHN
TABLET; ORAL						
AB	+ VALIDUS PHARMS	EQ 2.5MG BASE	N017962	001		Feb CAHN

BUDESONIDE

CAPSULE, DELAYED RELEASE; ORAL  
BUDESONIDE

AB	@ ALVOGEN	3MG	A206724	001	Nov 23, 2016	Apr CDFR
AB	AMNEAL PHARMS	3MG	A206200	001	Jul 31, 2017	Apr CDFR
AB	MAYNE PHARMA	3MG	A206623	001	Apr 08, 2016	Apr CDFR
AB	MYLAN	3MG	A090410	001	May 16, 2011	Apr CDFR
AB	RISING	3MG	A207367	001	Apr 07, 2017	Apr CDFR
AB	SCIECURE PHARMA INC	3MG	A209041	001	Sep 28, 2017	Apr CDFR
AB	ZYDUS PHARMS	3MG	A206134	001	May 04, 2017	Apr CDFR
SUSPENSION; INHALATION						
BUDESONIDE						
AN	SUN PHARM	0.25MG/2ML	A211922	001	Apr 14, 2021	Apr NEWA
AN		0.5MG/2ML	A211922	002	Apr 14, 2021	Apr NEWA
AN		1MG/2ML	A211922	003	Apr 14, 2021	Apr NEWA

BUPIVACAINE

SOLUTION, EXTENDED RELEASE; INFILTRATION

POSIMIR

+ @ DURECT	660MG/5ML (132MG/ML)
+!	660MG/5ML (132MG/ML)

N204803	001	Feb 01, 2021	Mar DISC
N204803	001	Feb 01, 2021	Feb NEWA

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

BUPIVACAINE HYDROCHLORIDE

AP HIKMA PHARMS	0.25%	A205141	001	Feb 11, 2021	Feb NEWA
AP	0.5%	A205141	002	Feb 11, 2021	Feb NEWA
	BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE				
AP HIKMA PHARMS	0.25%	A204842	001	Feb 11, 2021	Feb NEWA
AP	0.5%	A204842	002	Feb 11, 2021	Feb NEWA
AP	0.75%	A204842	003	Feb 11, 2021	Feb NEWA

BUPIVACAINE; MELOXICAM

SOLUTION, EXTENDED RELEASE; PERIARTICULAR

ZYNRELEF KIT

+! HERON THERAPS INC	60MG/2.3ML (29.25MG/ML); 1.8MG/2.3ML	N211988	001	May 12, 2021	Jun NEWA
+!	200MG/7ML (29.25MG/ML); 6MG/7ML (0.88MG/ML)	N211988	002	May 12, 2021	Jun NEWA
+!	300MG/10.5ML (29.25MG/ML); 9MG/10.5ML	N211988	003	May 12, 2021	Jun NEWA
+!	400MG/14ML (29.25MG/ML); 12MG/14ML (0.88MG/ML)	N211988	004	May 12, 2021	Jun NEWA

BUPRENORPHINE

FILM, EXTENDED RELEASE; TRANSDERMAL

BUPRENORPHINE

>A>	@ MYLAN TECH VIATRIS	5MCG/HR	A210162	001	May 03, 2021	Aug DISC
>A>	@	5MCG/HR	A210162	001	May 03, 2021	Aug DISC
>A>	@	7.5MCG/HR	A210162	002	May 03, 2021	Aug DISC
>A>	@	7.5MCG/HR	A210162	002	May 03, 2021	Aug DISC
>A>	@	10MCG/HR	A210162	003	May 03, 2021	Aug DISC
>A>	@	10MCG/HR	A210162	003	May 03, 2021	Aug DISC
>A>	@	15MCG/HR	A210162	004	May 03, 2021	Aug DISC
>A>	@	15MCG/HR	A210162	004	May 03, 2021	Aug DISC
>A>	@	20MCG/HR	A210162	005	May 03, 2021	Aug DISC
>A>	@	20MCG/HR	A210162	005	May 03, 2021	Aug DISC
>D> AB MYLAN TECHNOLOGIES	5MCG/HR	A210162	001	May 03, 2021	Aug DISC	
AB	5MCG/HR	A210162	001	May 03, 2021	Apr NEWA	
>D> AB AB	7.5MCG/HR	A210162	002	May 03, 2021	Aug DISC	
>D> AB AB	7.5MCG/HR	A210162	002	May 03, 2021	Apr NEWA	
>D> AB AB	10MCG/HR	A210162	003	May 03, 2021	Aug DISC	
>D> AB AB	10MCG/HR	A210162	003	May 03, 2021	Apr NEWA	
>D> AB AB	15MCG/HR	A210162	004	May 03, 2021	Aug DISC	
>D> AB AB	15MCG/HR	A210162	004	May 03, 2021	Apr NEWA	
>D> AB AB	20MCG/HR	A210162	005	May 03, 2021	Aug DISC	
AB WATSON LABS TEVA	20MCG/HR	A210162	005	May 03, 2021	Apr NEWA	
AB	7.5MCG/HR	A204937	005	Jun 29, 2021	Jun NEWA	

BUPRENORPHINE HYDROCHLORIDE

FILM; Buccal

BUPRENORPHINE HYDROCHLORIDE

>D> AB ALVOGEN	EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Aug CAHN
>A> AB AB	EQ 0.075MG BASE	A211594	001	Aug 03, 2021	Aug CAHN
>D> AB AB	EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Jul NFTG
>A> AB AB	EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Aug CAHN
>D> AB AB	EQ 0.15MG BASE	A211594	002	Aug 03, 2021	Jul NFTG
>D> AB AB	EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Aug CAHN
>A> AB AB	EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Aug CAHN
>D> AB AB	EQ 0.3MG BASE	A211594	003	Aug 03, 2021	Jul NFTG
>D> AB AB	EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Aug CAHN
>A> AB AB	EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Aug CAHN
>D> AB AB	EQ 0.45MG BASE	A211594	004	Aug 03, 2021	Jul NFTG
>D> AB AB	EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Aug CAHN
>A> AB AB	EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Aug CAHN
>D> AB AB	EQ 0.6MG BASE	A211594	005	Aug 03, 2021	Jul NFTG
>D> AB AB	EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Aug CAHN
>A> AB AB	EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Aug CAHN

FILM;BUCCALBUPRENORPHINE HYDROCHLORIDE

AB		EQ 0.75MG BASE	A211594	006	Aug 03, 2021	Jul NFTG
>D>	AB	EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Aug CAHN
>A>	AB	EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Aug CAHN
AB		EQ 0.9MG BASE	A211594	007	Aug 03, 2021	Jul NFTG

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDETABLET;SUBLINGUALBUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB	ALKEM LABS LTD	EQ 2MG BASE;EQ 0.5MG BASE	A214930	001	Jun 15, 2021	Jun NEWA
AB		EQ 8MG BASE;EQ 2MG BASE	A214930	002	Jun 15, 2021	Jun NEWA
	@ MAYNE PHARMA INC	EQ 2MG BASE;EQ 0.5MG BASE	A206953	001	Jul 17, 2020	Jan DISC
	@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Jul DISC
AB		EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	May CMFD
	@	EQ 8MG BASE;EQ 2MG BASE	A206953	002	Jul 17, 2020	Jan DISC
AB	RHODES PHARMS	EQ 2MG BASE;EQ 0.5MG BASE	A205601	001	Mar 30, 2020	Jul CMFD
AB		EQ 8MG BASE;EQ 2MG BASE	A205601	002	Mar 30, 2020	Jul CMFD

BUPROPION HYDROBROMIDETABLET, EXTENDED RELEASE;ORALAPLENZIN

+	BAUSCH	174MG	N022108	001	Apr 23, 2008	Feb CAHN
+		348MG	N022108	002	Apr 23, 2008	Feb CAHN
+!		522MG	N022108	003	Apr 23, 2008	Feb CAHN

BUPROPION HYDROCHLORIDETABLET;ORALBUPROPION HYDROCHLORIDE

>D>	AB	MYLAN	75MG	A075491	001	Apr 17, 2000	Aug DISC
>A>		@	75MG	A075491	001	Apr 17, 2000	Aug DISC
>D>	AB		100MG	A075491	002	Apr 17, 2000	Aug DISC
>A>		@	100MG	A075491	002	Apr 17, 2000	Aug DISC

TABLET, EXTENDED RELEASE;ORALBUPROPION HYDROCHLORIDE

>D>	AB3	IMPAK LABS	150MG	A077415	001	Nov 26, 2008	Aug DISC
>A>		@	150MG	A077415	001	Nov 26, 2008	Aug DISC
>D>	AB1		200MG	A076711	001	Dec 03, 2004	Aug DISC
>A>		@	200MG	A076711	001	Dec 03, 2004	Aug DISC
		@ TORRENT	100MG	A203969	001	Oct 31, 2014	Jan DISC
		@	150MG	A203969	002	Oct 31, 2014	Jan DISC
		@	200MG	A203969	003	Oct 31, 2014	Jan DISC
			WELLBUTRIN XL				
AB3	+	BAUSCH	150MG	N021515	001	Aug 28, 2003	Feb CAHN
AB3	+	!	300MG	N021515	002	Aug 28, 2003	Feb CAHN

BUSPIRONE HYDROCHLORIDETABLET;ORALBUSPIRONE HYDROCHLORIDE

AB	RUBICON	5MG	A075521	001	Apr 05, 2002	Feb CMFD
AB		7.5MG	A075521	004	Mar 16, 2021	Mar NEWA
AB		10MG	A075521	002	Apr 05, 2002	Feb CMFD
AB		15MG	A075521	003	Apr 05, 2002	Feb CMFD
AB		30MG	A075521	005	Mar 16, 2021	Mar NEWA

BUSULFANINJECTABLE;INJECTIONBUSULFAN

AP	AM REGENT	6MG/ML	A202259	001	Dec 22, 2015	Feb CAHN
----	-----------	--------	---------	-----	--------------	----------

BUTABARBITAL SODIUMTABLET;ORALBUTABARBITAL SODIUM

>D>		@ SANDOZ	15MG	A085938	001	Aug CRLD
>A>		+ @	15MG	A085938	001	Aug CRLD

CABERGOLINETABLET;ORALDOSTINEX

+ @	PFIZER	0.5MG	N020664	001	Dec 23, 1996	Jan CAHN
-----	--------	-------	---------	-----	--------------	----------

CABOTEGRAVIR SODIUM

TABLET;ORAL  
VOCABRIA  
+! VIIV HLTHCARE EQ 30MG BASE N212887 001 Jan 21, 2021 Jan NEWA

CABOTEGRAVIR; RILPIVIRINE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR  
CABENUVA KIT  
+! VIIV HLTHCARE 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) N212888 001 Jan 21, 2021 Jan NEWA  
+! 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) N212888 002 Jan 21, 2021 Jan NEWA

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS  
CAF'CIT  
AP +! HIKMA PHARMS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 001 Sep 21, 1999 Jul CAHN  
SOLUTION;ORAL  
CAF'CIT  
AA +! HIKMA PHARMS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N020793 002 Apr 12, 2000 Jul CAHN

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL  
CAFERGOT  
>D> @ SANDOZ 100MG;1MG A084294 001 Aug CRLD  
>A> + @ 100MG;1MG A084294 001 Aug CRLD  
@ 100MG;1MG A084294 001 Jul DISC  
ERGOTAMINE TARTRATE AND CAFFEINE  
! MIKART 100MG;1MG A040590 001 Sep 16, 2005 Jul CHRS  
100MG;1MG A040590 001 Sep 16, 2005 Jul CTEC

CALCITONIN SALMON

INJECTABLE;INJECTION  
CALCITONIN-SALMON  
AP CUSTOPHARM INC 200 IU/ML A212416 001 May 14, 2021 May NFTG

CALCIUM ACETATE

TABLET;ORAL  
CALCIUM ACETATE  
AB ! CHARTWELL MOLECULAR 667MG A202420 001 Feb 05, 2013 Apr CHRS

CALCIUM CARBONATE; RISEDRONATE SODIUM

TABLET;ORAL  
ACTONEL WITH CALCIUM (COPACKAGED)  
+ @ WARNER CHILCOTT EQ 500MG BASE;35MG N021823 001 Aug 12, 2005 Jul CPOT  
+ @ EQ 500MG BASE,N/A;N/A,35MG N021823 001 Aug 12, 2005 Jul CDFR

CALCIUM GLUCEPTATE

INJECTABLE;INJECTION  
CALCIUM GLUCEPTATE  
>D> @ ABBOTT EQ 90MG CALCIUM/5ML A080001 001 Aug CRLD  
>A> + @ EQ 90MG CALCIUM/5ML A080001 001 Aug CRLD

CALCIUM GLUCONATE

SOLUTION;INTRAVENOUS  
CALCIUM GLUCONATE IN SODIUM CHLORIDE  
>A> +! FRESENIUS KABI USA 1GM/50ML (20MG/ML) N208418 004 Jun 17, 2021 Aug NEWA  
>A> +! 2GM/100ML (20MG/ML) N208418 005 Jun 17, 2021 Aug NEWA  
+! HQ SPCLT PHARMA 1GM/100ML (10MG/ML) N210906 003 Jun 04, 2021 Jun NEWA

CAPREOMYCIN SULFATE

INJECTABLE;INJECTION  
CAPASTAT SULFATE  
+ @ AKORN EQ 1GM BASE/VIAL N050095 001 Jun DISC

CAPTOPRIL

TABLET;ORAL  
Captopril  
AB ANNORA PHARMA 12.5MG A074737 001 Oct 28, 1998 Jul CMFD  
AB 25MG A074737 002 Oct 28, 1998 Jul CMFD  
AB 50MG A074737 003 Oct 28, 1998 Jul CMFD

TABLET;ORAL  
CAPTOPRIL

AB 100MG A074737 004 Oct 28, 1998 Jul CMFD

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL  
Captopril And Hydrochlorothiazide

>D>	MYLAN	25MG;15MG	A074896	001	Dec 29, 1997	Aug CAHN
>A>	@	25MG;15MG	A074896	001	Dec 29, 1997	Aug CAHN
>D>	!	25MG;25MG	A074896	002	Dec 29, 1997	Aug CAHN
>A>	@	25MG;25MG	A074896	002	Dec 29, 1997	Aug CAHN
>D>	!	50MG;15MG	A074896	004	Dec 29, 1997	Aug CAHN
>A>	@	50MG;15MG	A074896	004	Dec 29, 1997	Aug CAHN
>D>		50MG;25MG	A074896	003	Dec 29, 1997	Aug CAHN
>A>	@	50MG;25MG	A074896	003	Dec 29, 1997	Aug CAHN

CARBAMAZEPINE

TABLET;ORAL  
CARBAMAZEPINE

>A> AB	VGYAAN	200MG	A214328	001	Aug 16, 2021	Aug NEWA
TABLET, EXTENDED RELEASE;ORAL CARBAMAZEPINE						
AB	CSPC OUYI	100MG	A213311	001	Apr 13, 2021	Apr NEWA
AB		200MG	A213311	002	Apr 13, 2021	Apr NEWA
AB		400MG	A213311	003	Apr 13, 2021	Apr NEWA

CARBIDOPA; LEVODOPA

TABLET;ORAL  
CARBIDOPA AND LEVODOPA

AB	SCIEGEN PHARMS INC	10MG;100MG	A214092	001	May 07, 2021	Apr NEWA
AB		25MG;100MG	A214092	002	May 07, 2021	Apr NEWA
AB		25MG;250MG	A214092	003	May 07, 2021	Apr NEWA
SINEMET						
>D> AB	+	MERCK SHARP DOHME	10MG;100MG	N017555	001	Aug CAHN
>D> AB	+		25MG;100MG	N017555	003	Aug CAHN
>D> AB	+		25MG;250MG	N017555	002	Aug CAHN
>A> AB	+	ORGANON	10MG;100MG	N017555	001	Aug CAHN
>A> AB	+		25MG;100MG	N017555	003	Aug CAHN
>A> AB	+		25MG;250MG	N017555	002	Aug CAHN
TABLET, ORALLY DISINTEGRATING;ORAL CARBIDOPA AND LEVODOPA						
>D> AB	MYLAN	10MG;100MG	A078893	001	Sep 18, 2008	Aug CAHN
>A>	@	10MG;100MG	A078893	001	Sep 18, 2008	Aug CAHN
>D> AB		25MG;100MG	A078893	002	Sep 18, 2008	Aug CAHN
>A>	@	25MG;100MG	A078893	002	Sep 18, 2008	Aug CAHN
>D> AB	!	25MG;250MG	A078893	003	Sep 18, 2008	Aug CAHN
>A>	@	25MG;250MG	A078893	003	Sep 18, 2008	Aug CAHN
>D> AB	SUN PHARM	25MG;250MG	A078690	003	Jul 31, 2009	Aug CTEC
>A>	!	25MG;250MG	A078690	003	Jul 31, 2009	Aug CTEC

CARBOPLATIN

INJECTABLE; INTRAVENOUS  
CARBOPLATIN

AP	! HOSPIRA	50MG/5ML (10MG/ML)	A076517	001	Oct 14, 2004	Mar CHRS
AP	!	150MG/15ML (10MG/ML)	A076517	002	Oct 14, 2004	Mar CHRS
AP	!	450MG/45ML (10MG/ML)	A076517	003	Oct 14, 2004	Mar CHRS
AP	!	600MG/60ML (10MG/ML)	A077059	001	Nov 23, 2004	Mar CHRS
>D> AP	MEITHEAL	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Aug DISC
>A>	@	50MG/5ML (10MG/ML)	A077096	001	Jun 14, 2005	Aug DISC
>D> AP		150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Aug DISC
>A>	@	150MG/15ML (10MG/ML)	A077096	002	Jun 14, 2005	Aug DISC
>D> AP		450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Aug DISC
>A>	@	450MG/45ML (10MG/ML)	A077096	003	Jun 14, 2005	Aug DISC
>D> AP		600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Aug DISC
>A>	@	600MG/60ML (10MG/ML)	A077096	004	Jun 03, 2013	Aug DISC
AP	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Mar CHRS
AP		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Mar CHRS
AP		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Mar CHRS
AP		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Mar CHRS

CARBOPROST TROMETHAMINE

INJECTABLE; INJECTION  
CARBOPROST TROMETHAMINE

AP	SUNNY PHARMTECH INC	EQ 0.25MG BASE/ML	A213118	001	Mar 25, 2021	Mar NEWA
----	---------------------	-------------------	---------	-----	--------------	----------

CARFILZOMIB

POWDER; INTRAVENOUS

>D>	CARFILZOMIB					
>D> AP	BRECKENRIDGE	10MG/VIAL	A209330	001	Jun 11, 2021	Aug DISC
>A> AP	@	10MG/VIAL	A209330	001	Jun 11, 2021	Aug DISC
>D> AP		10MG/VIAL	A209330	001	Jun 11, 2021	Jun NFTG
>D> AP		60MG/VIAL	A209330	002	Jun 11, 2021	Aug DISC
>A> AP	@	60MG/VIAL	A209330	002	Jun 11, 2021	Aug DISC
AP		60MG/VIAL	A209330	002	Jun 11, 2021	Jun NEWA
KYPROLIS						
>D> AP	+ ONYX THERAP	10MG/VIAL	N202714	003	Jun 07, 2018	Aug CTEC
>A> AP	+	10MG/VIAL	N202714	003	Jun 07, 2018	Aug CTEC

CARMUSTINE

INJECTABLE; INJECTION  
BICNU

>A> AP	+! AVET LIFESCIENCES	100MG/VIAL	N017422	001		Aug CAHN
>D> AP	+! EMCURE PHARMS LTD	100MG/VIAL	N017422	001		Aug CAHN
CARMUSTINE						
AP	HONG KONG	100MG/VIAL	A213460	001	Aug 02, 2021	Jul NEWA
AP	JIANGSU HENGRI MED	100MG/VIAL	A211202	001	Mar 12, 2021	Mar NEWA

CARVEDILOL

TABLET; ORAL  
CARVEDILOL

>A>	@ AXELENT PHARMA	3.125MG	A078786	001	Dec 22, 2009	Aug CAHN
>A>	@	6.25MG	A078786	002	Dec 22, 2009	Aug CAHN
>A>	@	12.5MG	A078786	003	Dec 22, 2009	Aug CAHN
>A>	@	25MG	A078786	004	Dec 22, 2009	Aug CAHN
>D>	@ WOCKHARDT LTD	3.125MG	A078786	001	Dec 22, 2009	Aug CAHN
>D>	@	6.25MG	A078786	002	Dec 22, 2009	Aug CAHN
>D>	@	12.5MG	A078786	003	Dec 22, 2009	Aug CAHN
>D>	@	25MG	A078786	004	Dec 22, 2009	Aug CAHN
COREG						
AB	+ WOODWARD	3.125MG	N020297	004	May 29, 1997	Jul CAHN
AB	+	6.25MG	N020297	003	Sep 14, 1995	Jul CAHN
AB	+!	12.5MG	N020297	002	Sep 14, 1995	Jul CAHN
AB	+	25MG	N020297	001	Sep 14, 1995	Jul CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL  
COREG CR

AB	+ WOODWARD	10MG	N022012	001	Oct 20, 2006	Jul CAHN
AB	+	20MG	N022012	002	Oct 20, 2006	Jul CAHN
AB	+!	40MG	N022012	003	Oct 20, 2006	Jul CAHN
AB	+	80MG	N022012	004	Oct 20, 2006	Jul CAHN

CASIMERSEN

SOLUTION; INTRAVENOUS  
AMONDYS 45

+! SAREPTA THERAPS INC	100MG/2ML (50MG/ML)	N213026	001	Feb 25, 2021	Feb NEWA
------------------------	---------------------	---------	-----	--------------	----------

CEFAZOLIN SODIUM

SOLUTION; INTRAVENOUS

CEFAZOLIN IN PLASTIC CONTAINER

+! BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	Mar NEWA
+!	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar CRLD
!	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Mar CHRS

CEFDINIR

CAPSULE;ORAL  
CEFDINIR

AB	ALKEM LABS LTD	300MG	A210220	001	Feb 19, 2021	Feb NEWA
FOR SUSPENSION;ORAL						
CEFDINIR						
AB	ALKEM LABS LTD	125MG/5ML	A210534	001	Feb 19, 2021	Feb NEWA
AB		250MG/5ML	A210534	002	Feb 19, 2021	Feb NEWA

CEFEPIME HYDROCHLORIDE

INJECTABLE;INJECTION  
CEFEPIME HYDROCHLORIDE

@ ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Mar DISC
@	EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Mar DISC

CEFIXIME

FOR SUSPENSION;ORAL  
CEFIXIME

AB	ALKEM LABS LTD	100MG/5ML	A211775	001	Feb 19, 2021	Feb NEWA
AB		200MG/5ML	A211775	002	Feb 19, 2021	Feb NEWA

CEFOTAXIME SODIUM

INJECTABLE;INJECTION  
CLAFORAN

+ @ VALIDUS PHARMS	EQ 500MG BASE/VIAL	N050547	001		Feb CAHN
+ @	EQ 1GM BASE/VIAL	N050547	002		Feb CAHN
+ @	EQ 2GM BASE/VIAL	N050547	003		Feb CAHN
+ @	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Feb CAHN
CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER					
@ VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Feb CAHN
@	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Feb CAHN
CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER					
@ VALIDUS PHARMS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Feb CAHN
@	EQ 40MG BASE/ML	N050596	003	May 20, 1985	Feb CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION  
FORTAZ IN PLASTIC CONTAINER

@ TELIGENT	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Feb CAHN
+ @	EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Feb CAHN
+ @	EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Feb CAHN

CEFUROXIME SODIUM

INJECTABLE;INJECTION  
ZINACEF

AP +! TELIGENT	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Feb CAHN
AP +!	EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Feb CAHN
INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
AP +! TELIGENT	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Feb CAHN

CELECOXIB

CAPSULE;ORAL  
CELEBREX

AB + UPJOHN	50MG	N020998	004	Dec 15, 2006	Apr CAHN
AB +	100MG	N020998	001	Dec 31, 1998	Apr CAHN
AB +	200MG	N020998	002	Dec 31, 1998	Apr CAHN
AB +!	400MG	N020998	003	Aug 29, 2002	Apr CAHN
CELECOXIB					
@ ACIC PHARMS	200MG	A212925	001	Dec 09, 2020	Jun DISC
@	400MG	A212925	002	Dec 09, 2020	Jun DISC
@ JUBILANT GENERICS	50MG	A207061	001	Apr 04, 2017	Jun DISC
@	100MG	A207061	002	Apr 04, 2017	Jun DISC
@	200MG	A207061	003	Apr 04, 2017	Jun DISC
@	400MG	A207061	004	Apr 04, 2017	Jun DISC
AB UNICHEM	50MG	A213301	001	Jan 12, 2021	Jan NEWA
AB	100MG	A213301	002	Jan 12, 2021	Jan NEWA
AB	200MG	A213301	003	Jan 12, 2021	Jan NEWA
AB	400MG	A213301	004	Jan 12, 2021	Jan NEWA
AB YILING	50MG	A211412	001	Mar 06, 2020	Jun CMFD
AB	100MG	A211412	002	Mar 06, 2020	Jun CMFD

CAPSULE;ORAL  
CELECOXIB

AB		200MG	A211412	003	Mar 06, 2020	Jun CMFD
AB		400MG	A211412	004	Mar 06, 2020	Jun CMFD

CENOBAIMATE

TABLET;ORAL  
XCOPRI

+!	SK LIFE	12.5MG	N212839	001	Mar 10, 2020	Jul CHRS
+		200MG	N212839	006	Mar 10, 2020	Jul CHRS

CEPHALEXIN

CAPSULE;ORAL  
CEPHALEXIN

>D>	@ YUNG SHIN PHARM	EQ 250MG BASE	A065152	001	Feb 24, 2005	Aug CMFD
>A> AB		EQ 250MG BASE	A065152	001	Feb 24, 2005	Aug CMFD
	@	EQ 250MG BASE	A065152	001	Feb 24, 2005	Mar DISC
>D>	@	EQ 500MG BASE	A065152	002	Feb 24, 2005	Aug CMFD
>A> AB		EQ 500MG BASE	A065152	002	Feb 24, 2005	Aug CMFD
	@	EQ 500MG BASE	A065152	002	Feb 24, 2005	Mar DISC
	KEFLEX					
	+ @ PRAGMA	EQ 250MG BASE	N050405	002		May DISC
	+ @	EQ 500MG BASE	N050405	003		May DISC

CETIRIZINE HYDROCHLORIDE

## SYRUP;ORAL

## CETIRIZINE HYDROCHLORIDE

>A> AA	MICRO LABS	5MG/5ML	A090191	001	Nov 12, 2009	Aug CAHN
>D> AA	MLV	5MG/5ML	A090191	001	Nov 12, 2009	Aug CAHN
AA	! PADAGIS US	5MG/5ML	A078398	001	Jun 17, 2008	Jul CAHN

CHLORDIAZEPOXIDE HYDROCHLORIDE

## CAPSULE;ORAL

## CHLORDIAZEPOXIDE HYDROCHLORIDE

	@ CHARTWELL RX	5MG	A084678	001		Apr CAHN
	@	10MG	A084041	001		Apr CAHN
	@	25MG	A084679	002		Apr CAHN
>D>	@ UPSHER SMITH LABS	10MG	A084920	001		Aug CRLD
>A>	+ @ LIBRIUM	10MG	A084920	001		Aug CRLD
>D> AB	! VALEANT PHARM INTL	25MG	A085475	001		Aug CRLD
>A> AB	+!	25MG	A085475	001		Aug CRLD

CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE

## CAPSULE;ORAL

## CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

AB	ALKEM LABS LTD	5MG;2.5MG	A214065	001	Apr 26, 2021	Apr NEWA
AB	DR REDDYS	5MG;2.5MG	A214698	001	May 10, 2021	Apr NEWA

CHLORHEXIDINE GLUCONATE

## SOLUTION;DENTAL

## CHLORHEXIDINE GLUCONATE

AT	BAJAJ	0.12%	A075561	001	Nov 14, 2000	Feb CMFD
----	-------	-------	---------	-----	--------------	----------

CHLOROQUINE PHOSPHATE

## TABLET;ORAL

## CHLOROQUINE PHOSPHATE

>A> AA	SUVEN PHARMS	500MG	A214756	001	Sep 03, 2021	Aug NEWA
--------	--------------	-------	---------	-----	--------------	----------

CHLORPROMAZINE HYDROCHLORIDE

## CONCENTRATE;ORAL

## CHLORPROMAZINE HYDROCHLORIDE

	GENUS	30MG/ML	A214542	001	Jun 02, 2021	May NEWA
		100MG/ML	A214542	002	Jun 02, 2021	May NEWA

## TABLET;ORAL

## CHLORPROMAZINE HYDROCHLORIDE

AB	GLENMARK PHARMS LTD	10MG	A212144	001	Mar 23, 2021	Mar NEWA
AB		25MG	A212144	002	Mar 23, 2021	Mar NEWA
AB		50MG	A212144	003	Mar 23, 2021	Mar NEWA
AB		100MG	A212144	004	Mar 23, 2021	Mar NEWA
AB		200MG	A212144	005	Mar 23, 2021	Mar NEWA
AB	LANNETT CO INC	10MG	A212996	001	Jan 22, 2021	Jan NEWA

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB		25MG	A212996	002	Jan 22, 2021	Jan NEWA
AB		50MG	A212996	003	Jan 22, 2021	Jan NEWA
AB		100MG	A212996	004	Jan 22, 2021	Jan NEWA
AB		200MG	A212996	005	Jan 22, 2021	Jan NEWA
	@ MAYNE PHARMA	10MG	A213590	001	Aug 31, 2020	Mar DISC
	@	25MG	A213590	002	Aug 31, 2020	Mar DISC
	@	50MG	A213590	003	Aug 31, 2020	Mar DISC
	@	100MG	A213590	004	Aug 31, 2020	Mar DISC
	@	200MG	A213590	005	Aug 31, 2020	Mar DISC
>D> AB	UPSHER SMITH LABS	10MG	A083386	001		Aug CRLD
>A> AB	+	10MG	A083386	001		Aug CRLD
>D> AB	!	25MG	A084112	001		Aug CRLD
>A> AB	+!	25MG	A084112	001		Aug CRLD
>D> AB		50MG	A084113	001		Aug CRLD
>A> AB	+	50MG	A084113	001		Aug CRLD
>D> AB	!	100MG	A084114	001		Aug CRLD
>A> AB	+!	100MG	A084114	001		Aug CRLD
>D> AB		200MG	A084115	001		Aug CRLD
>A> AB	+	200MG	A084115	001		Aug CRLD

CHLORPROPAMIDETABLET;ORAL  
CHLORPROPAMIDE

@ RISING	100MG	A088725	001	Aug 31, 1984	Jan CAHN
@	250MG	A088726	001	Aug 31, 1984	Jan CAHN

CHLORTHALIDONETABLET;ORAL  
CHLORTHALIDONE

>D> AB	MYLAN	25MG	A086831	002		Aug CRLD
>A> AB	+	25MG	A086831	002		Aug CRLD
>D> AB	!	50MG	A086831	001		Aug CRLD
>A> AB	+!	50MG	A086831	001		Aug CRLD
	THALITONE					
	+ CASPER PHARMA LLC	15MG	N019574	001	Dec 20, 1988	May CMFD
BX	+!	25MG	N019574	002	Feb 12, 1992	May CMFD

CHLORZOXAZONETABLET;ORAL  
CHLORZOXAZONE

>D> AA	HAVIX	250MG	A215158	001	Jul 29, 2021	Aug CAHN
AA		250MG	A215158	001	Jul 29, 2021	Jul NEWA
AA	!	MIKART	A207483	001	Jun 24, 2016	Jul CTEC
AB	PAR PHARM INC	375MG	A212743	002	Apr 29, 2021	Apr NEWA
>A> AA	SENORES PHARMS	250MG	A215158	001	Jul 29, 2021	Aug CAHN

CHOLESTYRAMINEPOWDER;ORAL  
CHOLESTYRAMINE

AB	TAGI	EQ 4GM RESIN/PACKET	A209597	001	Mar 09, 2021	Feb NEWA
AB		EQ 4GM RESIN/SCOOPFUL	A209597	002	Mar 09, 2021	Feb NEWA
	LOCHOLEST LIGHT					
	@ CHARTWELL RX	EQ 4GM RESIN/PACKET	A074562	001	Aug 15, 1996	Apr CAHN
	@	EQ 4GM RESIN/SCOOPFUL	A074562	002	Aug 15, 1996	Apr CAHN

CHOLINE FENOFIBRATECAPSULE, DELAYED RELEASE;ORAL  
FENOFLIBRIC ACID

>A> AB	ADAPTIS	EQ 45MG FENOFLIBRIC ACID	A211626	001	Jul 18, 2019	Aug CAHN
>A> AB		EQ 135MG FENOFLIBRIC ACID	A211626	002	Jul 18, 2019	Aug CAHN
>D> AB	GRAVITI PHARMS	EQ 45MG FENOFLIBRIC ACID	A211626	001	Jul 18, 2019	Aug CAHN
>D> AB		EQ 135MG FENOFLIBRIC ACID	A211626	002	Jul 18, 2019	Aug CAHN
	@ YICHANG HUMANWELL	EQ 45MG FENOFLIBRIC ACID	A212562	001	Dec 23, 2020	Jun DISC
	@	EQ 135MG FENOFLIBRIC ACID	A212562	002	Dec 23, 2020	Jun DISC

CICLESONIDE

SPRAY, METERED;NASAL  
OMNARIS  
+! COVIS 0.05MG/SPRAY N022004 001 Oct 20, 2006 May CPOT

CICLOPIROX

GEL;TOPICAL  
CICLOPIROX  
AB +! ALVOGEN 0.77% N020519 001 Jul 21, 1997 Jun CAHN  
SOLUTION;TOPICAL  
CICLOPIROX  
@ AKORN 8% A078975 001 Feb 17, 2010 Apr DISC  
AT RISING 8% A078124 001 Sep 18, 2007 May CAHN

CILOSTAZOL

TABLET;ORAL  
CILOSTAZOL  
@ EPIC PHARMA LLC 50MG A077022 002 Mar 11, 2005 Jan CMS1  
@ NOSTRUM LABS INC 50MG A077708 001 Sep 28, 2009 Mar DISC  
AB @ 50MG A077708 001 Sep 28, 2009 Jan CAHN  
@ 100MG A077708 002 Sep 28, 2009 Mar DISC  
AB 100MG A077708 002 Sep 28, 2009 Jan CAHN

CIMETIDINE

TABLET;ORAL  
CIMETIDINE  
@ NOVITIUM PHARMA 300MG A074340 001 Jun 23, 1995 Feb CAHN  
@ 400MG A074340 002 Jun 23, 1995 Feb CAHN  
@ 800MG A074339 001 Jun 23, 1995 Feb CAHN

CINACALCET HYDROCHLORIDE

TABLET;ORAL  
CINACALCET HYDROCHLORIDE  
>D> AB MYLAN EQ 30MG BASE A203422 001 Oct 16, 2018 Aug CAHN  
>A> @ EQ 30MG BASE A203422 001 Oct 16, 2018 Aug CAHN  
>D> AB @ EQ 60MG BASE A203422 002 Oct 16, 2018 Aug CAHN  
>A> @ EQ 60MG BASE A203422 002 Oct 16, 2018 Aug CAHN  
>D> AB @ EQ 90MG BASE A203422 003 Oct 16, 2018 Aug CAHN  
>A> @ EQ 90MG BASE A203422 003 Oct 16, 2018 Aug CAHN

CIPROFLOXACIN

INJECTABLE, SUSPENSION;OTIC  
OTIPRIO  
+! ALK ABELLO 6% (60MG/ML) N207986 001 Dec 10, 2015 Jun CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION  
CISATRACURIUM BESYLATE  
@ SAGENT PHARMS INC EQ 2MG BASE/ML A201851 001 Nov 06, 2020 Jul DISC  
@ ZYDUS PHARMS EQ 2MG BASE/ML A213527 001 Aug 31, 2020 Feb DISC

CITRIC ACID; UREA C-13

FOR SOLUTION, TABLET, FOR SOLUTION;ORAL  
IDKIT:HP  
+! EXALENZ BIOSCIENCE 4GM;75MG N021314 001 Dec 17, 2002 Jul CPOT

CLARITHROMYCIN

TABLET;ORAL  
CLARITHROMYCIN  
@ WOCKHARDT 250MG A065266 001 May 31, 2006 Jan DISC  
@ 500MG A065266 002 May 31, 2006 Jan DISC

CLASCOTERONE

CREAM;TOPICAL  
WINLEVI  
+ @ CASSIOPEA SPA 1% N213433 001 Aug 26, 2020 Mar DISC

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLEOCIN HYDROCHLORIDE

AB	+	Pfizer	EQ 75MG BASE	N050162	001	Feb CAHN
AB	+		EQ 150MG BASE	N050162	002	Feb CAHN
AB	+!		EQ 300MG BASE	N050162	003	Apr 14, 1988

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION;ORAL

CLEOCIN

AA	!	Pfizer	EQ 75MG BASE/5ML	A062644	001	Apr 07, 1986	Feb CAHN
----	---	--------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATE

CREAM;VAGINAL

CLEOCIN

AB	@	Pfizer	EQ 2% BASE	N050680	001	Aug 11, 1992	Feb CAHN
AB	+!		EQ 2% BASE	N050680	002	Mar 02, 1998	Feb CAHN

GEL;TOPICAL

CLEOCIN T

>D> AB	+!	Pfizer	EQ 1% BASE	N050615	001	Jan 07, 1987	Aug CTEC
>A> AB1	+!		EQ 1% BASE	N050615	001	Jan 07, 1987	Aug CTEC
AB	+!		EQ 1% BASE	N050615	001	Jan 07, 1987	Feb CAHN

CLINDAMYCIN PHOSPHATE

>D> AB		ENCUBE	EQ 1% BASE	A212438	001	Mar 11, 2021	Aug CTEC
>A> AB1			EQ 1% BASE	A212438	001	Mar 11, 2021	Aug CTEC
AB			EQ 1% BASE	A212438	001	Mar 11, 2021	Mar NEWA
>D> AB		FOUGERA PHARMS	EQ 1% BASE	A064160	001	Jan 28, 2000	Aug CTEC
>A> AB1			EQ 1% BASE	A064160	001	Jan 28, 2000	Aug CTEC
>D> AB		GLENMARK PHARMS LTD	EQ 1% BASE	A214251	001	Feb 10, 2021	Aug CTEC
>A> AB1			EQ 1% BASE	A214251	001	Feb 10, 2021	Aug CTEC
AB			EQ 1% BASE	A214251	001	Feb 10, 2021	Jan NEWA
>D> AB		PADAGIS ISRAEL	EQ 1% BASE	A212104	001	Dec 31, 2020	Aug CTEC
>A> AB1			EQ 1% BASE	A212104	001	Dec 31, 2020	Aug CTEC
AB			EQ 1% BASE	A212104	001	Dec 31, 2020	Jan CAHN
>D> AB		PERRIGO UK FINCO	EQ 1% BASE	A211872	001	Jul 29, 2020	Aug CTEC
>D> AB		SOLARIS PHARMA CORP	EQ 1% BASE	A211872	001	Jul 29, 2020	Aug CTEC
>A> AB1			EQ 1% BASE	A212842	001	Aug 13, 2021	Aug NFTG
>A> AB2			EQ 1% BASE	A214052	001	Nov 10, 2020	Aug CTEC
>D> AB		TARO PHARMS	EQ 1% BASE	A214052	001	Nov 10, 2020	Aug CTEC
>A> AB1			EQ 1% BASE				

INJECTABLE;INJECTION

CLEOCIN PHOSPHATE

AP		Pfizer	EQ 150MG BASE/ML	A062803	001	Oct 16, 1987	Feb CAHN
AP	+!		EQ 150MG BASE/ML	N050441	001		Feb CAHN

CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

+ @ Pfizer		EQ 6MG BASE/ML	N050639	001	Aug 30, 1989	Feb CAHN
+ @		EQ 12MG BASE/ML	N050639	002	Aug 30, 1989	Feb CAHN
+ @		EQ 18MG BASE/ML	N050639	003	Apr 10, 1991	Feb CAHN

CLINDAMYCIN PHOSPHATE

AP		ALMAJECT	EQ 150MG BASE/ML	A062800	001	Jul 24, 1987	Jul CAHN
AP	@		EQ 150MG BASE/ML	A062801	001	Jul 24, 1987	Jul CAHN
AP			EQ 150MG BASE/ML	A062943	001	Sep 29, 1988	Jul CAHN

@ MYLAN LABS LTD

EQ 150MG BASE/ML	A204748	001	Oct 10, 2017	Jan DISC
------------------	---------	-----	--------------	----------

LOTION;TOPICAL

CLEOCIN T

AB	+!	Pfizer	EQ 1% BASE	N050600	001	May 31, 1989	Feb CAHN
AB			CLINDAMYCIN PHOSPHATE				

TARO PHARMS

AB			EQ 1% BASE	A214526	001	Jun 28, 2021	Jun NEWA
AB			SOLUTION;TOPICAL				

CLEOCIN T

+ @ Pfizer		EQ 1% BASE	N050537	001		Feb CAHN
+ @ PHARMACIA AND UPJOHN		EQ 1% BASE	N050537	001		Jan DISC

SUPPOSITORY;VAGINAL

CLEOCIN

+! Pfizer		100MG	N050767	001	Aug 13, 1999	Feb CAHN
SWAB;TOPICAL						
CLEOCIN						

+ @ Pfizer

+ @ Pfizer	+!	EQ 1% BASE	N050537	002	Feb 22, 1994	Mar DISC
AT						

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

ZIANA

AB +! BAUSCH 1.2%;0.025% N050802 001 Nov 07, 2006 May CAHN

CLOBAZAM

SUSPENSION;ORAL

CLOBAZAM

AB ALKEM LABS LTD 2.5MG/ML A213039 001 May 06, 2021 Apr NEWA

AB TARO 2.5MG/ML A210978 001 Apr 15, 2019 Jul CMFD

TABLET;ORAL

CLOBAZAM

@ CELLTRION 10MG A211959 001 Dec 09, 2020 Jun DISC

@ 20MG A211959 002 Dec 09, 2020 Jun DISC

@ LANNETT CO INC 10MG A212092 001 Oct 30, 2019 Mar DISC

@ 20MG A212092 002 Oct 30, 2019 Mar DISC

AB MSN 10MG A213404 001 May 11, 2021 Apr NEWA

AB 20MG A213404 002 May 11, 2021 Apr NEWA

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE

AB1 GLASSHOUSE PHARMS 0.05% A211207 001 Mar 26, 2021 Mar NEWA

IMPOYZ

+! PRIMUS PHARMS 0.025%

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

@ TORRENT 0.05% A212926 001 Oct 25, 2019 Jan DISC

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

AB AMNEAL 0.05% A214895 001 Jun 14, 2021 Jun NEWA

AB TARO PHARMS 0.05% A214867 001 Mar 25, 2021 Mar NEWA

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT PRINSTON INC 0.05% A213139 001 Feb 08, 2021 Jan NEWA

SPRAY;TOPICAL

CLOBETASOL PROPIONATE

@ AKORN 0.05% A207218 001 Apr 28, 2017 Apr DISC

CLOFARABINE

SOLUTION;INTRAVENOUS

CLOFARABINE

AP MEITHEAL 20MG/20ML (1MG/ML) A213461 001 Oct 23, 2020 Jan CAHN

@ NOVAST LABS 20MG/20ML (1MG/ML) A210270 001 Sep 14, 2018 Mar DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB ALEMBIC PHARMS LTD 25MG A211822 001 Aug 04, 2021 Jul NEWA

AB 50MG A211822 002 Aug 04, 2021 Jul NEWA

AB 75MG A211822 003 Aug 04, 2021 Jul NEWA

AB VGYAAN 25MG A213221 001 Jun 22, 2020 May CMFD

AB 50MG A213221 002 Jun 22, 2020 May CMFD

AB 75MG A213221 003 Jun 22, 2020 May CMFD

CLONIDINE

SYSTEM;TRANSDERMAL

CATAPRES-TTS-1

AB + LAVIPHARM 0.1MG/24HR N018891 001 Oct 10, 1984 Jan CAHN

AB + TECHNOMED 0.1MG/24HR N018891 001 Oct 10, 1984 Jan CAHN

CATAPRES-TTS-2

AB + LAVIPHARM 0.2MG/24HR N018891 002 Oct 10, 1984 Jan CAHN

AB + TECHNOMED 0.2MG/24HR N018891 002 Oct 10, 1984 Jan CAHN

CATAPRES-TTS-3

AB +! LAVIPHARM 0.3MG/24HR N018891 003 Oct 10, 1984 Jan CAHN

AB +! TECHNOMED 0.3MG/24HR N018891 003 Oct 10, 1984 Jan CAHN

CLONIDINE HYDROCHLORIDE

INJECTABLE; INJECTION  
CLONIDINE HYDROCHLORIDE

AP ! HIKMA FARMACEUTICA	5MG/10ML (0.5MG/ML)	A200300	002	Jan 26, 2011	Mar CHRS
DURACLON					
+ @ MYLAN INSTITUTIONAL	5MG/10ML (0.5MG/ML)	N020615	002	Apr 27, 1999	Mar DISC

CLOPIDOGREL BISULFATE

TABLET; ORAL  
CLOPIDOGREL BISULFATE

AB POLYGEN PHARMS	EQ 75MG BASE	A213351	001	Jul 17, 2020	Feb CMFD
AB	EQ 300MG BASE	A213351	002	Jul 17, 2020	Feb CMFD

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL  
TRANXENE

+ @ RECORDATI RARE	3.75MG	N017105	001	May CRLD
+ @	7.5MG	N017105	002	May CRLD
+ @	15MG	N017105	003	May CRLD

TABLET; ORAL  
CLORAZEPATE DIPOTASSIUM

AB AUROLIFE PHARMA LLC	3.75MG	A071858	002	Jul 17, 1987	Jan CAHN
AB	7.5MG	A071858	003	Jul 17, 1987	Jan CAHN
AB !	15MG	A071858	001	Jul 17, 1987	Jan CAHN

TRANXENE

+ @ RECORDATI RARE	3.75MG	N017105	006	May CRLD
TRANXENE SD				
+ @ RECORDATI RARE	11.25MG	N017105	005	May CRLD
+ @	22.5MG	N017105	004	May CRLD

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL  
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA AKORN	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040674	001	Dec 23, 2014	Feb CAHN
----------	-------------------------------	---------	-----	--------------	----------

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL  
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

>D> AA ! ACTAVIS MID ATLANTIC	10MG/5ML; 6.25MG/5ML	A088763	001	Oct 31, 1984	Aug CRLD
>A> AA +!	10MG/5ML; 6.25MG/5ML	A088763	001	Oct 31, 1984	Aug CRLD

COLCHICINE

TABLET; ORAL  
COLCHICINE

>A> AB HETERO LABS LTD V	0.6MG	A208993	001	Aug 13, 2021	Aug NEWA
>A> AB PAR PHARM INC	0.6MG	A203976	001	Aug 12, 2021	Aug NEWA

COLCHICINE; PROBENECID

TABLET; ORAL  
COL-PROBENECID

>D> AB ! WATSON LABS	0.5MG; 500MG	A084279	001	Aug CRLD
>A> AB +!	0.5MG; 500MG	A084279	001	Aug CRLD

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION; ORAL  
COLESEVELAM HYDROCHLORIDE

GLENMARK PHARMS LTD	1.875GM/PACKET	A202190	001	Jul 16, 2018	Feb CTEC
@ WATSON LABS INC	1.875GM/PACKET	A202178	001	Sep 01, 2020	Feb DISC
@	3.75GM/PACKET	A202178	002	Sep 01, 2020	Feb DISC

TABLET; ORAL  
COLESEVELAM HYDROCHLORIDE

@ WATSON LABS INC	625MG	A200830	001	Sep 02, 2020	Feb DISC
-------------------	-------	---------	-----	--------------	----------

COlestipol HYDROCHLORIDE

GRANULE; ORAL  
COlestid

AB + PFIZER	5GM/SCOOPFUL	N017563	003	Sep 22, 1995	Feb CAHN
AB +!	5GM/PACKET	N017563	004	Sep 22, 1995	Feb CAHN

FLAVORED COlestid

+ PFIZER	5GM/PACKET	N017563	001		Feb CAHN
----------	------------	---------	-----	--	----------

	GRANULE;ORAL FLAVORED COLESTID					
	+ 5GM/SCOOPFUL		N 017563	002		Feb CAHN
	TABLET;ORAL COLESTID					
AB	+! PFIZER 1GM		N 020222	001 Jul 19, 1994		Feb CAHN
	<u>CROTAMITON</u>					
	CREAM;TOPICAL EURAX					
	+ @ JOURNEY 10%		N 006927	001		Jan CAHN
	LOTION;TOPICAL EURAX					
AT	+! JOURNEY 10%		N 009112	003		Jan CAHN
	<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE</u>					
	SOLUTION;INTRAVENOUS MULTRY'S					
>A>	+! AM REGENT (1ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML		N 209376	001 Jul 02, 2020		Aug CTNA
>A>	+! (5ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML		N 209376	002 Dec 02, 2020		Aug CTNA
>A>	+! (1ML) EQ 0.06MG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG BASE/ML;EQ 1MG BASE/ML		N 209376	003 Jun 30, 2021		Aug CTNA
>D>	TRALEMENT					
>D>	+! AM REGENT (1ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML		N 209376	001 Jul 02, 2020		Aug CTNA
	+! (1ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML		N 209376	001 Jul 02, 2020		Jan CPOT
>D>	+! (5ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML		N 209376	002 Dec 02, 2020		Aug CTNA
	+! (5ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML		N 209376	002 Dec 02, 2020		Jan NEWA
>D>	+! (1ML) EQ 0.06MG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG BASE/ML;EQ 1MG BASE/ML		N 209376	003 Jun 30, 2021		Aug CTNA
	+! (1ML) EQ 0.06MG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG BASE/ML;EQ 1MG BASE/ML		N 209376	003 Jun 30, 2021		Jul NEWA
	<u>CYANOCOBALAMIN</u>					
	INJECTABLE;INJECTION CYANOCOBALAMIN					
>A> AP	XIROMED 1MG/ML		A 215046	001 Aug 20, 2021		Aug NEWA
	VIBISONE					
>D> AP	! FRESENIUS KABI USA 1MG/ML		A 080557	003		Aug CRLD
>A> AP	+! 1MG/ML		A 080557	003		Aug CRLD
	<u>CYCLOBENZAPRINE HYDROCHLORIDE</u>					
	TABLET;ORAL CYCLOBENZAPRINE HYDROCHLORIDE					
>D> AB	MYLAN PHARMS INC 5MG		A 073144	002 Feb 03, 2006		Aug DISC
>A>	@ 5MG		A 073144	002 Feb 03, 2006		Aug DISC
>D> AB	7.5MG		A 073144	003 Mar 25, 2013		Aug DISC
>A>	@ 7.5MG		A 073144	003 Mar 25, 2013		Aug DISC
>D> AB	10MG		A 073144	001 May 30, 1991		Aug DISC
>A>	@ 10MG		A 073144	001 May 30, 1991		Aug DISC
	<u>CYCLOPENTOLATE HYDROCHLORIDE</u>					
	SOLUTION/DROPS;OPHTHALMIC AKPENTOLATE					
>D>	@ AKORN 2%		A 040165	001 Jan 13, 1997		Aug CMFD
>A> AT	2%		A 040165	001 Jan 13, 1997		Aug CMFD
	CYCLOGYL					
>D> AT	! ALCON LABS INC 0.5%		A 084109	001		Aug CRLD
>A> AT	+! 0.5%		A 084109	001		Aug CRLD
>D> AT	! 1%		A 084110	001		Aug CRLD
>A> AT	+! 1%		A 084110	001		Aug CRLD

SOLUTION/DROPS;OPHTHALMIC  
CYCLOGYL

>D>	!	2%	A 084108 001	Aug CRLD
>A> AT	+!	2%	A 084108 001	Aug CRLD

CYCLOPHOSPHAMIDE

SOLUTION;INTRAVENOUS  
CYCLOPHOSPHAMIDE

>A>	+!	AUROMEDICS PHARMA	500MG/2.5ML (200MG/ML)	N 210735 001 Aug 25, 2021	Aug NEWA
>A>	+!		1GM/5ML (200MG/ML)	N 210735 002 Aug 25, 2021	Aug NEWA

CYCLOSPORINE

EMULSION;OPHTHALMIC  
VERKAZIA

+!	SANTEN	0.1%	N 214965 001 Jun 23, 2021	Jun NEWA
----	--------	------	---------------------------	----------

CYPROHEPTADINE HYDROCHLORIDE

SYRUP;ORAL  
CYPROHEPTADINE HYDROCHLORIDE

>D>	@	ACTAVIS MID ATLANTIC	2MG/5ML	A 086833 001	Aug CRLD
-----	---	----------------------	---------	--------------	----------

>A>	+ @		2MG/5ML	A 086833 001	Aug CRLD
-----	-----	--	---------	--------------	----------

TABLET;ORAL  
CYPROHEPTADINE HYDROCHLORIDE

>D> AA	!	HERITAGE PHARMA	4MG	A 087056 001	Aug CRLD
>A> AA	+!		4MG	A 087056 001	Aug CRLD
AA		QUAGEN	4MG	A 212491 001 Feb 24, 2021	Feb NEWA

CYSTEAMINE BITARTRATE

CAPSULE, DELAYED RELEASE;ORAL  
PROCYSB

+ HORIZON	EQ 25MG BASE	N 203389 001 Apr 30, 2013	May CAHN
+!	EQ 75MG BASE	N 203389 002 Apr 30, 2013	May CAHN

CYTARABINE

INJECTABLE;INJECTION  
CYTARABINE

>D> AP		MEITHEAL	20MG/ML	A 206190 001 Nov 09, 2017	Aug DISC
>A>	@		20MG/ML	A 206190 001 Nov 09, 2017	Aug DISC
	@	MYLAN LABS LTD	20MG/ML	A 200914 001 Dec 13, 2011	May DISC

DABIGATRAN ETEXILATE MESYLATE

PELLET;ORAL  
PRADAXA

+ BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N 214358 001 Jun 21, 2021	Jun NEWA
+	EQ 30MG BASE/PACKET	N 214358 002 Jun 21, 2021	Jun NEWA
+	EQ 40MG BASE/PACKET	N 214358 003 Jun 21, 2021	Jun NEWA
+	EQ 50MG BASE/PACKET	N 214358 004 Jun 21, 2021	Jun NEWA
+	EQ 110MG BASE/PACKET	N 214358 005 Jun 21, 2021	Jun NEWA
+!	EQ 150MG BASE/PACKET	N 214358 006 Jun 21, 2021	Jun NEWA

PELLETS;ORAL  
PRADAXA

+ BOEHRINGER INGELHEIM	EQ 20MG BASE/PACKET	N 214358 001 Jun 21, 2021	Jul CDFR
+	EQ 30MG BASE/PACKET	N 214358 002 Jun 21, 2021	Jul CDFR
+	EQ 40MG BASE/PACKET	N 214358 003 Jun 21, 2021	Jul CDFR
+	EQ 50MG BASE/PACKET	N 214358 004 Jun 21, 2021	Jul CDFR
+	EQ 110MG BASE/PACKET	N 214358 005 Jun 21, 2021	Jul CDFR
+!	EQ 150MG BASE/PACKET	N 214358 006 Jun 21, 2021	Jul CDFR

DACTINOMYCIN

INJECTABLE;INJECTION  
DACTINOMYCIN

>D> AP		AUROMEDICS PHARMA	0.5MG/VIAL	A 203385 001 Nov 09, 2017	Aug CAHN
AP			0.5MG/VIAL	A 203385 001 Nov 09, 2017	Jan CAHN
>A> AP		EUGIA PHARMA	0.5MG/VIAL	A 203385 001 Nov 09, 2017	Aug CAHN
	@	HIKMA PHARMS	0.5MG/VIAL	A 090304 001 Mar 16, 2010	Jul CAHN
AP		MEITHEAL	0.5MG/VIAL	A 213463 001 Nov 13, 2020	Feb CAHN

DAPSONE

TABLET;ORAL

DAPSONE

AB	ALVOGEN	25MG	A205429	001	Jan 07, 2016	Jun CAHN
AB		100MG	A205429	002	Jan 07, 2016	Jun CAHN
>D>	AB	JACOBUS	25MG	A086841	001	Aug CRLD
>A>	AB	+	25MG	A086841	001	Aug CRLD
>D>	AB	!	100MG	A086842	001	Aug CRLD
>A>	AB	+	100MG	A086842	001	Aug CRLD

DAPTOMYCIN

POWDER; INTRAVENOUS

DAPTOMYCIN

>A>	AP	AUROBINDO PHARMA LTD	500MG/VIAL	A213171	001	Sep 02, 2021	Aug NEWA
	AP	HISUN PHARM HANGZHOU	500MG/VIAL	A212250	001	Apr 21, 2021	Apr NEWA
>D>	AP	HONG KONG	500MG/VIAL	A213623	001	Jun 29, 2021	Aug CAHN
	AP		500MG/VIAL	A213623	001	Jun 29, 2021	Jun NEWA
	+!	HOSPIRA INC	350MG/VIAL	N210282	001	Jun 21, 2021	Jun NEWA
	+!		500MG/VIAL	N210282	002	Jun 21, 2021	Jun NEWA
>A>	AP	MEITHEAL	500MG/VIAL	A213623	001	Jun 29, 2021	Aug CAHN
>A>	AP	QILU	500MG/VIAL	A215316	001	Aug 24, 2021	Aug NEWA
		POWDER; IV (INFUSION)					
		DAPTOMYCIN					
	@	DR REDDYS	350MG/VIAL	A211403	001	Aug 31, 2020	May DISC
>D>	AP	HONG KONG	350MG/VIAL	A213786	001	Jun 29, 2021	Aug CAHN
	AP		350MG/VIAL	A213786	001	Jun 29, 2021	Jun NEWA
>A>	AP	MEITHEAL	350MG/VIAL	A213786	001	Jun 29, 2021	Aug CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

DARIFENACIN HYDROBROMIDE

@ JUBILANT GENERICS	EQ 7.5MG BASE	A205550	001	Oct 12, 2016	Jun DISC
@	EQ 15MG BASE	A205550	002	Oct 12, 2016	Jun DISC

DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR

TABLET;ORAL

VIEKIRA PAK (COPACKAGED)

>A>	+!	ABBVIE INC	EQ 250MG BASE;12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014	Aug CPOT
-----	----	------------	----------------------------------	---------	-----	--------------	----------

DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR

TABLET, TABLET;ORAL

VIEKIRA PAK (COPACKAGED)

>D>	+!	ABBVIE INC	250.0MG;12.5MG;75.0MG;EQ 250MG BASE,N/A,N/A,N/A; N/A,12.5MG,75MG,50MG	N206619	001	Dec 19, 2014	Aug CPOT
-----	----	------------	---	---------	-----	--------------	----------

DASIGLUCAGON HYDROCHLORIDE

SOLUTION;SUBCUTANEOUS

ZEGALOGUE

+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	May CAHN
+!		EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	001	Mar 22, 2021	Mar NEWA
	ZEGALOGUE (AUTOINJECTOR)					
+!	ZEALAND PHARMA	EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	May CAHN
+!		EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML)	N214231	002	Mar 22, 2021	Mar NEWA

DAUNORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DAUNORUBICIN HYDROCHLORIDE

AP	+!	HIKMA PHARMS	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Jul CAHN
----	----	--------------	----------------	---------	-----	--------------	----------

DECITABINE

INJECTABLE;INTRAVENOUS

DECITABINE

@	APOTEX	50MG/VIAL	A205539	001	Nov 23, 2020	May DISC
@	CIPPLA	50MG/VIAL	A208601	001	Nov 16, 2017	May DISC
AP	GLAND	50MG/VIAL	A205539	001	Nov 23, 2020	Jul CMFD
@		50MG/VIAL	A205539	001	Nov 23, 2020	Jul CAHN
AP	HONG KONG	50MG/VIAL	A212959	001	Jul 02, 2021	Jun NEWA

INJECTABLE; INTRAVENOUS  
DECITABINE

AP QILU 50MG/VIAL A212826 001 Apr 12, 2021 Apr NEWA

DEFERASIROX

GRANULE; ORAL  
DEFERASIROX

AB	AMNEAL	90MG	A214194	003	Aug 02, 2021	Jul NEWA
AB		180MG	A214194	001	Feb 09, 2021	Jan NEWA
AB		360MG	A214194	002	Feb 09, 2021	Jan NEWA
AB	AUCTA	90MG	A214559	001	Mar 09, 2021	Feb NEWA
AB		180MG	A214559	002	Mar 09, 2021	Feb NEWA
AB		360MG	A214559	003	Mar 09, 2021	Feb NEWA
AB	MSN	180MG	A214650	001	Mar 17, 2021	Mar NEWA
AB		360MG	A214650	002	Mar 17, 2021	Mar NEWA

## TABLET; ORAL

## DEFERASIROX

AB	ANNORA PHARMA	90MG	A214341	001	May 14, 2021	May NEWA
AB		180MG	A214341	002	May 14, 2021	May NEWA
AB		360MG	A214341	003	May 14, 2021	May NEWA
AB	CELLTRION	90MG	A212669	001	May 27, 2021	May NEWA
AB		180MG	A212669	002	May 27, 2021	May NEWA
AB		360MG	A212669	003	May 27, 2021	May NEWA

DEFERIPRONE

SOLUTION; ORAL  
FERRIPROX

>D>	+ CHIESI	80MG/ML	N208030	002	Apr 20, 2018	Aug DISC
>A>	+ @	80MG/ML	N208030	002	Apr 20, 2018	Aug DISC
	TABLET; ORAL					
	DEFERIPRONE					
AB	HIKMA PHARMS	500MG	A213239	001	Mar 29, 2021	Mar NEWA
	FERRIPROX					
AB	+! CHIESI	500MG	N021825	001	Oct 14, 2011	Mar CTEC

DEOXYCHOLIC ACID

SOLUTION; SUBCUTANEOUS  
DEOXYCHOLIC ACID

AP	SLAYBACK PHARMA LLC	20MG/2ML (10MG/ML)	A212296	001	Apr 02, 2021	Mar NFTG
----	---------------------	--------------------	---------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL  
DESIPRAMINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	10MG	A209785	001	Jul 07, 2021	Jun NEWA
AB		25MG	A209785	002	Jul 07, 2021	Jun NEWA
AB		50MG	A209785	003	Jul 07, 2021	Jun NEWA
AB		75MG	A209785	004	Jul 07, 2021	Jun NEWA
AB		100MG	A209785	005	Jul 07, 2021	Jun NEWA
AB		150MG	A209785	006	Jul 07, 2021	Jun NEWA
	NORPRAMIN					
AB	+ VALIDUS PHARMS	10MG	N014399	007	Feb 11, 1982	Feb CAHN
AB	+	25MG	N014399	001		Feb CAHN
AB	+	50MG	N014399	003		Feb CAHN
AB	+	75MG	N014399	004		Feb CAHN
AB	+!	100MG	N014399	005		Feb CAHN
AB	+	150MG	N014399	006		Feb CAHN

DESLORATADINE

TABLET; ORAL  
CLARINEX

>D> AB	+! MERCK SHARP DOHME	5MG	N021165	001	Dec 21, 2001	Aug CAHN
>A> AB	+! ORGANON	5MG	N021165	001	Dec 21, 2001	Aug CAHN
	DESLORATADINE					
>D> AB	SUN PHARM IND'S	5MG	A078359	001	Nov 16, 2010	Aug DISC
>A>	@	5MG	A078359	001	Nov 16, 2010	Aug DISC

DESLORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE; ORAL  
CLARINEX-D 12 HOUR

+! ORGANON 2.5MG;120MG

N021313 001 Feb 01, 2006 Jun CAHN

DESMOPRESSIN ACETATE

SPRAY, METERED;NASAL					
NOCTIVA					
+ @ ROIVANT	0.00083MG/SPRAY	N 201656	001	Mar 03, 2017	Feb CAHN
+ @	0.00166MG/SPRAY	N 201656	002	Mar 03, 2017	Feb CAHN

DESONIDE

GEL;TOPICAL					
DESONATE					
+ @ LEO PHARMA AS	0.05%	N 021844	001	Oct 20, 2006	Mar DISC
DESONIDE					
! CINTEX SVCS	0.05%	A 202470	001	May 11, 2020	Mar CHRS
	0.05%	A 202470	001	May 11, 2020	Mar CTEC

DESOXIMETASONE

CREAM;TOPICAL					
DESOXIMETASONE					
@ AKORN	0.05%	A 203787	001	Jan 06, 2017	Apr DISC
@	0.25%	A 203234	001	Jun 12, 2015	Apr DISC
OINTMENT;TOPICAL					
DESOXIMETASONE					
AB ! GLENMARK GENERICS	0.25%	A 202838	001	Sep 20, 2013	Apr CHRS
TOPICORT					
@ TARO PHARM INDS LTD	0.25%	A 074286	001	Jun 07, 1996	Apr DISC

DEXAMETHASONE

ELIXIR;ORAL					
DEXAMETHASONE					
>D> AA WOCKHARDT BIO AG	0.5MG/5ML	A 088254	001	Jul 27, 1983	Aug CRLD
>A> AA +	0.5MG/5ML	A 088254	001	Jul 27, 1983	Aug CRLD
TABLET;ORAL					
DEXAMETHASONE					
BP ALVOGEN	0.5MG	A 088481	002	Apr 28, 1983	Jun CAHN
BP	0.75MG	A 088481	003	Apr 28, 1983	Jun CAHN
BP	4MG	A 088481	004	Apr 28, 1983	Jun CAHN
BP	6MG	A 088481	001	Nov 28, 1983	Jun CAHN
BP ! HIKMA PHARMS	1MG	A 088306	001	Sep 15, 1983	Apr CHRS
BP !	2MG	A 087916	001	Aug 26, 1982	Apr CHRS

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION					
DEXAMETHASONE SODIUM PHOSPHATE					
AP GLAND PHARMA LTD	EQ 4MG PHOSPHATE/ML	A 215654	001	Aug 04, 2021	Jul NEWA
>D> @ LUITPOLD	EQ 4MG PHOSPHATE/ML	A 087440	001	Jul 21, 1982	Aug CRLD
>A> + @	EQ 4MG PHOSPHATE/ML	A 087440	001	Jul 21, 1982	Aug CRLD

DEXAMETHASONE; TOBRAMYCIN

SUSPENSION/DROPS;OPHTHALMIC					
TOBRAMYCIN AND DEXAMETHASONE					
AB AMNEAL	0.1%;0.3%	A 212991	001	Jul 15, 2021	Jul NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP;ORAL					
DEXCHLORPHENIRAMINE MALEATE					
>D> AA ! WOCKHARDT BIO AG	2MG/5ML	A 088251	001	Mar 23, 1984	Aug CRLD
>A> AA +!	2MG/5ML	A 088251	001	Mar 23, 1984	Aug CRLD
TABLET;ORAL					
POLARAMINE					
>D> @ SCHERING	2MG	A 086835	001		Aug CRLD
>A> + @	2MG	A 086835	001		Aug CRLD

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION					
DEXMEDETOMIDINE HYDROCHLORIDE					
AP GLAND	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A 202126	001	Aug 20, 2015	May CAHN
AP HIKMA PHARMS	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A 205046	001	Apr 26, 2017	Jul CAHN
AP HONG KONG	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A 204843	001	Jan 18, 2019	Jun CMFD
>A> AP PIRAMAL CRITICAL	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A 214794	001	Sep 03, 2021	Aug NEWA

INJECTABLE; INJECTION  
 DEXMEDETOMIDINE HYDROCHLORIDE  
 BASE/ML)

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
 DEXMETHYLPHENIDATE HYDROCHLORIDE

@ MYLAN	5MG	A204266	001	Aug 25, 2015	Jul DISC
@	10MG	A204266	002	Aug 25, 2015	Jul DISC
@	15MG	A204266	003	Aug 25, 2015	Jul DISC
@	20MG	A204266	004	Dec 21, 2015	Jul DISC
@	25MG	A204266	005	May 04, 2021	Jul DISC
AB	25MG	A204266	005	May 04, 2021	Apr NEWA
@	30MG	A202580	001	Aug 28, 2013	Jul CAHN
@	30MG	A202580	001	Aug 28, 2013	Jul DISC
AB	35MG	A204266	006	May 04, 2021	Jul DISC
AB	35MG	A204266	006	May 04, 2021	Apr NEWA
@	40MG	A204266	007	Aug 25, 2015	Jul DISC

DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE

CAPSULE; ORAL  
 AZSTARYS

+ COMMAVE THERAP	EQ 5.2MG BASE; EQ 26.1MG BASE	N212994	001	May 07, 2021	May NEWA
+ !	EQ 7.8MG BASE; EQ 39.2MG BASE	N212994	002	May 07, 2021	May NEWA
+ !	EQ 10.4MG BASE; EQ 52.3MG BASE	N212994	003	May 07, 2021	May NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION  
 DEXRAZOXANE HYDROCHLORIDE

>D> AP	AUROMEDICS PHARMA	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Aug CHRS
AP		EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Jan CAHN
>D> AP		EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Aug CHRS
AP		EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Jan CAHN
>A> AP	! EUGIA PHARMA	EQ 250MG BASE/VIAL	A200752	001	Oct 19, 2011	Aug CHRS
>A> AP	!	EQ 500MG BASE/VIAL	A200752	002	Oct 19, 2011	Aug CHRS
	TOTECT					
>D>	+ ! CLINIGEN	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Aug DISC
>A>	+ @ ZINECARD	EQ 500MG BASE/VIAL	N022025	001	Sep 06, 2007	Aug DISC
>D> AP	+ ! PFIZER	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Aug DISC
>A>	+ @	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Aug DISC
AP	+ !	EQ 250MG BASE/VIAL	N020212	001	May 26, 1995	Mar CAHN
>D> AP	+ !	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Aug DISC
>A>	+ @	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Aug DISC
AP	+ !	EQ 500MG BASE/VIAL	N020212	002	May 26, 1995	Mar CAHN

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL  
 DEXEDRINE

>D>	@ GLAXOSMITHKLINE	5MG	A084935	001		Aug CRLD
>A>	+ @	5MG	A084935	001		Aug CRLD
	DEXTROAMPHETAMINE SULFATE					
AA	ARBOR PHARMS LLC	2.5MG	A090533	001	Oct 25, 2011	May CTEC
AA		7.5MG	A090533	003	Oct 25, 2011	May CTEC
AA		15MG	A090533	005	Oct 25, 2011	May CTEC
AA		20MG	A090533	006	Oct 25, 2011	May CTEC
AA		30MG	A090533	007	Oct 25, 2011	May CTEC
AA	WINDER LABS LLC	2.5MG	A212160	001	Jun 07, 2021	May NEWA
AA		5MG	A212160	002	Jun 07, 2021	May NEWA
AA		7.5MG	A212160	003	Jun 07, 2021	May NEWA
AA		10MG	A212160	004	Jun 07, 2021	May NEWA
AA		15MG	A212160	005	Jun 07, 2021	May NEWA
AA		20MG	A212160	006	Jun 07, 2021	May NEWA
AA		30MG	A212160	007	Jun 07, 2021	May NEWA
	DEXTROSTAT					
>D>	@ SHIRE	5MG	A084051	001		Aug CRLD
>A>	+ @	5MG	A084051	001		Aug CRLD
>D>	@	10MG	A084051	002		Aug CRLD
>A>	+ @	10MG	A084051	002		Aug CRLD

DEXTROSE; POTASSIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075%					
@ FRESENIUS KABI USA 5GM/100ML;75MG/100ML	A212346	001	Sep 10, 2020	Mar	DISC
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15%					
@ FRESENIUS KABI USA 5GM/100ML;150MG/100ML	A212346	002	Sep 10, 2020	Mar	DISC
DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER					
+ BAXTER HLTHCARE 5GM/100ML;224MG/100ML	N017634	003		Mar	CTEC

DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML	A212348	001	Jul 30, 2021	Jul	NFTG
POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP FRESENIUS KABI USA 5GM/100ML;74.5MG/100ML;450MG/100ML	A213523	001	Mar 09, 2021	Feb	NEWA
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER					
AP FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML	A212348	002	Jul 30, 2021	Jul	NFTG
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP FRESENIUS KABI USA 5GM/100ML;149MG/100ML;450MG/100ML	A213523	002	Mar 09, 2021	Feb	NEWA
POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP FRESENIUS KABI USA 5GM/100ML;149MG/100ML;900MG/100ML	A213445	001	Mar 09, 2021	Feb	NFTG
POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP FRESENIUS KABI USA 5GM/100ML;224MG/100ML;450MG/100ML	A213523	003	Mar 09, 2021	Feb	NEWA
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP FRESENIUS KABI USA 5GM/100ML;298MG/100ML;450MG/100ML	A213523	004	Mar 09, 2021	Feb	NEWA
POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP FRESENIUS KABI USA 5GM/100ML;298MG/100ML;900MG/100ML	A213445	002	Mar 09, 2021	Feb	NFTG

DEXTROSE; SODIUM CHLORIDE

## INJECTABLE; INJECTION

DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER					
AP FRESENIUS KABI USA 2.5GM/100ML;450MG/100ML	A211190	001	Dec 20, 2019	May	CMFD
DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER					
AP FRESENIUS KABI USA 5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	May	CMFD
@ 5GM/100ML;300MG/100ML	A211194	001	Aug 26, 2020	Feb	DISC
AP +! ICU MEDICAL INC 5GM/100ML;300MG/100ML	N017799	001		May	CTEC
+! 5GM/100ML;300MG/100ML	N017799	001		Feb	CTEC
DEXTROSE 5% AND SODIUM CHLORIDE 0.45%					
AP FRESENIUS KABI USA 5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020	May	CMFD
@ 5GM/100ML;450MG/100ML	A211276	001	Sep 15, 2020	Mar	DISC
DEXTROSE 5% AND SODIUM CHLORIDE 0.9%					
AP FRESENIUS KABI USA 5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020	May	CMFD
@ 5GM/100ML;900MG/100ML	A211211	001	Sep 14, 2020	Mar	DISC

DIAZEPAM

## INJECTABLE; INJECTION

DIAZEPAM					
>D> ! BELOTECA INC 10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Aug	CTEC
>A> AP ! 10MG/2ML (5MG/ML)	A210363	001	Mar 18, 2019	Aug	CTEC
>A> AP HIKMA 10MG/2ML (5MG/ML)	A070313	001	Dec 16, 1985	Aug	CAHN
>D> @ WEST-WARD PHARMS INT 5MG/ML	A070313	001	Dec 16, 1985	Aug	CAHN

DICLOFENAC POTASSIUM

## TABLET; ORAL

CATAFLAM					
AB AMICI 25MG	A076561	002	Jul 21, 2021	Jul	NEWA
50MG	A076561	001	Mar 18, 2004	May	CTNA

DICLOFENAC SODIUM

## GEL; TOPICAL

## DICLOFENAC SODIUM

! TARO SOLARAZE 3%	A206298	001	Apr 28, 2016	Mar	CHRS
+ @ FOUGERA PHARMS SOLUTION;TOPICAL	N021005	001	Oct 16, 2000	Mar	DISC
DICLOFENAC SODIUM					
AT AKORN 1.5%	A206655	001	Jan 28, 2021	Jan	NEWA
@ RISING 1.5%	A206715	001	Aug 07, 2017	May	CAHN

SOLUTION/DROPS;OPHTHALMIC

DICLOFENAC SODIUM

>D>	AT	BAUSCH AND LOMB	0.1%	A078792	001	Dec 28, 2007	Aug CHRS	
>A>	AT	!	0.1%	A078792	001	Dec 28, 2007	Aug CHRS	
		VOLTAREN						
>D>	AT	+!	NOVARTIS	0.1%	N020037	001	Mar 28, 1991	Aug DISC
>A>		+	@	0.1%	N020037	001	Mar 28, 1991	Aug DISC
		TABLET, DELAYED RELEASE;ORAL						
		DICLOFENAC SODIUM						
		@ MICRO LABS	50MG	A074986	001	Feb 26, 1999	Feb CAHN	
		@	75MG	A074986	002	Feb 26, 1999	Feb CAHN	

DICLOFENAC SODIUM; MISOPROSTOL

TABLET, DELAYED RELEASE;ORAL

DICLOFENAC SODIUM AND MISOPROSTOL

AB	MICRO LABS	50MG;0.2MG	A204355	001	Jul 15, 2021	Jul NEWA
AB		75MG;0.2MG	A204355	002	Jul 15, 2021	Jul NEWA

DICLOXACILLIN SODIUM

CAPSULE;ORAL

DICLOXACILLIN SODIUM

	@ SANDOZ	EQ 125MG BASE	A061454	002		Jan DISC
	@	EQ 250MG BASE	A061454	001		Jan DISC
	@	EQ 500MG BASE	A061454	003		Jan DISC
	TEVA	EQ 250MG BASE	A062286	001	Jun 03, 1982	Jan CTEC
	!	EQ 500MG BASE	A062286	002	Jun 03, 1982	Jan CTEC
AB	!	EQ 500MG BASE	A062286	002	Jun 03, 1982	Jan CHRS

DICYCLOMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DICYCLOMINE HYDROCHLORIDE

AP	PRAZGEN	10MG/ML	A212058	001	Apr 26, 2019	Jun CAHN	
	SYRUP;ORAL						
	DICYCLOMINE HYDROCHLORIDE						
AA	NOVITIUM PHARMA	10MG/5ML	A214721	001	Apr 23, 2021	Apr NEWA	
	TABLET;ORAL						
	DICYCLOMINE HYDROCHLORIDE						
>D>	AB	MYLAN	20MG	A040317	001	Sep 07, 1999	Aug DISC
>A>		@	20MG	A040317	001	Sep 07, 1999	Aug DISC

DIDANOSINE

CAPSULE, DELAYED REL PELLETS;ORAL

DIDANOSINE

	@ AUROBINDO PHARMA	125MG	A090094	001	Sep 24, 2008	Jan DISC
	@	200MG	A090094	002	Sep 24, 2008	Jan DISC
	@	250MG	A090094	003	Sep 24, 2008	Jan DISC
	@	400MG	A090094	004	Sep 24, 2008	Jan DISC

DIFELIKEFALIN ACETATE

SOLUTION;INTRAVENOUS

KORSUVA

>A>		+!	CARA THERAP	EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML)	N214916	001	Aug 23, 2021	Aug NEWA
-----	--	----	-------------	--	---------	-----	--------------	----------

DIFLORASONE DIACETATE

CREAM;TOPICAL

DIFLORASONE DIACETATE

BX	!	ANI PHARMS	0.05%	A076263	001	Dec 20, 2002	Apr CAHN
	OINTMENT;TOPICAL						
	DIFLORASONE DIACETATE						
	@ AKORN	0.05%		A206572	001	Jul 24, 2015	Apr DISC

DIFLUPREDNATE

EMULSION;OPHTHALMIC

DIFLUPREDNATE

AB	CIPILA	0.05%	A211776	001	Aug 09, 2021	Jul NFTG
----	--------	-------	---------	-----	--------------	----------

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

AP PROVEPHARM SAS 1MG/ML A212046 001 Jan 07, 2020 Jan CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

AB1 GLENMARK PHARMS LTD 60MG A212317 001 Mar 22, 2021 Mar NEWA

AB1 90MG A212317 002 Mar 22, 2021 Mar NEWA

AB1 120MG A212317 003 Mar 22, 2021 Mar NEWA

AB1 MYLAN 60MG A074910 001 May 02, 1997 Mar CTEC

AB1 90MG A074910 002 May 02, 1997 Mar CTEC

AB1 ! 120MG A074910 003 May 02, 1997 Mar CTEC

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

@ INTL MEDICATION 5MG/ML A075749 001 Nov 21, 2001 Jan DISC

TABLET; ORAL

DILTIAZEM HYDROCHLORIDE

&gt;D&gt; AB MYLAN 30MG A072838 004 Nov 05, 1992 Aug CAHN

&gt;A&gt; @ 30MG A072838 004 Nov 05, 1992 Aug CAHN

&gt;D&gt; AB 60MG A072838 003 Nov 05, 1992 Aug CAHN

&gt;A&gt; @ 60MG A072838 003 Nov 05, 1992 Aug CAHN

&gt;D&gt; AB 90MG A072838 002 Nov 05, 1992 Aug CAHN

&gt;A&gt; @ 90MG A072838 002 Nov 05, 1992 Aug CAHN

&gt;D&gt; AB 120MG A072838 001 Nov 05, 1992 Aug CAHN

&gt;A&gt; @ 120MG A072838 001 Nov 05, 1992 Aug CAHN

DIMENHYDRINATE

INJECTABLE; INJECTION

DIMENHYDRINATE

&gt;D&gt; @ WATSON LABS TEVA 50MG/ML A080615 001 Aug CRLD

&gt;A&gt; + @ 50MG/ML A080615 001 Aug CRLD

TABLET; ORAL

DIMENHYDRINATE

&gt;D&gt; @ WATSON LABS 50MG A085166 001 Aug CRLD

&gt;A&gt; + @ 50MG A085166 001 Aug CRLD

DIMETHYL FUMARATE

CAPSULE, DELAYED RELEASE; ORAL

DIMETHYL FUMARATE

AB LUPIN 120MG A210226 001 Oct 05, 2020 Jul CAHN

AB 240MG A210226 002 Oct 05, 2020 Jul CAHN

AB PHARMATHEN 120MG A210436 001 Mar 26, 2021 Mar NEWA

AB 240MG A210436 002 Mar 26, 2021 Mar NEWA

@ ZYDUS PHARMS 120MG A210538 001 Sep 24, 2020 Feb DISC

@ 240MG A210538 002 Sep 24, 2020 Feb DISC

TECFIDERA

AB + BIOGEN INC 120MG N204063 001 Mar 27, 2013 Apr CAHN

AB +! 240MG N204063 002 Mar 27, 2013 Apr CAHN

DINOPROSTONE

GEL; ENDOCERVICAL

PREPIDIL

+! PFIZER 0.5MG/3GM N019617 001 Dec 09, 1992 Jan CAHN

SUPPOSITORY; VAGINAL

PROSTIN E2

+! PFIZER 20MG N017810 001 Jan CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

&gt;D&gt; AP ! WEST-WARD PHARMS INT 50MG/ML A080817 002 Aug CRLD

&gt;A&gt; AP +! 50MG/ML A080817 002 Aug CRLD

DIPYRIDAMOLE

TABLET;ORAL

DIPYRIDAMOLE

AB	OXFORD PHARMS	25MG	A040542	001	Apr 21, 2006	Jan CMFD
AB		50MG	A040542	002	Apr 21, 2006	Jan CMFD
AB		75MG	A040542	003	Apr 21, 2006	Jan CMFD

DIROXIMEL FUMARATE

CAPSULE, DELAYED RELEASE;ORAL

VUMERTY

+! BIOGEN INC

231MG

N211855 001 Oct 29, 2019 Apr CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE;ORAL

DISOPYRAMIDE PHOSPHATE

@ MAYNE PHARMA

EQ 100MG BASE

A070173 001 May 31, 1985 Feb DISC

@

EQ 150MG BASE

A070173 002 May 31, 1985 Feb DISC

DISULFIRAM

TABLET;ORAL

ANTABUSE

>D> AB	ODYSSEY PHARMS	250MG	A088482	001	Dec 08, 1983	Aug CRLD
>A> AB	+	250MG	A088482	001	Dec 08, 1983	Aug CRLD
>D> AB	!	500MG	A088483	001	Dec 08, 1983	Aug CRLD
>A> AB	+!	500MG	A088483	001	Dec 08, 1983	Aug CRLD

DIVALPROEX SODIUM

CAPSULE, DELAYED REL PELLETS;ORAL

DIVALPROEX SODIUM

@ TEVA PHARMS USA

EQ 125MG VALPROIC ACID

A211505 001 Nov 17, 2020 May DISC

TABLET, DELAYED RELEASE;ORAL

DIVALPROEX SODIUM

@ ANCHEN PHARMS

EQ 500MG VALPROIC ACID

A078411 001 Nov 03, 2008 May DISC

TABLET, EXTENDED RELEASE;ORAL

DIVALPROEX SODIUM

AB	AMTA	EQ 250MG VALPROIC ACID	A214462	001	Mar 15, 2021	Mar NEWA
AB		EQ 500MG VALPROIC ACID	A214462	002	Mar 15, 2021	Mar NEWA

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	EUGIA PHARMA	20MG/2ML (10MG/ML)	A214575	001	Jun 25, 2021	Jun NEWA
AP		80MG/8ML (10MG/ML)	A214575	002	Jun 25, 2021	Jun NEWA
AP		160MG/16ML (10MG/ML)	A214575	003	Jun 25, 2021	Jun NEWA
AP	GLAND PHARMA LTD	20MG/2ML (10MG/ML)	A213510	001	Jul 01, 2021	Jun NEWA
AP		80MG/8ML (10MG/ML)	A213510	002	Jul 01, 2021	Jun NEWA
AP		160MG/16ML (10MG/ML)	A213510	003	Jul 01, 2021	Jun NEWA
AP	HIKMA	20MG/ML (20MG/ML)	A204490	001	Jan 14, 2021	Jan NEWA
AP		80MG/4ML (20MG/ML)	A204490	002	Jan 14, 2021	Jan NEWA
AP	HONG KONG	20MG/2ML (10MG/ML)	A209634	001	Aug 24, 2018	Jun CMFD
AP		80MG/8ML (10MG/ML)	A209634	002	Aug 24, 2018	Jun CMFD
AP		160MG/16ML (10MG/ML)	A209634	003	Aug 24, 2018	Jun CMFD
	@ INGENUS PHARMS LLC	20MG/2ML (10MG/ML)	A207563	001	Aug 31, 2017	Apr DISC
AP	+! SHILPA	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Apr CHRS
AP	+	20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Apr CRLD
AP		20MG/ML (20MG/ML)	N205934	001	Dec 22, 2015	Jan CAHN
AP	+	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Apr CHRS
AP	+	80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Apr CRLD
AP		80MG/4ML (20MG/ML)	N205934	002	Dec 22, 2015	Jan CAHN
AP	+	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Apr CHRS
AP	+	160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Apr CRLD
AP		160MG/8ML (20MG/ML)	N205934	003	Dec 22, 2015	Jan CAHN

DOFETILIDE

CAPSULE;ORAL

DOFETILIDE

@ RICONPHARMA LLC

0.125MG

A212410 001 Dec 27, 2019 Feb DISC

@

0.25MG

A212410 002 Dec 27, 2019 Feb DISC

@

0.5MG

A212410 003 Dec 27, 2019 Feb DISC

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

+ @ VALIDUS PHARMS	12.5MG/0.625ML (20MG/ML)	N020624	002	Sep 11, 1997	Feb CAHN
+ @	100MG/5ML (20MG/ML)	N020624	001	Sep 11, 1997	Feb CAHN
@	500MG/25ML (20MG/ML)	N020624	003	Dec 11, 2001	Feb CAHN

TABLET; ORAL

ANZEMET

+ @ VALIDUS PHARMS	50MG	N020623	001	Sep 11, 1997	Feb CAHN
+ @	100MG	N020623	002	Sep 11, 1997	Feb CAHN

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	ALEMBIC PHARMS LTD	EQ 2% BASE;EQ 0.5% BASE	A213099	001	May 04, 2021	Apr NEWA
AT	FDC LTD	EQ 2% BASE;EQ 0.5% BASE	A205295	001	Jun 13, 2019	Feb CMFD

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOPRAM

AP	+! HIKMA PHARMS	20MG/ML	N014879	001		Jul CAHN
----	-----------------	---------	---------	-----	--	----------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

@ MYLAN	EQ 1MG BASE	A075509	001	Oct 19, 2000	Jul DISC
@	EQ 2MG BASE	A075509	002	Oct 19, 2000	Jul DISC
@	EQ 4MG BASE	A075509	003	Oct 19, 2000	Jul DISC
@	EQ 8MG BASE	A075509	004	Oct 19, 2000	Jul DISC

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

DOXEPIN HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 10MG BASE	A215076	001	Apr 21, 2021	Apr NEWA
AB		EQ 25MG BASE	A215076	002	Apr 21, 2021	Apr NEWA
AB		EQ 50MG BASE	A215076	003	Apr 21, 2021	Apr NEWA
AB		EQ 75MG BASE	A215076	004	Apr 21, 2021	Apr NEWA
AB		EQ 100MG BASE	A215076	005	Apr 21, 2021	Apr NEWA
AB	APPCO	EQ 10MG BASE	A214908	001	Apr 01, 2021	Mar NEWA
AB		EQ 25MG BASE	A214908	002	Apr 01, 2021	Mar NEWA
AB		EQ 50MG BASE	A214908	003	Apr 01, 2021	Mar NEWA
AB		EQ 75MG BASE	A214908	004	Apr 01, 2021	Mar NEWA
AB		EQ 100MG BASE	A214908	005	Apr 01, 2021	Mar NEWA
>A>	@ CHARTWELL RX	EQ 10MG BASE	A210268	001	Sep 04, 2020	Aug CAHN
>A>	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Aug CAHN
>A>	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Aug CAHN
>A>	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Aug CAHN
>A>	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Aug CAHN
AB	LEADING PHARMA LLC	EQ 10MG BASE	A211619	001	Mar 09, 2021	Feb NEWA
AB		EQ 25MG BASE	A211619	002	Mar 09, 2021	Feb NEWA
AB		EQ 50MG BASE	A211619	003	Mar 09, 2021	Feb NEWA
AB		EQ 75MG BASE	A211619	004	Mar 09, 2021	Feb NEWA
AB		EQ 100MG BASE	A211619	005	Mar 09, 2021	Feb NEWA
AB		EQ 150MG BASE	A211618	001	Mar 01, 2021	Feb NEWA
>D>	@ UPSHER SMITH LABS	EQ 10MG BASE	A210268	001	Sep 04, 2020	Aug CAHN
>D>	@	EQ 10MG BASE	A210268	001	Sep 04, 2020	May CAHN
>D>	@	EQ 10MG BASE	A210268	001	Sep 04, 2020	Feb DISC
>D>	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Aug CAHN
>D>	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	May CAHN
>D>	@	EQ 25MG BASE	A210268	002	Sep 04, 2020	Feb DISC
>D>	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Aug CAHN
>D>	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	May CAHN
>D>	@	EQ 50MG BASE	A210268	003	Sep 04, 2020	Feb DISC
>D>	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Aug CAHN
>D>	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	May CAHN
>D>	@	EQ 75MG BASE	A210268	004	Sep 04, 2020	Feb DISC
>D>	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Aug CAHN
>D>	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	May CAHN
>D>	@	EQ 100MG BASE	A210268	005	Sep 04, 2020	Feb DISC

TABLET;ORAL

DOXEPEPIN HYDROCHLORIDE

AB	@ PAR PHARM INC	EQ 3MG BASE	A202510	001	Jul 24, 2020	Jan DISC
	@	EQ 6MG BASE	A202510	002	Jul 24, 2020	Jan DISC
AB	RK PHARMA	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan CAHN
		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

>D> AP	SUN PHARM	2MCG/ML (2MCG/ML)	A203875	001	Nov 14, 2019	Aug DISC
>A>	@	2MCG/ML (2MCG/ML)	A203875	001	Nov 14, 2019	Aug DISC
>D> AP		4MCG/2ML (2MCG/ML)	A203875	002	Nov 14, 2019	Aug DISC
>A>	@	4MCG/2ML (2MCG/ML)	A203875	002	Nov 14, 2019	Aug DISC

DOXORUBICIN HYDROCHLORIDE

INJECTABLE;INJECTION

DOXORUBICIN HYDROCHLORIDE

@ ALMAJECT 2MG/ML

A065515 001 Nov 08, 2012 Jul CAHN

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	@ MYLAN	EQ 50MG BASE	A208942	001	Jan 21, 2021	Jan DISC
	@	EQ 75MG BASE	A208942	001	Jan 21, 2021	Jan NEWA
AB		EQ 75MG BASE	A208942	002	Jan 21, 2021	Jan DISC
	@	EQ 100MG BASE	A208942	002	Jan 21, 2021	Jan NEWA
AB		EQ 100MG BASE	A208942	003	Jan 21, 2021	Jan DISC

MONODOX

AB	+	CHARTWELL RX	EQ 50MG BASE	N050641	002	Feb 10, 1992	Jun CMFD
AB	+		EQ 75MG BASE	N050641	003	Oct 18, 2006	Jun CMFD
AB	+		EQ 100MG BASE	N050641	001	Dec 29, 1989	Jun CMFD

FOR SUSPENSION;ORAL  
DOXYCYCLINE

AB	CHARTWELL	EQ 25MG BASE/5ML	A065454	001	Jul 16, 2008	Jun CAHN
----	-----------	------------------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

CAPSULE;ORAL

DOXYCYCLINE HYCLATE

AB	CHARTWELL	EQ 50MG BASE	A062500	001	Sep 11, 1984	Jun CAHN
AB		EQ 100MG BASE	A062500	002	Sep 11, 1984	Jun CAHN
	@ NOSTRUM LABS INC	EQ 50MG BASE	A209393	001	Dec 10, 2020	Jul DISC
	@	EQ 100MG BASE	A209393	002	Dec 10, 2020	Jul DISC

CAPSULE, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

@ BAUSCH EQ 75MG BASE

A065281 001 Dec 21, 2005 May CAHN

@ EQ 100MG BASE

A065281 002 Dec 21, 2005 May CAHN

INJECTABLE;INJECTION

DOXYCYCLINE HYCLATE

AP	WEST-WARD PHARMS INT	EQ 100MG BASE/VIAL	A062992	001	Feb 16, 1989	May CMFD
AP		EQ 200MG BASE/VIAL	A062992	002	Feb 16, 1989	May CMFD

TABLET;ORAL

DOXYCYCLINE HYCLATE

AB	CARIBE HOLDINGS	EQ 50MG BASE	A062269	003	Oct 05, 1983	Jul CTEC
AB	CHARTWELL	EQ 50MG BASE	A062505	002	Jul 27, 2021	Jul NEWA
AB		EQ 100MG BASE	A062505	001	Sep 11, 1984	Jun CAHN
AB		EQ 100MG BASE	A062505	001	Sep 11, 1984	Jun CAHN
	@ MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jul DISC
	@ ORYZA	EQ 100MG BASE	A213475	001	Mar 10, 2021	Apr DISC
AB		EQ 100MG BASE	A213475	001	Mar 10, 2021	Feb NEWA

TABLET, DELAYED RELEASE;ORAL

DOXYCYCLINE HYCLATE

>D>	@ MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	Aug CAHN
>A>	@	EQ 50MG BASE	A090431	003	May 23, 2016	Aug CAHN
	@	EQ 50MG BASE	A090431	003	May 23, 2016	Jul DISC
>D>	@	EQ 75MG BASE	A090431	001	Dec 28, 2010	Aug CAHN
>A>	@	EQ 75MG BASE	A090431	001	Dec 28, 2010	Aug CAHN
>D>	@	EQ 80MG BASE	A090431	004	Apr 29, 2016	Aug CAHN
>A>	@	EQ 80MG BASE	A090431	004	Apr 29, 2016	Aug CAHN
>D>	@	EQ 100MG BASE	A090431	002	Dec 28, 2010	Aug CAHN
>A>	@	EQ 100MG BASE	A090431	002	Dec 28, 2010	Aug CAHN

TABLET, DELAYED RELEASE;ORAL  
DOXYCYCLINE HYCLATE

>D>	@	EQ 200MG BASE	A090431	005	May 19, 2016	Aug CAHN
>A>	@	EQ 200MG BASE	A090431	005	May 19, 2016	Aug CAHN

DROSPIRENONE; ESTETROL

TABLET;ORAL  
NEXTSTELLIS  
+! MAYNE PHARMA 3MG;14.2MG

N214154	001	Apr 15, 2021	Apr NEWA
---------	-----	--------------	----------

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL  
DROSPIRENONE AND ETHINYL ESTRADIOL

AB	HLTHCARE	3MG;0.02MG	A203291	001	Jul 18, 2017	Jun CAHN
	@ JUBILANT CADISTA	3MG;0.02MG	A209423	001	Dec 22, 2017	Jun DISC
>D>	KYRA					
>D> AB	SUN PHARM	3MG;0.02MG	A202318	001	Jul 23, 2019	Aug DISC
>A>	@	3MG;0.02MG	A202318	001	Jul 23, 2019	Aug DISC
TABLET;ORAL-28						
	DROSPIRENONE AND ETHINYL ESTRADIOL					
	@ JUBILANT CADISTA	3MG;0.03MG	A210017	001	Sep 10, 2018	Jun DISC
>D>	KEMEYA					
>D> AB	SUN PHARM	3MG;0.03MG	A202138	001	Mar 13, 2019	Aug DISC
>A>	@	3MG;0.03MG	A202138	001	Mar 13, 2019	Aug DISC

DROXIDOPA

CAPSULE;ORAL  
DROXIDOPA

AB	AJANTA PHARMA LTD	100MG	A214391	001	Feb 18, 2021	Feb NFTG
AB		200MG	A214391	002	Feb 18, 2021	Feb NFTG
AB		300MG	A214391	003	Feb 18, 2021	Feb NFTG
AB	ALKEM LABS LTD	100MG	A213911	001	Feb 18, 2021	Feb NFTG
AB		200MG	A213911	002	Feb 18, 2021	Feb NFTG
AB		300MG	A213911	003	Feb 18, 2021	Feb NFTG
AB	ANNORA	100MG	A211726	002	Aug 09, 2021	Jul NEWA
AB		200MG	A211726	003	Aug 09, 2021	Jul NEWA
AB		300MG	A211726	001	Feb 18, 2021	Feb NFTG
AB	AUROBINDO PHARMA LTD	100MG	A214387	001	Feb 18, 2021	Feb NFTG
AB		200MG	A214387	002	Feb 18, 2021	Feb NFTG
AB		300MG	A214387	003	Feb 18, 2021	Feb NFTG
AB	BIONPHARMA INC	100MG	A213033	001	Apr 28, 2021	May CAHN
AB		200MG	A213033	002	Apr 28, 2021	May CAHN
AB		300MG	A213033	003	Apr 28, 2021	May CAHN
AB	BLUEPHARMA	100MG	A214543	001	May 05, 2021	Apr NEWA
AB		200MG	A214543	002	May 05, 2021	Apr NEWA
AB		300MG	A214543	003	May 05, 2021	Apr NEWA
AB	HIKMA PHARMS	100MG	A212835	001	Feb 18, 2021	Feb NFTG
AB		200MG	A212835	002	Feb 18, 2021	Feb NFTG
AB		300MG	A212835	003	Feb 18, 2021	Feb NFTG
AB	LUPIN PHARMS	100MG	A211652	001	Feb 18, 2021	Feb NFTG
AB		200MG	A211652	002	Feb 18, 2021	Feb NFTG
AB		300MG	A211652	003	Feb 18, 2021	Feb NFTG
AB	MSN PHARMS INC	100MG	A211741	001	Feb 18, 2021	Feb NFTG
AB		200MG	A211741	002	Feb 18, 2021	Feb NFTG
AB		300MG	A211741	003	Feb 18, 2021	Feb NFTG
AB	MYLAN API	100MG	A213033	001	Apr 28, 2021	Apr NEWA
AB		200MG	A213033	002	Apr 28, 2021	Apr NEWA
AB		300MG	A213033	003	Apr 28, 2021	Apr NEWA
AB	SCIEGEN PHARMS INC	100MG	A214017	001	Feb 18, 2021	Feb NFTG
AB		200MG	A214017	002	Feb 18, 2021	Feb NFTG
AB		300MG	A214017	003	Feb 18, 2021	Feb NFTG
AB	SUN PHARM	100MG	A214384	001	Feb 18, 2021	Feb NFTG
AB		200MG	A214384	002	Feb 18, 2021	Feb NFTG
AB		300MG	A214384	003	Feb 18, 2021	Feb NFTG
AB	TASMAN PHARMA	100MG	A213661	001	Feb 18, 2021	Feb NFTG
AB		200MG	A213661	002	Feb 18, 2021	Feb NFTG
AB		300MG	A213661	003	Feb 18, 2021	Feb NFTG
>D> AB	TEVA PHARMS USA INC	100MG	A213162	001	Feb 18, 2021	Aug DISC
>A>	@	100MG	A213162	001	Feb 18, 2021	Aug DISC
AB		100MG	A213162	001	Feb 18, 2021	Feb NFTG
>D> AB		200MG	A213162	002	Feb 18, 2021	Aug DISC
>A>	@	200MG	A213162	002	Feb 18, 2021	Aug DISC
AB		200MG	A213162	002	Feb 18, 2021	Feb NFTG

CAPSULE;ORAL  
DROXIDOPA

>D> AB		300MG	A213162	003	Feb 18, 2021	Aug DISC
>A>	@	300MG	A213162	003	Feb 18, 2021	Aug DISC
AB		300MG	A213162	003	Feb 18, 2021	Feb NFTG
AB	TRIS PHARMA INC	100MG	A214543	001	May 05, 2021	Jun CAHN
AB		200MG	A214543	002	May 05, 2021	Jun CAHN
AB		300MG	A214543	003	May 05, 2021	Jun CAHN
AB	ZYDUS PHARMS	100MG	A211818	001	Feb 18, 2021	Feb NFTG
AB		200MG	A211818	002	Feb 18, 2021	Feb NFTG
AB		300MG	A211818	003	Feb 18, 2021	Feb NFTG

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL  
DRIZALMA SPRINKLE  
+ SUN PHARMA GLOBAL EQ 20MG BASE  
+ EQ 30MG BASE  
+ EQ 40MG BASE  
+! EQ 60MG BASE

N212516	001	Jul 19, 2019	Apr CDFR
N212516	002	Jul 19, 2019	Apr CDFR
N212516	003	Jul 19, 2019	Apr CDFR
N212516	004	Jul 19, 2019	Apr CDFR

## DULOXETINE HYDROCHLORIDE

AB	SUNSHINE	EQ 20MG BASE	A212328	001	Feb 11, 2021	Feb NEWA
AB		EQ 30MG BASE	A212328	002	Feb 11, 2021	Feb NEWA
AB		EQ 60MG BASE	A212328	003	Feb 11, 2021	Feb NEWA

DUTASTERIDE

CAPSULE;ORAL  
AVODART  
AB +! WOODWARD 0.5MG  
DUTASTERIDE  
@ NOSTRUM LABS INC 0.5MG

N021319	001	Nov 20, 2001	Jul CAHN
A204705	001	Nov 20, 2015	Apr CAHN

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

AB	+! WOODWARD	0.5MG; 0.4MG	N022460	001	Jun 14, 2010	Jul CAHN
----	-------------	--------------	---------	-----	--------------	----------

DYDROGESTERONE

TABLET;ORAL  
GYNOREST  
@ SOLVAY 5MG  
@ 10MG

N017388	001	Jul CRLD
N017388	002	Jul CRLD

ECHOTHIOPHATE IODIDE

FOR SOLUTION;OPHTHALMIC  
PHOSPHOLINE IODIDE

>A>	@ FERA PHARMS LLC	0.03%	N011963	002	Aug CAHN
>A>	@	0.06%	N011963	004	Aug CAHN
>A>	+!	0.125%	N011963	001	Aug CAHN
>A>	@	0.25%	N011963	003	Aug CAHN
>D>	@ WYETH PHARMS	0.03%	N011963	002	Aug CAHN
>D>	@	0.06%	N011963	004	Aug CAHN
>D>	+!	0.125%	N011963	001	Aug CAHN
>D>	@	0.25%	N011963	003	Aug CAHN

ECONAZOLE NITRATE

AEROSOL, FOAM;TOPICAL  
ECOZA  
+! RESILIA PHARMS 1%

N205175	001	Oct 24, 2013	Feb CAHN
---------	-----	--------------	----------

EDETADE CALCIUM DISODIUM

INJECTABLE;INJECTION  
CALCIUM DISODIUM VERSENATE  
+! BAUSCH 200MG/ML  
TABLET;ORAL  
CALCIUM DISODIUM VERSENATE  
@ BAUSCH 500MG

N008922	001	May CAHN
N008922	002	May CAHN

EFAVIRENZ

TABLET;ORAL

EFAVIRENZ

AB STRIDES PHARMA 600MG A078509 001 Jun 16, 2021 Jun NEWA

EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+ @ AUROBINDO PHARMA LTD 600MG;300MG;300MG

N022343 001 Aug 15, 2018 Feb DISC

EFINACONAZOLE

SOLUTION;TOPICAL

EFINACONAZOLE

AB ACRUX DDS 10% A211969 001 Jun 21, 2021 Jun NEWA

AB AUROBINDO PHARMA LTD 10% A212066 001 Mar 29, 2021 Mar NEWA

AB TEVA PHARMS USA 10% A211827 001 Dec 16, 2020 Feb CTEC

JUBLIA

AB +! BAUSCH 10% N203567 001 Jun 06, 2014 Feb CTEC

ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

TABLET;ORAL

TRIKAFTA (COPACKAGED)

+ VERTEX PHARMS INC 50MG,37.5MG,25MG; 75MG

N212273 002 Jun 08, 2021 Jun NEWA

+! 100MG,75MG,50MG; 150MG

N212273 001 Oct 21, 2019 Jun CPOT

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

ELIGLUSTAT TARTRATE

&gt;A&gt; AB AIZANT EQ 84MG BASE A212463 001 Sep 08, 2021 Aug NFTG

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

AB APOTEX 200MG;300MG A208740 001 Jun 16, 2021 Jun NEWA

AB CIPLA 200MG;300MG A090958 001 Apr 02, 2021 Mar NEWA

AB LAURUS LABS LTD 200MG;300MG A212114 001 Jul 26, 2019 Jan CMFD

AB LUPIN LTD 200MG;300MG A204131 001 Jun 04, 2021 May NEWA

AB MACLEODS PHARMS LTD 200MG;300MG A203442 001 May 15, 2020 Feb CMFD

AB MYLAN 200MG;300MG A206436 001 Apr 09, 2018 Feb CMFD

AB STRIDES PHARMA 200MG;300MG A091055 001 Jan 13, 2021 Jan NEWA

AB ZYDUS PHARMS 100MG;150MG A212689 002 Jul 01, 2021 Jun NEWA

AB 133MG;200MG A212689 003 Jul 01, 2021 Jun NEWA

AB 167MG;250MG A212689 004 Jul 01, 2021 Jun NEWA

ENALAPRIL MALEATE

SOLUTION;ORAL

ENALAPRIL MALEATE

AB BIONPHARMA INC 1MG/ML A212408 001 Aug 10, 2021 Jul NFTG

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ MYLAN 5MG;12.5MG

A075624 001 Sep 18, 2001 Jul DISC

@ 10MG;25MG

A075624 002 Sep 18, 2001 Jul DISC

ENZALUTAMIDE

CAPSULE;ORAL

ENZALUTAMIDE

AB ACTAVIS LABS FL INC 40MG A209614 001 May 14, 2021 May NFTG

EPHEDRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

REZIPRES

+! ETON 23.5MG/5ML (4.7MG/ML)

N213536 001 Jun 14, 2021 Jun CAHN

+ @ 47MG/ML (47MG/ML)

N213536 002 Jun 14, 2021 Jun DISC

+! 47MG/ML (47MG/ML)

N213536 002 Jun 14, 2021 Jun CAHN

+ @ 47MG/5ML (9.4MG/ML)

N213536 003 Jun 14, 2021 Jun DISC

+! 47MG/5ML (9.4MG/ML)

N213536 003 Jun 14, 2021 Jun CAHN

+! SINTETICA SA 23.5MG/5ML (4.7MG/ML)

N213536 001 Jun 14, 2021 Jun NEWA

+! 47MG/ML (47MG/ML)

N213536 002 Jun 14, 2021 Jun NEWA

+! 47MG/5ML (9.4MG/ML)

N213536 003 Jun 14, 2021 Jun NEWA

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS  
AKOVAZ

>A>	+!	EXELA PHARMA	25MG/5ML (5MG/ML)	N 208289	002	Aug 02, 2021	Aug NEWA
AP		AUROBINDO PHARMA LTD	50MG/ML (50MG/ML)	A 214579	001	Jun 14, 2021	Jun NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION  
LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE

>A> AP	B BRAUN MEDICAL INC	0.005MG/ML;1.5%	A 208475	001	Sep 08, 2021	Aug NEWA
--------	---------------------	-----------------	----------	-----	--------------	----------

EPLERENONE

TABLET; ORAL  
EPLERENONE

AB		CHARTWELL RX	25MG	A 078482	001	Jul 30, 2008	Apr CAHN
AB	@	PIRAMAL HLTHCARE UK	50MG	A 078482	002	Jul 30, 2008	Apr CAHN
	@		25MG	A 212765	001	Aug 10, 2020	Feb DISC
	@		50MG	A 212765	002	Aug 10, 2020	Feb DISC
		INSPRA					
AB	+	UPJOHN	25MG	N 021437	001	Sep 27, 2002	Apr CAHN
AB	+!		50MG	N 021437	002	Sep 27, 2002	Apr CAHN
	@		100MG	N 021437	003	Sep 27, 2002	Apr CAHN

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION  
EPOPROSTENOL SODIUM

AP2		SUN PHARM	EQ 0.5MG BASE/VIAL	A 210473	001	Jan 15, 2021	Feb CTEC
AP			EQ 0.5MG BASE/VIAL	A 210473	001	Jan 15, 2021	Jan NFTG
AP2			EQ 1.5MG BASE/VIAL	A 210473	002	Jan 15, 2021	Feb CTEC
AP			EQ 1.5MG BASE/VIAL	A 210473	002	Jan 15, 2021	Jan NFTG
AP1		TEVA PHARMS USA	EQ 0.5MG BASE/VIAL	A 078396	001	Apr 23, 2008	Feb CTEC
AP1			EQ 1.5MG BASE/VIAL	A 078396	002	Apr 23, 2008	Feb CTEC
		FLOLAN					
AP1	+!	GLAXOSMITHKLINE LLC	EQ 0.5MG BASE/VIAL	N 020444	001	Sep 20, 1995	Feb CTEC
AP1	+!		EQ 1.5MG BASE/VIAL	N 020444	002	Sep 20, 1995	Feb CTEC
		VELETRI					
AP2	+!	ACTELION	EQ 0.5MG BASE/VIAL	N 022260	002	Jun 28, 2012	Feb CAHN
AP2	+!		EQ 1.5MG BASE/VIAL	N 022260	001	Jun 27, 2008	Feb CAHN
AP2	+!	ACTELION PHARMS LTD	EQ 0.5MG BASE/VIAL	N 022260	002	Jun 28, 2012	Feb CHRS
AP2	+		EQ 0.5MG BASE/VIAL	N 022260	002	Jun 28, 2012	Feb CTEC
AP2	+!		EQ 1.5MG BASE/VIAL	N 022260	001	Jun 27, 2008	Feb CTEC

EPTIFIBATIDE

INJECTABLE; INJECTION  
EPTIFIBATIDE

AP	!	MYLAN LABS LTD	2MG/ML	A 203258	001	Jul 20, 2018	Apr CHRS
AP	!		75MG/100ML	A 203258	002	Jul 20, 2018	Apr CHRS
>A> AP		SHUANGCHENG	2MG/ML	A 213081	001	Sep 07, 2021	Aug NEWA
		INTEGRILIN					
	+ @	SCHERING	2MG/ML	N 020718	001	May 18, 1998	Apr DISC
	+ @		75MG/100ML	N 020718	002	May 18, 1998	Apr DISC

ERGOCALCIFEROL

CAPSULE; ORAL  
DRISDOL

AA	+!	VALIDUS PHARMS	50,000 IU	N 003444	001		Feb CAHN
----	----	----------------	-----------	----------	-----	--	----------

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL  
ERLOTINIB HYDROCHLORIDE

AB		ALEMBIC PHARMS LTD	EQ 25MG BASE	A 214719	001	Jul 08, 2021	Jul NEWA
AB			EQ 100MG BASE	A 214719	002	Jul 08, 2021	Jul NEWA
AB			EQ 150MG BASE	A 214719	003	Jul 08, 2021	Jul NEWA
AB		MSN	EQ 25MG BASE	A 214366	001	May 10, 2021	Apr NEWA
AB			EQ 100MG BASE	A 214366	002	May 10, 2021	Apr NEWA
AB			EQ 150MG BASE	A 214366	003	May 10, 2021	Apr NEWA

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
ERTAPENEM SODIUM

>D>	AP	AUROBINDO PHARMA LTD	EQ 1GM BASE/VIAL	A209133	001	Jun 25, 2018	Aug CAHN
>A>	AP	EUGIA PHARMA	EQ 1GM BASE/VIAL	A209133	001	Jun 25, 2018	Aug CAHN
	AP	GLAND PHARMA LTD	EQ 1GM BASE/VIAL	A212040	001	Mar 26, 2021	Mar NEWA

ERYTHROMYCIN

SOLUTION; TOPICAL  
ERYTHRA-DERM

AT		SEPTALIS PHARMS	2%	A062687	001	Feb 05, 1988	Apr CMFD
		TABLET; ORAL					
		ERYTHROMYCIN					
AB		ORANGE	250MG	A213628	001	Jun 28, 2021	Jun NEWA
AB			500MG	A213628	002	Jun 28, 2021	Jun NEWA
AB		TEVA PHARMS USA INC	250MG	A214549	001	Feb 11, 2021	Feb NEWA
AB			500MG	A214549	002	Feb 11, 2021	Feb NEWA
		TABLET, DELAYED RELEASE; ORAL					
		ERYTHROMYCIN					
AB		TORRENT	250MG	A211975	001	Jul 26, 2021	Jul NEWA
AB			500MG	A211975	002	Jul 26, 2021	Jul NEWA

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL  
ERYTHROMYCIN ETHYLSUCCINATE

@ PAR PHARM INC	EQ 200MG BASE/5ML	A211991	001	Oct 23, 2019	May DISC
@	EQ 400MG BASE/5ML	A211991	002	Oct 23, 2019	May DISC

ESCITALOPRAM OXALATE

SOLUTION; ORAL  
ESCITALOPRAM OXALATE

>D>	AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Aug DISC
>A>		@	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	Aug DISC

ESLICARBAZEPINE ACETATE

TABLET; ORAL  
ESLICARBAZEPINE ACETATE

AB		DR REDDYS LABS LTD	200MG	A211238	001	Jun 29, 2021	Jun NFTG
AB			400MG	A211238	002	Jun 29, 2021	Jun NFTG
AB			600MG	A211238	003	Jun 29, 2021	Jun NFTG
AB			800MG	A211238	004	Jun 29, 2021	Jun NFTG

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS; ORAL  
ESOMEPRAZOLE MAGNESIUM

@ AMTA		EQ 20MG BASE	A213859	001	Nov 18, 2020	May DISC	
@		EQ 40MG BASE	A213859	002	Nov 18, 2020	May DISC	
AB		ETHYPHARM	EQ 20MG BASE	A090841	001	Mar 31, 2021	Mar NEWA
AB			EQ 40MG BASE	A090841	002	Mar 31, 2021	Mar NEWA
AB		GRAVITI PHARMS	EQ 20MG BASE	A213486	001	Mar 19, 2021	Mar NEWA
AB			EQ 40MG BASE	A213486	002	Mar 19, 2021	Mar NEWA
AB		INDCHEMIE HEALTH	EQ 40MG BASE	A210559	002	Feb 26, 2021	Feb NEWA

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

TABLET, DELAYED RELEASE; ORAL  
NAPROXEN AND ESOMEPRAZOLE MAGNESIUM

AB		MYLAN	EQ 20MG BASE; 375MG	A204920	001	Jul 20, 2021	Jul NEWA
AB			EQ 20MG BASE; 500MG	A204920	002	Jul 20, 2021	Jul NEWA

ESTRADIOI

CREAM; VAGINAL  
ESTRACE

>D>	AB	! ALLERGAN	0.01%	A086069	001	Jan 31, 1984	Aug CRLD
>A>	AB	+!	0.01%	A086069	001	Jan 31, 1984	Aug CRLD
		ESTRADIOL					
>A>	AB	ALVOGEN	0.01%	A209767	001	Mar 05, 2018	Aug CAHN
>D>	AB	ALVOGEN PINE BROOK	0.01%	A209767	001	Mar 05, 2018	Aug CAHN
	AB	PRASCO LABS LLC	0.01%	A212313	001	Jul 15, 2021	Jul NEWA

## FILM, EXTENDED RELEASE; TRANSDERMAL

ALORA

@ ALLERGAN	0.025MG/24HR
@	0.05MG/24HR
@	0.075MG/24HR
@	0.1MG/24HR

N020655	004	Apr 05, 2002	Jul DISC
N020655	001	Dec 20, 1996	Jul DISC
N020655	002	Dec 20, 1996	Jul DISC
N020655	003	Dec 20, 1996	Jul DISC

## INSERT, EXTENDED RELEASE; VAGINAL

ESTRING

+! PFIZER	0.0075MG/24HR
-----------	---------------

N020472	001	Apr 26, 1996	Jan CAHN
---------	-----	--------------	----------

## TABLET; ORAL

ESTRACE

>D>	@ BRISTOL MYERS SQUIBB	1MG
>A>	+ @	1MG
>D>	@	2MG
>A>	+ @	2MG

A084499	001		Aug CRLD
A084499	001		Aug CRLD
A084500	001		Aug CRLD
A084500	001		Aug CRLD

ESTRADIOL CYPTIONATE

## INJECTABLE; INJECTION

DEPO-ESTRADIOL

@ PFIZER	1MG/ML
@	3MG/ML
!	5MG/ML

A085470	001		Mar CAHN
A085470	002		Mar CAHN
A085470	003		Mar CAHN

ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX

## TABLET; ORAL

MYFEMBREE

+! MYOVANT SCIENCES	1MG; 0.5MG; 40MG
---------------------	------------------

N214846	001	May 26, 2021	May NEWA
---------	-----	--------------	----------

ESTROPIPATE

## TABLET; ORAL

OGEN .625

>D>	@ PFIZER	0.75MG
>A>	+ @	0.75MG
	@	0.75MG
	OGEN 1.25	
>D>	@ PFIZER	1.5MG
>A>	+ @	1.5MG
	@	1.5MG
	OGEN 2.5	
>D>	@ PFIZER	3MG
>A>	+ @	3MG
	@	3MG
	OGEN 5	
>D>	PFIZER	6MG
>A>	+	6MG
		6MG

A083220	001		Aug CRLD
A083220	001		Aug CRLD
A083220	001		Jan CAHN
A083220	002		Aug CRLD
A083220	002		Aug CRLD
A083220	002		Jan CAHN
A083220	003		Aug CRLD
A083220	003		Aug CRLD
A083220	003		Jan CAHN
A083220	004		Aug CRLD
A083220	004		Aug CRLD
A083220	004		Jan CAHN

ESZOPICLONE

## TABLET; ORAL

ESZOPICLONE

@ NOSTRUM LABS INC	1MG
@	2MG
@	3MG

A203087	001	May 08, 2019	Jan CAHN
A203087	002	May 08, 2019	Jan CAHN
A203087	003	May 08, 2019	Jan CAHN

ETHACRYNIC ACID

## TABLET; ORAL

ETHACRYNIC ACID

AB	ALVOGEN	25MG
----	---------	------

A205709	001	Jul 24, 2018	Jun CAHN
---------	-----	--------------	----------

ETHINYL ESTRADIOL; ETONOGESTREL

## RING; VAGINAL

ETHINYL ESTRADIOL; ETONOGESTREL

AB	TEVA PHARMS USA INC	0.015MG/24HR; 0.12MG/24HR
----	---------------------	---------------------------

A204305	001	Jan 13, 2021	Jan NEWA
---------	-----	--------------	----------

ETHINYL ESTRADIOL; LEVONORGESTREL

## TABLET; ORAL

SYLEVIA

>D>	SUN PHARM	0.03MG; 0.15MG
>A>	@	0.03MG; 0.15MG

A202988	001	Feb 06, 2019	Aug DISC
A202988	001	Feb 06, 2019	Aug DISC

>D>	TABLET;ORAL-28 CERINTA						
>D> AB1	SUN PHARM	0.02MG;0.1MG	A202817	001	Jan 07, 2019	Aug DISC	
>A>	@	0.02MG;0.1MG	A202817	001	Jan 07, 2019	Aug DISC	
<b><u>ETHINYL ESTRADIOL; NORELGESTROMIN</u></b>							
FILM, EXTENDED RELEASE;TRANSDERMAL ETHINYL ESTRADIOL AND NORELGESTROMIN							
AB	AMNEAL	0.035MG/24HR;0.15MG/24HR	A213950	001	Feb 25, 2021	Feb NEWA	
ONSURA							
>A> AB	TEVA PHARMS USA	0.035MG/24HR;0.15MG/24HR	A213977	001	Aug 25, 2021	Aug NEWA	
XULANE							
AB	! MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Feb CTEC	
<b><u>ETHINYL ESTRADIOL; NORETHINDRONE</u></b>							
TABLET;ORAL-21 NORINYL 1+35 21-DAY							
@ ALLERGAN	0.035MG;1MG	N017565	001			Jul DISC	
TABLET;ORAL-28 CYCLAFEM 1/35							
>D> AB	VINTAGE PHARMS LLC	0.035MG;1MG	A076337	001	Nov 12, 2010	Aug DISC	
>A>	@ CYCLAFEM 7/7/7	0.035MG;1MG	A076337	001	Nov 12, 2010	Aug DISC	
>D> AB	VINTAGE PHARMS LLC	0.035MG,0.035MG,0.035MG;0.5MG,0.75 MG,1MG	A076338	001	Nov 16, 2010	Aug DISC	
>A>	@ NORINYL 1+35 28-DAY	0.035MG,0.035MG,0.035MG;0.5MG,0.75 MG,1MG	A076338	001	Nov 16, 2010	Aug DISC	
@ ALLERGAN	0.035MG;1MG	N017565	002			Jul DISC	
<b><u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE</u></b>							
CAPSULE;ORAL GEMMILY							
AB	XIROMED	0.02MG;1MG	A213317	001	Nov 09, 2020	Mar CAHN	
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
AB	AMNEAL PHARMS	0.02MG;1MG	A214292	001	Jul 20, 2021	Jul NEWA	
TABLET;ORAL-21 GILDESS 1/20							
@ VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012	Jul DISC		
TABLET;ORAL-28 GILDESS FE 1/20							
@ VINTAGE PHARMS LLC	0.02MG;1MG	A077077	001	May 20, 2005	Jul DISC		
<b><u>ETHOSUXIMIDE</u></b>							
SYRUP;ORAL ZARONTIN							
>D> AA	! PARKE-DAVIS	250MG/5ML	A080258	001		Aug CRLD	
>A> AA	+!	250MG/5ML	A080258	001		Aug CRLD	
<b><u>ETODOLAC</u></b>							
TABLET;ORAL ETODOLAC							
>D>	@ BAYSHORE PHARMS LLC	400MG	A210704	001	Dec 16, 2020	Aug CMFD	
>A> AB		400MG	A210704	001	Dec 16, 2020	Aug CMFD	
	@	400MG	A210704	001	Dec 16, 2020	Jul DISC	
>D>	@	500MG	A210704	002	Dec 16, 2020	Aug CMFD	
>A> AB		500MG	A210704	002	Dec 16, 2020	Aug CMFD	
	@	500MG	A210704	002	Dec 16, 2020	Jul DISC	
<b><u>ETOMIDATE</u></b>							
INJECTABLE;INJECTION ETOMIDATE							
AP	CAPLIN	2MG/ML	A215028	001	Dec 18, 2020	Jul CMFD	
@	2MG/ML	A215028	001	Dec 18, 2020	Jun DISC		
<b><u>ETRAVIRINE</u></b>							
TABLET;ORAL ETRAVIRINE							
AB	@ AMNEAL	25MG	A214196	001	Jun 14, 2021	Jul DISC	
		25MG	A214196	001	Jun 14, 2021	Jun NFTG	
AB		100MG	A214196	002	Jun 14, 2021	Jun NFTG	
AB		200MG	A214196	003	Jun 14, 2021	Jun NFTG	

TABLET;ORAL INTELLENCE + JANSSEN R AND D	25MG	N 022187 003 Mar 26, 2012 Jul CTEC
<u>EVEROLIMUS</u>		
TABLET;ORAL AFINITOR		
AB + NOVARTIS EVEROLIMUS	10MG	N 022334 002 Mar 30, 2009 Feb CTEC
>D> @ BIOCON PHARMA	2.5MG	A 214182 001 Feb 11, 2021 Aug CMFD
>A> AB	2.5MG	A 214182 001 Feb 11, 2021 Aug CMFD
AB @	2.5MG	A 214182 001 Feb 11, 2021 Feb DISC
AB 2.5MG		A 214182 001 Feb 11, 2021 Feb NEWA
>D> @	5MG	A 214182 002 Feb 11, 2021 Aug CMFD
>A> AB	5MG	A 214182 002 Feb 11, 2021 Aug CMFD
AB @	5MG	A 214182 002 Feb 11, 2021 Feb DISC
AB 5MG		A 214182 002 Feb 11, 2021 Feb NEWA
>D> @	7.5MG	A 214182 003 Feb 11, 2021 Aug CMFD
>A> AB	7.5MG	A 214182 003 Feb 11, 2021 Aug CMFD
AB @	7.5MG	A 214182 003 Feb 11, 2021 Feb DISC
AB 7.5MG		A 214182 003 Feb 11, 2021 Feb NEWA
>D> @	10MG	A 214182 004 Feb 11, 2021 Aug CMFD
>A> AB	10MG	A 214182 004 Feb 11, 2021 Aug CMFD
AB @	10MG	A 214182 004 Feb 11, 2021 Feb DISC
AB 10MG		A 214182 004 Feb 11, 2021 Feb NEWA
AB BRECKENRIDGE	0.25MG	A 205432 001 May 20, 2021 May NEWA
AB 0.5MG		A 205432 002 May 20, 2021 May NEWA
AB 0.75MG		A 205432 003 May 20, 2021 May NEWA
AB 2.5MG		A 205426 001 Mar 05, 2021 Feb NEWA
AB 5MG		A 205426 002 Mar 05, 2021 Feb NEWA
AB 7.5MG		A 205426 003 Mar 05, 2021 Feb NEWA
AB 10MG		A 205426 004 Mar 05, 2021 Feb NEWA
>D> @ MYLAN	10MG	A 212936 004 Jun 08, 2020 Aug CMFD
>A> AB	10MG	A 212936 004 Jun 08, 2020 Aug CMFD
TABLET, FOR SUSPENSION;ORAL		
AFINITOR DISPERZ		
>D> + NOVARTIS PHARM	2MG	N 203985 001 Aug 29, 2012 Aug CTEC
>A> AB +	2MG	N 203985 001 Aug 29, 2012 Aug CTEC
>D> +	3MG	N 203985 002 Aug 29, 2012 Aug CTEC
>A> AB +	3MG	N 203985 002 Aug 29, 2012 Aug CTEC
>D> +!	5MG	N 203985 003 Aug 29, 2012 Aug CTEC
>A> AB +!	5MG	N 203985 003 Aug 29, 2012 Aug CTEC
EVEROLIMUS		
>D> @ MYLAN	2MG	A 210130 001 Apr 19, 2019 Aug CMFD
>A> AB	2MG	A 210130 001 Apr 19, 2019 Aug CMFD
>D> @	3MG	A 210130 002 Apr 19, 2019 Aug CMFD
>A> AB	3MG	A 210130 002 Apr 19, 2019 Aug CMFD
>D> @	5MG	A 210130 003 Apr 19, 2019 Aug CMFD
>A> AB	5MG	A 210130 003 Apr 19, 2019 Aug CMFD
<u>EXEMESTANE</u>		
TABLET;ORAL		
AROMASIN		
AB +! PFIZER	25MG	N 020753 001 Oct 21, 1999 Mar CAHN
>D> EXENATIDE		
>D> SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS		
>D> BYDUREON BCISE		
>D> +! ASTRazeneca AB	2MG/0.85ML (2MG/0.85ML)	N 209210 001 Oct 20, 2017 Aug CAIN
<u>EXENATIDE SYNTHETIC</u>		
FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS		
BYDUREON		
+ @ ASTRazeneca AB	2MG/VIAL	N 022200 001 Jan 27, 2012 Feb DISC
BYDUREON PEN		
+ @ ASTRazeneca AB	2MG	N 022200 002 Feb 28, 2014 Feb DISC
>A> SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS		
>A> BYDUREON BCISE		
>A> +! ASTRazeneca AB	2MG/0.85ML (2MG/0.85ML)	N 209210 001 Oct 20, 2017 Aug CAIN

EZETIMIBE

TABLET;ORAL

ZETIA

AB +! ORGANON 10MG N021445 001 Oct 25, 2002 Feb CAHN

EZETIMIBE; ROSUVASTATIN CALCIUM

TABLET;ORAL

ROSZET

+ ALTHERA PHARMS	10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021	Mar NEWA
+	10MG;EQ 5MG BASE	N213072	001	Mar 23, 2021	Mar NEWA
+	10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021	Mar NEWA
+	10MG;EQ 10MG BASE	N213072	002	Mar 23, 2021	Mar NEWA
+	10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021	Mar NEWA
+	10MG;EQ 20MG BASE	N213072	003	Mar 23, 2021	Mar NEWA
+!	10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021	Mar NEWA
+!	10MG;EQ 40MG BASE	N213072	004	Mar 23, 2021	Mar NEWA

EZETIMIBE; SIMVASTATIN

TABLET;ORAL

EZETIMIBE AND SIMVASTATIN

@ ANI PHARMS	10MG;10MG	A201890	001	Apr 26, 2017	Jul DISC
@	10MG;20MG	A201890	002	Apr 26, 2017	Jul DISC
@	10MG;40MG	A201890	003	Apr 26, 2017	Jul DISC
@	10MG;80MG	A201890	004	Apr 26, 2017	Jul DISC
@ MYLAN	10MG;10MG	A200082	001	Dec 17, 2020	Jan DISC
@	10MG;20MG	A200082	002	Dec 17, 2020	Jan DISC
@	10MG;40MG	A200082	003	Dec 17, 2020	Jan DISC
@	10MG;80MG	A200082	004	Dec 17, 2020	Jan DISC

VYTORIN

AB + ORGANON	10MG;10MG	N021687	001	Jul 23, 2004	Feb CAHN
AB +	10MG;20MG	N021687	002	Jul 23, 2004	Feb CAHN
AB +	10MG;40MG	N021687	003	Jul 23, 2004	Feb CAHN
AB +!	10MG;80MG	N021687	004	Jul 23, 2004	Feb CAHN

FAMOTIDINE

FOR SUSPENSION;ORAL

FAMOTIDINE

AB AKORN	40MG/5ML	A201995	001	May 30, 2014	Feb CAHN
AB NOVITIUM PHARMA	40MG/5ML	A215043	001	Apr 20, 2021	Apr NEWA

FAMOTIDINE; IBUPROFEN

TABLET;ORAL

IBUPROFEN AND FAMOTIDINE

AB ALKEM LABS LTD 26.6MG;800MG A211890 001 Aug 03, 2021 Jul NFTG

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL

FELODIPINE

@ JUBILANT GENERICS	2.5MG	A203983	001	Aug 19, 2016	Jun DISC
@	5MG	A203983	002	Aug 19, 2016	Jun DISC
@	10MG	A203983	003	Aug 19, 2016	Jun DISC

FENOFOBIRATE

TABLET;ORAL

FENOFOBIRATE

>A> AB ADAPTIS	54MG	A210606	001	Aug 17, 2018	Aug CAHN
>A> AB	160MG	A210606	002	Aug 17, 2018	Aug CAHN
AB AUSTARPHARMA	48MG	A208476	001	Feb 10, 2021	Jan NEWA
AB	145MG	A208476	002	Feb 10, 2021	Jan NEWA
>D> AB GRAVITI PHARMS	54MG	A210606	001	Aug 17, 2018	Aug CAHN
>D> AB	160MG	A210606	002	Aug 17, 2018	Aug CAHN

FENOPROFEN CALCIUM

CAPSULE;ORAL

FENOPROFEN CALCIUM

@ RISING	EQ 200MG BASE	A072394	001	Oct 17, 1988	Jan CAHN
@	EQ 300MG BASE	A072395	001	Oct 17, 1988	Jan CAHN

<u>FENTANYL CITRATE</u>						
INJECTABLE; INJECTION						
FENTANYL CITRATE						
AP	FRESENIUS KABI USA @	EQ 0.05MG BASE/ML EQ 0.05MG BASE/ML		A212086 001 Sep 01, 2020		Jun CMFD
<u>FERRIC CARBOXYMALTOSE</u>				A212086 001 Sep 01, 2020		Mar DISC
SOLUTION; INTRAVENOUS						
INJECTAFER						
+!	AM REGENT	1GM IRON/20ML (50MG IRON/ML)		N203565 003 Apr 28, 2021		May NEWA
<u>FERRIC MALTOL</u>						
CAPSULE; ORAL						
ACCRUFER						
+!	SHIELD TX	30MG IRON		N212320 001 Jul 25, 2019		Apr CMFD
<u>FERRIC OXYHYDROXIDE</u>						
INJECTABLE; INJECTION						
DEXFERRUM						
@	AM REGENT	EQ 50MG IRON/ML		N040024 001 Feb 23, 1996		May CAIN
FERRLCIT						
AB	+! SANOFI AVENTIS US	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)		N020955 001 Feb 18, 1999		May CPOT
AB	+! INFED	62.5MG/5ML		N020955 001 Feb 18, 1999		May CAIN
BP	+! ALLERGAN	EQ 100MG IRON/2ML (EQ 50MG IRON/ML)		N017441 001		May CAIN
IRON DEXTRAN						
@	SANOFI AVENTIS US	EQ 50MG IRON/ML		N010787 002		May CAIN
PROFERDEX						
@	NEW RIVER	EQ 50MG IRON/ML		N017807 001		May CAIN
SODIUM FERRIC GLUCONATE						
COMPLEX IN SUCROSE						
AB	WEST-WARD PHARMS INT	EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML)		A078215 001 Mar 31, 2011		May CPOT
AB		62.5MG/5ML		A078215 001 Mar 31, 2011		May CAIN
INJECTABLE; INTRAVENOUS						
VENOFER						
+!	AM REGENT	EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML)		N021135 002 Mar 20, 2005		May CPOT
+		EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML)		N021135 002 Mar 20, 2005		May CAIN
@		EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML)		N021135 005 Mar 29, 2013		May CPOT
@		EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML)		N021135 005 Mar 29, 2013		May CAIN
@		EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML)		N021135 003 Mar 29, 2005		May CPOT
@		EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML)		N021135 003 Mar 29, 2005		May CAIN
+!		EQ 100MG IRON/5ML (EQ 20MG IRON/ML)		N021135 001 Nov 06, 2000		May CPOT
+!		EQ 100MG BASE/5ML (EQ 20MG BASE/ML)		N021135 001 Nov 06, 2000		May CAIN
+		EQ 200MG IRON/10ML (EQ 20MG IRON/ML)		N021135 004 Feb 09, 2007		May CPOT
+		EQ 200MG BASE/10ML (EQ 20MG BASE/ML)		N021135 004 Feb 09, 2007		May CAIN
TABLET, CHEWABLE; ORAL						
VELPHORO						
+!	VIFOR FRESENIUS	EQ 500MG IRON		N205109 001 Nov 27, 2013		May CPOT
+!		500MG		N205109 001 Nov 27, 2013		May CAIN
<u>FERUMOXYTOL</u>						
SOLUTION; INTRAVENOUS						
FERAHEME						
AB	+! COVIS	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)		N022180 001 Jun 30, 2009		Mar CAHN
FERUMOXYTOL						
AB	SANDOZ INC	EQ 510MG IRON/17ML (EQ 30MG IRON/ML)		A206604 001 Jan 15, 2021		Jan NFTG

FEXINIDAZOLE

TABLET;ORAL

FEXINIDAZOLE

+!	DNDI	600MG	N214429	001	Jul 16, 2021	Jul NEWA
+!	SANOFI	600MG	N214429	001	Jul 16, 2021	Jul CAHN

FINASTERIDE

TABLET;ORAL

FINASTERIDE

@	ACTAVIS TOTOWA TEVA	5MG	A077914	001	Mar 28, 2007	May DISC
---	---------------------	-----	---------	-----	--------------	----------

FINERENONE

TABLET;ORAL

KERENDIA

+	BAYER HLTHCARE	10MG	N215341	001	Jul 09, 2021	Jul NEWA
+!		20MG	N215341	002	Jul 09, 2021	Jul NEWA

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL

FINGOLIMOD HYDROCHLORIDE

>D>	AB	ALKEM LABS LTD	EQ 0.5MG BASE	A208004	001	Dec 30, 2020	Aug DISC
>A>		@	EQ 0.5MG BASE	A208004	001	Dec 30, 2020	Aug DISC
		@ APOTEX	EQ 0.5MG BASE	A207993	001	Dec 18, 2020	Jun DISC
	AB	DR REDDYS	EQ 0.5MG BASE	A208000	001	Mar 05, 2021	Feb NEWA
>D>	AB	GLENMARK PHARMS LTD	EQ 0.5MG BASE	A207985	001	Jun 18, 2020	Aug DISC
>A>		@	EQ 0.5MG BASE	A207985	001	Jun 18, 2020	Aug DISC
		@ MYLAN	EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan DISC
	AB		EQ 0.5MG BASE	A208005	001	Jan 19, 2021	Jan NEWA
>D>	AB	STRIDES PHARMA	EQ 0.5MG BASE	A207971	001	Jun 29, 2020	Aug DISC
>A>		@	EQ 0.5MG BASE	A207971	001	Jun 29, 2020	Aug DISC
>D>	AB	SUN PHARM	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Aug DISC
>A>		@	EQ 0.5MG BASE	A208014	001	Dec 04, 2019	Aug DISC
		@ ZYDUS PHARMS	EQ 0.5MG BASE	A207994	001	Oct 14, 2020	Mar DISC

FLECAINIDE ACETATE

TABLET;ORAL

TAMBOCOR

+	@ ALVOGEN	50MG	N018830	004	Aug 23, 1988	Jun CAHN
+	@	100MG	N018830	001	Oct 31, 1985	Jun CAHN
+	@	150MG	N018830	003	Jun 03, 1988	Jun CAHN
	@	200MG	N018830	002	Oct 31, 1985	Jun CAHN
+	@ CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Jan DISC
+	@	100MG	N018830	001	Oct 31, 1985	Jan DISC
+	@	150MG	N018830	003	Jun 03, 1988	Jan DISC

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP	CARDINAL HEALTH 414	20-500mCi/ML	A203603	002	Sep 27, 2018	Mar NEWA
	NUKEMED	4-500mCi/ML	A203911	001	Apr 22, 2015	Jan CAHN
AP	PHARMALOGIC HLDGS	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan CAHN
AP	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar CTEC

FLUMAZENIL

INJECTABLE; INJECTION

FLUMAZENIL

AP	BAXTER HLTHCARE CORP	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Mar CMFD
AP		1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Mar CMFD

FLUOCINOLONE ACETONIDE

OIL;TOPICAL

FLUOCINOLONE ACETONIDE

AT	@ AKORN	0.01%	A091514	001	Jun 25, 2015	Jul DISC
AT	SOLARIS PHARMA CORP	0.01%	A212760	001	Apr 02, 2021	Mar NEWA
AT		0.01%	A212761	001	Apr 02, 2021	Mar NEWA

OIL/DROPS;OTIC

FLUOCINOLONE ACETONIDE

AT	@ AKORN	0.01%	A202705	001	Sep 09, 2016	Jul DISC
AT	SOLARIS PHARMA CORP	0.01%	A212762	001	Apr 02, 2021	Mar NEWA
AT	TASMAN PHARMA	0.01%	A213264	001	Feb 05, 2021	Jan NEWA

FLUOCINONIDE

CREAM;TOPICAL	LIDEX					
+ @ ALVOGEN	0.05%	N 016908	002			Jun CAHN
LIDEX-E						
AB2 + ALVOGEN	0.05%	N 016908	003			Jun CAHN
VANOS						
AB +! BAUSCH	0.1%	N 021758	001	Feb 11, 2005		May CAHN
GEL;TOPICAL						
FLUOCINONIDE						
AB + ALVOGEN	0.05%	N 017373	001			Jun CAHN
OINTMENT;TOPICAL						
LIDEX						
AB + ALVOGEN	0.05%	N 016909	002			Jun CAHN
SOLUTION;TOPICAL						
LIDEX						
AT + ALVOGEN	0.05%	N 018849	001	Apr 06, 1984		Jun CAHN

FLUOROURACIL

CREAM;TOPICAL						
>D> FLUOROPLEX						
>D> +! ALMIRALL	1%	N 016988	001			Aug DISC
>A> + @	1%	N 016988	001			Aug DISC
INJECTABLE;INJECTION						
FLUOROURACIL						
AP FRESENIUS KABI USA	500MG/10ML (50MG/ML)	A 040279	002	Sep 30, 1998		May CHRS
AP	1GM/20ML (50MG/ML)	A 040279	001	Sep 30, 1998		May CHRS
AP	2.5GM/50ML (50MG/ML)	A 040278	001	Sep 30, 1998		May CHRS
AP	5GM/100ML (50MG/ML)	A 040278	002	Sep 30, 1998		May CHRS
	@ NOVAST LABS	5GM/100ML (50MG/ML)	A 209271	001	Dec 11, 2019	Mar CPOT
AP TEVA PHARMS USA	500MG/10ML (50MG/ML)	A 040333	001	Jan 27, 2000		May CHRS

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL						
FLUOXETINE HYDROCHLORIDE						
@ ACCORD HLTHCARE	EQ 10MG BASE	A 202729	001	Aug 27, 2020		Feb DISC
@	EQ 20MG BASE	A 202729	002	Aug 27, 2020		Feb DISC
@	EQ 40MG BASE	A 202729	003	Aug 27, 2020		Feb DISC
@ GRANULES	EQ 10MG BASE	A 078143	001	Jan 16, 2008		Jun CAHN
@	EQ 20MG BASE	A 078143	002	Jan 16, 2008		Jun CAHN
@	EQ 40MG BASE	A 078143	003	Jan 16, 2008		Jun CAHN
>D> @ HERITAGE PHARMS INC	EQ 10MG BASE	A 201336	001	Oct 01, 2012		Aug CMFD
>A> AB1	EQ 10MG BASE	A 201336	001	Oct 01, 2012		Aug CMFD
>D> @	EQ 20MG BASE	A 201336	002	Oct 01, 2012		Aug CMFD
>A> AB1	EQ 20MG BASE	A 201336	002	Oct 01, 2012		Aug CMFD
>D> @	EQ 40MG BASE	A 201336	003	Oct 01, 2012		Aug CMFD
>A> AB	EQ 40MG BASE	A 201336	003	Oct 01, 2012		Aug CMFD
TABLET;ORAL						
FLUOXETINE HYDROCHLORIDE						
AB ! DR REDDYS LABS LTD	EQ 20MG BASE	A 076006	002	Apr 23, 2018		Jul CHRS
@ MYLAN	EQ 10MG BASE	A 075755	001	Aug 02, 2001		Jul DISC
@	EQ 20MG BASE	A 075755	002	Aug 02, 2001		Jul DISC
TORRENT	EQ 10MG BASE	A 206937	001	Oct 21, 2016		Mar CHRS
!	EQ 20MG BASE	A 206937	002	Oct 21, 2016		Mar CHRS
AB UPSHER SMITH LABS	EQ 10MG BASE	A 211696	001	Jan 30, 2019		May CAHN
AB SARAFEM	EQ 20MG BASE	A 211696	002	Jan 30, 2019		May CAHN
+ @ APIL	EQ 10MG BASE	N 021860	001	May 19, 2006		Mar DISC
+ @	EQ 20MG BASE	N 021860	003	May 19, 2006		Mar DISC

FLUOXYMESTERONE

TABLET;ORAL						
FLUOXYMESTERONE						
@ UPSHER SMITH LABS	10MG	A 088342	001	Oct 21, 1983		Jan DISC

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

## FLUPHENAZINE HYDROCHLORIDE

AB	CEROVENE INC	1MG	A214534	001	Jan 07, 2021	Jan NEWA
AB		2.5MG	A214534	002	Jan 07, 2021	Jan NEWA
AB		5MG	A214534	003	Jan 07, 2021	Jan NEWA
AB		10MG	A214534	004	Jan 07, 2021	Jan NEWA
AB	NOVITIUM PHARMA	1MG	A214674	001	Mar 01, 2021	Feb NEWA
AB		2.5MG	A214674	002	Mar 01, 2021	Feb NEWA
AB		5MG	A214674	003	Mar 01, 2021	Feb NEWA
AB		10MG	A214674	004	Mar 01, 2021	Feb NEWA
AB	ZYDUS	1MG	A214552	001	May 27, 2021	May NEWA
AB		2.5MG	A214552	002	May 27, 2021	May NEWA
AB		5MG	A214552	003	May 27, 2021	May NEWA
AB		10MG	A214552	004	May 27, 2021	May NEWA

FLURBIPROFEN SODIUM

SOLUTION/DROPS;OPHTHALMIC

## FLURBIPROFEN SODIUM

!	BAUSCH AND LOMB	0.03%	A074447	001	Jan 04, 1995	Jan CHRS
		0.03%	A074447	001	Jan 04, 1995	Jan CTEC
	OCUFEN					
+	@ ALLERGAN	0.03%	N019404	001	Dec 31, 1986	Jan DISC

FLUTAMIDE

CAPSULE;ORAL

## FLUTAMIDE

!	CIPLA	125MG	A075780	001	Sep 19, 2001	Mar DISC
!	PAR PHARM	125MG	A075298	001	Sep 18, 2001	Mar CHRS
		125MG	A075298	001	Sep 18, 2001	Mar CTEC
!	WAYLIS THERAP	125MG	A075298	001	Sep 18, 2001	Jun CAHN

FLUTICASONE PROPIONATE

POWDER;INHALATION

## ARMONAIR RESPICLICK

+	TEVA PHARM	0.03MG/INH	N208798	007	Jul 09, 2021	Jul NEWA
---	------------	------------	---------	-----	--------------	----------

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

## FLUVASTATIN SODIUM

AB	BEIJING	EQ 80MG BASE	A209397	001	Apr 26, 2021	Apr NEWA
----	---------	--------------	---------	-----	--------------	----------

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

## FLUVOXAMINE MALEATE

@	BIONPHARMA INC	100MG	A212182	002	Sep 16, 2020	Feb DISC
---	----------------	-------	---------	-----	--------------	----------

FOLIC ACID

TABLET;ORAL

## FOLIC ACID

>D> AA	! WATSON LABS	1MG	A080680	001		Aug CRLD
>A> AA	+!	1MG	A080680	001		Aug CRLD

FORMOTEROL FUMARATE

SOLUTION;INHALATION

## FORMOTEROL FUMARATE

AN	TEVA PHARMS USA INC	0.02MG/2ML	A091141	001	Jun 22, 2021	Jun NFTG
----	---------------------	------------	---------	-----	--------------	----------

FORMOTEROL FUMARATE; MOMETASONE FUROATE

AEROSOL, METERED;INHALATION

## DULERA

+	ORGANON	0.005MG/INH;0.05MG/INH	N022518	003	Aug 12, 2019	Jun CAHN
+	!	0.005MG/INH;0.1MG/INH	N022518	001	Jun 22, 2010	Jun CAHN
+	!	0.005MG/INH;0.2MG/INH	N022518	002	Jun 22, 2010	Jun CAHN

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS

## FOSAPREPITANT DIMEGLUMINE

AP	ASPIRO	EQ 150MG BASE/VIAL	A214616	001	Jul 29, 2021	Jul NEWA
AP	AUROBINDO PHARMA LTD	EQ 150MG BASE/VIAL	A210625	001	Jan 12, 2021	Jan NEWA
	@ MYLAN LABS LTD	EQ 115MG BASE/VIAL	A204015	001	Sep 05, 2019	Mar DISC

	POWDER; INTRAVENOUS FOSAPREPITANT DIMEGLUMINE					
AP	PRAZGEN	EQ 150MG BASE/VIAL	A211624	001	Sep 05, 2019	Jun CAHN
<b><u>FOSCARNET SODIUM</u></b>						
	INJECTABLE; INJECTION FOSCARNET SODIUM					
AP	FRESENIUS KABI USA	2.4GM/100ML	A212483	001	Jan 29, 2021	Jan NEWA
AP	GLAND PHARMA LTD	2.4GM/100ML	A213001	001	Apr 21, 2021	Apr NEWA
	FOSCAVIR					
AP	+! CLINIGEN HLTHCARE	2.4GM/100ML	N020068	001	Sep 27, 1991	Jan CTEC
<b><u>FOSDENOPTERIN HYDROBROMIDE</u></b>						
	POWDER; INTRAVENOUS NULIBRY					
	+! ORIGIN	EQ 9.5MG BASE/VIAL	N214018	001	Feb 26, 2021	Feb NEWA
<b><u>FOSINOPRIL SODIUM</u></b>						
	TABLET; ORAL FOSINOPRIL SODIUM					
>A> AB	CHARTWELL RX	10MG	A076483	001	Apr 23, 2004	Aug CAHN
>A> AB		20MG	A076483	002	Apr 23, 2004	Aug CAHN
>A> AB		40MG	A076483	003	Apr 23, 2004	Aug CAHN
>D> AB	UPSHER SMITH LABS	10MG	A076483	001	Apr 23, 2004	Aug CAHN
>D> AB		20MG	A076483	002	Apr 23, 2004	Aug CAHN
>D> AB		40MG	A076483	003	Apr 23, 2004	Aug CAHN
<b><u>FOSPHENYTOIN SODIUM</u></b>						
	SOLUTION; INTRAVENOUS SESQUENT					
+ @	SEDO PHARMS LLC	EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML)	N210864	001	Nov 05, 2020	Jul DISC
+ @		EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML)	N210864	002	Nov 05, 2020	Jul DISC
<b><u>FULVESTRANT</u></b>						
	INJECTABLE; INTRAMUSCULAR FULVESTRANT					
AO	APOTEX	50MG/ML	A211730	001	Jun 11, 2021	Jun NEWA
>D> AO	AUROMEDICS PHARMA	50MG/ML	A208811	001	Jul 23, 2019	Aug CAHN
AO		50MG/ML	A208811	001	Jul 23, 2019	Jan CAHN
>A> AO	EUGIA PHARMA	50MG/ML	A208811	001	Jul 23, 2019	Aug CAHN
>A> AO	XIROMED	50MG/ML	A213553	001	Aug 13, 2021	Aug CAHN
AO	ZYDUS PHARMS	50MG/ML	A215234	001	Jul 29, 2021	Jul NEWA
<b><u>FUROSEMIDE</u></b>						
	INJECTABLE; INJECTION FUROSEMIDE					
AP	ACCORD HLTHCARE	10MG/ML	A070017	001	Dec 15, 1986	Apr CMFD
AP	ATHENEX INC	10MG/ML	A214766	001	Jan 27, 2021	Jan NEWA
@	HIKMA	10MG/ML	N018267	001		Jun CAHN
@	HIKMA PHARMS	10MG/ML	N018267	001		Jul CAHN
	TABLET; ORAL LASIX					
AB	+ VALIDUS PHARMS	20MG	N016273	002		Feb CAHN
AB	+	40MG	N016273	001		Feb CAHN
AB	+!	80MG	N016273	003		Feb CAHN
<b><u>GABAPENTIN</u></b>						
	CAPSULE; ORAL GABAPENTIN					
AB	ASCENT PHARMS INC	100MG	A214956	001	May 10, 2021	Apr NEWA
AB		300MG	A214956	002	May 10, 2021	Apr NEWA
AB		400MG	A214956	003	May 10, 2021	Apr NEWA
AB	GRAVITI PHARMS	100MG	A207099	001	Mar 24, 2017	Jun CAHN
AB		300MG	A207099	002	Mar 24, 2017	Jun CAHN
AB		400MG	A207099	003	Mar 24, 2017	Jun CAHN
AB	ZHEJIANG YONGTAI	100MG	A213603	001	Aug 17, 2020	Apr CMFD
@		100MG	A213603	001	Aug 17, 2020	Feb DISC
AB		300MG	A213603	002	Aug 17, 2020	Apr CMFD
@		300MG	A213603	002	Aug 17, 2020	Feb DISC
AB		400MG	A213603	003	Aug 17, 2020	Apr CMFD
@		400MG	A213603	003	Aug 17, 2020	Feb DISC

GALANTAMINE HYDROBROMIDE

TABLET;ORAL

GALANTAMINE HYDROBROMIDE

AB	! YABAO PHARM RAZADYNE	EQ 4MG BASE	A077604	001	Feb 06, 2009	May CHRS
+ @ JANSSEN PHARMS	EQ 4MG BASE	N021169	001	Feb 28, 2001	May DISC	
+ @	EQ 8MG BASE	N021169	002	Feb 28, 2001	May DISC	
+ @	EQ 12MG BASE	N021169	003	Feb 28, 2001	May DISC	

GANCICLOVIR SODIUM

INJECTABLE;INJECTION

CYTOVENE

+ @ CHEPLAPHARM GANCICLOVIR SODIUM

AP	! PHARMASCIENCE INC	EQ 500MG BASE/VIAL	N019661	001	Jun 23, 1989	Jul DISC
		EQ 500MG BASE/VIAL	A207645	001	Dec 08, 2017	Jul CHRS

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

AT	AKORN	0.5%	A203189	001	Sep 03, 2014	Feb CAHN
	@ MYLAN	0.5%	A206446	001	Jun 08, 2018	Jun DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP	HIKMA INTL PHARMS	EQ 200MG BASE/VIAL	A206617	001	Jun 25, 2021	Jun NEWA
AP		EQ 1GM BASE/VIAL	A206617	002	Jun 25, 2021	Jun NEWA
AP	! JIANGSU HANSOH PHARM	EQ 200MG BASE/VIAL	A202485	001	May 07, 2013	Feb CHRS
AP	!	EQ 1GM BASE/VIAL	A202485	002	May 07, 2013	Feb CHRS
AP	MEITHEAL	200MG/5.26ML (38MG/ML)	A212129	001	Dec 11, 2020	Jan CAHN
AP		1GM/26.3ML (38MG/ML)	A212129	002	Dec 11, 2020	Jan CAHN
AP		2GM/52.6ML (38MG/ML)	A212129	003	Dec 11, 2020	Jan CAHN
	GEMZAR					
+ @ LILLY		EQ 200MG BASE/VIAL	N020509	001	May 15, 1996	Feb DISC
+ @		EQ 1GM BASE/VIAL	N020509	002	May 15, 1996	Feb DISC

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

AB	ASCENT PHARMS INC	600MG	A214603	001	Jan 13, 2021	Jan NEWA
----	-------------------	-------	---------	-----	--------------	----------

GENTAMICIN SULFATE

INJECTABLE;INJECTION

GENTAMICIN SULFATE

@ HIKMA PHARMS	EQ 10MG BASE/ML	A062251	002		Jun CAHN
@	EQ 40MG BASE/ML	A062251	001		Jun CAHN

GLECAPREVIR; PIBRENTASVIR

PELLETS;ORAL

MAYVRET

+! ABBVIE INC	50MG;20MG/PACKET	N215110	001	Jun 10, 2021	Jun NEWA
---------------	------------------	---------	-----	--------------	----------

GLIPIZIDE

TABLET;ORAL

GLUCOTROL

>D>	@ PFIZER	2.5MG	N017783	003	May 11, 1993	Aug CRLD
>A>	+ @	2.5MG	N017783	003	May 11, 1993	Aug CRLD

GLYBURIDE

TABLET;ORAL

GLYNASE

AB	+ PFIZER	1.5MG	N020051	001	Mar 04, 1992	Feb CAHN
AB	+	3MG	N020051	002	Mar 04, 1992	Feb CAHN
	+ @	4.5MG	N020051	003	Sep 24, 1993	Feb CAHN
AB	+!	6MG	N020051	004	Sep 24, 1993	Feb CAHN
	MICRONASE					
+ @ PFIZER		1.25MG	N017498	001	May 01, 1984	Feb CAHN
@		2.5MG	N017498	002	May 01, 1984	Feb CAHN
+ @		5MG	N017498	003	May 01, 1984	Feb CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION

GLYCOPYRROLATE

AP	ATHENEX INC	0.2MG/ML	A210083	001	Feb 21, 2020	Jan CAHN
AP	HONG KONG	0.2MG/ML	A212802	001	Jul 06, 2021	Jun NEWA
AP	XIROMED	0.2MG/ML	A212227	001	Mar 04, 2021	Feb NEWA
	ROBINUL					
+ @	HIKMA PHARMS	0.2MG/ML	N017558	001		Jul CAHN
	SOLUTION; ORAL					
	GLYCOPYRROLATE					
AA	PAR PHARM INC	1MG/5ML	A204438	001	Aug 09, 2021	Jul NFTG
	TABLET; ORAL					
	ROBINUL					
AA	+ CASPER PHARMA LLC	1MG	N012827	001		Jun CMFD
	ROBINUL FORTE					
AA	+ CASPER PHARMA LLC	2MG	N012827	002		Jun CMFD

GLYCOPYRRONIUM TOSYLATE

CLOTH; TOPICAL

QBREXZA

+! JOURNEY

EQ 2.4% BASE

N210361 001 Jun 28, 2018 May CAHN

GONADORELIN HYDROCHLORIDE

INJECTABLE; INJECTION

FACTREL

@ HIKMA PHARMS

EQ 0.1MG BASE/VIAL

N018123 001 Sep 30, 1982 Jul CAHN

@

EQ 0.2MG BASE/VIAL

N018123 002 Sep 30, 1982 Jul CAHN

@

EQ 0.5MG BASE/VIAL

N018123 003 Sep 30, 1982 Jul CAHN

GRANISETRON HYDROCHLORIDE

SOLUTION; ORAL

GRANISOL

@ INTRA SANA LABS

EQ 2MG BASE/10ML

A078334 001 Feb 28, 2008 Jan CAHN

GUANABENZ ACETATE

TABLET; ORAL

GUANABENZ ACETATE

>A>	@ CHARTWELL RX	EQ 4MG BASE	A074517	001	Sep 30, 1998	Aug CAHN
>A>	@	EQ 8MG BASE	A074517	002	Sep 30, 1998	Aug CAHN
>D>	@ YAOPHARMA CO LTD	EQ 4MG BASE	A074517	001	Sep 30, 1998	Aug CAHN
>D>	@	EQ 8MG BASE	A074517	002	Sep 30, 1998	Aug CAHN

GUANFACINE HYDROCHLORIDE

TABLET; ORAL

GUANFACINE HYDROCHLORIDE

AB	! AMNEAL PHARM	EQ 2MG BASE	A075109	002	Nov 25, 1998	Jan CHRS
	@ MYLAN	EQ 1MG BASE	A074796	001	Jan 27, 1997	Jan DISC
	@	EQ 2MG BASE	A074796	002	Jan 27, 1997	Jan DISC
AB	UNICHEM	EQ 1MG BASE	A214689	001	Mar 03, 2021	Feb NEWA
AB		EQ 2MG BASE	A214689	002	Mar 03, 2021	Feb NEWA

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

AB	@ YICHANG HUMANWELL	EQ 1MG BASE	A213428	001	Nov 25, 2020	May DISC
	@	EQ 2MG BASE	A213428	002	Nov 25, 2020	May DISC
	@	EQ 3MG BASE	A213428	003	Nov 25, 2020	May DISC
	@	EQ 4MG BASE	A213428	004	Nov 25, 2020	May DISC

HALCINONIDE

CREAM; TOPICAL

HALCINONIDE

>A> AB	GLASSHOUSE PHARMS	0.1%	A214723	001	Sep 08, 2021	Aug NEWA
	SOLUTION; TOPICAL					
	HALOG					
+!	SUN PHARM INDs INC	0.1%	N017823	001		Apr CRLD

HALOBETASOL PROPIONATE

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

@ COSETTE 0.05%  
ULTRAVATE  
+ @ SUN PHARM IND'S INC 0.05%A077721 001 Sep 07, 2006 Mar DISC  
N019968 001 Dec 17, 1990 Mar DISCHALOPERIDOL

TABLET;ORAL

HALOPERIDOL

AB CYCLE PHARMS LTD  
AB 2MG  
AB 5MG  
AB 10MGA071130 001 Feb 17, 1987 Apr CMFD  
A071131 001 Feb 17, 1987 Apr CMFD  
A071132 001 May 12, 1987 Apr CMFDHALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

AO HONG KONG EQ 50MG BASE/ML  
AO EQ 100MG BASE/MLA214507 001 Jul 26, 2021 Jul NEWA  
A214507 002 Jul 26, 2021 Jul NEWAHALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALDOL

+ @ ORTHO MCNEIL

EQ 2MG BASE/ML

N015922 001 Mar CRLD

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

@ BE PHARMS 1,000 UNITS/ML  
@ 10,000 UNITS/ML  
AP +! HIKMA PHARMS 1,000 UNITS/ML  
AP +! 5,000 UNITS/ML  
@ 5,000 UNITS/0.5ML  
AP +! 10,000 UNITS/ML  
>D> AP NANJING KING-FRIEND 5,000 UNITS/ML  
>A> @ 5,000 UNITS/ML  
HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
AP FRESENIUS KABI USA 200 UNITS/100ML  
@ 200 UNITS/100ML  
HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER  
AP FRESENIUS KABI USA 200 UNITS/100ML  
@ 200 UNITS/100ML  
HEPARIN SODIUM PRESERVATIVE FREE  
>D> AP NANJING KING-FRIEND 10,000 UNITS/ML  
>A> @ 10,000 UNITS/ML  
@ SHENZHEN TECHDOW 1,000 UNITS/MLA214804 001 Dec 29, 2020 Jun DISC  
A214839 001 Dec 29, 2020 Jun DISC  
N017037 001 Jul CAHN  
N017037 002 Jul CAHN  
N017037 013 Apr 07, 1986 Jul CAHN  
N017037 003 Jul CAHN  
A212061 001 Jul 15, 2020 Aug DISC  
A212061 001 Jul 15, 2020 Aug DISC  
A212441 001 Jul 24, 2020 Apr CMFD  
A212441 001 Jul 24, 2020 Jan DISC  
A212441 002 Jul 24, 2020 Apr CMFD  
A212441 002 Jul 24, 2020 Jan DISC  
A212060 001 Apr 02, 2020 Aug DISC  
A212060 001 Apr 02, 2020 Aug DISC  
A202732 001 Jun 12, 2014 Apr DISCHYDRALAZINE HYDROCHLORIDE

TABLET;ORAL

HYDRALAZINE HYDROCHLORIDE

>D> AA ! PLIVA 25MG  
>A> AA +! 25MG  
>D> AA ! 50MG  
>A> AA +! 50MG  
>D> AA UPSHER SMITH LABS 10MG  
>A> @ 10MG  
AA 10MG  
>D> AA 25MG  
>A> @ 25MG  
AA 25MG  
>D> AA 50MG  
>A> @ 50MG  
AA 50MG  
>D> AA 100MG  
>A> @ 100MG  
AA 100MGA088467 001 May 01, 1984 Aug CRLD  
A088467 001 May 01, 1984 Aug CRLD  
A088468 001 May 01, 1984 Aug CRLD  
A088468 001 May 01, 1984 Aug CRLD  
A209251 001 Jul 09, 2018 Aug DISC  
A209251 001 Jul 09, 2018 Aug DISC  
A209251 001 Jul 09, 2018 May CAHN  
A209251 002 Jul 09, 2018 Aug DISC  
A209251 002 Jul 09, 2018 Aug DISC  
A209251 002 Jul 09, 2018 May CAHN  
A209251 003 Jul 09, 2018 Aug DISC  
A209251 003 Jul 09, 2018 Aug DISC  
A209251 003 Jul 09, 2018 May CAHN  
A209251 004 Jul 09, 2018 Aug DISC  
A209251 004 Jul 09, 2018 Aug DISC  
A209251 004 Jul 09, 2018 May CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE;ORAL					
APRESAZIDE					
>D>	@ NOVARTIS	25MG;25MG	A 084735	001	Aug CRLD
>A>	+ @	25MG;25MG	A 084735	001	Aug CRLD
>D>	@	50MG;50MG	A 084810	001	Aug CRLD
>A>	+ @	50MG;50MG	A 084810	001	Aug CRLD

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL					
MICROZIDE					
AB	+! TEVA BRANDED PHARM	12.5MG	N 020504	001	Dec 27, 1996 Mar CAHN
SOLUTION;ORAL					
HYDROCHLOROTHIAZIDE					
>D>	@ ROXANE	50MG/5ML	A 088587	001	Jul 02, 1984 Aug CRLD
>A>	+ @	50MG/5ML	A 088587	001	Jul 02, 1984 Aug CRLD
TABLET;ORAL					
HYDROCHLOROTHIAZIDE					
>D> AB	IVAX SUB TEVA PHARMS	25MG	A 083177	001	Aug CRLD
>A> AB	+	25MG	A 083177	001	Aug CRLD
>D> AB	!	50MG	A 083177	002	Aug CRLD
>A> AB	+!	50MG	A 083177	002	Aug CRLD
>D>	@	100MG	A 085022	001	Aug CRLD
>A>	+ @	100MG	A 085022	001	Aug CRLD

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL					
ZESTORETIC					
AB	+ ALMATICA	12.5MG;10MG	N 019888	003	Nov 18, 1993 Jan CAHN
AB	+!	12.5MG;20MG	N 019888	001	Sep 20, 1990 Jan CAHN
AB	+!	25MG;20MG	N 019888	002	Jul 20, 1989 Jan CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET;ORAL					
HYZAAR					
>D>	+ @ ORGANON	12.5MG;50MG	N 020387	001	Apr 28, 1995 Aug CMFD
>A> AB	+	12.5MG;50MG	N 020387	001	Apr 28, 1995 Aug CMFD
>D>	+ @	25MG;100MG	N 020387	002	Nov 10, 1998 Aug CMFD
>A> AB	+	25MG;100MG	N 020387	002	Nov 10, 1998 Aug CMFD
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE					
AB	JUBILANT CADISTA	12.5MG;50MG	A 201845	001	Sep 18, 2012 Jun CAHN
AB		12.5MG;100MG	A 201845	002	Sep 18, 2012 Jun CAHN
AB		25MG;100MG	A 201845	003	Sep 18, 2012 Jun CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL					
DUTOPROL					
+ @ CONCORDIA	12.5MG;EQ 25MG TARTRATE	N 021956	001	Aug 28, 2006 Jun DISC	
+ @	12.5MG;EQ 50MG TARTRATE	N 021956	002	Aug 28, 2006 Jun DISC	
+ @	12.5MG;EQ 100MG TARTRATE	N 021956	003	Aug 28, 2006 Jun DISC	

HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

TABLET;ORAL					
LOPRESSOR HCT					
AB	+ VALIDUS PHARMS	25MG;50MG	N 018303	001	Dec 31, 1984 Feb CAHN
	+ @	25MG;100MG	N 018303	002	Dec 31, 1984 Feb CAHN
	+ @	50MG;100MG	N 018303	003	Dec 31, 1984 Feb CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL					
PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE					
>D>	@ ANJ PHARMS	25MG;40MG	A 070705	002	Oct 01, 1986 Jul CMS1
>A>	! MYLAN	25MG;40MG	A 070947	002	Mar 04, 1987 Aug CAHN
>D> AB	@	25MG;40MG	A 070947	002	Mar 04, 1987 Aug CAHN
>A>	!	25MG;80MG	A 070947	001	Apr 01, 1987 Aug CAHN
	@	25MG;80MG	A 070947	001	Apr 01, 1987 Aug CAHN

HYDROCHLOROTHIAZIDE; VALSARTAN

## TABLET; ORAL

## VALSARTAN AND HYDROCHLOROTHIAZIDE

>A>	@ CADILA	12.5MG; 80MG	A203000	001	Mar 15, 2019	Aug CAHN
>A>	@	12.5MG; 160MG	A203000	002	Mar 15, 2019	Aug CAHN
>A>	@	12.5MG; 320MG	A203000	003	Mar 15, 2019	Aug CAHN
>A>	@	25MG; 160MG	A203000	004	Mar 15, 2019	Aug CAHN
>A>	@	25MG; 320MG	A203000	005	Mar 15, 2019	Aug CAHN
>D>	@ ZYDUS PHARMS	12.5MG; 80MG	A203000	001	Mar 15, 2019	Aug CAHN
>D>	@	12.5MG; 160MG	A203000	002	Mar 15, 2019	Aug CAHN
>D>	@	12.5MG; 320MG	A203000	003	Mar 15, 2019	Aug CAHN
>D>	@	25MG; 160MG	A203000	004	Mar 15, 2019	Aug CAHN
>D>	@	25MG; 320MG	A203000	005	Mar 15, 2019	Aug CAHN

HYDROCODONE BITARTRATECAPSULE, EXTENDED RELEASE; ORAL  
ZOHYDRO ER

AB	+! RECRO GAINESVILLE	10MG	N202880	001	Oct 25, 2013	May CAHN
AB	+	15MG	N202880	002	Oct 25, 2013	May CAHN
AB	+	20MG	N202880	003	Oct 25, 2013	May CAHN
AB	+	30MG	N202880	004	Oct 25, 2013	May CAHN
AB	+	40MG	N202880	005	Oct 25, 2013	May CAHN
AB	+	50MG	N202880	006	Oct 25, 2013	May CAHN

TABLET, EXTENDED RELEASE; ORAL  
HYDROCODONE BITARTRATE

AB	ALVOGEN PINE BROOK	20MG	A208269	001	Mar 01, 2021	Feb NFTG
AB		30MG	A208269	002	Mar 01, 2021	Feb NFTG
AB		40MG	A208269	003	Mar 01, 2021	Feb NFTG
AB		60MG	A208269	004	Mar 01, 2021	Feb NFTG
AB		80MG	A208269	005	Mar 01, 2021	Feb NFTG
AB		100MG	A208269	006	Mar 01, 2021	Feb NFTG
AB		120MG	A208269	007	Mar 01, 2021	Feb NFTG

HYDROCODONE BITARTRATE; IBUPROFEN

## TABLET; ORAL

## HYDROCODONE BITARTRATE AND IBUPROFEN

AB	NOSTRUM LABS INC	5MG; 200MG	A077727	001	Nov 06, 2006	Jan CAHN
AB		7.5MG; 200MG	A077723	001	Nov 06, 2006	Jan CAHN
		10MG; 200MG	A077723	002	Nov 06, 2006	Mar CTEC
AB		10MG; 200MG	A077723	002	Nov 06, 2006	Jan CAHN
	REPREXAIN					
	@ AMNEAL PHARMS NY	2.5MG; 200MG	A076642	003	Oct 19, 2007	Mar DISC
	@	10MG; 200MG	A076642	004	Oct 19, 2007	Mar DISC

HYDROCORTISONE

## CREAM; TOPICAL

## HYTONE

>D>	@ VALEANT INTL	1%	A080472	003		Aug CRLD
>A>	+	1%	A080472	003		Aug CRLD
>D>	@	2.5%	A080472	004		Aug CRLD
>A>	+	2.5%	A080472	004		Aug CRLD
	SYNACORT					
	@ BAUSCH	0.5%	A087459	001		May CAHN
>D>	@	1%	A087458	001		Aug CRLD
>A>	+	1%	A087458	001		Aug CRLD
	@	1%	A087458	001		May CAHN
>D>	@	2.5%	A087457	001		Aug CRLD
>A>	+	2.5%	A087457	001		Aug CRLD
	@	2.5%	A087457	001		May CAHN

## ENEMA; RECTAL

## COLOCORT

AB	CHARTWELL	100MG/60ML	A075172	001	Dec 03, 1999	Apr CAHN
----	-----------	------------	---------	-----	--------------	----------

## LOTION; TOPICAL

## HYTONE

>D>	@ VALEANT INTL	1%	A080473	003		Aug CRLD
>A>	+	1%	A080473	003		Aug CRLD
>D>	@	2.5%	A080473	004	Nov 30, 1982	Aug CRLD
>A>	+	2.5%	A080473	004	Nov 30, 1982	Aug CRLD
	OINTMENT; TOPICAL					
	HYDROCORTISONE					

>D> AT	! FOUGERA PHARMS	1%	A080692	001		Aug CRLD
--------	------------------	----	---------	-----	--	----------

OINTMENT;TOPICAL  
HYDROCORTISONE

>A> AT	+!	1%	A 080692	001	Aug CRLD
		HYTONE			
>D>	@ DERMIC LABS	1%	A 080474	003	Aug CRLD
>A>	+ @	1%	A 080474	003	Aug CRLD
>D>	@	2.5%	A 080474	004	Aug CRLD
>A>	+ @	2.5%	A 080474	004	Aug CRLD
		SOLUTION;TOPICAL			
		PENECHT			
>D>	@ ALLERGAN HERBERT	1%	A 088214	001 Jun 06, 1984	Aug CRLD
>A>	+ @	1%	A 088214	001 Jun 06, 1984	Aug CRLD

HYDROCORTISONE ACETATE

CREAM;TOPICAL  
CARMOL HC

>D>	@ FOUGERA PHARMS	1%	A 080505	001	Aug CRLD
>A>	+ @	1%	A 080505	001	Aug CRLD
		HYDROCORTISONE ACETATE			
>D>	@ PUREPAC PHARM	1%	A 086052	001	Aug CRLD
>A>	+ @	1%	A 086052	001	Aug CRLD

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

CREAM;TOPICAL  
CORTISPORIN

+ @ MONARCH PHARMS	0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N 050218	001 Aug 09, 1985	Jul DISC
--------------------	---------------------------------------	----------	------------------	----------

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL  
PROCTOFOAM HC

>D> BX	MYLAN SPECIALITY LP	1%;1%	A 086195	001	Aug CHRS
>A> BX	+ !	1%;1%	A 086195	001	Aug CHRS

HYDROCORTISONE PROBUTATE

CREAM;TOPICAL  
PANDEL

+! ANI PHARMS 0.1%

N 020453 001 Feb 28, 1997 Apr CAHN

HYDROCORTISONE SODIUM PHOSPHATE

INJECTABLE;INJECTION  
HYDROCORTONE

+ @ MERCK EQ 50MG BASE/ML

N 012052 001

Feb CRLD

HYDROCORTISONE VALERATE

CREAM;TOPICAL  
HYDROCORTISONE VALERATE

AB	COSETTE	0.2%	A 213724	001 Feb 11, 2021	Feb NEWA
----	---------	------	----------	------------------	----------

HYDROMORPHONE HYDROCHLORIDE

TABLET;ORAL

HYDROMORPHONE HYDROCHLORIDE

@ LANNETT CO INC	2MG	A 077471	002 Dec 09, 2009	Mar DISC
@	4MG	A 077471	003 Dec 09, 2009	Mar DISC
@	8MG	A 077471	001 Dec 09, 2009	Mar DISC

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

HYDROXYCHLOROQUINE SULFATE

>A>	ACCORD HLTHCARE	100MG	A 213342	002 Aug 18, 2021	Aug NEWA
>A>		300MG	A 213342	003 Aug 18, 2021	Aug NEWA
>A>		400MG	A 213342	004 Aug 18, 2021	Aug NEWA
AB	SENORES PHARMS	200MG	A 212902	001 May 14, 2020	Jul CAHN

HYDROXYPROGESTERONE CAPROATE

SOLUTION;INTRAMUSCULAR  
MAKENA

AP1	+! COVIS	1250MG/5ML (250MG/ML)	N 021945	001 Feb 03, 2011	Mar CAHN
		MAKENA PRESERVATIVE FREE			
AP	+! COVIS	250MG/ML (250MG/ML)	N 021945	002 Feb 19, 2016	Mar CAHN

SOLUTION;SUBCUTANEOUS  
MAKENA (AUTOINJECTOR)

+! COVIS 275MG/1.1ML (250MG/ML)

N021945 004 Feb 14, 2018 Mar CAHN

HYDROXYUREA

TABLET;ORAL  
SIKLOS

+! ADDMEDICA SAS 1GM

N208843 002 Dec 21, 2017 Mar CHRS

HYDROXYZINE HYDROCHLORIDE

SYRUP;ORAL  
HYDROXYZINE HYDROCHLORIDE

>D> AA ! WOCKHARDT BIO AG 10MG/5ML  
>A> AA +! 10MG/5ML

A087294 001 Apr 12, 1982 Aug CRLD  
A087294 001 Apr 12, 1982 Aug CRLD

TABLET;ORAL  
HYDROXYZINE HYDROCHLORIDE

>D> AB ! PLIVA 10MG  
>A> AB +! 10MG  
>D> AB ! 25MG  
>A> AB +! 25MG  
>D> AB ! 50MG  
>A> AB +! 50MG  
AB PRINSTON INC 10MG  
AB 25MG

A088617 001 Jan 10, 1986 Aug CRLD  
A088617 001 Jan 10, 1986 Aug CRLD  
A088618 001 Jan 10, 1986 Aug CRLD  
A088618 001 Jan 10, 1986 Aug CRLD  
A088619 001 Jan 10, 1986 Aug CRLD  
A088619 001 Jan 10, 1986 Aug CRLD  
A040580 003 May 27, 2005 Feb CMS1  
A040580 002 May 27, 2005 Feb CMS1

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS  
IBANDRONATE SODIUM

AP NANG KUANG PHARM CO EQ 3MG BASE/3ML

A204329 001 Jun 16, 2021 Jun NEWA

IBREXAFUNGERP CITRATE

TABLET;ORAL  
BREXAFEMME

+! SCYNEXIS EQ 150MG BASE

N214900 001 Jun 01, 2021 Jun NEWA

IBRUTINIB

CAPSULE;ORAL  
IBRUTINIB

AB @ ZYDUS 70MG  
AB @ 70MG  
AB 140MG  
AB 140MG  
IMBRUVICA  
+ PHARMACYCLICS INC 70MG  
+! 140MG

A211344 001 Mar 31, 2021 Jul DISC  
A211344 001 Mar 31, 2021 Mar NFTG  
A211344 002 Mar 31, 2021 Jul DISC  
A211344 002 Mar 31, 2021 Mar NFTG  
N205552 002 Dec 20, 2017 Jul CTEC  
N205552 001 Nov 13, 2013 Jul CTEC

IBUPROFEN

SUSPENSION;ORAL  
IBUPROFEN

AB PADAGIS US 100MG/5ML  
AB TABLET;ORAL  
IBUPROFEN  
AB L PERRIGO CO 400MG  
AB 600MG  
AB 800MG  
AB @ VINTAGE PHARMS 400MG

A076925 001 Sep 23, 2004 Jul CAHN  
A077114 001 Jul 18, 2005 Jul CAHN  
A077114 002 Jul 18, 2005 Jul CAHN  
A077114 003 Jul 18, 2005 Jul CAHN  
A071644 001 Feb 01, 1988 Feb DISC

IBUTILIDE FUMARATE

INJECTABLE;INJECTION  
CONVERT

AP +! PFIZER 0.1MG/ML

N020491 001 Dec 28, 1995 Feb CAHN

ICATIBANT ACETATE

INJECTABLE;SUBCUTANEOUS  
ICATIBANT ACETATE

AP @ DR REDDYS EQ 30MG BASE/3ML (EQ 10MG BASE/ML)  
AP GLENMARK PHARMS LTD EQ 30MG BASE/3ML (EQ 10MG BASE/ML)

A213054 001 Oct 05, 2020 May DISC  
A213222 001 May 21, 2021 May NEWA

ICOSAPENT ETHYL

CAPSULE;ORAL  
ICOSAPENT ETHYL

AB	APOTEX	1GM	A209437	001	Jun 30, 2021	Jun NEWA
	@ TEVA PHARMS USA	500MG	A209525	001	Sep 11, 2020	Mar DISC
	@	1GM	A209525	002	Sep 11, 2020	Mar DISC
	VASCEPA					
	+ AMARIN PHARMS	500MG	N202057	002	Feb 16, 2017	Mar CTEC

ILOPROST

SOLUTION;INHALATION  
VENTAVIS

+! ACTELION	10MCG/ML (10MCG/ML)	N021779	002	Dec 08, 2005	Feb CAHN
@	20MCG/2ML (10MCG/ML)	N021779	001	Dec 29, 2004	Feb CAHN
+!	20MCG/ML (20MCG/ML)	N021779	003	Aug 07, 2009	Feb CAHN

IMIPRAMINE HYDROCHLORIDE

TABLET;ORAL  
IMIPRAMINE HYDROCHLORIDE

>D> AB	SPECGX LLC	10MG	A087846	002	May 22, 1984	Aug CRLD
>A> AB	+	10MG	A087846	002	May 22, 1984	Aug CRLD
>D> AB		25MG	A087846	003	May 22, 1984	Aug CRLD
>A> AB	+	25MG	A087846	003	May 22, 1984	Aug CRLD
	TOFRANIL					
>D> AB	! SPECGX LLC	50MG	A087846	001	May 22, 1984	Aug CRLD
>A> AB	+!	50MG	A087846	001	May 22, 1984	Aug CRLD

IMIQUIMOD

CREAM;TOPICAL  
IMIQUIMOD

AB	TARO	3.75%	A205971	001	Jan 26, 2021	Jan NFTG
----	------	-------	---------	-----	--------------	----------

INDAPAMIDE

TABLET;ORAL  
INDAPAMIDE

AB	! ANJ PHARMS	2.5MG	A074299	001	Jul 27, 1995	Jul CHRS
	@ MYLAN	1.25MG	A074461	002	Mar 26, 1997	Jul DISC
	@	2.5MG	A074461	001	Mar 27, 1996	Jul DISC

INDOCYANINE GREEN

INJECTABLE;INJECTION  
INDOCYANINE GREEN

AP	RENEW PHARMS	25MG/VIAL	A040811	001	Nov 21, 2007	Jun CAHN
----	--------------	-----------	---------	-----	--------------	----------

INDOMETHACIN

CAPSULE;ORAL  
INDOMETHACIN

AB	@ JUBILANT GENERICS	25MG	A205215	001	Aug 25, 2017	Jan DISC
	@	50MG	A205215	002	Aug 25, 2017	Jan DISC
	TIVORBEX					
+ @ GENUS		20MG	N204768	001	Feb 24, 2014	Apr DISC
+ @		40MG	N204768	002	Feb 24, 2014	Apr DISC
	CAPSULE, EXTENDED RELEASE;ORAL					
	INDOMETHACIN					
	@ AUROBINDO PHARMA LTD	75MG	A204243	001	Dec 27, 2016	Jan DISC
	@ JUBILANT GENERICS	75MG	A202706	001	Oct 05, 2015	Jun DISC

INFIGRATINIB PHOSPHATE

CAPSULE;ORAL  
TRUSELTIQ

+ QED THERAP	25MG	N214622	001	May 28, 2021	May NEWA
+!	100MG	N214622	002	May 28, 2021	May NEWA

TOPAMIDOL

INJECTABLE;INJECTION  
ISOVUE-300

+! BRACCO	61%	N018735	002	Dec 31, 1985	Jan CTEC
ISOVUE-370					
+! BRACCO	76%	N018735	003	Dec 31, 1985	Jan CTEC

INJECTABLE; INJECTION

SCANLUX-300						
@ SANOCHEMIA CORP USA	61%		A090394	001	Jun 18, 2010	Jan DISC
SCANLUX-370						
@ SANOCHEMIA CORP USA	76%		A090394	002	Jun 18, 2010	Jan DISC

IPRATROPIUM BROMIDESOLUTION; INHALATION  
IPRATROPIUM BROMIDE

>D> AN	AUROBINDO PHARMA LTD	0.02%	A206543	001	Oct 27, 2016	Aug CAHN
>A> AN	LUOXIN AUROVITAS	0.02%	A206543	001	Oct 27, 2016	Aug CAHN

IRBESARTANTABLET; ORAL  
IRBESARTAN

@ US ANTIBIOTICS	75MG	A203161	001	Sep 27, 2012	May CAHN
@	150MG	A203161	002	Sep 27, 2012	May CAHN
@	300MG	A203161	003	Sep 27, 2012	May CAHN

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION  
IRINOTECAN HYDROCHLORIDE

@ US ANTIBIOTICS	40MG/2ML (20MG/ML)	A078953	001	Apr 15, 2010	May CAHN
@	100MG/5ML (20MG/ML)	A078953	002	Apr 15, 2010	May CAHN

ISOETHARINE HYDROCHLORIDESOLUTION; INHALATION  
ISOETHARINE HYDROCHLORIDE

>D>	@ ASTRAZENECA	0.062%	A087937	001	Nov 15, 1982	Aug CRLD
>A>	+ @	0.062%	A087937	001	Nov 15, 1982	Aug CRLD
>D>	@	0.125%	A087938	001	Nov 15, 1982	Aug CRLD
>A>	+ @	0.125%	A087938	001	Nov 15, 1982	Aug CRLD
>D>	@	0.167%	A088470	001	Mar 14, 1984	Aug CRLD
>A>	+ @	0.167%	A088470	001	Mar 14, 1984	Aug CRLD
>D>	@	0.2%	A088471	001	Mar 14, 1984	Aug CRLD
>A>	+ @	0.2%	A088471	001	Mar 14, 1984	Aug CRLD
>D>	@	0.25%	A088472	001	Mar 14, 1984	Aug CRLD
>A>	+ @	0.25%	A088472	001	Mar 14, 1984	Aug CRLD
>D>	@ DEY	1%	A086763	001		Aug CRLD
>A>	+ @	1%	A086763	001		Aug CRLD

ISOFLURANELIQUID; INHALATION  
ISOFLURANE

>D> AN	PIRAMAL ENT	99.9%	A074502	001	Jun 27, 1995	Aug CAHN
>A> AN	PIRAMAL PHARMA	99.9%	A074502	001	Jun 27, 1995	Aug CAHN

ISONIAZIDSYRUP; ORAL  
ISONIAZID

>D>	! CMP PHARMA INC	50MG/5ML	A088235	001	Nov 10, 1983	Aug CRLD
>A>	+!	50MG/5ML	A088235	001	Nov 10, 1983	Aug CRLD

ISOPROTERENOL HYDROCHLORIDEINJECTABLE; INJECTION  
ISOPROTERENOL HYDROCHLORIDE

AP	AMRING PHARMS	0.2MG/ML	A211237	001	May 19, 2021	May NEWA
>D> AP	AUROBINDO PHARMA LTD	0.2MG/ML	A211864	001	Feb 09, 2021	Aug DISC
>A>	@	0.2MG/ML	A211864	001	Feb 09, 2021	Aug DISC
AP		0.2MG/ML	A211864	001	Feb 09, 2021	Jan NEWA
>D> AP	CIPLA	0.2MG/ML	A211738	001	Jun 28, 2019	Aug DISC
>A>	@	0.2MG/ML	A211738	001	Jun 28, 2019	Aug DISC
AP	MICRO LABS	0.2MG/ML	A210845	001	Feb 16, 2021	Feb NEWA

ISOTRETINOINCAPSULE; ORAL  
AMNESTEEM

AB1	MYLAN PHARMS INC	10MG	A075945	001	Nov 08, 2002	Mar CTEC
AB1		20MG	A075945	002	Nov 08, 2002	Mar CTEC
AB1		40MG	A075945	003	Nov 08, 2002	Mar CTEC
	CLARAVIS					
AB1	TEVA PHARMS USA	10MG	A076356	001	Apr 11, 2003	Mar CTEC

CAPSULE;ORAL  
CLARAVIS

AB1		20MG	A076135	002	Apr 11, 2003	Mar CTEC
AB1		30MG	A076135	003	May 11, 2006	Mar CTEC
AB1 !		40MG	A076135	001	Apr 11, 2003	Mar CTEC
ISOTRETINOIN						
AB2	ACTAVIS LABS FL	10MG	A205063	001	Mar 31, 2021	Mar NFTG
AB2		20MG	A205063	002	Mar 31, 2021	Mar NFTG
AB2		25MG	A205063	003	Mar 31, 2021	Mar NFTG
AB2		30MG	A205063	004	Mar 31, 2021	Mar NFTG
AB2		35MG	A205063	005	Mar 31, 2021	Mar NFTG
AB2		40MG	A205063	006	Mar 31, 2021	Mar NFTG
AB1	AMNEAL PHARMS NY	10MG	A207792	001	Sep 29, 2017	Mar CTEC
AB1		20MG	A207792	002	Sep 29, 2017	Mar CTEC
AB1		30MG	A207792	003	Sep 29, 2017	Mar CTEC
AB1		40MG	A207792	004	Sep 29, 2017	Mar CTEC
AB2	UPSHER SMITH LABS	40MG	A213571	001	Apr 12, 2021	Apr NEWA
MYORISAN						
AB1	DOUGLAS PHARMS	10MG	A076485	001	Jan 19, 2012	Mar CTEC
AB1		20MG	A076485	002	Jan 19, 2012	Mar CTEC
AB1		30MG	A076485	004	Aug 25, 2015	Mar CTEC
AB1		40MG	A076485	003	Jan 19, 2012	Mar CTEC
ZENATANE						
AB1	DR REDDYS LABS LTD	10MG	A202099	001	Mar 25, 2013	Mar CTEC
AB1		20MG	A202099	002	Mar 25, 2013	Mar CTEC
AB1		30MG	A202099	004	Feb 23, 2015	Mar CTEC
AB1		40MG	A202099	003	Mar 25, 2013	Mar CTEC

ITRACONAZOLE

TABLET;ORAL ONMEL						
+ @	SEBELA IRELAND LTD	200MG	N022484	001	Apr 29, 2010	Apr DISC

IVACAFTOR; IVACAFTOR, TEZACAFTOR

TABLET;ORAL SYMDEKO (COPACKAGED)						
+ !	VERTEX PHARMS INC	75MG;75MG, 50MG	N210491	002	Jun 21, 2019	Jul CPOT
+ !		75MG,N/A;75MG, 50MG	N210491	002	Jun 21, 2019	Jul CDFR
+ !		150MG;150MG, 100MG	N210491	001	Feb 12, 2018	Jul CPOT
+ !		150MG,N/A;150MG, 100MG	N210491	001	Feb 12, 2018	Jul CDFR

IVOSIDENIB

TABLET;ORAL TIBSOVO						
+ !	SERVIER	250MG	N211192	001	Jul 20, 2018	Apr CAHN

IXAZOMIB CITRATE

CAPSULE;ORAL NINLARO						
+ !	TAKEDA PHARMS USA	EQ 2.3MG BASE	N208462	001	Nov 20, 2015	May CAHN
+ !		EQ 3MG BASE	N208462	002	Nov 20, 2015	May CAHN
+ !		EQ 4MG BASE	N208462	003	Nov 20, 2015	May CAHN

KETAMINE HYDROCHLORIDE

INJECTABLE;INJECTION KETAMINE HYDROCHLORIDE						
>D> AP	AUROMEDICS PHARMA	EQ 10MG BASE/ML	A076092	001	Sep 30, 2008	Aug CAHN
AP		EQ 10MG BASE/ML	A076092	001	Sep 30, 2008	Jan CAHN
>D> AP		EQ 50MG BASE/ML	A076092	002	Dec 28, 2001	Aug CAHN
AP		EQ 50MG BASE/ML	A076092	002	Dec 28, 2001	Jan CAHN
>D> AP		EQ 100MG BASE/ML	A076092	003	Oct 25, 2002	Aug CAHN
AP		EQ 100MG BASE/ML	A076092	003	Oct 25, 2002	Jan CAHN
>A> AP	EUGIA PHARMA	EQ 10MG BASE/ML	A076092	001	Sep 30, 2008	Aug CAHN
>A> AP		EQ 50MG BASE/ML	A076092	002	Dec 28, 2001	Aug CAHN
>A> AP		EQ 100MG BASE/ML	A076092	003	Oct 25, 2002	Aug CAHN

KETOCONAZOLE

AEROSOL, FOAM;TOPICAL KETOCONAZOLE						
AT	XIROMED	2%	A213601	001	May 21, 2021	May NEWA

CREAM;TOPICAL  
KETOCONAZOLE

AB	ENCUBE	2%	A212443	001	May 20, 2021	May NEWA
	TABLET;ORAL					
	KETOCONAZOLE					
>D> AB	HAVIX	200MG	A075912	001	Jan 10, 2002	Aug CAHN
	@ MYLAN	200MG	A075597	001	Dec 23, 1999	Mar DISC
>A> AB	SENORES PHARMS	200MG	A075912	001	Jan 10, 2002	Aug CAHN

KETOPROFEN

CAPSULE;ORAL  
KETOPROFEN

AB	! HERITAGE PHARMS INC	75MG	A074014	003	Jan 29, 1993	Jul CTEC
	!	75MG	A074014	003	Jan 29, 1993	Jul CHRS
	@ RISING	50MG	A074024	001	Dec 29, 1995	Jan CAHN
	@	75MG	A074024	002	Dec 29, 1995	Jan CAHN
	@ TEVA	75MG	A073517	001	Dec 22, 1992	Jul DISC

KETOROLAC TROMETHAMINE

INJECTABLE;INJECTION  
KETOROLAC TROMETHAMINE

@ AUROBINDO PHARMA LTD	15MG/ML	A212939	001	Oct 20, 2020	Apr DISC
@	30MG/ML	A212939	002	Oct 20, 2020	Apr DISC
@ HOSPIRA	15MG/ML	A074993	001	Jan 27, 1999	Mar DISC

LABETALOL HYDROCHLORIDE

INJECTABLE;INJECTION  
LABETALOL HYDROCHLORIDE

AP	BAXTER HLTHCARE CORP	5MG/ML	A076051	001	Jul 05, 2002	Mar CMFD
>A> AP	CAPLIN	5MG/ML	A214533	001	Sep 07, 2021	Aug NEWA

## TABLET;ORAL

## LABETALOL HYDROCHLORIDE

AB	! PAR FORM	200MG	A200908	002	Jul 10, 2012	Jul CHRS
>A> AB	RUBICON	100MG	A211953	001	Aug 18, 2021	Aug NEWA
>A> AB		200MG	A211953	002	Aug 18, 2021	Aug NEWA
>A> AB		300MG	A211953	003	Aug 18, 2021	Aug NEWA
	TRANDATE					
AB	+ @ ALVOGEN	100MG	N018716	001	May 24, 1985	Jul DISC
AB	+	100MG	N018716	001	May 24, 1985	Jul CAHN
AB	+ @	200MG	N018716	002	Aug 01, 1984	Jul DISC
AB	+!	200MG	N018716	002	Aug 01, 1984	Jul CAHN
AB	+ @	300MG	N018716	003	Aug 01, 1984	Jul DISC
AB	+	300MG	N018716	003	Aug 01, 1984	Jul CAHN
AB	+ @	400MG	N018716	004	Aug 01, 1984	Jul CAHN
AB	+! CNTY LINE PHARMS	200MG	N018716	002	Aug 01, 1984	Apr CHRS

LACTULOSE

SOLUTION;ORAL  
LACTULOSE

AA	TORRENT	10GM/15ML	A207786	001	Jun 11, 2018	Jun CMFD
----	---------	-----------	---------	-----	--------------	----------

## SOLUTION;ORAL, RECTAL

## LACTULOSE

AA	TORRENT	10GM/15ML	A203762	001	Mar 27, 2015	Jun CMFD
----	---------	-----------	---------	-----	--------------	----------

LAMIVUDINE

TABLET;ORAL  
LAMIVUDINE

AB	CENTAUR PHARMS PVT	150MG	A203586	001	Nov 21, 2016	Jun CAHN
----	--------------------	-------	---------	-----	--------------	----------

LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE

## TABLET;ORAL

## LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE

+ @ AUROBINDO PHARMA LTD	300MG;300MG	N022344	001	May 15, 2018	Feb DISC	
	TEMIXYS					
>D>	+! CELLTRION	300MG;300MG	N211284	001	Nov 16, 2018	Aug DISC
>A>	+ @	300MG;300MG	N211284	001	Nov 16, 2018	Aug DISC

LAMOTRIGINE

TABLET;ORAL						
LAMOTRIGINE						
@ GRANULES	25MG		A078982	001	Jan 27, 2009	Jun CAHN
@	100MG		A078982	002	Jan 27, 2009	Jun CAHN
@	150MG		A078982	003	Jan 27, 2009	Jun CAHN
@	200MG		A078982	004	Jan 27, 2009	Jun CAHN
TABLET, CHEWABLE;ORAL						
LAMOTRIGINE						
@ JUBILANT GENERICS	5MG		A200220	001	Feb 28, 2011	Jun DISC
@	25MG		A200220	002	Feb 28, 2011	Jun DISC
TABLET, EXTENDED RELEASE;ORAL						
LAMOTRIGINE						
AB ACTAVIS ELIZABETH	250MG		A200672	006	Nov 13, 2013	Jul CMS1
TABLET, ORALLY DISINTEGRATING;ORAL						
LAMOTRIGINE						
AB AJANTA PHARMA LTD	25MG		A213271	001	Jan 19, 2021	Jan NEWA
AB	50MG		A213271	002	Jan 19, 2021	Jan NEWA
AB	100MG		A213271	003	Jan 19, 2021	Jan NEWA
AB	200MG		A213271	004	Jan 19, 2021	Jan NEWA

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL						
PREVACID						
+ @ TAKEDA PHARMS USA	15MG		N020406	001	May 10, 1995	Jun DISC
TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL						
LANSOPRAZOLE						
AB DR REDDYS LABS LTD	15MG		A210465	001	Feb 01, 2021	Jan NEWA
AB	30MG		A210465	002	Feb 01, 2021	Jan NEWA

LASMIDITAN SUCCINATE

TABLET;ORAL						
REYVOW						
+ ELI LILLY AND CO	EQ 50MG BASE		N211280	001	Jan 31, 2020	May CPOT
>D> +	EQ 100MG BASE		N211280	002	Jan 31, 2020	Aug CHRS
>A> +!	EQ 100MG BASE		N211280	002	Jan 31, 2020	Aug CHRS
+ +	EQ 100MG BASE		N211280	002	Jan 31, 2020	May CHRS
+ +!	EQ 100MG BASE		N211280	002	Jan 31, 2020	May CPOT
>D> +!	EQ 200MG BASE		N211280	003	Dec 18, 2020	Aug DISC
>A> + @	EQ 200MG BASE		N211280	003	Dec 18, 2020	Aug DISC
+ +!	EQ 200MG BASE		N211280	003	Dec 18, 2020	May CHRS
+ +	EQ 200MG BASE		N211280	003	Dec 18, 2020	May CPOT

LEFLUNOMIDE

TABLET;ORAL						
LEFLUNOMIDE						
AB AET PHARMA	10MG		A213497	001	May 10, 2021	Jun CAHN
AB	20MG		A213497	002	May 10, 2021	Jun CAHN
AB AUROBINDO PHARMA LTD	10MG		A213652	001	Mar 29, 2021	Mar NEWA
AB	20MG		A213652	002	Mar 29, 2021	Mar NEWA
AB AXUNIO	10MG		A213497	001	May 10, 2021	Apr NEWA
AB	20MG		A213497	002	May 10, 2021	Apr NEWA

LENALIDOMIDE

CAPSULE;ORAL						
LENALIDOMIDE						
AB ARROW INTL	5MG		A201452	001	May 21, 2021	Jul CAHN
AB	10MG		A201452	002	May 21, 2021	Jul CAHN
AB	15MG		A201452	003	May 21, 2021	Jul CAHN
AB	25MG		A201452	004	May 21, 2021	Jul CAHN
AB NATCO PHARMA LTD	5MG		A201452	001	May 21, 2021	May NFTG
AB	10MG		A201452	002	May 21, 2021	May NFTG
AB	15MG		A201452	003	May 21, 2021	May NFTG
AB	25MG		A201452	004	May 21, 2021	May NFTG

LETROZOLE

TABLET;ORAL						
LETROZOLE						
@ APOTEX INC	2.5MG		A091303	001	Apr 19, 2012	Jan DISC

LETROZOLE; RIBOCICLIB SUCCINATE

TABLET;ORAL

KISQALI FEMARA CO-PACK (COPACKAGED)

+! NOVARTIS	2.5MG;EQ 200MG BASE	N 209935 001 May 04, 2017 Jul CPOT
+!	2.5MG,N/A;N/A, EQ 200MG BASE	N 209935 001 May 04, 2017 Jul CDFR

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION

LEUCOVORIN CALCIUM

AP ! HIKMA PHARMS	EQ 50MG BASE/VIAL	A 089384 001 Sep 14, 1987 Jul CAHN
AP !	EQ 100MG BASE/VIAL	A 089717 001 Mar 28, 1988 Jul CAHN
TABLET;ORAL		
LEUCOVORIN CALCIUM		
AB EPIC PHARMA LLC	EQ 10MG BASE	A 074544 003 May 19, 2021 May NEWA
AB	EQ 15MG BASE	A 074544 004 May 19, 2021 May NEWA

LEUPROLIDE ACETATE

INJECTABLE;INJECTION

LEUPROLIDE ACETATE

>A> AP VGYAAN	1MG/0.2ML	A 213829 001 Aug 13, 2021 Aug NEWA
---------------	-----------	------------------------------------

LEUPROLIDE ACETATE; NORETHINDRONE ACETATE

INJECTABLE, TABLET;INTRAMUSCULAR, ORAL

LUPANETA PACK

>D> + ABBVIE ENDOCRINE	3.75MG/VIAL,N/A;N/A,5MG	N 203696 001 Dec 14, 2012 Aug DISC
>A> + @	3.75MG/VIAL,N/A;N/A,5MG	N 203696 001 Dec 14, 2012 Aug DISC
>D> +!	11.25MG/VIAL,N/A;N/A,5MG	N 203696 002 Dec 14, 2012 Aug DISC
>A> + @	11.25MG/VIAL,N/A;N/A,5MG	N 203696 002 Dec 14, 2012 Aug DISC

LEUPROLIDE MESYLATE

EMULSION;SUBCUTANEOUS

CAMCEVI KIT

+! FORESEE PHARMS	EQ 42MG BASE	N 211488 001 May 25, 2021 May NEWA
-------------------	--------------	------------------------------------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION

LEVALBUTEROL HYDROCHLORIDE

>D> AN AUROBINDO PHARMA LTD	EQ 0.25% BASE	A 207628 001 Jan 31, 2017 Aug CAHN
>D> AN	EQ 0.0103% BASE	A 207625 001 Dec 30, 2016 Aug CAHN
>D> AN	EQ 0.021% BASE	A 207625 002 Dec 30, 2016 Aug CAHN
>D> AN	EQ 0.042% BASE	A 207625 003 Dec 30, 2016 Aug CAHN
>A> AN LUOXIN AUROVITAS	EQ 0.25% BASE	A 207628 001 Jan 31, 2017 Aug CAHN
>A> AN	EQ 0.0103% BASE	A 207625 001 Dec 30, 2016 Aug CAHN
>A> AN	EQ 0.021% BASE	A 207625 002 Dec 30, 2016 Aug CAHN
>A> AN	EQ 0.042% BASE	A 207625 003 Dec 30, 2016 Aug CAHN

LEVETIRACETAM

INJECTABLE;INTRAVENOUS

LEVETIRACETAM

@ JUBILANT GENERICS 500MG/5ML (100MG/ML)

LEVETIRACETAM IN SODIUM CHLORIDE

A 206838 001 Jun 02, 2016 Jun DISC

AP AUROBINDO PHARMA LTD	1GM/100ML (10MG/ML)	A 207160 002 Jan 04, 2017 Feb CPOT
AP	1.5GM/100ML (15MG/ML)	A 207160 003 Jan 04, 2017 Feb CPOT
AP GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A 206880 002 Oct 25, 2017 Feb CPOT
AP	1.5GM/100ML (15MG/ML)	A 206880 003 Oct 25, 2017 Feb CDFR
AP +! HQ SPECIALITY PHARMA	1GM/100ML (10MG/ML)	N 202543 002 Nov 09, 2011 Feb CPOT
AP +!	1.5GM/100ML (15MG/ML)	N 202543 003 Nov 09, 2011 Feb CPOT
AP NEXUS PHARMS	1GM/100ML (10MG/ML)	A 213532 002 Jul 06, 2020 Feb CPOT
AP	1.5GM/100ML (15MG/ML)	A 213532 003 Jul 06, 2020 Feb CPOT

SOLUTION;ORAL

LEVETIRACETAM

AA AKORN	100MG/ML	A 090601 001 Feb 28, 2012 Feb CAHN
TABLET;ORAL		

LEVETIRACETAM

>D> AB LOTUS PHARM CO LTD	250MG	A 090906 002 Oct 31, 2016 Aug DISC
>A> @	250MG	A 090906 002 Oct 31, 2016 Aug DISC
>D> AB	750MG	A 090906 003 Oct 31, 2016 Aug DISC
>A> @	750MG	A 090906 003 Oct 31, 2016 Aug DISC
>D> AB	1GM	A 090906 004 Oct 31, 2016 Aug DISC
>A> @	1GM	A 090906 004 Oct 31, 2016 Aug DISC
@ NOSTRUM LABS INC		A 090511 001 Aug 18, 2011 Mar DISC

TABLET;ORAL  
LEVETIRACETAM

AB		250MG	A090511	001	Aug 18, 2011	Jan CAHN
	@	500MG	A090511	002	Aug 18, 2011	Mar DISC
AB		500MG	A090511	002	Aug 18, 2011	Jan CAHN
	@	750MG	A090511	003	Aug 18, 2011	Mar DISC
AB		750MG	A090511	003	Aug 18, 2011	Jan CAHN
	@	1GM	A090511	004	Aug 18, 2011	Mar DISC
AB		1GM	A090511	004	Aug 18, 2011	Jan CAHN
AB	SCIEGEN PHARMS INC	750MG	A215069	001	Jun 11, 2021	Jun NEWA
AB		1GM	A215069	002	Jun 11, 2021	Jun NEWA
TABLET, EXTENDED RELEASE;ORAL						
ELEPSIA XR						
	+ TRIPPOINT	1GM	N204417	001	Dec 20, 2018	Jan CAHN
	+!	1.5GM	N204417	002	Dec 20, 2018	Jan CAHN
LEVETIRACETAM						
>D> AB	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	Aug DISC
>A>	@	500MG	A202095	002	Jun 06, 2016	Aug DISC
>D> AB		750MG	A202095	001	Jun 06, 2016	Aug DISC
>A>	@	750MG	A202095	001	Jun 06, 2016	Aug DISC
AB	OVERSEAS	750MG	A212688	001	Jun 11, 2020	May CMFD

LEVOBUNOLOL HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## AKBETA

@ AKORN	0.25%	A074779	001	Oct 29, 1996	Jul DISC
@	0.5%	A074780	001	Oct 29, 1996	Jul DISC
BETAGAN					

+ @ ALLERGAN	0.25%	N019814	001	Jun 28, 1989	Jun DISC
--------------	-------	---------	-----	--------------	----------

LEVO CETIRIZINE DIHYDROCHLORIDE

## SOLUTION;ORAL

## LEVO CETIRIZINE DIHYDROCHLORIDE

AA	! PADAGIS US	2.5MG/5ML	A091263	001	Nov 07, 2011	Jul CAHN
	XYZAL					
+ @ SANOFI		2.5MG/5ML	N022157	001	Jan 28, 2008	Apr DISC
TABLET;ORAL						
LEVO CETIRIZINE DIHYDROCHLORIDE						
AB	! GLENMARK GENERICS	5MG	A090385	001	Feb 24, 2011	Apr CHRS
	@ GRANULES	5MG	A090486	001	Mar 26, 2013	Apr CAHN
	@ NEOPHARMA	5MG	A204323	001	Dec 20, 2016	Mar DISC
	@ US ANTIBIOTICS	5MG	A204323	001	Dec 20, 2016	May CAHN
	XYZAL					
+ @ SANOFI		5MG	N022064	001	May 25, 2007	Apr DISC

LEVOFLOXACIN

## TABLET;ORAL

## LEVOFLOXACIN

AB	CADILA	250MG	A077652	001	Sep 07, 2012	Jun CAHN
		500MG	A077652	002	Sep 07, 2012	Jun CAHN
AB		750MG	A077652	003	Sep 07, 2012	Jun CAHN
	@ JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun DISC
	@	500MG	A203613	002	Jun 19, 2015	Jun DISC

LEVOLEUCOVORIN CALCIUM

## POWDER;INTRAVENOUS

## LEVOLEUCOVORIN CALCIUM

AP	HIKMA PHARMS	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jul CAHN
----	--------------	-------------------	---------	-----	--------------	----------

LEVORPHANOL TARTRATE

## TABLET;ORAL

## LEVORPHANOL TARTRATE

AB	NOVITIUM PHARMA	1MG	A213479	003	Jul 20, 2021	Jul NEWA
		3MG	A213479	002	Jan 12, 2021	Jan NEWA
AB	! SENTYNL THERAPS INC	3MG	A074278	003	Jun 18, 2018	Jan CTEC
AB	SUN PHARM IND'S INC	2MG	A213906	001	Jun 17, 2021	Jun NEWA

LEVOTHYROXINE SODIUM

## CAPSULE;ORAL

## LEVOTHYROXINE SODIUM

AB	@ TEVA PHARMS USA INC	0.075MG	A211369	001	Oct 28, 2020	Apr DISC
	@	0.088MG	A213256	001	Jan 06, 2021	Jul DISC
	@	0.1MG	A213256	002	Jan 06, 2021	Jul DISC
		0.112MG	A211369	003	Apr 16, 2021	Apr NFTG
	@	0.125MG	A213256	003	Jan 06, 2021	Jul DISC
	@	0.15MG	A211369	002	Oct 28, 2020	Apr DISC
	TIROSINT					
+ INSTITUT BIOCHIMIQUE	0.075MG	N021924	004	Oct 13, 2006	Apr CTEC	
+	0.15MG	N021924	007	Oct 13, 2006	Apr CTEC	
POWDER; INTRAVENOUS						
LEVOTHYROXINE SODIUM						
@ DR REDDYS	100MCG/VIAL	A208837	001	Mar 27, 2020	Feb DISC	
SOLUTION; INTRAVENOUS						
LEVOTHYROXINE SODIUM						
+! CUSTOPHARM INC	100MCG/ML	N214253	001	May 17, 2021	May NEWA	
SOLUTION; ORAL						
THYQUIDITY						
+! VISTAPHARM	100MCG/5ML	N214047	001	Nov 30, 2020	Apr CAHN	
TIROSINT-SOL						
+ INSTITUT BIOCHIMIQUE	37.5MCG/ML	N206977	013	Jan 13, 2021	Jan NEWA	
+	44MCG/ML	N206977	014	Jan 13, 2021	Jan NEWA	
+	62.5MCG/ML	N206977	015	Jan 13, 2021	Jan NEWA	

LIDOCAINE

## OINTMENT;TOPICAL

## LIDOCAINE

>D> AT	! FOUGERA PHARMS INC	5%	A080198	001		Aug CRLD
>A> AT	+!	5%	A080198	001		Aug CRLD
AT	QUAGEN	5%	A212695	001	Apr 20, 2021	Apr NEWA
	@ RISING	5%	A208604	001	Sep 20, 2017	May CAHN
PATCH;TOPICAL						
LIDOCAINE						
AB	NAL PHARM	5%	A205882	001	Apr 29, 2021	Apr NEWA
	@ NOVEN PHARMS INC	5%	A203265	001	Dec 01, 2020	Jun DISC

LIDOCAINE HYDROCHLORIDE

## JELLY;TOPICAL

## XYLOCAINE

+ @ AKORN	2%	N008816	001			Jan DISC
SOLUTION;ORAL						
LIDOCAINE HYDROCHLORIDE VISCOUS						
AT LANNETT CO INC	2%	A040708	001	Feb 27, 2007	Jan CMFD	

LIDOCAINE; PRILOCaine

## CREAM;TOPICAL

## LIDOCAINE AND PRILOCaine

AB ACRUX DDS PTY	2.5%;2.5%	A212482	001	Jul 27, 2021	Jul NEWA	
------------------	-----------	---------	-----	--------------	----------	--

LINACLOTIDE

## CAPSULE;ORAL

## LINACLOTIDE

AB @ MYLAN	145MCG	A209564	001	Feb 09, 2021	Feb DISC	
	145MCG	A209564	001	Feb 09, 2021	Jan NFTG	
AB @	290MCG	A209564	002	Feb 09, 2021	Feb DISC	
	290MCG	A209564	002	Feb 09, 2021	Jan NFTG	
LINZESS						
+! ALLERGAN	145MCG	N202811	001	Aug 30, 2012	Feb CTEC	
+	290MCG	N202811	002	Aug 30, 2012	Feb CTEC	

LINAGLIPTIN

## TABLET;ORAL

## LINAGLIPTIN

>A> LINAGLIPTIN		A208335	001	Aug 31, 2021	Aug NFTG	
>A> AB SUNSHINE	5MG					

LINAGLITPIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL

>A>	LINAGLITPIN AND METFORMIN HYDROCHLORIDE		
>A> AB	SUNSHINE	2.5MG;500MG	A208336 001 Aug 30, 2021 Aug NFTG
>A> AB		2.5MG;850MG	A208336 002 Aug 30, 2021 Aug NFTG
>A> AB		2.5MG;1GM	A208336 003 Aug 30, 2021 Aug NFTG

LINCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

LINCOCIN

AP	+! PFIZER	EQ 300MG BASE/ML	N050317 001 Feb CAHN
AP	PRAZGEN	EQ 300MG BASE/ML	A212770 001 Mar 12, 2021 Mar NEWA

LIOTHYRONINE SODIUM

TABLET;ORAL

LIOTHYRONINE SODIUM

AB	ZYDUS	EQ 0.005MG BASE	A214803 001 Jan 22, 2021 Jan NEWA
AB		EQ 0.025MG BASE	A214803 002 Jan 22, 2021 Jan NEWA
AB		EQ 0.05MG BASE	A214803 003 Jan 22, 2021 Jan NEWA

LISINOPRIL

TABLET;ORAL

LISINOPRIL

AB	YILING	20MG	A208920 001 Mar 04, 2021 Feb NEWA
AB		30MG	A208920 002 Mar 04, 2021 Feb NEWA
AB		40MG	A208920 003 Mar 04, 2021 Feb NEWA

LOPINAVIR; RITONAVIR

TABLET;ORAL

LOPINAVIR AND RITONAVIR

AB	HETERO LABS LTD III	100MG;25MG	A091677 001 Jun 04, 2021 May NFTG
AB		200MG;50MG	A091677 002 Jun 04, 2021 May NFTG

LORAZEPAM

>A>	CAPSULE, EXTENDED RELEASE;ORAL		
>A>	LOREEV XR		
>A>	+ ALMATICHA	1MG	N214826 001 Aug 27, 2021 Aug NEWA
>A>	+!	2MG	N214826 002 Aug 27, 2021 Aug NEWA
>A>	+!	3MG	N214826 003 Aug 27, 2021 Aug NEWA
	CONCENTRATE;ORAL		
	LORAZEPAM		
AA	AKORN	2MG/ML	A200169 001 Jan 30, 2012 Feb CAHN
	INJECTABLE; INJECTION		
	ATIVAN		
AP	+! HIKMA PHARMS	2MG/ML	N018140 001 Jul CAHN
AP	+!	4MG/ML	N018140 002 Jul CAHN

LOSARTAN POTASSIUM

TABLET;ORAL

COZAAR

>D>	+ @ ORGANON	25MG	N020386 001 Apr 14, 1995 Aug CMFD
>A> AB	+	25MG	N020386 001 Apr 14, 1995 Aug CMFD
>D>	+ @	50MG	N020386 002 Apr 14, 1995 Aug CMFD
>A> AB	+	50MG	N020386 002 Apr 14, 1995 Aug CMFD
	LOSARTAN POTASSIUM		
AB	HIKMA PHARMS	25MG	A077459 001 Oct 06, 2010 Jul CMFD
AB		50MG	A077459 002 Oct 06, 2010 Jul CMFD
AB		100MG	A077459 003 Oct 06, 2010 Jul CMFD
AB	JUBILANT CADISTA	25MG	A201170 001 Sep 18, 2012 Jun CAHN
AB		50MG	A201170 002 Sep 18, 2012 Jun CAHN
AB		100MG	A201170 003 Sep 18, 2012 Jun CAHN

LOTEPREDNOL ETABONATE

GEL;OPHTHALMIC

LOTEPREDNOL ETABONATE

AB	AKORN	0.5%	A212080 001 Feb 10, 2021 Jan NFTG
	SUSPENSION/DROPS;OPHTHALMIC		
	LOTEPREDNOL ETABONATE		
AB	SUN PHARM	0.5%	A212450 001 Feb 26, 2021 Feb NEWA

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

>D>	@ MYLAN	EQ 5MG BASE	A076762	001	Nov 01,	2004	Aug CAHN
>A>	@	EQ 5MG BASE	A076762	001	Nov 01,	2004	Aug CAHN
	@	EQ 5MG BASE	A076762	001	Nov 01,	2004	Jul DISC
>D>	@	EQ 10MG BASE	A076762	002	Nov 01,	2004	Aug CAHN
>A>	@	EQ 10MG BASE	A076762	002	Nov 01,	2004	Aug CAHN
	@	EQ 10MG BASE	A076762	002	Nov 01,	2004	Jul DISC
>D>	@	EQ 25MG BASE	A076762	003	Nov 01,	2004	Aug CAHN
>A>	@	EQ 25MG BASE	A076762	003	Nov 01,	2004	Aug CAHN
	@	EQ 25MG BASE	A076762	003	Nov 01,	2004	Jul DISC
>D>	@	EQ 50MG BASE	A076762	004	Nov 01,	2004	Aug CAHN
>A>	@	EQ 50MG BASE	A076762	004	Nov 01,	2004	Aug CAHN
	@	EQ 50MG BASE	A076762	004	Nov 01,	2004	Jul DISC

LULICONAZOLE

CREAM;TOPICAL

LUZU

+! BAUSCH

1%

N204153 001 Nov 14, 2013 May CAHN

LURASIDONE HYDROCHLORIDE

TABLET;ORAL

LURASIDONE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	20MG	A213248	001	May 13,	2021	May NEWA
AB		40MG	A213248	002	May 13,	2021	May NEWA
AB		60MG	A213248	003	May 13,	2021	May NEWA
AB		80MG	A213248	004	May 13,	2021	May NEWA
AB		120MG	A213248	005	May 13,	2021	May NEWA
>A> AB	DR REDDYS LABS LTD	20MG	A208047	001	Aug 24,	2021	Aug NEWA
>A> AB		40MG	A208047	002	Aug 24,	2021	Aug NEWA
>A> AB		60MG	A208047	003	Aug 24,	2021	Aug NEWA
>A> AB		80MG	A208047	004	Aug 24,	2021	Aug NEWA
>D> AB	PIRAMAL HLTHCARE UK	20MG	A212091	001	Dec 28,	2020	Aug DISC
>A>	@	20MG	A212091	001	Dec 28,	2020	Aug DISC
>D> AB		40MG	A212091	002	Dec 28,	2020	Aug DISC
>A>	@	40MG	A212091	002	Dec 28,	2020	Aug DISC
>D> AB		60MG	A212091	003	Dec 28,	2020	Aug DISC
>A>	@	60MG	A212091	003	Dec 28,	2020	Aug DISC
>D> AB		80MG	A212091	004	Dec 28,	2020	Aug DISC
>A>	@	80MG	A212091	004	Dec 28,	2020	Aug DISC
>D> AB		120MG	A212091	005	Dec 28,	2020	Aug DISC
>A>	@	120MG	A212091	005	Dec 28,	2020	Aug DISC
AB	WATSON LABS TEVA	20MG	A208016	001	Feb 02,	2021	Jan NEWA
AB		40MG	A208016	002	Feb 02,	2021	Jan NEWA
AB		60MG	A208016	003	Feb 02,	2021	Jan NEWA
AB		80MG	A208016	004	Feb 02,	2021	Jan NEWA
AB		120MG	A208016	005	Feb 02,	2021	Jan NEWA

MACITENTAN

TABLET;ORAL

MACITENTAN

>D>	MACITENTAN		A211224	001	Apr 06,	2021	Aug DISC
>D> AB	ZYDUS	10MG	A211224	001	Apr 06,	2021	Aug DISC
>A>	@	10MG	A211224	001	Apr 06,	2021	Mar NFTG
AB		10MG					
	OPSUMIT						
>D> AB	+! ACTELION	10MG	N204410	001	Oct 18,	2013	Aug CTEC
>A>	+!	10MG	N204410	001	Oct 18,	2013	Aug CTEC
	+!	10MG	N204410	001	Oct 18,	2013	Feb CAHN

MAGNESIUM SULFATE

INJECTABLE;INJECTION

MAGNESIUM SULFATE

AP	B BRAUN MEDICAL INC	2GM/50ML (40MG/ML)	A207967	001	Apr 26,	2021	Apr NEWA
AP		4GM/100ML (40MG/ML)	A207967	002	Apr 26,	2021	Apr NEWA
AP		4GM/50ML (80MG/ML)	A207967	003	Apr 26,	2021	Apr NEWA
	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	BAXTER HLTHCARE CORP	1GM/100ML	A211965	001	Aug 11,	2020	Feb CMFD
	MAGNESIUM SULFATE IN PLASTIC CONTAINER						
AP	BAXTER HLTHCARE CORP	2GM/50ML (40MG/ML)	A211966	001	Jun 01,	2020	Feb CMFD
AP		4GM/50ML (80MG/ML)	A211966	002	Jun 01,	2020	Feb CMFD
AP		4GM/100ML (40MG/ML)	A211966	003	Jun 01,	2020	Feb CMFD

MAPROTILINE HYDROCHLORIDE

TABLET;ORAL

MAPROTILINE HYDROCHLORIDE

@ HERITAGE PHARMA	50MG	A072163	001	Jun 01, 1988	Jun CAHN
@ MYLAN	25MG	A072285	002	Oct 03, 1988	Jul DISC
@	50MG	A072285	001	Oct 03, 1988	Jul DISC
@	75MG	A072285	003	Oct 03, 1988	Jul DISC

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION

DEPO-PROVERA

+ @ PFIZER	100MG/ML	N012541	002		Mar CAHN
+!	150MG/ML	N020246	001	Oct 29, 1992	Mar CAHN
+ @	400MG/ML	N012541	003		May DISC
+!	400MG/ML	N012541	003		Mar CAHN
INJECTABLE; SUBCUTANEOUS					
DEPO-SUBQ PROVERA 104					
+! PFIZER	104MG/0.65ML	N021583	001	Dec 17, 2004	Mar CAHN
TABLET; ORAL					
PROVERA					
AB + PFIZER	2.5MG	N011839	001		Mar CAHN
AB +	5MG	N011839	003		Mar CAHN
AB +!	10MG	N011839	004		Mar CAHN

MEFENAMIC ACID

CAPSULE;ORAL

MEFENAMIC ACID

@ STRIDES PHARMA	250MG	A209209	001	Sep 18, 2020	Mar DISC
------------------	-------	---------	-----	--------------	----------

MEFLOQUINE HYDROCHLORIDE

TABLET;ORAL

MEFLOQUINE HYDROCHLORIDE

>D>	! BARR	250MG	A076392	001	Dec 29, 2003	Aug CTEC
>A> AB	!	250MG	A076392	001	Dec 29, 2003	Aug CTEC
>D>	@ HIKMA	250MG	A076523	001	Oct 01, 2004	Aug CMFD
>A> AB	HIKMA PHARMS	250MG	A076523	001	Oct 01, 2004	Aug CMFD

MELOXICAM

CAPSULE;ORAL

MELOXICAM

AB LUPIN LTD	5MG	A209487	001	Jun 01, 2020	Feb CTEC
AB !	10MG	A209487	002	Jun 01, 2020	Feb CTEC
AB NOVITIUM PHARMA	5MG	A211398	001	Mar 09, 2021	Feb NEWA
AB	10MG	A211398	002	Mar 09, 2021	Feb NEWA

MELPHALAN

TABLET;ORAL

MELPHALAN

! ALVOGEN	2MG	A207809	001	Mar 22, 2017	Jan CAHN
-----------	-----	---------	-----	--------------	----------

MELPHALAN FLUFENAMIDE

POWDER; INTRAVENOUS

PEPAXTO

+! ONCOPEPTIDES AB	20MG/VIAL	N214383	001	Feb 26, 2021	Feb NEWA
--------------------	-----------	---------	-----	--------------	----------

MELPHALAN FLUFENAMIDE HYDROCHLORIDE

POWDER; INTRAVENOUS

PEPAXTO

+! ONCOPEPTIDES AB	EQ 20MG BASE/VIAL	N214383	001	Feb 26, 2021	Mar CPOT
+!	20MG/VIAL	N214383	001	Feb 26, 2021	Mar CAIN

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION

ALKERAN

+ @ APOTEX	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan DISC
MELPHALAN HYDROCHLORIDE					

AP ALMAJECT	EQ 50MG BASE/VIAL	A204817	001	May 17, 2019	Jul CAHN
AP HIKMA PHARMS	EQ 50MG BASE/VIAL	A090303	001	Oct 28, 2010	Jul CAHN
>D> AP HONG KONG	EQ 50MG BASE/VIAL	A212960	001	May 28, 2021	Aug CAHN
AP	EQ 50MG BASE/VIAL	A212960	001	May 28, 2021	May NEWA
>A> AP MEITHEAL	EQ 50MG BASE/VIAL	A212960	001	May 28, 2021	Aug CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
MEMANTINE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	7MG	A214651	001	Aug 09, 2021	Jul NEWA
AB		14MG	A214651	002	Aug 09, 2021	Jul NEWA
AB		21MG	A214651	003	Aug 09, 2021	Jul NEWA
AB		28MG	A214651	004	Aug 09, 2021	Jul NEWA
	@ MYLAN	7MG	A206032	001	Sep 28, 2016	Jul DISC
	@	14MG	A206032	002	Sep 28, 2016	Jul DISC
	@	21MG	A206032	003	Sep 28, 2016	Jul DISC
	@	28MG	A206032	004	Sep 28, 2016	Jul DISC
AB	YICHANG HUMANWELL	7MG	A211100	001	Apr 02, 2021	Mar NEWA
AB		14MG	A211100	002	Apr 02, 2021	Mar NEWA
AB		21MG	A211100	003	Apr 02, 2021	Mar NEWA
AB		28MG	A211100	004	Apr 02, 2021	Mar NEWA
	SOLUTION;ORAL					
	MEMANTINE HYDROCHLORIDE					
AA	SETON PHARMS	2MG/ML	A210319	001	Aug 31, 2020	May CAHN
	TABLET;ORAL					
	MEMANTINE HYDROCHLORIDE					
	@ JUBILANT GENERICS	5MG	A091585	001	Oct 13, 2015	Jun DISC
	@	10MG	A091585	002	Oct 13, 2015	Jun DISC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

DEMEROL

@	VALIDUS PHARMS	25MG/ML	N005010	007		Feb CAHN
@		50MG/ML	N005010	002		Feb CAHN
@		75MG/ML	N005010	009		Feb CAHN
@		100MG/ML	N005010	003		Feb CAHN

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

>D>	@ ICU MEDICAL INC	10MG/ML	A088432	001	Aug 16, 1984	Aug CRLD
>A>	+ @	10MG/ML	A088432	001	Aug 16, 1984	Aug CRLD

SYRUP;ORAL

DEMEROL

@	VALIDUS PHARMS	50MG/5ML	N005010	005		Feb CAHN
	TABLET;ORAL					
	DEMEROL					
+ @	VALIDUS PHARMS	50MG	N005010	001		Feb CAHN

+ @ VALIDUS PHARMS

100MG

N005010 004

Feb CAHN

MEPROBAMATE

TABLET;ORAL

MEPROBAMATE

AA	! ALEMBIC PHARMS LTD	200MG	A090122	001	Feb 18, 2009	Mar CHRS
AA	!	400MG	A090122	002	Feb 18, 2009	Mar CHRS
>D>	@ WATSON LABS	200MG	A083304	001		Aug CRLD
>A>	+ @	200MG	A083304	001		Aug CRLD
	@	200MG	A083304	001		Mar DISC
>D>	@	400MG	A083308	001		Aug CRLD
>A>	+ @	400MG	A083308	001		Aug CRLD
	@	400MG	A083308	001		Mar DISC

MEROPENEM

INJECTABLE; INJECTION

MEROPENEM

>D> AP	AUROBINDO PHARMA LTD	500MG/VIAL	A205835	001	Mar 27, 2017	Aug CAHN
>D> AP		1GM/VIAL	A205835	002	Mar 27, 2017	Aug CAHN
>A> AP	EUGIA PHARMA	500MG/VIAL	A205835	001	Mar 27, 2017	Aug CAHN
>A> AP		1GM/VIAL	A205835	002	Mar 27, 2017	Aug CAHN

MEROPENEM; VABORBACTAM

POWDER; INTRAVENOUS

VABOMERE

+! REMPEX

1GM/VIAL;1GM/VIAL

N209776 001 Aug 29, 2017 Feb CAHN

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL  
MESALAMINE

AB	ALKEM LABS LTD	375MG	A214242	001	Jul 15, 2021	Jul NEWA
>A> AB	ZYDUS PHARMS	375MG	A208954	001	Aug 12, 2021	Aug NEWA

METARAMINOL BITARTRATE

INJECTABLE;INJECTION  
METARAMINOL BITARTRATE

>A>	SLAYBACK PHARMA LLC	EQ 10MG BASE/ML	A211304	001	Aug 24, 2021	Aug NEWA
-----	---------------------	-----------------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

TABLET;ORAL  
METFORMIN HYDROCHLORIDE

AB	CHARTWELL	500MG	A075972	001	Jan 24, 2002	Jun CAHN
		625MG	A075972	005	Jan 24, 2002	Jun CAHN
		750MG	A075972	004	Jan 24, 2002	Jun CAHN
AB		850MG	A075972	002	Jan 24, 2002	Jun CAHN
AB	@ INDICUS PHARMA	1GM	A075972	003	Jan 24, 2002	Jun CAHN
	@	500MG	A079148	001	Nov 25, 2008	May DISC
	@	850MG	A079148	002	Nov 25, 2008	May DISC
	@	1GM	A079148	003	Nov 25, 2008	May DISC

TABLET, EXTENDED RELEASE;ORAL  
METFORMIN HYDROCHLORIDE

AB3	AJANTA PHARMA LTD	500MG	A213962	001	Mar 09, 2021	Feb NEWA
AB3		1GM	A213962	002	Mar 09, 2021	Feb NEWA
AB2	AMTA	500MG	A213394	001	Aug 03, 2021	Jul NEWA
AB2		1GM	A213394	002	Aug 03, 2021	Jul NEWA
	@ APOTEX	500MG	A076706	001	Dec 14, 2004	Apr DISC
AB3	GRANULES	500MG	A213344	001	Jan 12, 2021	Jan NEWA
AB3		1GM	A213344	002	Jan 12, 2021	Jan NEWA
AB3	SCIEGEN PHARMS INC	500MG	A213334	001	Apr 16, 2021	Apr NEWA
AB3		1GM	A213334	002	Apr 16, 2021	Apr NEWA
AB1	UNICHEM	500MG	A213359	001	Aug 11, 2021	Jul NEWA
AB		750MG	A213359	002	Aug 11, 2021	Jul NEWA

METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET;ORAL  
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE  
@ TORRENT PHARMS LTD 500MG;EQ 15MG BASE  
@ 850MG;EQ 15MG BASE

A202001	001	Feb 13, 2013	Jan DISC
A202001	002	Feb 13, 2013	Jan DISC

METHADONE HYDROCHLORIDE

CONCENTRATE;ORAL  
METHADONE HYDROCHLORIDE

>D> AA	LANNETT CO INC	10MG/ML	A212094	001	Mar 03, 2021	Aug DISC
>A>	@	10MG/ML	A212094	001	Mar 03, 2021	Aug DISC
AA		10MG/ML	A212094	001	Mar 03, 2021	Feb NEWA

SOLUTION;ORAL  
METHADONE HYDROCHLORIDE

>D> AA	! HIKMA PHARMS	5MG/5ML	A087393	001		Aug CRLD
>A> AA	+!	5MG/5ML	A087393	001		Aug CRLD
>D> AA	!	10MG/5ML	A087997	001	Aug 30, 1982	Aug CRLD
>A> AA	+!	10MG/5ML	A087997	001	Aug 30, 1982	Aug CRLD

METHENAMINE HIPPURATE

TABLET;ORAL  
HIPREX

AB	+ @ VALIDUS PHARMS	1GM	N017681	001		Mar DISC
AB	+!	1GM	N017681	001		Feb CAHN
AB	METHENAMINE HIPPURATE					
AB	! AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Mar CHRS
AB	UREX					
AB	ALVOGEN	1GM	N016151	001		Jul CAHN

METHOCARBAMOL

SOLUTION;IM-IV  
ROBAXIN

AP	+! HIKMA PHARMS	1GM/10ML (100MG/ML)	N011790	001		Jul CAHN
----	-----------------	---------------------	---------	-----	--	----------

TABLET;ORAL

## METHOCARBAMOL

AA	@ AUROBINDO PHARMA LTD	750MG GRANULATION TECH	A213967 001 Aug 12, 2020	Feb DISC
AA		750MG	A212623 001 Apr 30, 2021	Apr NEWA
AA	MLV	500MG	A212623 002 Apr 30, 2021	Apr NEWA
AA		750MG	A212623 001 Apr 30, 2021	Jun CAHN
AA		750MG	A212623 002 Apr 30, 2021	Jun CAHN

METHOTREXATE SODIUM

## INJECTABLE; INJECTION

## FOLEX

>D>	@ PHARMACIA AND UPJOHN	EQ 25MG BASE/VIAL	A087695 001 Apr 08, 1983	Aug CRLD
>A>	+ @	EQ 25MG BASE/VIAL	A087695 001 Apr 08, 1983	Aug CRLD
>D>	@	EQ 100MG BASE/VIAL	A087695 003 Apr 08, 1983	Aug CRLD
>A>	+ @	EQ 100MG BASE/VIAL	A087695 003 Apr 08, 1983	Aug CRLD
	METHOTREXATE SODIUM			
AP	! HIKMA PHARMS	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341 001 Sep 16, 1986	Jul CAHN
	!	EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342 001 Sep 16, 1986	Jul CAHN
	METHOTREXATE SODIUM PRESERVATIVE FREE			
AP	! HIKMA PHARMS	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340 001 Sep 16, 1986	Jul CAHN
AP	!	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343 001 Sep 16, 1986	Jul CAHN
>A>	@ MYLAN	EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530 001 Mar 29, 2012	Aug CAHN
	@ MYLAN LABS LTD	EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A201529 004 Mar 29, 2012	May DISC
>D> AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A201530 001 Mar 29, 2012	Aug CAHN
	MEXATE			
>D>	@ BRISTOL	EQ 20MG BASE/VIAL	A086358 001	Aug CRLD
>A>	+ @	EQ 20MG BASE/VIAL	A086358 001	Aug CRLD
>D>	@	EQ 50MG BASE/VIAL	A086358 002	Aug CRLD
>A>	+ @	EQ 50MG BASE/VIAL	A086358 002	Aug CRLD
>D>	@	EQ 100MG BASE/VIAL	A086358 003	Aug CRLD
>A>	+ @	EQ 100MG BASE/VIAL	A086358 003	Aug CRLD
>D>	@	EQ 250MG BASE/VIAL	A086358 004	Aug CRLD
>A>	+ @	EQ 250MG BASE/VIAL	A086358 004	Aug CRLD
	METHOTREXATE SODIUM			
AB	LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787 001 Apr 23, 2021	Apr NEWA

METHYLERGONOVINE MALEATE

## TABLET;ORAL

## METHYLERGONOVINE MALEATE

AB	RISING	0.2MG	A211919 001 Jan 15, 2021	Jan NEWA
----	--------	-------	--------------------------	----------

METHYLPHENIDATE HYDROCHLORIDE

## SOLUTION;ORAL

## METHYLPHENIDATE HYDROCHLORIDE

AA	ASCENT PHARMS INC	5MG/5ML	A207417 001 Jan 29, 2021	Jan NEWA
AA		10MG/5ML	A207417 002 Jan 29, 2021	Jan NEWA
	@ LANNETT CO INC	5MG/5ML	A207414 001 Dec 16, 2020	Jan DISC
	@	10MG/5ML	A207414 002 Dec 16, 2020	Jan DISC

## TABLET;ORAL

## METHYLPHENIDATE HYDROCHLORIDE

@ ALVOGEN	5MG	A206840 001 Sep 15, 2016	Jun CAHN
@	10MG	A206840 002 Sep 15, 2016	Jun CAHN
@	20MG	A206840 003 Sep 15, 2016	Jun CAHN

## TABLET, EXTENDED RELEASE;ORAL

## METHYLPHENIDATE HYDROCHLORIDE

AB	ALVOGEN	10MG	A204772 001 Feb 29, 2016	Jun CAHN
>A> AB		18MG	A210818 001 Nov 30, 2018	Aug CAHN
AB		20MG	A204772 002 Feb 29, 2016	Jun CAHN
>A> AB		27MG	A210818 002 Nov 30, 2018	Aug CAHN
>A> AB		36MG	A210818 003 Nov 30, 2018	Aug CAHN
>A> AB		54MG	A210818 004 Nov 30, 2018	Aug CAHN
>D> AB	ALVOGEN PINE BROOK	18MG	A210818 001 Nov 30, 2018	Aug CAHN
>D> AB		27MG	A210818 002 Nov 30, 2018	Aug CAHN
>D> AB		36MG	A210818 003 Nov 30, 2018	Aug CAHN
>D> AB		54MG	A210818 004 Nov 30, 2018	Aug CAHN

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB PRAXGEN 4MG A212262 001 Jun 27, 2019 Feb CAHN

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	GENEYORK PHARMS	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	Apr NEWA
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	Apr NEWA
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	Apr NEWA
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	Apr NEWA
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	Apr NEWA
AP	TIANJIN KINGYORK	EQ 40MG BASE/VIAL	A212396	001	Apr 20, 2021	May CAHN
AP		EQ 125MG BASE/VIAL	A212396	002	Apr 20, 2021	May CAHN
AP		EQ 500MG BASE/VIAL	A212396	003	Apr 20, 2021	May CAHN
AP		EQ 1GM BASE/VIAL	A212396	004	Apr 20, 2021	May CAHN
AP		EQ 2GM BASE/VIAL	A212396	005	Apr 20, 2021	May CAHN

METHYLTESTOSTERONE

CAPSULE; ORAL

TESTRED

>D>	@ BAUSCH	10MG	A083976	001	Aug	CRLD
>A>	+ @	10MG	A083976	001	Aug	CRLD

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

REGLAN

@ HIKMA PHARMS	EQ 5MG BASE/ML	N017862	001	Jul	CAHN
@	EQ 10MG BASE/ML	N017862	004	May 28,	1987 Jul CAHN

METOLAZONE

TABLET; ORAL

METOLAZONE

AB	BAYSHORE PHARMS LLC	2.5MG	A214799	001	Mar 30, 2021	Mar NEWA
AB		5MG	A214799	002	Mar 30, 2021	Mar NEWA
AB		10MG	A214799	003	Mar 30, 2021	Mar NEWA
AB	INNOGENIX	2.5MG	A213827	001	Mar 30, 2021	Mar NEWA
AB		5MG	A213827	002	Mar 30, 2021	Mar NEWA
AB		10MG	A213827	003	Mar 30, 2021	Mar NEWA
>A> AB	RUBICON	2.5MG	A215184	001	Aug 20, 2021	Aug NEWA
>A> AB		5MG	A215184	002	Aug 20, 2021	Aug NEWA
>A> AB		10MG	A215184	003	Aug 20, 2021	Aug NEWA
AB	! SANDOZ	5MG	A076466	001	Dec 19, 2003	May CHRS
AB	!	10MG	A076466	002	Dec 19, 2003	May CHRS
	ZAROXOLYN					
+ @	LANNETT CO INC	2.5MG	N017386	001		May DISC
+ @		5MG	N017386	002		May DISC
+ @		10MG	N017386	003		May DISC

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

METOPROLOL SUCCINATE

AB	ACTAVIS ELIZABETH	EQ 25MG TARTRATE	A204161	001	Nov 25, 2016	May CMFD
AB		EQ 50MG TARTRATE	A204161	002	Nov 25, 2016	May CMFD
AB		EQ 100MG TARTRATE	A204161	003	Nov 25, 2016	May CMFD
AB		EQ 200MG TARTRATE	A204161	004	Nov 25, 2016	May CMFD
AB	YICHANG HUMANWELL	EQ 100MG TARTRATE	A213854	001	Feb 12, 2021	Feb NEWA
AB		EQ 200MG TARTRATE	A213854	002	Feb 12, 2021	Feb NEWA

METOPROLOL TARTRATE

TABLET; ORAL

LOPRESSOR

AB	+ VALIDUS PHARMS	50MG	N017963	001	Feb	CAHN
AB	+	100MG	N017963	002	Feb	CAHN

METRONIDAZOLE

GEL;TOPICAL

METRONIDAZOLE

&gt;A&gt; AB ALEOR DERMACEUTICALS 1% A212646 001 Sep 03, 2021 Aug NEWA

MEXILETINE HYDROCHLORIDE

CAPSULE;ORAL

MEXILETINE HYDROCHLORIDE

AB RICONPHARMA LLC 150MG A214352 001 Jan 25, 2021 Jan NEWA  
AB 200MG A214352 002 Jan 25, 2021 Jan NEWA  
AB 250MG A214352 003 Jan 25, 2021 Jan NEWAMICAFUNGIN SODIUM

INJECTABLE; INTRAVENOUS

MICAFUNGIN SODIUM

AP HIKMA EQ 50MG BASE/VIAL A213261 001 Jul 09, 2021 Jul NEWA  
AP EQ 100MG BASE/VIAL A213261 002 Jul 09, 2021 Jul NEWA  
AP JIANGSU HANSOH PHARM EQ 50MG BASE/VIAL A213363 001 Jul 09, 2021 Jul NEWA  
AP EQ 100MG BASE/VIAL A213363 002 Jul 09, 2021 Jul NEWA  
AP XELLIA PHARMS APS EQ 50MG BASE/VIAL A211713 001 Jun 02, 2021 May NEWA  
AP EQ 100MG BASE/VIAL A211713 002 Jun 02, 2021 May NEWA  
  
POWDER; INTRAVENOUS  
MICAFUNGIN  
+! PAR STERILE PRODUCTS EQ 50MG BASE/VIAL N212156 001 Jun 16, 2021 Jun NEWA  
+! EQ 100MG BASE/VIAL N212156 002 Jun 16, 2021 Jun NEWA  
+! TEVA PHARMS USA INC EQ 50MG BASE/VIAL N212125 001 Jul 30, 2021 Jul NEWA  
+! EQ 100MG BASE/VIAL N212125 002 Jul 30, 2021 Jul NEWAMIDAZOLAM

SOLUTION; INTRAVENOUS

MIDAZOLAM IN 0.9% SODIUM CHLORIDE

+! INFORLIFE 50MG/50ML (1MG/ML) N211844 001 Mar 22, 2021 Mar NEWA  
+! 100MG/100ML (1MG/ML) N211844 002 Mar 22, 2021 Mar NEWAMIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

>D> AP HOSPIRA EQ 1MG BASE/ML A075856 001 Jun 13, 2002 Aug DISC  
>A> @ EQ 1MG BASE/ML A075856 001 Jun 13, 2002 Aug DISC  
>D> AP EQ 5MG BASE/ML A075856 002 Jun 13, 2002 Aug DISC  
>A> @ EQ 5MG BASE/ML A075856 002 Jun 13, 2002 Aug DISCMIDODRINE HYDROCHLORIDE

TABLET; ORAL

MIDODRINE HYDROCHLORIDE

AB ALEMBIC PHARMS LTD 2.5MG A214734 001 Jan 21, 2021 Jan NEWA  
AB 5MG A214734 002 Jan 21, 2021 Jan NEWA  
AB 10MG A214734 003 Jan 21, 2021 Jan NEWAMIGLITOL

TABLET; ORAL

GLYSET

AB +! PFIZER 25MG N020682 001 Dec 18, 1996 Feb CAHN  
AB + 50MG N020682 002 Dec 18, 1996 Feb CAHN  
AB + 100MG N020682 003 Dec 18, 1996 Feb CAHNMILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

>A> @ LIBERTY PHARMA INC 12.5MG A205071 001 Jan 27, 2016 Aug CAHN  
>A> @ 25MG A205071 002 Jan 27, 2016 Aug CAHN  
>A> @ 50MG A205071 003 Jan 27, 2016 Aug CAHN  
>A> @ 100MG A205071 004 Jan 27, 2016 Aug CAHN  
>D> @ USPHARMA 12.5MG A205071 001 Jan 27, 2016 Aug CAHN  
>D> @ 25MG A205071 002 Jan 27, 2016 Aug CAHN  
>D> @ 50MG A205071 003 Jan 27, 2016 Aug CAHN  
>D> @ 100MG A205071 004 Jan 27, 2016 Aug CAHN

<u>MILRINONE LACTATE</u>						
INJECTABLE; INJECTION						
MILRINONE LACTATE						
AP	CAPLIN	EQ 1MG BASE/ML		A214380	001	Apr 16, 2021
						Apr NEWA
<u>MINOCYCLINE HYDROCHLORIDE</u>						
AEROSOL, FOAM; TOPICAL						
AMZEEQ						
+!	VYNE	EQ 4% BASE		N212379	001	Oct 18, 2019
	ZILXI					Mar CAHN
+!	VYNE	EQ 1.5% BASE		N213690	001	May 28, 2020
CAPSULE; ORAL						
DYNACIN						
AB	ALVOGEN	EQ 50MG BASE		A063067	003	Aug 14, 1990
AB		EQ 75MG BASE		A063067	002	Sep 15, 1999
AB		EQ 100MG BASE		A063067	001	Jul 31, 1990
						Jun CAHN
INJECTABLE; INJECTION						
MINOCIN						
+!	REMPLEX	EQ 100MG BASE/VIAL		N050444	001	
TABLET, EXTENDED RELEASE; ORAL						May CAHN
MINOCYCLINE HYDROCHLORIDE						
@	BARR LABS INC	EQ 65MG BASE		A065485	004	May 18, 2012
@		EQ 80MG BASE		A065485	007	Apr 26, 2017
@		EQ 105MG BASE		A065485	008	Apr 26, 2017
@		EQ 115MG BASE		A065485	005	May 18, 2012
SOLODYN						
+ @	BAUSCH	EQ 45MG BASE		N050808	001	May 08, 2006
AB	+	EQ 55MG BASE		N050808	008	Aug 27, 2010
AB	+	EQ 65MG BASE		N050808	004	Jul 23, 2009
AB	+	EQ 80MG BASE		N050808	007	Aug 27, 2010
+ @		EQ 90MG BASE		N050808	002	May 08, 2006
AB	+	EQ 105MG BASE		N050808	006	Aug 27, 2010
AB	+	EQ 115MG BASE		N050808	005	Jul 23, 2009
+ @		EQ 135MG BASE		N050808	003	May 08, 2006
						May CAHN
<u>MINOXIDIL</u>						
TABLET; ORAL						
LONITEN						
+ @	PFIZER	2.5MG		N018154	001	
+ @		10MG		N018154	003	
						Feb CAHN
						Feb CAHN
<u>MIRABEGRON</u>						
FOR SUSPENSION, EXTENDED RELEASE; ORAL						
MYRBETRIQ GRANULES						
+!	APGDI	8MG/ML		N213801	001	Mar 25, 2021
						Mar NEWA
<u>MODAFINIL</u>						
TABLET; ORAL						
MODAFINIL						
@	MYLAN PHARMS INC	100MG		A076594	001	Jul 16, 2012
@		200MG		A076594	002	Jul 16, 2012
						Jul DISC
<u>MOMETASONE FUROATE</u>						
AEROSOL, METERED; INHALATION						
ASMANEX HFA						
+!	ORGANON	0.05MG/INH		N205641	003	Aug 12, 2019
+!		0.10MG/INH		N205641	001	Apr 25, 2014
+!		0.20MG/INH		N205641	002	Apr 25, 2014
OINTMENT; TOPICAL						
MOMETASONE FUROATE						
@	TORRENT	0.1%		A207899	001	Jul 13, 2018
POWDER; INHALATION						
ASMANEX TWISTHALER						
+!	ORGANON	0.11MG/INH		N021067	002	Feb 01, 2008
+!		0.22MG/INH		N021067	001	Mar 30, 2005
SPRAY, METERED; NASAL						
MOMETASONE FUROATE						
AB	! APOTEX INC	0.05MG/SPRAY		A091161	001	Mar 22, 2016
	NASONEX					May CHRS
+ @	ORGANON	0.05MG/SPRAY		N020762	001	Oct 01, 1997
						May DISC

SPRAY, METERED;NASAL  
NASONEX

AB	+!	0.05MG/SPRAY	N 020762	001	Oct 01, 1997	Feb CAHN
----	----	--------------	----------	-----	--------------	----------

MONTELUKAST SODIUM

## TABLET;ORAL

## MONTELUKAST SODIUM

@ AJANTA PHARMA LTD

EQ 10MG BASE

A203432 001 Jul 31, 2015 Jul DISC

## TABLET, CHEWABLE;ORAL

## MONTELUKAST SODIUM

@ AJANTA PHARMA LTD

EQ 4MG BASE

A203328 001 Jul 31, 2015 Jul DISC

@

EQ 5MG BASE

A203328 002 Jul 31, 2015 Jul DISC

@ HIKMA PHARMS

EQ 4MG BASE

A091128 001 Aug 03, 2012 Jul DISC

@

EQ 5MG BASE

A091128 002 Aug 03, 2012 Jul DISC

&gt;D&gt; @ UNICHEM

EQ 4MG BASE

A208621 001 Jul 02, 2018 Aug CMFD

&gt;A&gt; AB

EQ 4MG BASE

A208621 001 Jul 02, 2018 Aug CMFD

&gt;D&gt;

EQ 5MG BASE

A208621 002 Jul 02, 2018 Aug CMFD

&gt;A&gt; AB

EQ 5MG BASE

A208621 002 Jul 02, 2018 Aug CMFD

EQ 5MG BASE

A208621 002 Jul 02, 2018 Aug CMFD

MORPHINE SULFATE

## CAPSULE, EXTENDED RELEASE;ORAL

## KADIAN

+ @ ALLERGAN

40MG

N 020616 009 Jul 09, 2012 May DISC

+ @

70MG

N 020616 010 Jul 09, 2012 May DISC

+ @

130MG

N 020616 011 Jul 09, 2012 May DISC

+ @

150MG

N 020616 012 Jul 09, 2012 May DISC

+ @

200MG

N 020616 007 Feb 27, 2007 May DISC

## MORPHINE SULFATE

IMPAK LABS INC

40MG

A200411 007 Jul 25, 2018 May CTEC

AB NORTEC DEV ASSOC

20MG

A203158 001 Aug 04, 2021 Jul NEWA

AB

30MG

A203158 002 Aug 04, 2021 Jul NEWA

AB

50MG

A203158 003 Aug 04, 2021 Jul NEWA

AB

60MG

A203158 004 Aug 04, 2021 Jul NEWA

AB

80MG

A203158 005 Aug 04, 2021 Jul NEWA

AB

100MG

A203158 006 Aug 04, 2021 Jul NEWA

## INJECTABLE;INJECTION

## MORPHINE SULFATE

+! HOSPIRA INC

50MG/ML

N 202515 006 Apr 29, 2021 Apr NEWA

INTL MEDICATION SYS

1MG/ML

A202861 001 Apr 29, 2021 Apr NFTG

## SOLUTION;ORAL

## MORPHINE SULFATE

@ ANI PHARMS

10MG/5ML

A205509 001 Apr 17, 2018 Jan DISC

@

20MG/5ML

A205509 002 Apr 17, 2018 Jan DISC

@

100MG/5ML

A205509 003 Apr 17, 2018 Jan DISC

&gt;D&gt; AA WINDER LABS LLC

10MG/5ML

A211454 001 Feb 12, 2021 Aug DISC

&gt;A&gt;

10MG/5ML

A211454 001 Feb 12, 2021 Aug DISC

AA

10MG/5ML

A211454 001 Feb 12, 2021 Feb NEWA

&gt;D&gt; AA

20MG/5ML

A211454 002 Feb 12, 2021 Aug DISC

&gt;A&gt;

20MG/5ML

A211454 002 Feb 12, 2021 Aug DISC

AA

20MG/5ML

A211454 002 Feb 12, 2021 Feb NEWA

&gt;D&gt; AA

100MG/5ML

A211454 003 Feb 12, 2021 Aug DISC

&gt;A&gt;

100MG/5ML

A211454 003 Feb 12, 2021 Aug DISC

AA

100MG/5ML

A211454 003 Feb 12, 2021 Feb NEWA

## TABLET;ORAL

## MORPHINE SULFATE

AB UPSHER SMITH LABS

15MG

A210610 001 Jul 22, 2019 May CAHN

AB

30MG

A210610 002 Jul 22, 2019 May CAHN

MOXIFLOXACIN HYDROCHLORIDE

## SOLUTION/DROPS;OPHTHALMIC

## MOXIFLOXACIN HYDROCHLORIDE

AT1 UPSHER SMITH LABS EQ 0.5% BASE

A212616 001 Feb 10, 2021 Jan NEWA

MUPIROCIN CALCIUM

## CREAM;TOPICAL

## MUPIROCIN

&gt;A&gt; AB

ENCUBE EQ 2% BASE

A213076 001 Aug 31, 2021 Aug NEWA

MYCOPHENOLATE MOFETIL

SUSPENSION;ORAL

MYCOPHENOLATE MOFETIL

AB LANNETT CO INC 200MG/ML A214525 001 Jul 29, 2021 Jul NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

INJECTABLE;INJECTION

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

AP AMNEAL 500MG/VIAL A211374 001 Mar 05, 2021 Feb NEWA

AP MEITHEAL 500MG/VIAL A212130 001 Jan 15, 2021 Jan CAHN

AP NANJING KING-FRIEND 500MG/VIAL A212130 001 Jan 15, 2021 Jan NEWA

MYCOPHENOLIC ACID

TABLET, DELAYED RELEASE;ORAL

MYCOPHENOLIC ACID

AB AMTA 180MG A214376 001 Feb 10, 2021 Jan NEWA

AB AMTA 360MG A214376 002 Feb 10, 2021 Jan NEWA

NABUMETONE

TABLET;ORAL

NABUMETONE

AB ANNORA PHARMA 500MG A090445 001 Jan 12, 2011 Mar CAHN

AB ANNORA PHARMA 750MG A090445 002 Jan 12, 2011 Mar CAHN

NADOLOL

TABLET;ORAL

NADOLOL

@ NOVAST LABS 20MG A210786 001 Jun 01, 2018 May DISC

@ NOVAST LABS 40MG A210786 002 Jun 01, 2018 May DISC

@ NOVAST LABS 80MG A210786 003 Jun 01, 2018 May DISC

AB VGYAAN 20MG A212856 001 Sep 13, 2019 May CMFD

AB VGYAAN 40MG A212856 002 Sep 13, 2019 May CMFD

AB VGYAAN 80MG A212856 003 Sep 13, 2019 May CMFD

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION

NALOXONE HYDROCHLORIDE

AP AUROBINDO PHARMA LTD 1MG/ML A213279 001 Jan 14, 2021 Jan NEWA

@ BAXTER HLTHCARE CORP 0.4MG/ML A214785 001 Jan 29, 2021 Jul DISC

AP BAXTER HLTHCARE CORP 0.4MG/ML A214785 001 Jan 29, 2021 Jan NEWA

SPRAY;NASAL

KLOXXADO

+! HIKMA PHARMS 8MG/SPRAY N212045 001 Apr 29, 2021 Apr NEWA

NALTREXONE HYDROCHLORIDE

TABLET;ORAL

REVIA

+ @ TEVA WOMENS 50MG N018932 001 Nov 20, 1984 Jul CRLD

NANDROLONE DECANOATE

INJECTABLE;INJECTION

NANDROLONE DECANOATE

&gt;D&gt; @ WATSON LABS 200MG/ML A088128 001 Dec 05, 1983 Aug CRLD

&gt;A&gt; + @ 200MG/ML A088128 001 Dec 05, 1983 Aug CRLD

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

NAPHCON FORTE

&gt;D&gt; @ ALCON 0.1% A080229 001 Aug CRLD

&gt;A&gt; + @ 0.1% A080229 001 Aug CRLD

NAPROXEN

SUSPENSION;ORAL

NAPROXEN

AB NOVITIUM PHARMA 25MG/ML A211910 001 Mar 10, 2021 Feb NEWA

TABLET;ORAL

NAPROXEN

AB GRANULES 250MG A074140 001 Dec 21, 1993 Feb CMFD

AB GRANULES 375MG A074140 002 Dec 21, 1993 Feb CMFD

AB GRANULES 500MG A074140 003 Dec 21, 1993 Feb CMFD

AB L PERRIGO CO 250MG A077339 001 Apr 27, 2005 Jul CAHN

TABLET;ORAL  
NAPROXEN

AB		375MG	A077339	002	Apr 27, 2005	Jul CAHN
AB		500MG	A077339	003	Apr 27, 2005	Jul CAHN

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL  
NEBIVOLOL HYDROCHLORIDE

AB	ANI PHARMS	EQ 2.5MG BASE	A203659	001	Apr 16, 2015	Jul CMFD
AB		EQ 5MG BASE	A203659	002	Apr 16, 2015	Jul CMFD
AB		EQ 10MG BASE	A203659	003	Apr 16, 2015	Jul CMFD
AB		EQ 20MG BASE	A203659	004	Apr 16, 2015	Jul CMFD
AB	INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015	Jul CMFD
AB		EQ 5MG BASE	A203828	002	Jul 29, 2015	Jul CMFD
AB		EQ 10MG BASE	A203828	003	Jul 29, 2015	Jul CMFD
AB		EQ 20MG BASE	A203828	004	Jul 29, 2015	Jul CMFD
>D>	@ TORRENT	EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Aug CMFD
>A> AB		EQ 2.5MG BASE	A203966	001	Mar 02, 2018	Aug CMFD
>D>	@	EQ 5MG BASE	A203966	002	Mar 02, 2018	Aug CMFD
>A> AB		EQ 5MG BASE	A203966	002	Mar 02, 2018	Aug CMFD
>D>	@	EQ 10MG BASE	A203966	003	Mar 02, 2018	Aug CMFD
>A> AB		EQ 10MG BASE	A203966	003	Mar 02, 2018	Aug CMFD
>D>	@	EQ 20MG BASE	A203966	004	Mar 02, 2018	Aug CMFD
>A> AB		EQ 20MG BASE	A203966	004	Mar 02, 2018	Aug CMFD

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS  
NEOSTIGMINE METHYLSULFATE

AP	CAPLIN	5MG/10ML (0.5MG/ML)	A213074	001	Apr 20, 2021	Apr NEWA
AP		10MG/10ML (1MG/ML)	A213074	002	Apr 20, 2021	Apr NEWA
AP	HONG KONG	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Mar NEWA
AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Mar NEWA
AP	MEITHEAL	5MG/10ML (0.5MG/ML)	A212804	001	Apr 05, 2021	Apr CAHN
AP		10MG/10ML (1MG/ML)	A212804	002	Apr 05, 2021	Apr CAHN

NIACIN

TABLET;ORAL  
NICOLAR

>D>	@ SANOFI AVENTIS US	500MG	A083823	001		Aug CRLD
>A>	+ @	500MG	A083823	001		Aug CRLD

## TABLET, EXTENDED RELEASE;ORAL

## NIACIN

@	JUBILANT GENERICS	500MG	A209156	001	May 14, 2018	Jun DISC
@		750MG	A209156	002	May 14, 2018	Jun DISC
@		1GM	A209156	003	May 14, 2018	Jun DISC
>D> AB	SUN PHARM	750MG	A201273	001	Apr 23, 2014	Aug CHRS
>A> AB	!	750MG	A201273	001	Apr 23, 2014	Aug CHRS
>D> AB		1GM	A200484	002	Apr 23, 2014	Aug CHRS
>A> AB	!	1GM	A200484	002	Apr 23, 2014	Aug CHRS
>D>	NIASPAN					
>D> AB	+ ABBVIE	500MG	N020381	002	Jul 28, 1997	Aug DISC
>A>	+ @	500MG	N020381	002	Jul 28, 1997	Aug DISC
>D> AB	+ !	750MG	N020381	003	Jul 28, 1997	Aug DISC
>A>	+ @	750MG	N020381	003	Jul 28, 1997	Aug DISC
>D> AB	+ !	1GM	N020381	004	Jul 28, 1997	Aug DISC
>A>	+ @	1GM	N020381	004	Jul 28, 1997	Aug DISC

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL  
NICARDIPINE HYDROCHLORIDE

AB	ANI PHARMS	20MG	A074670	001	Oct 28, 1996	May CMFD
AB		30MG	A074670	002	Oct 28, 1996	May CMFD
AB	EPIC PHARMA	20MG	A074928	001	Mar 19, 1998	May CTEC
AB	!	30MG	A074928	002	Mar 19, 1998	May CTEC

## INJECTABLE;INJECTION

## NICARDIPINE HYDROCHLORIDE

AP	! AM REGENT	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Apr CTEC
	!	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Feb CHRS
AP	AUROBINDO PHARMA LTD	25MG/10ML (2.5MG/ML)	A211121	001	Apr 08, 2021	Apr NEWA
AP	SUN PHARM	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009	Jun CMFD
	@	25MG/10ML (2.5MG/ML)	N078405	001	Nov 17, 2009	Jun CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

AB1	AUROBINDO PHARMA LTD	30MG	A213361	001	Jul 19, 2021	Jul NEWA
AB1		60MG	A213361	002	Jul 19, 2021	Jul NEWA
AB1		90MG	A213361	003	Jul 19, 2021	Jul NEWA
@	ELITE	90MG	A212016	001	Nov 18, 2020	Jun DISC
@	MYLAN	30MG	A201071	001	Dec 03, 2010	Jul DISC
@		60MG	A201071	002	Dec 03, 2010	Jul DISC
@		90MG	A201071	003	Dec 03, 2010	Jul DISC
@	PAR PHARM	30MG	A077899	001	Dec 13, 2006	Apr DISC
@		60MG	A077899	002	Dec 13, 2006	Apr DISC
@		90MG	A077899	003	May 25, 2012	Apr DISC

NISOLDIPINE

TABLET, EXTENDED RELEASE;ORAL

NISOLDIPINE

!	MYLAN	20MG	A079051	001	Jul 25, 2008	Jan CHRS
		30MG	A079051	002	Jul 25, 2008	Jan CHRS

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN

AB	ALEMBIC PHARMS LTD	25MG	A211935	001	Jun 25, 2021	Jun NEWA
AB		50MG	A211935	002	Jun 25, 2021	Jun NEWA
AB		100MG	A211935	003	Jun 25, 2021	Jun NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

@	MYLAN	75MG;25MG
---	-------	-----------

A076648 001 Mar 22, 2004 Jul DISC

NITROGLYCERIN

FILM, EXTENDED RELEASE;TRANSDERMAL

MINITRAN

@	BAUSCH	0.4MG/HR
	NITRO-DUR	

A089773 001 Aug 30, 1996 May CAHN

>D> BX	+!	USPHARMA	0.1MG/HR	N020145	001	Apr 04, 1995	Aug CTEC
>A>	+		0.1MG/HR	N020145	001	Apr 04, 1995	Aug CTEC
>D> BX	+		0.2MG/HR	N020145	002	Apr 04, 1995	Aug CTEC
>A>	+		0.2MG/HR	N020145	002	Apr 04, 1995	Aug CTEC
>D> BX	+		0.4MG/HR	N020145	004	Apr 04, 1995	Aug CTEC
>A>	+		0.4MG/HR	N020145	004	Apr 04, 1995	Aug CTEC
>D> BX	+		0.6MG/HR	N020145	005	Apr 04, 1995	Aug CTEC
>A>	+		0.6MG/HR	N020145	005	Apr 04, 1995	Aug CTEC

TABLET;SUBLINGUAL

NITROGLYCERIN

AB	RUBICON	0.3MG	A209779	001	May 03, 2021	Apr NEWA
AB		0.4MG	A209779	002	May 03, 2021	Apr NEWA
AB		0.6MG	A209779	003	May 03, 2021	Apr NEWA

NOREPINEPHRINE BITARTRATE

INJECTABLE;INJECTION

NOREPINEPHRINE BITARTRATE

AP	ANDERSEN GLOBAL	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Jan NEWA
AP	BRECKENRIDGE	EQ 1MG BASE/ML	A214455	001	Jan 22, 2021	Mar CAHN
AP	GLAND PHARMA LTD	EQ 1MG BASE/ML	A214323	001	May 06, 2021	Apr NEWA
AP	SUN PHARM	EQ 1MG BASE/ML	A211980	001	Jan 29, 2021	Jan NEWA

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE;ORAL

NORTRIPTYLINE HYDROCHLORIDE

>D> AB	ZYDUS	EQ 10MG BASE	A213441	001	Feb 24, 2021	Aug DISC
>A>	@	EQ 10MG BASE	A213441	001	Feb 24, 2021	Aug DISC
AB		EQ 10MG BASE	A213441	001	Feb 24, 2021	Feb NEWA
>D> AB		EQ 25MG BASE	A213441	002	Feb 24, 2021	Aug DISC
>A>	@	EQ 25MG BASE	A213441	002	Feb 24, 2021	Aug DISC
AB		EQ 25MG BASE	A213441	002	Feb 24, 2021	Feb NEWA
>D> AB		EQ 50MG BASE	A213441	003	Feb 24, 2021	Aug DISC
>A>	@	EQ 50MG BASE	A213441	003	Feb 24, 2021	Aug DISC
AB		EQ 50MG BASE	A213441	003	Feb 24, 2021	Feb NEWA

CAPSULE;ORAL  
NORTRIPTYLINE HYDROCHLORIDE

>D> AB		EQ 75MG BASE	A213441	004	Feb 24, 2021	Aug DISC
>A>	@	EQ 75MG BASE	A213441	004	Feb 24, 2021	Aug DISC
AB		EQ 75MG BASE	A213441	004	Feb 24, 2021	Feb NEWA

NYSTATIN

CREAM;TOPICAL  
NYSTATIN

AT	MACLEODS PHARMS LTD	100,000 UNITS/GM	A213566	001	Aug 10, 2021	Jul NEWA
	OINTMENT;TOPICAL NYSTATIN					
AT	MACLEODS PHARMS LTD	100,000 UNITS/GM	A213826	001	Jan 14, 2021	Jan NEWA
	POWDER;TOPICAL NYSTATIN					
AT	ZYDUS PHARMS	100,000 UNITS/GM	A208581	001	Jun 08, 2017	Jul CAHN
	SUSPENSION;ORAL NYSTATIN					
AA	NIVAGEN PHARMS INC	100,000 UNITS/ML	A062832	001	Dec 27, 1991	Jun CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL  
NYSTATIN AND TRIAMCINOLONE ACETONIDE

AT	ALEOR DERMACEUTICALS	100,000 UNITS/GM;0.1%	A214090	001	Mar 31, 2021	Mar NEWA
	OINTMENT;TOPICAL NYSTATIN AND TRIAMCINOLONE ACETONIDE					
>A> AT	MACLEODS PHARMS LTD	100,000 UNITS/GM;0.1%	A214751	001	Aug 17, 2021	Aug NEWA

ODEVIXIBAT

CAPSULE;ORAL  
BYLVAY

+ ALBIREO	0.4MG	N215498	002	Jul 20, 2021	Jul NEWA
+!	1.2MG	N215498	004	Jul 20, 2021	Jul NEWA
CAPSULE, PELLETS;ORAL BYLVAY					
+ ALBIREO	0.2MG	N215498	001	Jul 20, 2021	Jul NEWA
+!	0.6MG	N215498	003	Jul 20, 2021	Jul NEWA

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC  
OFLOXACIN

@ ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Jun CAHN
@	0.3%	A076830	001	Aug 31, 2004	Jan DISC

SOLUTION/DROPS;OTIC  
OFLOXACIN

@ ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Jun CAHN
-----------	------	---------	-----	--------------	----------

TABLET;ORAL  
FLOXIN

+ @ JANSSEN PHARMS	200MG	N019735	001	Dec 28, 1990	Jan CRLD
+ @	300MG	N019735	002	Dec 28, 1990	Jan CRLD
+ @	400MG	N019735	003	Dec 28, 1990	Jan CRLD

	OFLOXACIN					
AB	LARKEN LABS	400MG	A076093	003	Sep 02, 2003	May CMFD

OLANZAPINE

TABLET;ORAL  
OLANZAPINE

AB	@ HISUN PHARM HANGZHOU	2.5MG	A206924	001	Dec 31, 2020	Jul DISC
		2.5MG	A206924	001	Dec 31, 2020	Feb CAHN
AB	@	5MG	A206924	002	Dec 31, 2020	Jul DISC
		5MG	A206924	002	Dec 31, 2020	Feb CAHN
AB	@	7.5MG	A206924	003	Dec 31, 2020	Jul DISC
		7.5MG	A206924	003	Dec 31, 2020	Feb CAHN
AB	@	10MG	A206924	004	Dec 31, 2020	Jul DISC
		10MG	A206924	004	Dec 31, 2020	Feb CAHN
AB	@	15MG	A206924	005	Dec 31, 2020	Jul DISC
		15MG	A206924	005	Dec 31, 2020	Feb CAHN
AB	@	20MG	A206924	006	Dec 31, 2020	Jul DISC
		20MG	A206924	006	Dec 31, 2020	Feb CAHN

**TABLET, ORALLY DISINTEGRATING;ORAL  
OLANZAPINE**

AB	@ HISUN PHARM HANGZHOU	5MG	A206892	001	Dec 31, 2020	Jul DISC
		5MG	A206892	001	Dec 31, 2020	Feb CAHN
AB	@	10MG	A206892	002	Dec 31, 2020	Jul DISC
		10MG	A206892	002	Dec 31, 2020	Feb CAHN
AB	@	15MG	A206892	003	Dec 31, 2020	Jul DISC
		15MG	A206892	003	Dec 31, 2020	Feb CAHN
AB	@	20MG	A206892	004	Dec 31, 2020	Jul DISC
		20MG	A206892	004	Dec 31, 2020	Feb CAHN
>A> AB	TORRENT	5MG	A091415	001	Oct 25, 2011	Aug CAHN
>A> AB		10MG	A091415	002	Oct 25, 2011	Aug CAHN
>A> AB		15MG	A091415	003	Oct 25, 2011	Aug CAHN
>A> AB		20MG	A091415	004	Oct 25, 2011	Aug CAHN
>D> AB	TORRENT PHARMS LLC	5MG	A091415	001	Oct 25, 2011	Aug CAHN
>D> AB		10MG	A091415	002	Oct 25, 2011	Aug CAHN
>D> AB		15MG	A091415	003	Oct 25, 2011	Aug CAHN
>D> AB		20MG	A091415	004	Oct 25, 2011	Aug CAHN

**OLANZAPINE; SAMIDORPHAN L-MALATE**

TABLET;ORAL	LYBALVI					
+ ! ALKERMES INC	5MG;EQ 10MG BASE	N213378	001	May 28, 2021	May NEWA	
+	10MG;EQ 10MG BASE	N213378	002	May 28, 2021	May NEWA	
+	15MG;EQ 10MG BASE	N213378	003	May 28, 2021	May NEWA	
+	20MG;EQ 10MG BASE	N213378	004	May 28, 2021	May NEWA	

**OLMESARTAN MEDOXOMIL**

TABLET;ORAL	OLMESARTAN MEDOXOMIL					
>D> AB	LUPIN LTD	5MG	A206631	001	Apr 27, 2017	Aug DISC
>A>	@	5MG	A206631	001	Apr 27, 2017	Aug DISC
>D> AB		20MG	A206631	002	Apr 27, 2017	Aug DISC
>A>	@	20MG	A206631	002	Apr 27, 2017	Aug DISC
>D> AB		40MG	A206631	003	Apr 27, 2017	Aug DISC
>A>	@	40MG	A206631	003	Apr 27, 2017	Aug DISC
	MYLAN	5MG	A078276	001	Oct 26, 2016	Jul DISC
	@	20MG	A078276	002	Oct 26, 2016	Jul DISC
	@	40MG	A078276	003	Oct 26, 2016	Jul DISC

**OLOPATADINE HYDROCHLORIDE**

SOLUTION/DROPS;OPHTHALMIC	OLOPATADINE HYDROCHLORIDE					
AKORN	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Mar CTEC	
SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Jul CTEC	
>D> @ WOCKHARDT LTD	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Aug CMKT	
@	EQ 0.1% BASE	A200810	001	Jun 28, 2017	Jul DISC	
SPRAY, METERED;NASAL	OLOPATADINE HYDROCHLORIDE					
AB AMNEAL	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Mar CMFD	
@	0.665MG/SPRAY	A210901	001	Jan 28, 2020	Jan DISC	

**OMEGA-3-ACID ETHYL ESTERS**

CAPSULE;ORAL	LOVAZA					
AB + ! WOODWARD	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Feb CAHN	

**ONDANSETRON**

FILM;ORAL	ZUPLENZ					
+ @ AQUESTIVE	4MG	N022524	001	Jul 02, 2010	Feb CAHN	
+ @	8MG	N022524	002	Jul 02, 2010	Feb CAHN	

**ONDANSETRON HYDROCHLORIDE**

INJECTABLE;INJECTION	ONDANSETRON HYDROCHLORIDE					
@ HOSPIRA	EQ 2MG BASE/ML	A077840	001	Jan 19, 2007	Jun DISC	
ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE		A078945	001	Jan 03, 2013	May DISC	
@ EMCURE PHARMS LTD	EQ 2MG BASE/ML					

ORITAVANCIN DIPHOSPHATE

POWDER; INTRAVENOUS  
KIMYRSA

+! MELINTA THERAP	EQ 1.2GM BASE/VIAL	N214155	001	Mar 12, 2021	Mar NEWA
ORBACTIV					
+! MELINTA THERAP	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	May CAHN

ORPHENADRINE CITRATE

TABLET, EXTENDED RELEASE; ORAL  
NORFLEX

+ @ BAUSCH	100MG	N012157	001		May CAHN
ORPHENADRINE CITRATE					
@ IMPAX PHARMS	100MG	A040368	001	Jun 23, 2000	Jan DISC

OSELTAMIVIR PHOSPHATE

CAPSULE; ORAL  
OSELTAMIVIR PHOSPHATE

@ MYLAN	EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan DISC
AB	EQ 30MG BASE	A210157	001	Jan 21, 2021	Jan NEWA
@	EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan DISC
AB	EQ 45MG BASE	A210157	002	Jan 21, 2021	Jan NEWA
@	EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan DISC
AB	EQ 75MG BASE	A210157	003	Jan 21, 2021	Jan NEWA

FOR SUSPENSION; ORAL  
OSELTAMIVIR PHOSPHATE

>A> AB	APTAPHARMA INC	EQ 6MG BASE/ML	A212858	001	Aug 30, 2021	Aug NEWA
--------	----------------	----------------	---------	-----	--------------	----------

OXALIPLATIN

INJECTABLE; INTRAVENOUS  
OXALIPLATIN

@ CIPLA	50MG/10ML (5MG/ML)	A208523	001	Feb 10, 2017	May DISC
@	100MG/20ML (5MG/ML)	A208523	002	Feb 10, 2017	May DISC
>D> AP	QILU	A204368	001	Jun 07, 2016	Aug CAHN
>D> AP		A204368	002	Jun 07, 2016	Aug CAHN
>D>	!	A204368	003	Jun 07, 2016	Aug CAHN
>A> AP	QILU PHARM HAINAN	A204368	001	Jun 07, 2016	Aug CAHN
>A> AP		A204368	002	Jun 07, 2016	Aug CAHN
>A>	!	A204368	003	Jun 07, 2016	Aug CAHN

OXCARBAZEPINE

SUSPENSION; ORAL  
OXCARBAZEPINE

AB	AKORN	300MG/5ML	A211420	001	Jul 09, 2021	Jul NEWA
AB	GLASSHOUSE PHARMS	300MG/5ML	A212428	001	Jun 21, 2021	Jun NEWA

OXICONAZOLE NITRATE

LOTION; TOPICAL  
OXISTAT

+! ANI PHARMS	EQ 1% BASE	N020209	001	Sep 30, 1992	Apr CAHN
---------------	------------	---------	-----	--------------	----------

OXYBUTYNIN CHLORIDE

TABLET; ORAL  
OXYBUTYNIN CHLORIDE

AB	APPCO	5MG	A209025	001	Dec 21, 2017	Jan CAHN
	@ STRIDES PHARMA	5MG	A208165	001	Dec 17, 2020	Jun DISC

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL  
OXYCODONE HYDROCHLORIDE

@ LANNETT CO INC	5MG	A203823	001	Aug 01, 2014	Apr DISC
------------------	-----	---------	-----	--------------	----------

SOLUTION; ORAL  
OXYCODONE HYDROCHLORIDE

AA	QUAGEN	5MG/5ML	A213761	001	Jun 02, 2021	May NEWA
AA		100MG/5ML	A213761	002	Jun 02, 2021	May NEWA

TABLET; ORAL  
OXAYDO

+ ZYLA	5MG	N202080	001	Jun 17, 2011	Mar CRLD
+	7.5MG	N202080	002	Jun 17, 2011	Mar CRLD

OXYCODONE HYDROCHLORIDE

AB	ALVOGEN	5MG	A202116	001	Dec 30, 2011	Apr CAHN
AB		15MG	A202116	002	Dec 30, 2011	Apr CAHN

	TABLET;ORAL OXYCODONE HYDROCHLORIDE	30MG	A202116	003	Dec 30, 2011	Apr CAHN
AB	<u>OXYMETHOLONE</u>					
	TABLET;ORAL ANADROL-50					
+ @ MYLAN SPECIALITY LP	50MG		N016848	001		Apr DISC
	<u>OXYTOCIN</u>					
	INJECTABLE;INJECTION OXYTOCIN					
AP	+! HIKMA PHARMS	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Jul CAHN
AP	+! +!	100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Jul CAHN
	<u>OZANIMOD HYDROCHLORIDE</u>					
	CAPSULE;ORAL ZEPOSIA					
+ CELGENE INTL	EQ 0.23MG BASE		N209899	001	Mar 25, 2020	May CPOT
+ +!	EQ 0.46MG BASE		N209899	002	Mar 25, 2020	May CPOT
	EQ 0.92MG BASE		N209899	003	Mar 25, 2020	May CPOT
	<u>PACLITAXEL</u>					
	INJECTABLE;INJECTION PACLITAXEL					
AP	ACCORD HLTHCARE	6MG/ML	A205720	001	Aug 17, 2018	May CMFD
@ MYLAN LABS LTD	6MG/ML		A091540	001	Sep 29, 2011	Mar DISC
	<u>PALIPERIDONE PALMITATE</u>					
	SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR INVEGA SUSTENNA					
AB	+ JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	Jul CTEC
AB	+	78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	Jul CTEC
AB	+	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	Jul CTEC
AB	+!	156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	Jul CTEC
AB	+	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	Jul CTEC
	PALIPERIDONE PALMITATE					
AB	TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	Jul CTEC
AP		39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	Jun NFTG
AB		78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	Jul CTEC
AP		78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	Jun NFTG
AB		117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	Jul CTEC
AP		117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	Jun NFTG
AB		156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	Jul CTEC
AP		156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	Jun NFTG
AB		234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	Jul CTEC
AP		234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	Jun NFTG
	<u>PALONOSETRON HYDROCHLORIDE</u>					
	INJECTABLE;INTRAVENOUS ALOXI					
+ @ HELSINN HLTHCARE	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)		N021372	002	Feb 29, 2008	Apr DISC
+ @	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)		N021372	001	Jul 25, 2003	Apr DISC
	PALONOSETRON HYDROCHLORIDE					
AP	ACCORD HLTHCARE	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A204615	001	Mar 15, 2021	Mar NEWA
AP	! DR REDDYS LABS LTD	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr CHRS
	EMCURE PHARMS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A202951	001	Jun 29, 2021	Jun NEWA
AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A202951	002	Jun 29, 2021	Jun NEWA
	@ HOSPIRA INC	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A207005	002	Sep 19, 2018	Apr DISC
	@ QILU	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A205648	002	Sep 19, 2018	Apr DISC
	@ TEVA PHARMS USA	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A090713	002	Mar 23, 2018	Apr DISC
	SOLUTION;INTRAVENOUS PALONOSETRON HYDROCHLORIDE					
+ @ FRESENIUS KABI USA	EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)		N208109	001	Nov 21, 2017	May DISC

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION  
PAMIDRONATE DISODIUM

AP	+!	HIKMA PHARMS	30MG/10ML (3MG/ML)	N 021113	001	Mar 04, 2002	Jul CAHN
AP	+!		90MG/10ML (9MG/ML)	N 021113	002	Mar 04, 2002	Jul CAHN

PANTOPRAZOLE SODIUM

INJECTABLE; IV (INFUSION)  
PANTOPRAZOLE SODIUM

>A>	AP	ACIC PHARMS	EQ 40MG BASE/VIAL	A 209524	001	Aug 30, 2021	Aug NEWA
		TABLET, DELAYED RELEASE; ORAL PANTOPRAZOLE SODIUM					
		@ JUBILANT GENERICS	EQ 20MG BASE	A 090901	001	Aug 30, 2011	Jun DISC
		@	EQ 40MG BASE	A 090901	002	Aug 30, 2011	Jun DISC

PAROXETINE HYDROCHLORIDE

SUSPENSION; ORAL  
PAROXETINE HYDROCHLORIDE

>A>	AB	NOVITIUM PHARMA	EQ 10MG BASE/5ML	A 215003	001	Sep 03, 2021	Aug NEWA
		PAXIL					
>D>		+! APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N 020710	001	Jun 25, 1997	Aug CTEC
>A>	AB	+!	EQ 10MG BASE/5ML	N 020710	001	Jun 25, 1997	Aug CTEC
		TABLET, EXTENDED RELEASE; ORAL PAROXETINE HYDROCHLORIDE					
>A>	AB	CADILA PHARMS LTD	EQ 12.5MG BASE	A 212645	001	Aug 27, 2021	Aug NEWA
>A>	AB		EQ 25MG BASE	A 212645	002	Aug 27, 2021	Aug NEWA
>A>	AB		EQ 37.5MG BASE	A 212645	003	Aug 27, 2021	Aug NEWA
	AB	CSPC OUYI	EQ 12.5MG BASE	A 213485	001	Feb 16, 2021	Feb NEWA
	AB		EQ 25MG BASE	A 213485	002	Feb 16, 2021	Feb NEWA
	AB		EQ 37.5MG BASE	A 213485	003	Feb 16, 2021	Feb NEWA
	AB	SINOTHERAPEUTICS INC	EQ 12.5MG BASE	A 213612	001	Aug 11, 2021	Jul NEWA
	AB		EQ 25MG BASE	A 213612	002	Aug 11, 2021	Jul NEWA

PATIROMER SORBITEX CALCIUM

POWDER; ORAL  
VELTASSA

+	VIFOR PHARMA	EQ 8.4GM BASE/PACKET	N 205739	001	Oct 21, 2015	Jun CAHN
+		EQ 16.8GM BASE/PACKET	N 205739	002	Oct 21, 2015	Jun CAHN
+		EQ 25.2GM BASE/PACKET	N 205739	003	Oct 21, 2015	Jun CAHN

PEGCETACOPLAN

SOLUTION; SUBCUTANEOUS  
EMPAVELI

+! APELLIS PHARMS 1080MG/20ML (54MG/ML)

N 215014 001 May 14, 2021 May NEWA

PEMETREXED

SOLUTION; INTRAVENOUS  
PEMETREXED

+ @ ACTAVIS LLC	100MG/4ML (25MG/ML)	N 208419	001	Aug 21, 2020	Jan DISC
+ @	500MG/20ML (25MG/ML)	N 208419	002	Aug 21, 2020	Jan DISC
+ @	1GM/40ML (25MG/ML)	N 208419	003	Aug 21, 2020	Jan DISC

PENICILLAMINE

CAPSULE; ORAL  
PENICILLAMINE

>A>	AB	AGGREGA	250MG	A 215409	001	Aug 23, 2021	Aug NEWA
>A>	AB	INVAGEN PHARMS	250MG	A 213293	001	Aug 19, 2021	Aug NEWA

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION  
PENICILLIN G POTASSIUM

AP		HQ SPECLT PHARMA	1,000,000 UNITS/VIAL	A 065149	001	Jul 23, 2009	Mar CAHN
AP			5,000,000 UNITS/VIAL	A 065149	002	Jul 23, 2009	Mar CAHN
			20,000,000 UNITS/VIAL	A 065149	003	Jul 23, 2009	Mar CAHN

PENICILLIN V POTASSIUM

FOR SOLUTION;ORAL

PENICILLIN V POTASSIUM

@ DAVA PHARMS INC	EQ 125MG BASE/5ML	A062981	001	Feb 10, 1989	Mar DISC
@	EQ 250MG BASE/5ML	A062981	002	Feb 10, 1989	Mar DISC
PENICILLIN-VK					
TEVA	EQ 125MG BASE/5ML	A060456	001		Mar CTEC
!	EQ 250MG BASE/5ML	A060456	002		Mar CTEC

PENTAMIDINE ISETHIONATE

INJECTABLE; INJECTION

PENTAMIDINE ISETHIONATE

AP	EMCURE PHARMS LTD	300MG/VIAL	A213806	001	Jan 07, 2021	Jan NEWA
----	-------------------	------------	---------	-----	--------------	----------

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION

NEMBUTAL SODIUM

>D> AP	!	AKORN	50MG/ML	A083246	001	Aug CRLD
>A> AP	+	!	50MG/ML	A083246	001	Aug CRLD

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIL

@ UPSHER SMITH LABS	400MG	A074962	001	Mar 31, 1999	May DISC
TRENTAL		N018631	001	Aug 30, 1984	Feb CAHN

PERAMPANEL

TABLET;ORAL

FYCOMPA

+ EISAI INC	2MG	N202834	001	Oct 22, 2012	Jun CTEC
+	4MG	N202834	002	Oct 22, 2012	Jun CTEC
+	6MG	N202834	003	Oct 22, 2012	Jun CTEC
+	8MG	N202834	004	Oct 22, 2012	Jun CTEC
+	10MG	N202834	005	Oct 22, 2012	Jun CTEC
+	12MG	N202834	006	Oct 22, 2012	Jun CTEC

PHENDIMETRAZINE TARTRATE

TABLET;ORAL

BONTRIL PDM

>D> AA	!	VALEANT	35MG	A085272	001	Aug CRLD
>A> AA	+	!	35MG	A085272	001	Aug CRLD

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

ADIPEX-P

>D> AA	!	TEVA	37.5MG	A088023	001	Aug 02, 1983	Aug CRLD
>A> AA	+	!	37.5MG	A088023	001	Aug 02, 1983	Aug CRLD
		PHENTERMINE HYDROCHLORIDE					
>D> AA	!	SANDOZ	15MG	A087190	002		Aug CRLD
>A> AA	+	!	15MG	A087190	002		Aug CRLD
>D> AA	!		30MG	A086945	001	Jul 20, 1983	Aug CRLD
>A> AA	+	!	30MG	A086945	001	Jul 20, 1983	Aug CRLD

TABLET;ORAL

ADIPEX-P

>D> AA	!	TEVA	37.5MG	A085128	001	Aug CRLD	
>A> AA	+	!	37.5MG	A085128	001	Aug CRLD	
		PHENTERMINE HYDROCHLORIDE					
>D>	@	USL PHARMA	8MG	A083804	001		Aug CRLD
>A>	+	@	8MG	A083804	001		Aug CRLD

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION;INTRAVENOUS

BIORPHEN

+! ETON PHARMS	0.5MG/5ML (0.1MG/ML)	N212909	001	Oct 21, 2019	Feb CPOT
+ @	10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Apr DISC
+!	10MG/ML (10MG/ML)	N212909	002	Mar 11, 2021	Mar NEWA

PHENYLEPHRINE HYDROCHLORIDE

AP2	AUROBINDO PHARMA LTD	10MG/ML (10MG/ML)	A210696	001	Jan 07, 2021	Jan NEWA
AP1	CAPLIN	10MG/ML (10MG/ML)	A213318	001	Jun 11, 2020	Jul CMFD
AP1		50MG/5ML (10MG/ML)	A213318	002	Jun 11, 2020	Jul CMFD

SOLUTION; INTRAVENOUS  
PHENYLEPHRINE HYDROCHLORIDE

AP1		100MG/10ML (10MG/ML)	A213318	003	Jun 11, 2020	Jul CMFD
AP1	GLAND PHARMA LTD	10MG/ML (10MG/ML)	A211920	003	Apr 08, 2021	Apr NEWA
AP2	+! HIKMA	10MG/ML (10MG/ML)	N203826	001	Dec 20, 2012	Jan CAHN
AP2	+!	50MG/5ML (10MG/ML)	N203826	002	Jun 19, 2019	Jan CAHN
AP2	+!	100MG/10ML (10MG/ML)	N203826	003	Jun 19, 2019	Jan CAHN
AP1	PROVEPHARM SAS	10MG/ML (10MG/ML)	A211081	001	Jul 17, 2020	Jan CAHN
AP1		50MG/5ML (10MG/ML)	A211081	002	Jul 17, 2020	Jan CAHN
AP1		100MG/10ML (10MG/ML)	A211081	003	Jul 17, 2020	Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

	SYRUP; ORAL	PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE				
AA	AKORN	5MG/5ML; 6.25MG/5ML	A040675	001	Dec 23, 2014	Feb CAHN
	PROMETH VC PLAIN					
>D>	@ G AND W LABS INC	5MG/5ML; 6.25MG/5ML	A088761	001	Nov 08, 1984	Aug CRLD
>A>	+ @	5MG/5ML; 6.25MG/5ML	A088761	001	Nov 08, 1984	Aug CRLD

PHENYTOIN

	TABLET, CHEWABLE; ORAL	DILANTIN				
>D> AB	! PHARMACIA	50MG	A084427	001		Aug CRLD
>A> AB	+!	50MG	A084427	001		Aug CRLD

PHENYTOIN SODIUM

	CAPSULE; ORAL	DILANTIN				
>D>	! UPJOHN	30MG EXTENDED	A084349	001		Aug CRLD
>A>	+!	30MG EXTENDED	A084349	001		Aug CRLD
>D> AB	!	100MG EXTENDED	A084349	002		Aug CRLD
>A> AB	+!	100MG EXTENDED	A084349	002		Aug CRLD
	INJECTABLE; INJECTION					
	PHENYTOIN SODIUM					
>D> AP	! WEST-WARD PHARMS INT	50MG/ML	A084307	001		Aug CRLD
>A> AP	+!	50MG/ML	A084307	001		Aug CRLD

PHYTONADIONE

	INJECTABLE; INJECTION	PHYTONADIONE				
BP	+! INTL MEDICATION	1MG/0.5ML	A083722	001		May CRLD
	VITAMIN K1					
>D> AB	! HOSPIRA	10MG/ML	A087955	001	Jul 25, 1983	Aug CRLD
>A> AB	+!	10MG/ML	A087955	001	Jul 25, 1983	Aug CRLD

PIFLUFOLASTAT F-18

	SOLUTION; INTRAVENOUS					
	PYLARIFY					
+!	PROGENICS PHARMS INC	50ML (1-80mCi/ML)	N214793	001	May 26, 2021	May NEWA

PILOCARPINE HYDROCHLORIDE

	TABLET; ORAL	PILOCARPINE HYDROCHLORIDE				
>A> AB	INNOGENIX	5MG	A076963	001	Dec 22, 2004	Aug CAHN
>A> AB		7.5MG	A076963	002	Feb 27, 2007	Aug CAHN
>D> AB	MLV	5MG	A076963	001	Dec 22, 2004	Aug CAHN
>D> AB		7.5MG	A076963	002	Feb 27, 2007	Aug CAHN

PIOGLITAZONE HYDROCHLORIDE

	TABLET; ORAL	PIOGLITAZONE HYDROCHLORIDE				
AB	ANNORA PHARMA	EQ 15MG BASE	A204133	001	Apr 07, 2014	Jan CAHN
AB		EQ 30MG BASE	A204133	002	Apr 07, 2014	Jan CAHN
AB		EQ 45MG BASE	A204133	003	Apr 07, 2014	Jan CAHN
AB	SHUANGCHENG	EQ 15MG BASE	A210165	001	Jan 22, 2021	Jan NEWA
AB		EQ 30MG BASE	A210165	002	Jan 22, 2021	Jan NEWA
AB		EQ 45MG BASE	A210165	003	Jan 22, 2021	Jan NEWA

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

## INJECTABLE; INJECTION

## PIPERACILLIN AND TAZOBACTAM

@	MYLAN LABS LTD	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Apr DISC
@		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Mar DISC
@		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Jul DISC
AP	PROVEPHARM SAS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A207847	001	Jan 13, 2017	Jan CAHN
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A207847	002	Jan 13, 2017	Jan CAHN
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207848	002	Jan 13, 2017	Jan CAHN
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A207847	003	Jan 13, 2017	Jan CAHN
AP		EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A207848	001	May 11, 2018	Jan CAHN
AP	SAGENT PHARMS INC	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A208674	001	Feb 16, 2021	Feb NEWA
AP		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A208674	002	Feb 16, 2021	Feb NEWA
AP		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A208674	003	Feb 16, 2021	Feb NEWA
AP		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A208675	001	Feb 16, 2021	Feb NEWA
AP	SANDOZ INC	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A203557	002	Jul 08, 2021	Jul NEWA
AP	! WOCKHARDT BIO AG	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A206996	001	Mar 22, 2017	Jan CHRS
AP	!	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A206996	002	Mar 22, 2017	Jan CHRS
AP	!	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A206996	003	Mar 22, 2017	Jan CHRS
AP	!	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A207146	001	Mar 17, 2017	Jan CHRS
	ZOSYN					
+ @	WYETH PHARMS	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	N050684	001	Oct 22, 1993	Jan DISC
+ @		EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	N050684	002	Oct 22, 1993	Jan DISC
+ @		EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	N050684	003	Oct 22, 1993	Jan DISC
+ @		EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	N050684	004	Oct 22, 1993	Jan DISC

PIRBUTEROL ACETATE

## AEROSOL, METERED; INHALATION

## MAXAIR

@ BAUSCH

EQ 0.2MG BASE/INH

N020014 001 Nov 30, 1992 May CAHN

PIROXICAM

## CAPSULE; ORAL

## PIROXICAM

AB	NOSTRUM LABS INC	10MG	A074118	002	Jun 15, 1993	Jan CMS1
----	------------------	------	---------	-----	--------------	----------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

## FOR SOLUTION; ORAL

## LAX-LYTE WITH FLAVOR PACKS

>A> AA	L PERRIGO CO	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A079232	001	Feb 25, 2010	Aug CAHN
>D> AA	PADDICK LLC	420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT	A079232	001	Feb 25, 2010	Aug CAHN

POLYMYXIN B SULFATE

## INJECTABLE; INJECTION

## POLYMYXIN B SULFATE

@	GLAND	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	May DISC
AP	! XELLIA PHARMS APS	EQ 500,000 UNITS BASE/VIAL	A202766	001	Jan 15, 2014	May CHRS

POMALIDOMIDE

CAPSULE;ORAL						
POMALIDOMIDE						
@ BRECKENRIDGE	1MG		A210111	001	Oct 30, 2020	Feb DISC
@	2MG		A210111	002	Oct 30, 2020	Feb DISC
@	3MG		A210111	003	Oct 30, 2020	Feb DISC
@	4MG		A210111	004	Oct 30, 2020	Feb DISC
@ EUGIA PHARMA	1MG		A210249	001	Oct 30, 2020	Apr DISC
@	2MG		A210249	002	Oct 30, 2020	Apr DISC
@	3MG		A210249	003	Oct 30, 2020	Apr DISC
@	4MG		A210249	004	Oct 30, 2020	Apr DISC
POMALYST						
+ CELGENE	1MG		N204026	001	Feb 08, 2013	Apr CTEC
+	2MG		N204026	002	Feb 08, 2013	Apr CTEC
+	3MG		N204026	003	Feb 08, 2013	Apr CTEC
+!	4MG		N204026	004	Feb 08, 2013	Apr CTEC

PONATINIB HYDROCHLORIDE

TABLET;ORAL						
ICLUSIG						
+ TAKEDA PHARMS USA	EQ 10MG BASE		N203469	004	Dec 18, 2020	May CAHN
+	EQ 15MG BASE		N203469	001	Dec 14, 2012	May CAHN
+	EQ 30MG BASE		N203469	003	Apr 23, 2015	May CAHN
+!	EQ 45MG BASE		N203469	002	Dec 14, 2012	May CAHN

PONESIMOD

TABLET;ORAL						
PONVORY						
+ JANSSEN PHARMS	2MG		N213498	001	Mar 18, 2021	Mar NEWA
+	3MG		N213498	002	Mar 18, 2021	Mar NEWA
+	4MG		N213498	003	Mar 18, 2021	Mar NEWA
+	5MG		N213498	004	Mar 18, 2021	Mar NEWA
+	6MG		N213498	005	Mar 18, 2021	Mar NEWA
+	7MG		N213498	006	Mar 18, 2021	Mar NEWA
+	8MG		N213498	007	Mar 18, 2021	Mar NEWA
+	9MG		N213498	008	Mar 18, 2021	Mar NEWA
+	10MG		N213498	009	Mar 18, 2021	Mar NEWA
+!	20MG		N213498	010	Mar 18, 2021	Mar NEWA

POSACONAZOLE

FOR SUSPENSION, DELAYED RELEASE;ORAL						
NOXAFIL POWDERMIX KIT						
+! MSD MERCK CO	300MG		N214770	001	May 31, 2021	May NEWA
TABLET, DELAYED RELEASE;ORAL						
POSACONAZOLE						
AB AET PHARMA	100MG		A213454	001	Feb 01, 2021	Jan NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL						
POTASSIUM CHLORIDE						
AB GRANULES	8MEQ		A214686	001	Feb 16, 2021	Feb NEWA
AB	10MEQ		A214686	002	Feb 16, 2021	Feb NEWA
FOR SOLUTION;ORAL						
POTASSIUM CHLORIDE						
>D> AA STRIDES PHARMA	20MEQ		A211667	001	Mar 11, 2021	Aug DISC
>A> @	20MEQ		A211667	001	Mar 11, 2021	Aug DISC
AA	20MEQ		A211667	001	Mar 11, 2021	Mar NEWA
INJECTABLE;INJECTION						
POTASSIUM CHLORIDE						
>D> @ ABRAXIS PHARM	2MEQ/ML		A080204	001		Aug CRLD
>A> + @	2MEQ/ML		A080204	001		Aug CRLD
>D> AP FRESENIUS KABI USA	2MEQ/ML		A080225	001		Aug CRLD
>A> AP +	2MEQ/ML		A080225	001		Aug CRLD
POTASSIUM CHLORIDE 10MEQ						
@ FRESENIUS KABI USA	14.9MG/ML		A211087	001	Sep 09, 2020	Mar DISC
@	746MG/100ML		A211087	002	Sep 09, 2020	Mar DISC
AP NEXUS PHARMS	14.9MG/ML		A214727	001	Mar 18, 2021	Mar NFTG
AP	745MG/100ML		A214727	002	Mar 18, 2021	Mar NFTG
POTASSIUM CHLORIDE 20MEQ						
@ FRESENIUS KABI USA	29.8MG/ML		A211087	003	Sep 09, 2020	Mar DISC
	1.49GM/100ML		A211087	005	May 07, 2021	Apr NEWA

INJECTABLE; INJECTIONPOTASSIUM CHLORIDE 20MEQ

AP	NEXUS PHARMS	29.8MG/ML 1.49GM/100ML	A214727	003	Mar 18, 2021	Mar NFTG
AP	POTASSIUM CHLORIDE 40MEQ		A214727	004	Mar 18, 2021	Mar NFTG
AP	@ FRESENIUS KABI USA	2.98GM/100ML	A211087	004	Sep 09, 2020	Mar DISC
AP	NEXUS PHARMS	2.98GM/100ML	A214727	005	Mar 18, 2021	Mar NFTG
	SOLUTION;ORAL					
	POTASSIUM CHLORIDE					
AA	GRANULES	20MEQ/15ML	A213392	001	Jan 29, 2021	Jan NEWA
AA		40MEQ/15ML	A213392	002	Jan 29, 2021	Jan NEWA
AA	SAPTALIS PHARMS	20MEQ/15ML	A211648	001	May 21, 2021	May NEWA
AA		40MEQ/15ML	A211648	002	May 21, 2021	May NEWA
	TABLET, EXTENDED RELEASE;ORAL					
	POTASSIUM CHLORIDE					
AB1	@ AMTA	10MEQ	A214395	001	Jan 28, 2021	Jul DISC
		10MEQ	A214395	001	Jan 28, 2021	Jan NEWA
AB1	@	20MEQ	A214395	002	Jan 28, 2021	Jul DISC
AB1		20MEQ	A214395	002	Jan 28, 2021	Jan NEWA
AB1	AUROBINDO PHARMA LTD	10MEQ	A214728	001	Mar 31, 2021	Mar NEWA
AB1		15MEQ	A214728	002	Mar 31, 2021	Mar NEWA
AB1		20MEQ	A214728	003	Mar 31, 2021	Mar NEWA
	@ CENTAUR PHARMS PVT	10MEQ	A213588	001	Aug 21, 2020	Mar DISC
	@	20MEQ	A213588	002	Aug 21, 2020	Mar DISC

POTASSIUM CHLORIDE; SODIUM CHLORIDEINJECTABLE; INJECTIONPOTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%

+!	BAXTER HLTHCARE	150MG/100ML; 450MG/100ML	N017648	005	Nov 26, 2002	Mar CTNA
+!		150MG/100ML; 450MG/100ML	N017648	005	Nov 26, 2002	Mar CTEC
@	FRESENIUS KABI USA	150MG/100ML; 450MG/100ML	A212347	001	Sep 17, 2020	Mar DISC
	POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%					
AP	+! BAXTER HLTHCARE	150MG/100ML; 900MG/100ML	N017648	001		Mar CTNA
AP	+!	150MG/100ML; 900MG/100ML	N017648	001		Mar CHRS
AP	FRESENIUS KABI USA	150MG/100ML; 900MG/100ML	A212347	003	Jun 02, 2021	May NEWA
	POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%					
+!	BAXTER HLTHCARE	300MG/100ML; 900MG/100ML	N017648	002		Mar CTNA
+!		300MG/100ML; 900MG/100ML	N017648	002		Mar CHRS
+		300MG/100ML; 900MG/100ML	N017648	002		Mar CTEC
@	FRESENIUS KABI USA	300MG/100ML; 900MG/100ML	A212347	002	Sep 17, 2020	Mar DISC
	SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075%					
@	BAXTER HLTHCARE	75MG/100ML; 900MG/100ML	N017648	004		Mar CTNA

POTASSIUM CITRATETABLET, EXTENDED RELEASE;ORALPOTASSIUM CITRATE

AB	ASCENT PHARMS INC	5MEQ	A214420	001	Feb 05, 2021	Jan NEWA
AB		10MEQ	A214420	002	Feb 05, 2021	Jan NEWA
AB		15MEQ	A214420	003	Feb 05, 2021	Jan NEWA
AB	BIONPHARMA INC	10MEQ	A212799	001	Jun 29, 2020	Apr CMFD
	@	10MEQ	A212799	001	Jun 29, 2020	Feb DISC
AB		15MEQ	A212799	002	Jun 29, 2020	Apr CMFD
	@	15MEQ	A212799	002	Jun 29, 2020	Feb DISC
AB	EYWA	5MEQ	A214426	001	Feb 19, 2021	Feb NEWA
AB		10MEQ	A214426	002	Feb 19, 2021	Feb NEWA
AB		15MEQ	A214426	003	Feb 19, 2021	Feb NEWA

PRALSETINIBCAPSULE; ORALGAVRETO

+! GENENTECH INC 100MG

N213721 001 Sep 04, 2020 Mar CAHN

PRAMIPEXOLE DIHYDROCHLORIDETABLET;ORALPRAMIPEXOLE DIHYDROCHLORIDE

AB	@ NOSTRUM LABS INC	0.125MG	A091450	001	Oct 08, 2010	Jul DISC
		0.125MG	A091450	001	Oct 08, 2010	Apr CAHN
AB	@	0.25MG	A091450	002	Oct 08, 2010	Jul DISC
AB		0.25MG	A091450	002	Oct 08, 2010	Apr CAHN
	@	0.5MG	A091450	003	Oct 08, 2010	Jul DISC
AB		0.5MG	A091450	003	Oct 08, 2010	Apr CAHN
	@	1MG	A091450	004	Oct 08, 2010	Jul DISC

**TABLET; ORAL**

**PRAMIPEXOLE DIHYDROCHLORIDE**

AB		1MG	A091450	004	Oct 08, 2010	Apr CAHN
	@	1.5MG	A091450	005	Oct 08, 2010	Jul DISC
AB		1.5MG	A091450	005	Oct 08, 2010	Apr CAHN
TABLET, EXTENDED RELEASE;ORAL PRAMIPEXOLE DIHYDROCHLORIDE						
AB	XIAMEN LP PHARM CO	0.375MG	A212797	001	Jun 11, 2021	Jun NEWA
AB		0.75MG	A212797	002	Jun 11, 2021	Jun NEWA

PRASUGREL HYDROCHLORIDE

## TABLET; ORAL

## **PRASUGREL**

@	DR REDDYS LABS LTD	EQ 5MG BASE	A205926	001	Jul 07, 2020	Jan DISC
@		EQ 10MG BASE	A205926	002	Jul 07, 2020	Jan DISC
AB	PANACEA	EQ 5MG BASE	A205897	001	Oct 16, 2017	Jul CAHN
AB		EQ 10MG BASE	A205897	002	Oct 16, 2017	Jul CAHN

## PRAVASTATIN SODIUM

**TABLET; ORAL**

## PRAVACHOL

+ @	BRISTOL MYERS SQUIBB	20MG	N019898	003	Oct 31, 1991	Jun DISC
+ @		40MG	N019898	004	Mar 22, 1993	Jun DISC
+ @		80MG	N019898	008	Dec 18, 2001	Jun DISC
PRAVASTATIN SODIUM						
AB	BIOCON PHARMA	10MG	A209869	001	Apr 13, 2018	Jan CAHN
AB		20MG	A209869	002	Apr 13, 2018	Jan CAHN
AB		40MG	A209869	003	Apr 13, 2018	Jan CAHN
AB		80MG	A209869	004	Apr 13, 2018	Jan CAHN
@	HISUN PHARM HANGZHOU	20MG	A206061	001	Nov 23, 2018	Jan DISC
@		40MG	A206061	002	Nov 23, 2018	Jan DISC
@		80MG	A206061	003	Nov 23, 2018	Jan DISC
AB	TEVA PHARMS	80MG	A077793	001	Jan 15, 2008	Jun CHRS

## PRAZOSIN HYDROCHLORIDE

## CAPSULE; ORAT.

## PRAZOSIN HYDROCHLORIDE

AB	ANI PHARMS	EQ 1MG BASE	A 072577	002	May 16, 1989	Feb CMFD
AB		EQ 2MG BASE	A 072577	001	May 16, 1989	Feb CMFD
AB		EQ 5MG BASE	A 072577	003	May 16, 1989	Feb CMFD

## PREDNISOLONE

**SYRUP; ORAL**

## PREDNISOLONE

AA CHARTWELL RX 15MG/5ML A040323 001 May 13, 1999 Mar CMFD  
TABLET;ORAL  
PREDNISOLONE  
@ RISING 5MG A084773 001 Jan CAHN

PREDNISOLONE SODIUM PHOSPHATE

## SOLUTION; ORAL

PREDNISOLONE SODIUM PHOSPHATE

@ BAUSCH EQ 15MG BASE/5ML A075250 001 Jul 12, 2002 May CAHN  
SOLUTION/DROPS; OPHTHALMIC

INFLAMASE FORTE					
>D>	@ NOVARTIS	EQ 0.9% PHOSPHATE	A 080751	002	Aug CRLD
>A>	+ @	EQ 0.9% PHOSPHATE	A 080751	002	Aug CRLD
INFLAMASE MILD					
>D>	@ NOVARTIS	EQ 0.11% PHOSPHATE	A 080751	001	Aug CRLD

>A> + @ EQ 0.11% PHOSPHATE A 080751 001 Aug CRLD  
TABLET, ORALLY DISINTEGRATING;ORAL

+ CONCORDIA PHARMS INC EQ 10MG BASE N 021959 001 Jun 01, 2006 Jul CTEC  
+ EQ 15MG BASE N 021959 002 Jun 01, 2006 Jul CTEC

+! EQ 30MG BASE N021959 003 Jun 01, 2006 Jul CTEC  
 PREDNISOLONE SODIUM PHOSPHATE  
 @ MYLAN PHARMS INC EQ 10MG BASE A202179 001 Apr 10, 2013 Jul DISC  
 @ EQ 15MG BASE A202179 002 Apr 10, 2013 Jul DISC  
 @ EQ 30MG BASE A202179 003 Apr 10, 2013 Jul DISC

PREDNISONE

## TABLET;ORAL

## PREDNISONE

>D>	AB	! HIKMA PHARMS	1MG	A087800	001	Apr 22, 1982	Aug CRLD
>A>	AB	+! RISING	1MG	A087800	001	Apr 22, 1982	Aug CRLD
>D>	AB	! NOVITIUM PHARMA	10MG	A084122	001		Aug CRLD
>A>	AB	+! STRIDES PHARMA	10MG	A084122	001		Aug CRLD
>D>	AB	! NOVITIUM PHARMA	20MG	A087342	001		Aug CRLD
>A>	AB	+! STRIDES PHARMA	20MG	A087342	001		Aug CRLD
	AB	NOVITIUM PHARMA	1MG	A215246	001	Jul 06, 2021	Jun NEWA
	@	RISING	10MG	A089983	001	Jan 12, 1989	Jan CAHN
	@		20MG	A085813	001		Jan CAHN
	@		50MG	A089984	001	Jan 12, 1989	Jan CAHN
AB		STRIDES PHARMA	10MG	A208412	001	Feb 11, 2021	Feb NEWA
AB			20MG	A208412	002	Feb 11, 2021	Feb NEWA
TABLET, DELAYED RELEASE;ORAL							
RAYOS							
	+	HORIZON	1MG	N202020	001	Jul 26, 2012	Apr CAHN
	+		2MG	N202020	002	Jul 26, 2012	Apr CAHN
	+!		5MG	N202020	003	Jul 26, 2012	Apr CAHN

PREGABALIN

## CAPSULE;ORAL

## LYRICA

AB	+	UPJOHN	25MG	N021446	001	Dec 30, 2004	Apr CAHN
AB	+		50MG	N021446	002	Dec 30, 2004	Apr CAHN
AB	+		75MG	N021446	003	Dec 30, 2004	Apr CAHN
AB	+		100MG	N021446	004	Dec 30, 2004	Apr CAHN
AB	+		150MG	N021446	005	Dec 30, 2004	Apr CAHN
AB	+		200MG	N021446	006	Dec 30, 2004	Apr CAHN
AB	+		225MG	N021446	007	Dec 30, 2004	Apr CAHN
AB	+!		300MG	N021446	008	Dec 30, 2004	Apr CAHN
PREGABALIN							
AB		ALKEM LABS LTD	25MG	A207799	007	Sep 30, 2019	Feb CMS1
AB			50MG	A207799	008	Sep 30, 2019	Feb CMS1
AB		APOTEX	25MG	A211685	001	Jul 07, 2021	Jun NEWA
AB			50MG	A211685	002	Jul 07, 2021	Jun NEWA
AB			75MG	A211685	003	Jul 07, 2021	Jun NEWA
AB			100MG	A211685	004	Jul 07, 2021	Jun NEWA
AB			150MG	A211685	005	Jul 07, 2021	Jun NEWA
AB			200MG	A211685	006	Jul 07, 2021	Jun NEWA
AB			225MG	A211685	007	Jul 07, 2021	Jun NEWA
AB			300MG	A211685	008	Jul 07, 2021	Jun NEWA
AB		CHANGZHOU PHARM	50MG	A214322	001	Jul 15, 2021	Jul NEWA
AB			75MG	A214322	002	Jul 15, 2021	Jul NEWA
AB			100MG	A214322	003	Jul 15, 2021	Jul NEWA
AB			150MG	A214322	004	Jul 15, 2021	Jul NEWA
AB			200MG	A214322	005	Jul 15, 2021	Jul NEWA
AB			225MG	A214322	006	Jul 15, 2021	Jul NEWA
AB			300MG	A214322	007	Jul 15, 2021	Jul NEWA

## SOLUTION;ORAL

## LYRICA

AA	+!	UPJOHN	20MG/ML	N022488	001	Jan 04, 2010	Apr CAHN
TABLET, EXTENDED RELEASE;ORAL							
LYRICA CR							
AB	+	UPJOHN	82.5MG	N209501	001	Oct 11, 2017	Apr CAHN
AB	+		165MG	N209501	002	Oct 11, 2017	Apr CAHN
AB	+!		330MG	N209501	003	Oct 11, 2017	Apr CAHN
PREGABALIN							
AB		ALVOGEN	82.5MG	A211687	001	Jul 06, 2021	Jun NEWA
AB			165MG	A211687	002	Jul 06, 2021	Jun NEWA
AB			330MG	A211687	003	Jul 06, 2021	Jun NEWA
AB		ALVOGEN PINE BROOK	82.5MG	A211593	001	Apr 13, 2021	Apr NFTG
AB			165MG	A211593	002	Apr 13, 2021	Apr NFTG
AB			330MG	A211593	003	Apr 13, 2021	Apr NFTG
AB		APOTEX	165MG	A213313	001	Apr 13, 2021	Apr NFTG
AB			330MG	A213313	002	Apr 13, 2021	Apr NFTG
AB		MSN	82.5MG	A213226	001	Apr 13, 2021	Apr NFTG
AB			165MG	A213226	002	Apr 13, 2021	Apr NFTG
AB			330MG	A213226	003	Apr 13, 2021	Apr NFTG
AB		MYLAN	82.5MG	A211948	001	Apr 13, 2021	Apr NFTG
AB			330MG	A211431	001	Jul 02, 2021	Jun NEWA

## TABLET, EXTENDED RELEASE;ORAL

## PREGABALIN

AB	SUN PHARM	82.5MG	A211889	001	Apr 13, 2021	Apr NFTG
AB		165MG	A211889	002	Apr 13, 2021	Apr NFTG
AB		330MG	A211889	003	Apr 13, 2021	Apr NFTG

PROBENECID

## TABLET;ORAL

## PROBENECID

>D> AB	MYLAN	500MG	A084211	002	Aug CAHN	
>A>	@	500MG	A084211	002	Aug CAHN	
>D>	! WATSON LABS TEVA	500MG	A084442	004	Mar 29, 1983	Aug CTEC
>A> AB	!	500MG	A084442	004	Mar 29, 1983	Aug CTEC

PROCAINAMIDE HYDROCHLORIDE

## TABLET, EXTENDED RELEASE;ORAL

## PROCAN SR

>D>	@ PARKE DAVIS	250MG	A086468	001	Aug CRLD	
>A>	+ @	250MG	A086468	001	Aug CRLD	
>D>	@ PARKADEL	500MG	A086065	001	Aug CRLD	
>A>	+ @	500MG	A086065	001	Aug CRLD	
>D>	@	750MG	A087510	001	Apr 01, 1982	Aug CRLD
>A>	+ @	750MG	A087510	001	Apr 01, 1982	Aug CRLD

PROCHLORPERAZINE EDISYLATE

## INJECTABLE; INJECTION

## PROCHLORPERAZINE EDISYLATE

AP	CAPLIN	EQ 5MG BASE/ML	A214379	001	Apr 22, 2021	Apr NEWA
	@ HIKMA PHARMS	EQ 5MG BASE/ML	A089523	001	May 03, 1988	Jul CAHN
AP		EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Jul CAHN

PROMETHAZINE HYDROCHLORIDE

## SYRUP;ORAL

## PROMETHAZINE HYDROCHLORIDE

>D>	@ AMNEAL PHARMS	6.25MG/5ML	A040882	001	Dec 30, 2009	Aug CMFD
>A> AA		6.25MG/5ML	A040882	001	Dec 30, 2009	Aug CMFD
	@	6.25MG/5ML	A040882	001	Dec 30, 2009	Feb DISC
AA	QUAGEN	6.25MG/5ML	A213890	001	Jul 12, 2021	Jul NEWA
	PROMETHAZINE PLAIN					
>D> AA	! WOCKHARDT BIO AG	6.25MG/5ML	A087953	001	Nov 15, 1982	Aug CRLD
>A> AA	+!	6.25MG/5ML	A087953	001	Nov 15, 1982	Aug CRLD

## TABLET;ORAL

## PROMETHAZINE HYDROCHLORIDE

>D> AB	SANDOZ	25MG	A084176	003	Aug CRLD	
>A> AB	+	25MG	A084176	003	Aug CRLD	
>D> AB	!	50MG	A084176	001	Aug CRLD	
>A> AB	+!	50MG	A084176	001	Aug CRLD	

PROPAFENONE HYDROCHLORIDE

## CAPSULE, EXTENDED RELEASE;ORAL

## PROPAFENONE HYDROCHLORIDE

	@ MYLAN	225MG	A203803	001	Apr 29, 2016	Jul DISC
	@	325MG	A203803	002	Apr 29, 2016	Jul DISC
	@	425MG	A203803	003	Apr 29, 2016	Jul DISC
AB	ZYDUS	225MG	A214184	001	Apr 21, 2021	Apr NEWA
AB		325MG	A214184	002	Apr 21, 2021	Apr NEWA
AB		425MG	A214184	003	Apr 21, 2021	Apr NEWA

PROPANTHELINE BROMIDE

## TABLET;ORAL

## PROPANTHELINE BROMIDE

	@ HIKMA PHARMS	15MG	A080927	002	Apr DISC	
--	----------------	------	---------	-----	----------	--

PROPRANOLOL HYDROCHLORIDE

## TABLET;ORAL

## PROPRANOLOL HYDROCHLORIDE

>D>	@ IMPAX LABS INC	40MG	A071972	003	Apr 06, 1988	Aug CMFD
>A> AB		40MG	A071972	003	Apr 06, 1988	Aug CMFD
	@ WATSON LABS	60MG	A070178	002	Apr 23, 2018	Apr DISC

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

BD QUAGEN 50MG A080154 001 Mar CMFD

PROTAMINE SULFATE

INJECTABLE;INJECTION

PROTAMINE SULFATE

@ HIKMA PHARMS 10MG/ML A089474 001 Nov 05, 1986 Jul CAHN  
@ 10MG/ML A089475 001 Nov 05, 1986 Jul CAHNPYRAZINAMIDE

TABLET;ORAL

PYRAZINAMIDE

>D> AB NOVITIUM PHARMA 500MG A080157 001 Aug CRLD  
>A> AB + 500MG A080157 001 Aug CRLD  
AB 500MG A080157 001 Apr CMFDPYRIDOXINE HYDROCHLORIDE

INJECTABLE;INJECTION

PYRIDOXINE HYDROCHLORIDE

>D> ! FRESENIUS KABI USA 100MG/ML A080618 001 Aug CRLD  
>A> +! 100MG/ML A080618 001 Aug CRLDPYRIMETHAMINE

TABLET;ORAL

PYRIMETHAMINE

>A> AB ALVOGEN 25MG A211271 001 Jul 27, 2021 Aug CAHN  
>D> AB FERA PHARMS LLC 25MG A211271 001 Jul 27, 2021 Aug CAHN  
AB 25MG A211271 001 Jul 27, 2021 Jul NEWA  
>A> AB TEVA PHARMS 25MG A215506 001 Aug 13, 2021 Aug NEWAQUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

@ JUBILANT GENERICS EQ 25MG BASE A203150 001 Nov 26, 2013 Jun DISC

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

@ ANCHEN PHARMS	EQ 150MG BASE	A090757 001 Dec 01, 2017	Jun DISC
@	EQ 200MG BASE	A090757 002 Dec 01, 2017	Jun DISC
@	EQ 300MG BASE	A090757 003 Dec 01, 2017	Jun DISC
@	EQ 400MG BASE	A090757 004 Dec 01, 2017	Jun DISC
@ MYLAN	EQ 50MG BASE	A202228 001 Feb 02, 2021	Feb DISC
AB	EQ 50MG BASE	A202228 001 Feb 02, 2021	Jan NEWA
@	EQ 150MG BASE	A202228 002 Feb 02, 2021	Feb DISC
AB	EQ 150MG BASE	A202228 002 Feb 02, 2021	Jan NEWA
@	EQ 200MG BASE	A202228 003 Feb 02, 2021	Feb DISC
AB	EQ 200MG BASE	A202228 003 Feb 02, 2021	Jan NEWA
@	EQ 300MG BASE	A202228 004 Feb 02, 2021	Feb DISC
AB	EQ 300MG BASE	A202228 004 Feb 02, 2021	Jan NEWA
@	EQ 400MG BASE	A202228 005 Feb 02, 2021	Feb DISC
AB	EQ 400MG BASE	A202228 005 Feb 02, 2021	Jan NEWA

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

@ RISING 324MG A089894 001 Dec 15, 1988 Jan CAHN

QUINIDINE SULFATE

TABLET;ORAL

CIN-QUIN

>D>	@ SOLVAY	100MG	A085299 001	Aug CRLD
>A>	+ @	100MG	A085299 001	Aug CRLD
>D>	@	200MG	A084932 001	Aug CRLD
>A>	+ @	200MG	A084932 001	Aug CRLD
	QUINORA			
>D>	@ SCHERING	300MG	A085222 001	Aug CRLD
>A>	+ @	300MG	A085222 001	Aug CRLD

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL  
ACIPHEX  
+ @ WOODWARD 10MG N020973 001 May 29, 2002 Jul CAHN  
AB +! 20MG N020973 002 Aug 19, 1999 Jul CAHN

RANITIDINE HYDROCHLORIDE

CAPSULE;ORAL  
RANITIDINE HYDROCHLORIDE  
@ AUROBINDO PHARMA LTD EQ 150MG BASE A211058 001 Jul 16, 2018 Jun DISC  
@ EQ 300MG BASE A211058 002 Jul 16, 2018 Jun DISC  
SYRUP;ORAL  
RANITIDINE HYDROCHLORIDE  
@ AUROBINDO PHARMA LTD EQ 15MG BASE/ML A090623 001 Jul 28, 2010 Jun DISC  
TABLET;ORAL  
RANITIDINE HYDROCHLORIDE  
@ WOCKHARDT LTD EQ 150MG BASE A075208 001 Dec 17, 1998 Jan DISC  
@ EQ 300MG BASE A075208 002 Dec 17, 1998 Jan DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL  
RANOLAZINE  
AB ACCORD HLTHCARE 500MG A212930 001 May 18, 2021 May NEWA  
AB 1GM A212930 002 May 18, 2021 May NEWA  
@ AMNEAL 500MG A207690 001 Mar 11, 2021 Apr DISC  
AB 500MG A207690 001 Mar 11, 2021 Mar NEWA  
@ 1GM A207690 002 Mar 11, 2021 Apr DISC  
AB 1GM A207690 002 Mar 11, 2021 Mar NEWA  
AB GRAVITI PHARMS 500MG A212889 001 Jan 28, 2021 Jan NEWA  
AB 1GM A212889 002 Jan 28, 2021 Jan NEWA  
AB PRAXGEN 500MG A212781 001 Mar 23, 2020 Feb CAHN  
AB 1GM A212781 002 Mar 23, 2020 Feb CAHN

REPAGLINIDE

TABLET;ORAL  
REPAGLINIDE  
AB PADAGIS US 0.5MG A201189 001 Jul 17, 2013 Jul CAHN  
AB 0.5MG A201189 001 Jul 17, 2013 Jul CAHN  
AB 1MG A201189 002 Jan 22, 2014 Jul CAHN  
AB 1MG A201189 002 Jan 22, 2014 Jul CAHN  
AB 2MG A201189 003 Jan 22, 2014 Jul CAHN  
AB 2MG A201189 003 Jan 22, 2014 Jul CAHN

RIFAXIMIN

TABLET;ORAL  
XIFAXAN  
>A> +! SALIX PHARMS 550MG N021361 002 Mar 24, 2010 Aug CMS1

RILUZOLE

FILM;ORAL  
EXSERVAN  
+! MITSUBISHI HOLDINGS 50MG N212640 001 Nov 22, 2019 Feb CAHN

RIMEGEPEANT SULFATE

TABLET, ORALLY DISINTEGRATING;ORAL  
NURTEC ODT  
+! BIOHAVEN IRELAND EQ 75MG BASE N212728 001 Feb 27, 2020 Jul CAHN

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL  
RISPERDAL  
+ @ JANSSEN PHARMS 0.5MG N021444 001 Apr 02, 2003 Feb DISC  
+ @ 1MG N021444 002 Apr 02, 2003 Feb DISC  
+ @ 2MG N021444 003 Apr 02, 2003 Feb DISC  
+ @ 3MG N021444 004 Dec 23, 2004 Feb DISC  
+ @ 4MG N021444 005 Dec 23, 2004 Feb DISC  
RISPERIDONE  
AB ! JUBILANT GENERICS 1MG A090839 002 Nov 04, 2011 Feb CHRS

RITONAVIR

CAPSULE;ORAL

RITONAVIR

@ HIKMA PHARMS

100MG

A205801 001 Dec 03, 2020 Mar DISC

RIZATRIPTAN BENZOATE

TABLET, ORALLY DISINTEGRATING;ORAL

RIZATRIPTAN BENZOATE

@ JUBILANT GENERICS

EQ 5MG BASE

A203334 001 Oct 16, 2015 Jun DISC

@

EQ 10MG BASE

A203334 002 Oct 16, 2015 Jun DISC

AB PANACEA

EQ 5MG BASE

A204722 001 Jan 11, 2017 Jul CAHN

AB

EQ 10MG BASE

A204722 002 Jan 11, 2017 Jul CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

REQUIP

+ @ GLAXOSMITHKLINE LLC

EQ 0.25MG BASE

N020658 001 Sep 19, 1997 Jul DISC

+ @

EQ 0.5MG BASE

N020658 002 Sep 19, 1997 Jul DISC

+ @

EQ 1MG BASE

N020658 003 Sep 19, 1997 Jul DISC

+ @

EQ 2MG BASE

N020658 004 Sep 19, 1997 Jul DISC

+ @

EQ 3MG BASE

N020658 006 Jan 27, 1999 Jul DISC

+ @

EQ 4MG BASE

N020658 007 Jan 27, 1999 Jul DISC

+ @

EQ 5MG BASE

N020658 005 Sep 19, 1997 Jul DISC

ROPINIROLE HYDROCHLORIDE

AB ! PRINSTON INC

EQ 0.25MG BASE

A078110 001 May 05, 2008 Jul CHRS

TABLET, EXTENDED RELEASE;ORAL

REQUIP XL

+ @ GLAXOSMITHKLINE LLC

EQ 2MG BASE

N022008 001 Jun 13, 2008 Jun DISC

+ @

EQ 2MG BASE

N022008 001 Jun 13, 2008 Jun CHRS

+ @

EQ 6MG BASE

N022008 006 Apr 10, 2009 Jun DISC

+ @

EQ 12MG BASE

N022008 005 Oct 31, 2008 Jun DISC

ROPINIROLE HYDROCHLORIDE

AB ! DR REDDYS LABS LTD

EQ 2MG BASE

A201576 001 Jun 06, 2012 Jun CHRS

ROPIVACAINE HYDROCHLORIDE

SOLUTION;INJECTION

NAROPIN

+ @ FRESENIUS KABI USA

50MG/10ML (5MG/ML)

N020533 013 May 01, 1998 Mar CRLD

+ @

75MG/10ML (7.5MG/ML)

N020533 012 Sep 24, 1996 Mar CRLD

ROPIVACAINE HYDROCHLORIDE

@ MYLAN ASI

150MG/30ML (5MG/ML)

A090318 002 Sep 23, 2014 Jan DISC

@

200MG/20ML (10MG/ML)

A090318 004 Sep 23, 2014 Jan DISC

ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDIA

+ WOODWARD

EQ 2MG BASE

N021071 002 May 25, 1999 Jul CAHN

+

EQ 4MG BASE

N021071 003 May 25, 1999 Jul CAHN

+ @

EQ 8MG BASE

N021071 004 May 25, 1999 Jul CAHN

ROSUVASTATIN CALCIUM

TABLET;ORAL

CRESTOR

AB + IPR

EQ 5MG BASE

N021366 002 Aug 12, 2003 Apr CPOT

AB +

EQ 10MG BASE

N021366 003 Aug 12, 2003 Apr CPOT

AB +!

EQ 40MG BASE

N021366 005 Aug 12, 2003 Apr CPOT

ROSVUSTATIN CALCIUM

AB ACCORD HLTHCARE

EQ 5MG BASE

A206434 001 Oct 31, 2016 Apr CPOT

AB

EQ 10MG BASE

A206434 002 Oct 31, 2016 Apr CPOT

AB

EQ 20MG BASE

A206434 003 Oct 31, 2016 Apr CPOT

AB

EQ 40MG BASE

A206434 004 Oct 31, 2016 Apr CPOT

AB ALKEM LABS LTD

EQ 5MG BASE

A206465 001 Mar 21, 2017 Apr CPOT

AB

EQ 10MG BASE

A206465 002 Mar 21, 2017 Apr CPOT

AB

EQ 20MG BASE

A206465 003 Mar 21, 2017 Apr CPOT

AB

EQ 40MG BASE

A206465 004 Mar 21, 2017 Apr CPOT

AB ALLIED

EQ 5MG BASE

A079168 001 Jul 19, 2016 Apr CPOT

AB

EQ 10MG BASE

A079168 002 Jul 19, 2016 Apr CPOT

AB

EQ 20MG BASE

A079168 003 Jul 19, 2016 Apr CPOT

AB

EQ 40MG BASE

A079168 004 Jul 19, 2016 Apr CPOT

@ AMNEAL PHARMS CO

EQ 5MG BASE

A208850 001 Oct 16, 2018 Apr CPOT

@

EQ 10MG BASE

A208850 002 Oct 16, 2018 Apr CPOT

## TABLET;ORAL

## ROSUVASTATIN CALCIUM

@		EQ 20MG BASE	A208850	003	Oct 16, 2018	Apr CPOT
@		EQ 40MG BASE	A208850	004	Oct 16, 2018	Apr CPOT
@ APOTEX INC		EQ 5MG BASE	A079145	001	Jul 19, 2016	Apr CPOT
@		EQ 10MG BASE	A079145	002	Jul 19, 2016	Apr CPOT
@		EQ 20MG BASE	A079145	003	Jul 19, 2016	Apr CPOT
@		EQ 40MG BASE	A079145	004	Jul 19, 2016	Apr CPOT
AB	AUROBINDO PHARMA LTD	EQ 5MG BASE	A079170	001	Jul 19, 2016	Apr CPOT
AB		EQ 10MG BASE	A079170	002	Jul 19, 2016	Apr CPOT
AB		EQ 20MG BASE	A079170	003	Jul 19, 2016	Apr CPOT
AB		EQ 40MG BASE	A079170	004	Jul 19, 2016	Apr CPOT
AB	BIOCON LTD	EQ 5MG BASE	A207752	001	Oct 31, 2016	Apr CPOT
AB		EQ 10MG BASE	A207752	002	Oct 31, 2016	Apr CPOT
AB		EQ 20MG BASE	A207752	003	Oct 31, 2016	Apr CPOT
AB		EQ 40MG BASE	A207752	004	Oct 31, 2016	Apr CPOT
AB	BIOCON PHARMA	EQ 5MG BASE	A207752	001	Oct 31, 2016	Jul CAHN
AB		EQ 10MG BASE	A207752	002	Oct 31, 2016	Jul CAHN
AB		EQ 20MG BASE	A207752	003	Oct 31, 2016	Jul CAHN
AB		EQ 40MG BASE	A207752	004	Oct 31, 2016	Jul CAHN
AB	CADILA PHARMS LTD	EQ 5MG BASE	A207453	001	Nov 23, 2016	Apr CPOT
AB		EQ 10MG BASE	A207453	002	Nov 23, 2016	Apr CPOT
AB		EQ 20MG BASE	A207453	003	Nov 23, 2016	Apr CPOT
AB		EQ 40MG BASE	A207453	004	Nov 23, 2016	Apr CPOT
AB	CHANGZHOU PHARM	EQ 5MG BASE	A207408	001	Oct 31, 2016	Apr CPOT
AB		EQ 10MG BASE	A207408	002	Oct 31, 2016	Apr CPOT
AB		EQ 20MG BASE	A207408	003	Oct 31, 2016	Apr CPOT
AB		EQ 40MG BASE	A207408	004	Oct 31, 2016	Apr CPOT
AB	GLENMARK PHARMS	EQ 5MG BASE	A079172	001	Jul 19, 2016	Apr CPOT
AB		EQ 10MG BASE	A079172	002	Jul 19, 2016	Apr CPOT
AB		EQ 20MG BASE	A079172	003	Jul 19, 2016	Apr CPOT
AB		EQ 40MG BASE	A079172	004	Jul 19, 2016	Apr CPOT
AB	HETERO LABS LTD V	EQ 5MG BASE	A207616	001	Oct 31, 2016	Apr CPOT
AB		EQ 10MG BASE	A207616	002	Oct 31, 2016	Apr CPOT
AB		EQ 20MG BASE	A207616	003	Oct 31, 2016	Apr CPOT
AB		EQ 40MG BASE	A207616	004	Oct 31, 2016	Apr CPOT
AB	@ INVENTIA	EQ 5MG BASE	A207653	001	Feb 05, 2021	May DISC
AB		EQ 5MG BASE	A207653	001	Feb 05, 2021	Apr CPOT
AB		5MG	A207653	001	Feb 05, 2021	Jan NEWA
AB	@	EQ 10MG BASE	A207653	002	Feb 05, 2021	May DISC
AB		EQ 10MG BASE	A207653	002	Feb 05, 2021	Apr CPOT
AB		10MG	A207653	002	Feb 05, 2021	Jan NEWA
AB	@	EQ 20MG BASE	A207653	003	Feb 05, 2021	May DISC
AB		EQ 20MG BASE	A207653	003	Feb 05, 2021	Apr CPOT
AB		20MG	A207653	003	Feb 05, 2021	Jan NEWA
AB	@	EQ 40MG BASE	A207653	004	Feb 05, 2021	May DISC
AB		EQ 40MG BASE	A207653	004	Feb 05, 2021	Apr CPOT
AB		40MG	A207653	004	Feb 05, 2021	Jan NEWA
AB	LUPIN	EQ 5MG BASE	A205587	001	Jul 31, 2017	Apr CPOT
AB		EQ 10MG BASE	A205587	002	Jul 31, 2017	Apr CPOT
AB		EQ 20MG BASE	A205587	003	Jul 31, 2017	Apr CPOT
AB		EQ 40MG BASE	A205587	004	Jul 31, 2017	Apr CPOT
AB	MSN	EQ 5MG BASE	A208898	001	Nov 22, 2017	Apr CPOT
AB		EQ 10MG BASE	A208898	002	Nov 22, 2017	Apr CPOT
AB		EQ 20MG BASE	A208898	003	Nov 22, 2017	Apr CPOT
AB		EQ 40MG BASE	A208898	004	Nov 22, 2017	Apr CPOT
AB	@ MYLAN	EQ 5MG BASE	A079161	001	Jul 19, 2016	Apr CPOT
AB	@	EQ 10MG BASE	A079161	002	Jul 19, 2016	Apr CPOT
AB	@	EQ 20MG BASE	A079161	003	Jul 19, 2016	Apr CPOT
AB	@	EQ 40MG BASE	A079161	004	Jul 19, 2016	Apr CPOT
AB	RENATA	EQ 5MG BASE	A207062	001	Oct 31, 2016	Apr CPOT
AB		EQ 10MG BASE	A207062	002	Oct 31, 2016	Apr CPOT
AB		EQ 20MG BASE	A207062	003	Oct 31, 2016	Apr CPOT
AB		EQ 40MG BASE	A207062	004	Oct 31, 2016	Apr CPOT
AB	SANDOZ INC	EQ 5MG BASE	A079171	001	Jul 19, 2016	Apr CPOT
AB		EQ 10MG BASE	A079171	002	Jul 19, 2016	Apr CPOT
AB		EQ 20MG BASE	A079171	003	Jul 19, 2016	Apr CPOT
AB		EQ 40MG BASE	A079171	004	Jul 19, 2016	Apr CPOT
AB	@ SCIEGEN PHARMS INC	EQ 5MG BASE	A206381	001	Apr 24, 2019	Apr CPOT
AB	@	EQ 10MG BASE	A206381	002	Apr 24, 2019	Apr CPOT
AB	@	EQ 20MG BASE	A206381	003	Apr 24, 2019	Apr CPOT
AB	@	EQ 40MG BASE	A206381	004	Apr 24, 2019	Apr CPOT
AB	SHANDONG	EQ 5MG BASE	A207375	001	May 07, 2019	Apr CPOT
AB		EQ 10MG BASE	A207375	002	May 07, 2019	Apr CPOT

**TABLET;ORAL**  
ROSUVASTATIN CALCIUM

AB		EQ 20MG BASE	A207375	003	May 07, 2019	Apr CPOT
AB		EQ 40MG BASE	A207375	004	May 07, 2019	Apr CPOT
AB	SUN PHARM	EQ 5MG BASE	A079169	001	Jul 19, 2016	Apr CPOT
AB		EQ 10MG BASE	A079169	002	Jul 19, 2016	Apr CPOT
AB		EQ 20MG BASE	A079169	003	Jul 19, 2016	Apr CPOT
AB		EQ 40MG BASE	A079169	004	Jul 19, 2016	Apr CPOT
	@ SUNSHINE	EQ 5MG BASE	A210667	001	Apr 01, 2020	Apr CPOT
	@	EQ 10MG BASE	A210667	002	Apr 01, 2020	Apr CPOT
	@	EQ 20MG BASE	A210667	003	Apr 01, 2020	Apr CPOT
	@	EQ 40MG BASE	A210667	004	Apr 01, 2020	Apr CPOT
	@ TEVA PHARMS USA	EQ 5MG BASE	A079166	001	Jul 19, 2016	Apr CPOT
	@	EQ 10MG BASE	A079166	002	Jul 19, 2016	Apr CPOT
	@	EQ 20MG BASE	A079166	003	Jul 19, 2016	Apr CPOT
	@	EQ 40MG BASE	A079166	004	Jul 19, 2016	Apr CPOT
AB	TORRENT	EQ 5MG BASE	A201619	001	Oct 31, 2016	Apr CPOT
AB		EQ 10MG BASE	A201619	002	Oct 31, 2016	Apr CPOT
AB		EQ 20MG BASE	A201619	003	Oct 31, 2016	Apr CPOT
AB		EQ 40MG BASE	A201619	004	Oct 31, 2016	Apr CPOT
	@ UMEDICA LABS PVT LTD	EQ 5MG BASE	A207626	001	Apr 09, 2019	Apr CPOT
	@	EQ 10MG BASE	A207626	002	Apr 09, 2019	Apr CPOT
	@	EQ 20MG BASE	A207626	003	Apr 09, 2019	Apr CPOT
	@	EQ 40MG BASE	A207626	004	Apr 09, 2019	Apr CPOT
AB	WATSON LABS INC	EQ 5MG BASE	A079167	001	Apr 29, 2016	Apr CPOT
AB		EQ 10MG BASE	A079167	002	Apr 29, 2016	Apr CPOT
AB		EQ 20MG BASE	A079167	003	Apr 29, 2016	Apr CPOT
AB		EQ 40MG BASE	A079167	004	Apr 29, 2016	Apr CPOT
AB	ZHEJIANG YONGTAI	EQ 5MG BASE	A212059	001	Nov 04, 2019	Apr CPOT
AB		5MG	A212059	001	Nov 04, 2019	Feb CMFD
AB		EQ 10MG BASE	A212059	002	Nov 04, 2019	Apr CPOT
AB		10MG	A212059	002	Nov 04, 2019	Feb CMFD
AB		EQ 20MG BASE	A212059	003	Nov 04, 2019	Apr CPOT
AB		20MG	A212059	003	Nov 04, 2019	Feb CMFD
AB		EQ 40MG BASE	A212059	004	Nov 04, 2019	Apr CPOT
AB		40MG	A212059	004	Nov 04, 2019	Feb CMFD
	@ ZYDUS PHARMS	EQ 5MG BASE	A206513	001	Mar 01, 2019	Apr CPOT
	@	EQ 10MG BASE	A206513	002	Mar 01, 2019	Apr CPOT
	@	EQ 20MG BASE	A206513	003	Mar 01, 2019	Apr CPOT
	@	EQ 40MG BASE	A206513	004	Mar 01, 2019	Apr CPOT

**RUFINAMIDE**

SUSPENSION;ORAL  
RUFINAMIDE

AB	ALKEM LABS LTD	40MG/ML	A213410	001	Feb 23, 2021	Feb NEWA
	TABLET;ORAL					
	RUFINAMIDE					
AB	HETERO LABS LTD III	200MG	A204993	001	May 11, 2021	Apr NEWA
AB		400MG	A204993	002	May 11, 2021	Apr NEWA
AB	MYLAN	200MG	A205095	001	May 16, 2016	May CMFD
AB		400MG	A205095	002	May 16, 2016	May CMFD

**SAFINAMIDE MESYLATE**

TABLET;ORAL  
XADAGO

+	MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Jul CPOT
+	!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Jul CPOT

**SAPROPTERIN DIHYDROCHLORIDE**

POWDER;ORAL  
SAPROPTERIN DIHYDROCHLORIDE

AB	DR REDDYS	100MG/PACKET	A209452	001	Mar 30, 2021	Mar NEWA
	TABLET;ORAL					
	SAPROPTERIN DIHYDROCHLORIDE					
AB	DR REDDYS	100MG	A207685	001	Jun 15, 2021	Jun NEWA

**SCOPOLAMINE**

SYSTEM;TRANSDERMAL  
SCOPOLAMINE

AB	PADAGIS US	1MG/72HR	A078830	001	Jan 30, 2015	Jul CAHN
AB	+! BAXTER HLTHCARE CORP	1MG/72HR	N017874	001		Mar CAHN

SELEGILINE HYDROCHLORIDE

CAPSULE;ORAL

SELEGILINE HYDROCHLORIDE

AB NOVITIUM PHARMA 5MG A075352 001 Nov 30, 1998 Apr CMFD

SELENIOUS ACID

SOLUTION;INTRAVENOUS

SELENIOUS ACID

>A> +! AM REGENT EQ 12MCG BASE/2ML (EQ 6MCG  
BASE/ML) N209379 003 Aug 30, 2021 Aug NEWA  
+! EQ 60MCG BASE/ML (EQ 60MCG  
BASE/ML) N209379 002 Jan 25, 2021 Jan NEWASELEXIPAG

POWDER;INTRAVENOUS

UPTRAVI

+! ACTELION 1.8MG/VIAL N214275 001 Jul 29, 2021 Jul NEWA

TABLET;ORAL

UPTRAVI

+ ACTELION 0.2MG N207947 001 Dec 21, 2015 Feb CAHN

+! 0.4MG N207947 002 Dec 21, 2015 Feb CAHN

+ 0.6MG N207947 003 Dec 21, 2015 Feb CAHN

+ 0.8MG N207947 004 Dec 21, 2015 Feb CAHN

+ 1MG N207947 005 Dec 21, 2015 Feb CAHN

+ 1.2MG N207947 006 Dec 21, 2015 Feb CAHN

+ 1.4MG N207947 007 Dec 21, 2015 Feb CAHN

+ 1.6MG N207947 008 Dec 21, 2015 Feb CAHN

SELINEXOR

TABLET;ORAL

XPOVIO

+ KARYOPHARM THERAPS 40MG N212306 002 Apr 15, 2021 Apr NEWA

+ 50MG N212306 003 Apr 15, 2021 Apr NEWA

+ 60MG N212306 004 Apr 15, 2021 Apr NEWA

SEMAGLUTIDE

SOLUTION;SUBCUTANEOUS

WEGOVY

+! NOVO 0.25MG/0.5ML (0.25MG/0.5ML) N215256 001 Jun 04, 2021 Jun NEWA

+! 0.5MG/0.5ML (0.5MG/0.5ML) N215256 002 Jun 04, 2021 Jun NEWA

+! 1MG/0.5ML (1MG/0.5ML) N215256 003 Jun 04, 2021 Jun NEWA

+! 1.7MG/0.75ML (1.7MG/0.75ML) N215256 004 Jun 04, 2021 Jun NEWA

+! 2.4MG/0.75ML (2.4MG/0.75ML) N215256 005 Jun 04, 2021 Jun NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

AB ACI HEALTHCARE LTD EQ 25MG BASE A076881 001 Feb 06, 2007 Jan CMFD  
AB EQ 50MG BASE A076881 002 Feb 06, 2007 Jan CMFD  
AB EQ 100MG BASE A076881 003 Feb 06, 2007 Jan CMFD  
AB ASCENT PHARMS INC EQ 25MG BASE A214790 001 May 03, 2021 Apr NEWA  
AB EQ 50MG BASE A214790 002 May 03, 2021 Apr NEWA  
AB EQ 100MG BASE A214790 003 May 03, 2021 Apr NEWA  
AB GRANULES EQ 25MG BASE A078403 001 Jan 08, 2008 May CAHN  
AB EQ 50MG BASE A078403 002 Jan 08, 2008 May CAHN  
AB EQ 100MG BASE A078403 003 Jan 08, 2008 May CAHN  
AB SCIEGEN PHARMS INC EQ 25MG BASE A076442 001 Apr 30, 2007 Apr CMFD  
AB EQ 50MG BASE A076442 002 Apr 30, 2007 Apr CMFD  
AB EQ 100MG BASE A076442 003 Apr 30, 2007 Apr CMFDSEVELAMER CARBONATE

FOR SUSPENSION;ORAL

SEVELAMER CARBONATE

>D> AB BIONPHARMA INC 800MG/PACKET A209374 001 May 17, 2021 May NEWA  
>A> AB @ IMPAX 800MG/PACKET A211316 001 Nov 20, 2020 Aug CMFD  
>A> AB @ 800MG/PACKET A211316 001 Nov 20, 2020 Aug CMFD  
>D> AB @ 2.4GM/PACKET A211316 001 Nov 20, 2020 Mar DISC  
>A> AB @ 2.4GM/PACKET A211316 002 Nov 20, 2020 Aug CMFD  
>A> AB @ 2.4GM/PACKET A211316 002 Nov 20, 2020 Aug CMFD  
@ 2.4GM/PACKET A211316 002 Nov 20, 2020 Mar DISC

TABLET;ORAL

SEVELAMER CARBONATE

AB	ANXIN	800MG	A212970	001	Apr 09, 2020	Mar CMFD
AB	LUPIN LTD	800MG	A204600	001	Jan 14, 2021	Jan NEWA

SEVELAMER HYDROCHLORIDETABLET;ORAL

SEVELAMER HYDROCHLORIDE

AB	LUPIN LTD	400MG	A213145	001	Jun 16, 2021	Jun NEWA
AB		800MG	A213145	002	Jun 16, 2021	Jun NEWA

SILDENAFIL CITRATEFOR SUSPENSION;ORAL

SILDENAFIL CITRATE

AB	APPCO	EQ 10MG BASE/ML	A213814	001	Apr 29, 2021	Apr NEWA
AB	HETERO LABS LTD V	EQ 10MG BASE/ML	A213014	001	May 11, 2021	Apr NEWA

TABLET;ORAL

SILDENAFIL CITRATE

AB	REYOUNG	EQ 25MG BASE	A208494	001	Jun 12, 2020	Mar CAHN
AB		EQ 50MG BASE	A208494	002	Jun 12, 2020	Mar CAHN
AB		EQ 100MG BASE	A208494	003	Jun 12, 2020	Mar CAHN
AB	UMEDICA LABS PVT LTD	EQ 25MG BASE	A209302	003	Jun 15, 2021	Jun NEWA
@	WATSON LABS INC	EQ 25MG BASE	A202506	001	Nov 25, 2020	May DISC
@		EQ 50MG BASE	A202506	002	Nov 25, 2020	May DISC
@		EQ 100MG BASE	A202506	003	Nov 25, 2020	May DISC

SIMVASTATINTABLET;ORAL

SIMVASTATIN

AB	BIOCON PHARMA	5MG	A078034	001	Dec 20, 2006	Mar CAHN
AB		10MG	A078034	002	Dec 20, 2006	Mar CAHN
AB		20MG	A078034	003	Dec 20, 2006	Mar CAHN
AB		40MG	A078034	004	Dec 20, 2006	Mar CAHN
AB		80MG	A078034	005	Dec 20, 2006	Mar CAHN
AB	HISUN PHARM HANGZHOU	10MG	A206557	001	Nov 13, 2017	Apr CMFD
AB		20MG	A206557	002	Nov 13, 2017	Apr CMFD
AB		40MG	A206557	003	Nov 13, 2017	Apr CMFD
AB		80MG	A206557	004	Nov 13, 2017	Apr CMFD
AB	! LUPIN ZOCOR	80MG	A078103	004	May 11, 2007	Jun CHRS
AB	+ ORGANON	5MG	N019766	001	Dec 23, 1991	Feb CAHN
AB	+	10MG	N019766	002	Dec 23, 1991	Feb CAHN
AB	+	20MG	N019766	003	Dec 23, 1991	Feb CAHN
AB	+	40MG	N019766	004	Dec 23, 1991	Feb CAHN
	+ @	80MG	N019766	005	Jul 10, 1998	Jun DISC
AB	+!	80MG	N019766	005	Jul 10, 1998	Feb CAHN

SINECATECHINSOINTMENT;TOPICAL

VEREGEN

+! ANI PHARMS

15%

N021902 001 Oct 31, 2006 Apr CAHN

SIPONIMOD FUMARIC ACIDTABLET;ORAL

MAYZENT

>A>	+ NOVARTIS	EQ 1MG BASE	N209884	003	Aug 24, 2021	Aug NEWA
-----	------------	-------------	---------	-----	--------------	----------

SIROLIMUSTABLET;ORAL

SIROLIMUS

AB	ALKEM LABS LTD	0.5MG	A214753	001	Mar 12, 2021	Mar NEWA
AB		1MG	A214753	002	Mar 12, 2021	Mar NEWA
AB		2MG	A214753	003	Mar 12, 2021	Mar NEWA

SODIUM ACETATEINJECTABLE;INJECTION

SODIUM ACETATE

AP	MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Apr NFTG
----	--------------	---------	---------	-----	--------------	----------

SODIUM BENZOATE; SODIUM PHENYLACETATE

SOLUTION; INTRAVENOUS

SODIUM PHENYLACETATE AND SODIUM BENZOATE

+! MAIA PHARMS INC 10%;10% (2GM/20ML;2GM/20ML)

N215025 001 Jun 10, 2021 Jun NEWA

SODIUM CHLORIDE

INJECTABLE; INJECTION

SODIUM CHLORIDE 0.9%

HIKMA PHARMS

9MG/ML

9MG/ML

A201833 001 Sep 24, 2013 Jul CAHN

A201850 001 Jan 20, 2012 Jul CAHN

&gt;D&gt; +! MEDEFIL INC 9MG/ML (9MG/ML) N202832 001 Jan 06, 2012 Aug DISC

&gt;A&gt; + @ 9MG/ML (9MG/ML) N202832 001 Jan 06, 2012 Aug DISC

&gt;D&gt; +! 18MG/2ML (9MG/ML) N202832 002 Jan 06, 2012 Aug DISC

&gt;A&gt; + @ 18MG/2ML (9MG/ML) N202832 002 Jan 06, 2012 Aug DISC

&gt;D&gt; +! 22.5MG/2.5ML (9MG/ML) N202832 003 Jan 06, 2012 Aug DISC

&gt;A&gt; + @ 22.5MG/2.5ML (9MG/ML) N202832 003 Jan 06, 2012 Aug DISC

&gt;D&gt; +! 27MG/3ML (9MG/ML) N202832 004 Jan 06, 2012 Aug DISC

&gt;A&gt; + @ 27MG/3ML (9MG/ML) N202832 004 Jan 06, 2012 Aug DISC

&gt;D&gt; +! 45MG/5ML (9MG/ML) N202832 005 Jan 06, 2012 Aug DISC

&gt;A&gt; + @ 45MG/5ML (9MG/ML) N202832 005 Jan 06, 2012 Aug DISC

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ JUBILANT CADISTA 9MG/ML

A203352 001 May 18, 2016 Jun DISC

SODIUM CHLORIDE 23.4%

FRESENIUS KABI USA 234MG/ML

A212248 001 Apr 28, 2021 Apr NFTG

SOLUTION; INTRAVENOUS

SODIUM CHLORIDE 14.6%

FRESENIUS KABI USA 50MEQ/20ML (2.5MEQ/ML)

A212070 001 Apr 28, 2021 Apr NFTG

AP 100MEQ/40ML (2.5MEQ/ML) A212070 002 Apr 28, 2021 Apr NFTG

SOLUTION FOR SLUSH; IRRIGATION

SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER

+! BAXTER HLTHCARE 900MG/100ML

N019319 002 May 17, 1985 Jul CHRS

+ 900MG/100ML N019319 002 May 17, 1985 Jul CRLD

SODIUM FLUORIDE F-18

INJECTABLE; INTRAVENOUS

SODIUM FLUORIDE F-18

&gt;D&gt; AP DECATUR 10-200mCi/ML A204464 001 Oct 21, 2014 Aug DISC

&gt;A&gt; @ 10-200mCi/ML A204464 001 Oct 21, 2014 Aug DISC

AP NUKEMED 10-200mCi/ML A203912 001 Apr 22, 2015 Jan CAHN

SODIUM NITROPRUSSIDE

INJECTABLE; INJECTION

SODIUM NITROPRUSSIDE

@ AUROBINDO PHARMA LTD 25MG/ML

A211934 001 Dec 10, 2020 Jun DISC

AP BE PHARMS 25MG/ML

A214971 001 Jul 12, 2021 Jul NEWA

&gt;D&gt; AP CIPLA 25MG/ML

A210855 001 Jul 16, 2018 Aug DISC

&gt;A&gt; @ 25MG/ML

A210855 001 Jul 16, 2018 Aug DISC

SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE

TABLET; ORAL

MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE

AB NOVEL LABS INC 0.398GM;1.102GM A079247 001 Dec 30, 2011 Jan CMFD

OSMOPREP

AB +! SALIX PHARMS 0.398GM;1.102GM N021892 001 Mar 16, 2006 Jan CTEC

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

KIONEX

AA ANI PHARMS 454GM/BOT A040029 001 Feb 06, 1998 Mar CAHN

AA L PERRIGO CO 454GM/BOT A040029 001 Feb 06, 1998 Mar CAHN

SODIUM POLYSTYRENE SULFONATE

&gt;D&gt; @ WOCKHARDT 453.6GM/BOT A088786 001 Sep 11, 1984 Aug CRLD

&gt;A&gt; + @ 453.6GM/BOT A088786 001 Sep 11, 1984 Aug CRLD

SUSPENSION; ORAL, RECTAL

KIONEX

@ ANI PHARMS 15GM/60ML

A040028 001 Sep 17, 2007 Mar CAHN

@ L PERRIGO CO 15GM/60ML

A040028 001 Sep 17, 2007 Mar CAHN

SODIUM POLYSTYRENE SULFONATE

@ ANI PHARMS 15GM/60ML

A090590 001 May 13, 2011 Mar CAHN

@ L PERRIGO CO 15GM/60ML

A090590 001 May 13, 2011 Mar CAHN

SUSPENSION;ORAL, RECTAL  
SPS

>D>	! CMP PHARMA INC	15GM/60ML	A087859	001	Dec 08, 1982	Aug CRLD
>A>	+!	15GM/60ML	A087859	001	Dec 08, 1982	Aug CRLD

SOFOSBUVIR; VELPATASVIR

PELLETS;ORAL  
EPCLUSA  
+ GILEAD SCIENCES INC 150MG;37.5MG/PACKET  
+! 200MG;50MG/PACKET

N214187	001	Jun 10, 2021	Jun NEWA
N214187	002	Jun 10, 2021	Jun NEWA

SOLIFENACIN SUCCINATE

## TABLET;ORAL

## SOLIFENACIN SUCCINATE

>D> AB	@ AJANTA PHARMA LTD	5MG	A205483	001	May 20, 2019	Jun DISC
>A>	@ BRECKENRIDGE	5MG	A205483	002	May 20, 2019	Jun DISC
>D> AB	@	5MG	A209818	001	May 20, 2019	Aug DISC
>A>	@	10MG	A209818	001	May 20, 2019	Aug DISC
	@ ZYDUS PHARMS	10MG	A209818	002	May 20, 2019	Aug DISC
	@	5MG	A207721	001	Oct 19, 2020	Mar DISC
	@	10MG	A207721	002	Oct 19, 2020	Mar DISC

SORAFENIB TOSYLATE

## TABLET;ORAL

## NEXAVAR

+! BAYER HLTHCARE	EQ 200MG BASE	N021923	001	Dec 20, 2005	May CTEC
SORAFENIB TOSYLATE		A209567	001	Nov 12, 2020	May DISC
@ TEVA PHARMS USA INC	EQ 200MG BASE				

SOTALOL HYDROCHLORIDE

## TABLET;ORAL

## SOTALOL HYDROCHLORIDE

@ MYLAN	80MG	A077616	001	Feb 07, 2007	Feb DISC
@	120MG	A077616	002	Feb 07, 2007	Feb DISC
@	160MG	A077616	003	Feb 07, 2007	Feb DISC

SOTORASIB

## TABLET;ORAL

## LUMAKRAS

+! AMGEN INC	120MG	N214665	001	May 28, 2021	May NEWA
--------------	-------	---------	-----	--------------	----------

SPIRONOLACTONE

## TABLET;ORAL

## SPIRONOLACTONE

>D> AB	OXFORD PHARMS	25MG	A040750	001	Aug 29, 2006	Aug DISC
>A>	@	25MG	A040750	001	Aug 29, 2006	Aug DISC
>D> AB		50MG	A040750	002	Aug 29, 2006	Aug DISC
>A>	@	50MG	A040750	002	Aug 29, 2006	Aug DISC
>D> AB		100MG	A040750	003	Aug 29, 2006	Aug DISC
>A>	@	100MG	A040750	003	Aug 29, 2006	Aug DISC

STERILE WATER FOR INJECTION

## LIQUID;N/A

## STERILE WATER FOR INJECTION

AP	HIKMA PHARMS	100% (10ML)	A206369	001	Sep 02, 2015	Jul CAHN
	@	100% (20ML)	A206369	002	Sep 02, 2015	Jul CAHN
	! NEPHRON	100% (5ML)	A211222	001	Feb 10, 2021	Jan NEWA

SUCCINYLCHOLINE CHLORIDE

## INJECTABLE;INJECTION

## SUCCINYLCHOLINE CHLORIDE

AP	ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	Mar CMFD
AP	HIKMA	20MG/ML	A213229	001	Jun 12, 2020	Apr CMFD
	@	20MG/ML	A213229	001	Jun 12, 2020	Feb DISC
AP	SAGENT PHARMS INC	20MG/ML	A215022	001	Mar 29, 2021	Mar NEWA
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS SUCCINYLCHOLINE CHLORIDE					
>A>	+! HIKMA PHARMS	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Aug NEWA

SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC  
BLEPH-10

>D> AT	!	ALLERGAN	10%	A080028	001	Aug CRLD
>A> AT	+	!	10%	A080028	001	Aug CRLD

SULFAMETHOXAZOLE

TABLET;ORAL  
SULFAMETHOXAZOLE  
@ RISING

500MG A085844 001

Jan CAHN

SULFASALAZINE

TABLET;ORAL  
AZULFIDINE  
AB +! PFIZER 500MG N007073 001 Mar CAHN  
SULFASALAZINE  
AB CHARTWELL 500MG A080197 001 Jun CMFD  
TABLET, DELAYED RELEASE;ORAL  
AZULFIDINE EN-TABS  
AB +! PFIZER 500MG N007073 002 Apr 06, 1983 Mar CAHN

SULFISOXAZOLE

TABLET;ORAL  
SULFISOXAZOLE  
@ RISING

500MG A085628 001

Jan CAHN

SULINDAC

TABLET;ORAL  
SULINDAC  
>D> AB MYLAN 150MG A073039 002 Jun 22, 1993 Aug CAHN  
>A> @ 150MG A073039 002 Jun 22, 1993 Aug CAHN  
>D> AB 200MG A073039 001 Jun 22, 1993 Aug CAHN  
>A> @ 200MG A073039 001 Jun 22, 1993 Aug CAHN

SUMATRIPTAN

SPRAY;NASAL  
SUMATRIPTAN  
AB CIPLA 20MG/SPRAY A214209 001 Feb 22, 2021 Feb NEWA  
AB FLORIDA 20MG/SPRAY A208967 001 Feb 17, 2021 Mar CAHN  
AB PHARMASERVE NW 20MG/SPRAY A208967 001 Feb 17, 2021 Feb NEWA

SUMATRIPTAN SUCCINATE

INJECTABLE;SUBCUTANEOUS  
SUMATRIPTAN SUCCINATE  
AP CAPLIN EQ 6MG BASE/0.5ML (EQ 12MG  
BASE/ML) A213998 001 Jul 13, 2021 Jul NEWA  
@ MYLAN ASI EQ 6MG BASE/0.5ML (EQ 12MG  
BASE/ML) A090314 001 Jun 10, 2010 May DISC  
@ EQ 6MG BASE/0.5ML (EQ 12MG  
BASE/ML) A090641 001 Jul 28, 2010 Jan DISC

SUNITINIB MALATE

CAPSULE;ORAL  
SUNITINIB MALATE  
>A> AB SUN PHARM EQ 12.5MG BASE A213914 001 Aug 16, 2021 Aug NFTG  
>A> AB EQ 25MG BASE A213914 002 Aug 16, 2021 Aug NFTG  
>A> AB EQ 37.5MG BASE A213914 003 Aug 16, 2021 Aug NFTG  
>A> AB EQ 50MG BASE A213914 004 Aug 16, 2021 Aug NFTG  
  
SUTENT  
>D> + CPPI CV EQ 12.5MG BASE N021938 001 Jan 26, 2006 Aug CTEC  
>A> AB + EQ 12.5MG BASE N021938 001 Jan 26, 2006 Aug CTEC  
>D> + EQ 25MG BASE N021938 002 Jan 26, 2006 Aug CTEC  
>A> AB + EQ 25MG BASE N021938 002 Jan 26, 2006 Aug CTEC  
>D> + EQ 37.5MG BASE N021938 004 Mar 31, 2009 Aug CTEC  
>A> AB + EQ 37.5MG BASE N021938 004 Mar 31, 2009 Aug CTEC  
>D> +! EQ 50MG BASE N021938 003 Jan 26, 2006 Aug CTEC  
>A> AB +! EQ 50MG BASE N021938 003 Jan 26, 2006 Aug CTEC

TACROLIMUS

CAPSULE;ORAL

TACROLIMUS

AB	@ CONCORD BIOTECH LTD PANACEA	EQ 0.5MG BASE EQ 0.5MG BASE	A213112 001 Nov 10, 2020	Apr DISC
AB		EQ 1MG BASE	A090802 002 Sep 28, 2012	Jul CAHN
AB		EQ 5MG BASE	A090802 003 Sep 28, 2012	Jul CAHN

TADALAFIL

TABLET;ORAL

CIALIS

AB1	+	LILLY	2.5MG 5MG 10MG	N021368 004 Jan 07, 2008 N021368 001 Nov 21, 2003 N021368 002 Nov 21, 2003	Feb CTEC
AB1		Tadalafil			
AB1		ACCORD HLTHCARE	2.5MG 5MG 10MG	A209167 001 Mar 26, 2019 A209167 002 Mar 26, 2019 A209167 003 Oct 23, 2019	Feb CTEC
AB1		AJANTA PHARMA LTD	2.5MG 5MG 10MG	A209654 001 Mar 26, 2019 A209654 002 Mar 26, 2019 A209654 003 Mar 26, 2019	Feb CTEC
AB1		ALEMBIC PHARMS LTD	2.5MG 5MG 10MG	A204809 001 Mar 26, 2019 A204809 002 Mar 26, 2019 A204809 003 Mar 26, 2019	Feb CTEC
AB1		AMNEAL PHARMS CO	2.5MG 5MG 10MG	A209744 001 Mar 26, 2019 A209744 002 Mar 26, 2019 A209744 003 Mar 26, 2019	Feb CTEC
AB1		AUROBINDO PHARMA LTD	2.5MG 5MG 10MG	A206285 001 Mar 26, 2019 A206285 002 Mar 26, 2019 A206285 003 Mar 26, 2019	Feb CTEC
AB1		Cipla	2.5MG 5MG 10MG	A209539 001 Mar 26, 2019 A209539 002 Mar 26, 2019 A209539 003 Mar 26, 2019	Feb CTEC
AB1		DR REDDYS LABS LTD	2.5MG 5MG 10MG	A210069 001 Mar 26, 2019 A210069 002 Mar 26, 2019 A210069 003 Mar 26, 2019	Feb CTEC
AB1		GLENMARK PHARMS LTD	2.5MG 5MG 10MG 20MG	A210716 001 Dec 29, 2020 A210716 002 Dec 29, 2020 A210716 003 Dec 29, 2020 A210716 004 Dec 29, 2020	Feb DISC
AB1		HETERO LABS LTD III	2.5MG 5MG 10MG	A209908 001 Mar 26, 2019 A209908 002 Mar 26, 2019 A209908 003 Mar 26, 2019	Feb CTEC
AB1		LUPIN LTD	2.5MG 5MG 10MG	A210567 001 Mar 26, 2019 A210567 002 Mar 26, 2019 A210567 003 Mar 26, 2019	Feb CTEC
AB1		MACLEODS PHARMS LTD	2.5MG 5MG 10MG	A207244 001 Oct 07, 2019 A207244 002 Oct 07, 2019 A207244 003 Oct 07, 2019	Feb CTEC
>D> AB1		MYLAN	2.5MG	A206956 001 Apr 29, 2019	Aug CAHN
>A>		@	2.5MG	A206956 001 Apr 29, 2019	Aug CAHN
AB1			2.5MG	A206956 001 Apr 29, 2019	Feb CTEC
>D> AB1			5MG	A206957 001 Apr 29, 2019	Aug CAHN
>A>		@	5MG	A206957 001 Apr 29, 2019	Aug CAHN
AB1			5MG	A206957 001 Apr 29, 2019	Feb CTEC
>D> AB1			10MG	A206956 002 Apr 29, 2019	Aug CAHN
>A>		@	10MG	A206956 002 Apr 29, 2019	Aug CAHN
AB1			10MG	A206956 002 Apr 29, 2019	Feb CTEC
>D> AB1			20MG	A206956 003 Apr 29, 2019	Aug CAHN
>A>		@	20MG	A206956 003 Apr 29, 2019	Aug CAHN
AB1		QILU	2.5MG	A210420 001 Mar 26, 2019	Feb CTEC
AB1			5MG	A210420 002 Mar 26, 2019	Feb CTEC
AB1			10MG	A210420 003 Mar 26, 2019	Feb CTEC
AB1		SUN PHARM	2.5MG	A208934 001 Mar 26, 2019	Feb CTEC
AB1			5MG	A208934 002 Mar 26, 2019	Feb CTEC
AB1			10MG	A208934 003 Mar 26, 2019	Feb CTEC
AB1		SUNSHINE	2.5MG	A211335 001 Mar 26, 2019	Feb CTEC
AB1			5MG	A211335 002 Mar 26, 2019	Feb CTEC
AB1			10MG	A211335 003 Mar 26, 2019	Feb CTEC
AB1		TEVA PHARMS USA	2.5MG	A090141 001 May 22, 2018	Feb CTEC
AB1			5MG	A090141 002 May 22, 2018	Feb CTEC
AB1			10MG	A090141 003 May 22, 2018	Feb CTEC
AB1		Torrent	2.5MG	A211839 001 Mar 26, 2019	Feb CTEC

TABLET;ORAL  
TADALAFIL

AB1		5MG	A211839	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A211839	003	Mar 26, 2019	Feb CTEC
AB1	UMEDICA LABS PVT LTD	2.5MG	A211298	001	Oct 23, 2020	Feb CTEC
AB1		5MG	A211298	002	Oct 23, 2020	Feb CTEC
AB1		10MG	A211298	003	Oct 23, 2020	Feb CTEC
AB1	UNICHEM	2.5MG	A209250	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A209250	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A209250	003	Mar 26, 2019	Feb CTEC
AB1	YANGLING BUCHANG	2.5MG	A208824	001	Oct 27, 2020	Feb CTEC
AB1		5MG	A208824	002	Oct 27, 2020	Feb CTEC
AB1		10MG	A208824	003	Oct 27, 2020	Feb CTEC
AB1	ZYDUS PHARMS	2.5MG	A206693	001	Mar 26, 2019	Feb CTEC
AB1		5MG	A206693	002	Mar 26, 2019	Feb CTEC
AB1		10MG	A206693	003	Mar 26, 2019	Feb CTEC

TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL  
TAMSULOSIN HYDROCHLORIDE

>D>	@ ANBISON LAB	0.4MG	A211885	001	Oct 17, 2019	Aug CMFD
>A> AB		0.4MG	A211885	001	Oct 17, 2019	Aug CMFD
	@ ANCHEN PHARMS	0.4MG	A202010	001	Jan 04, 2013	Jun DISC

TAVABOROLE

SOLUTION;TOPICAL  
TAVABOROLE

AB	CIPLA	5%	A212224	001	Feb 09, 2021	Jan NEWA
AB	FLATWING	5%	A211963	001	Feb 03, 2021	Feb CPOT
AB		5.0%	A211963	001	Feb 03, 2021	Jan NEWA
AB	IDENTIRX	5%	A211963	001	Feb 03, 2021	Feb CAHN
AB	LUPIN LTD	5%	A212168	001	Feb 08, 2021	Jan NEWA
AB	TARO PHARMS	5%	A212215	001	May 07, 2021	Apr NEWA

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE;INJECTION  
CIS-MDP

AP	SUN PHARM IND'S INC	N/A	N018124	001		Jul CTEC
AP	TECHNETIUM TC-99M MEDRONATE KIT					
AP	CARDINAL HEALTH 414	N/A	N018107	001		Jul CTNA
AP		N/A	N018107	001		Jul CMFD

TELMISARTAN

TABLET;ORAL  
TELMISARTAN

AB	CELLTRION	20MG	A078710	001	Jan 08, 2014	Feb CMFD
AB		40MG	A078710	002	Jan 08, 2014	Feb CMFD
AB		80MG	A078710	003	Jan 08, 2014	Feb CMFD
>D> AB	MYLAN	20MG	A202397	001	Jul 07, 2014	Aug CAHN
>A> AB		20MG	A202397	001	Jul 07, 2014	Aug CAHN
>D> AB		40MG	A202397	002	Jul 07, 2014	Aug CAHN
>A> AB		40MG	A202397	002	Jul 07, 2014	Aug CAHN
>D> AB		80MG	A202397	003	Jul 07, 2014	Aug CAHN
>A> AB		80MG	A202397	003	Jul 07, 2014	Aug CAHN

TEMOZOLOMIDE

CAPSULE;ORAL  
TEMOZOLOMIDE

@	HERITAGE	5MG	A078879	001	Mar 01, 2010	Feb CAHN
@		20MG	A078879	002	Mar 01, 2010	Feb CAHN
@		100MG	A078879	003	Mar 01, 2010	Feb CAHN
@		140MG	A078879	005	Mar 01, 2010	Feb CAHN
@		180MG	A078879	006	Mar 01, 2010	Feb CAHN
@		250MG	A078879	004	Mar 01, 2010	Feb CAHN
@	WATSON LABS TEVA	5MG	A203959	001	Apr 18, 2017	Jan DISC
@		20MG	A203959	002	Apr 18, 2017	Jan DISC
@		100MG	A203959	003	Apr 18, 2017	Jan DISC
@		140MG	A203959	004	Apr 18, 2017	Jan DISC
@		250MG	A203959	005	Apr 18, 2017	Jan DISC

TEPOTINIB HYDROCHLORIDE

TABLET;ORAL

TEPMETKO

+! EMD SERONO INC

EQ 225MG BASE

N214096 001 Feb 03, 2021 Feb NEWA

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

AB	HERITAGE PHARMA	EQ 1MG BASE	A075614	002	Jan 30, 2001	May CMFD
AB		EQ 2MG BASE	A075614	001	Jan 30, 2001	May CMFD
AB		EQ 5MG BASE	A075614	003	Jan 30, 2001	May CMFD
AB		EQ 10MG BASE	A075614	004	Jan 30, 2001	May CMFD
>D> AB	MYLAN	EQ 1MG BASE	A075140	002	Feb 11, 2000	Aug CAHN
>A>	@	EQ 1MG BASE	A075140	002	Feb 11, 2000	Aug CAHN
>D> AB		EQ 2MG BASE	A075140	003	Feb 11, 2000	Aug CAHN
>A>	@	EQ 2MG BASE	A075140	003	Feb 11, 2000	Aug CAHN
>D> AB		EQ 5MG BASE	A075140	001	Feb 11, 2000	Aug CAHN
>A>	@	EQ 5MG BASE	A075140	001	Feb 11, 2000	Aug CAHN
>D> AB		EQ 10MG BASE	A075140	004	Feb 11, 2000	Aug CAHN
>A>	@	EQ 10MG BASE	A075140	004	Feb 11, 2000	Aug CAHN

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

@ IMPAX

14MG

A209677 001 Jun 17, 2020 Feb DISC

TESTOSTERONE

GEL;TRANSDERMAL

TESTOSTERONE

AB2	ACTAVIS LABS UT INC	1.62% (20.25MG/1.25GM PACKET)	A204570	002	Jul 17, 2020	Feb NEWA
AB2		1.62% (40.5MG/2.5GM PACKET)	A204570	003	Jul 17, 2020	Feb NEWA
	GEL, METERED;TRANSDERMAL					
	TESTOSTERONE					
AB	ALEOR DERMACEUTICALS	1.62% (20.25MG/1.25GM ACTUATION)	A213922	001	Mar 03, 2021	Feb NEWA
	SOLUTION, METERED;TRANSDERMAL					
	TESTOSTERONE					
AT	ALEOR DERMACEUTICALS	30MG/1.5ML ACTUATION	A212882	001	Jun 14, 2021	Jun NEWA
	@ APOTEX	30MG/1.5ML ACTUATION	A209181	001	Nov 25, 2020	May DISC
AT	DASH PHARMS	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	May CAHN
AT	FEMPHARM	30MG/1.5ML ACTUATION	A212301	001	Jan 11, 2021	Jan NEWA
>A> AT	TWI PHARMS	30MG/1.5ML ACTUATION	A209836	001	Sep 03, 2021	Aug NEWA

TESTOSTERONE CYPIONATEINJECTABLE;INJECTION  
DEPO-TESTOSTERONE

@ PFIZER

50MG/ML

A085635 001

Mar CAHN

>D> AO	!	100MG/ML	A085635	002		Aug CRLD
>A> AO	+!	100MG/ML	A085635	002		Aug CRLD
AO	!	100MG/ML	A085635	002		Mar CAHN
>D> AO	!	200MG/ML	A085635	003		Aug CRLD
>A> AO	+!	200MG/ML	A085635	003		Aug CRLD
AO	!	200MG/ML	A085635	003		Mar CAHN
	TESTOSTERONE CYPIONATE					
AO	HIKMA PHARMS	100MG/ML	A090387	001	Jul 15, 2010	Jul CAHN
AO		200MG/ML	A090387	002	Jul 15, 2010	Jul CAHN

TETRABENAZINE

TABLET;ORAL

TETRABENAZINE

@ AJANTA PHARMA LTD

12.5MG

A213621 001 Dec 04, 2020 May DISC

@

25MG

A213621 002 Dec 04, 2020 May DISC

TETRACAINE HYDROCHLORIDE

SOLUTION;OPHTHALMIC

TETRACAINE HYDROCHLORIDE

+! BAUSCH LOMB IRELAND 0.5%

N210821 001 Mar 12, 2019 May CAHN

THALLOUS CHLORIDE TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

+ @ GE HEALTHCARE 1mCi/ML

N018110 002 Feb 27, 1996 Jun DISC

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL

SLO-PHYLLIN

>D>	@ SANOFI AVENTIS US	125MG	A085203	001	May 24, 1982	Aug CRLD
>A>	+ @ SOMOPHYLLIN-CRT	125MG	A085203	001	May 24, 1982	Aug CRLD
>D>	@ GRAHAM DM	250MG	A087193	001		Aug CRLD
>A>	+ @ THEO-24	250MG	A087193	001		Aug CRLD
>D>	AUXILIUM PHARMS LLC	200MG	A087943	001	Aug 22, 1983	Aug CRLD
>A>	+ ELIXIR; ORAL THEOPHYLLINE	200MG	A087943	001	Aug 22, 1983	Aug CRLD
>D>	@ PRECISION DOSE	80MG/15ML	A085863	001		Aug CRLD
>A>	+ @ SOLUTION; ORAL THEOPHYLLINE	80MG/15ML	A085863	001		Aug CRLD
>D>	@ ROXANE	80MG/15ML	A087449	001	Sep 15, 1983	Aug CRLD
>A>	+ @ SOLUTION, ELIXIR; ORAL ELIXOPHYLLIN	80MG/15ML	A087449	001	Sep 15, 1983	Aug CRLD
>D> AA	! NOSTRUM LABS INC	80MG/15ML	A085186	001		Aug CRLD
>A> AA	+!	80MG/15ML	A085186	001		Aug CRLD
	SYRUP; ORAL THEOPHYLLINE					
>D>	@ ALPHARMA US PHARMS	150MG/15ML	A086545	001		Aug CRLD
>A>	+ @ TABLET, EXTENDED RELEASE; ORAL THEO-DUR	150MG/15ML	A086545	001		Aug CRLD
>D>	@ SCHERING	200MG	A086998	001		Aug CRLD
>A>	+ @ THEOPHYLLINE	200MG	A086998	001		Aug CRLD
AB	ALEMBIC PHARMS LTD	300MG	A090430	001	Oct 27, 2010	May CTEC
AB	!	450MG	A090430	002	Oct 27, 2010	May CTEC
AB	GLENMARK PHARMS LTD	300MG	A212184	001	Jun 03, 2021	May NEWA
AB		450MG	A212184	002	Jun 03, 2021	May NEWA
	@ HERITAGE PHARMA	100MG	A089807	001	Apr 30, 1990	Jul DISC
	@	200MG	A089808	001	Apr 30, 1990	Jul DISC
>D> AB	RHODES PHARMS	400MG	A040086	002	Sep 01, 1982	Aug CRLD
>A> AB	+	400MG	A040086	002	Sep 01, 1982	Aug CRLD

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

BETALIN S

>D>	@ LILLY	100MG/ML	A080853	001		Aug CRLD
>A>	+ @ THIAMINE HYDROCHLORIDE	100MG/ML	A080853	001		Aug CRLD
>D> AP	! FRESENIUS KABI USA	100MG/ML	A080556	001		Aug CRLD
>A> AP	+!	100MG/ML	A080556	001		Aug CRLD
AP	WEST-WARD PHARMS INT	100MG/ML	A080575	001		Apr CMFD

THIORIDAZINE HYDROCHLORIDE

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

MYLAN	10MG	A088004	002	Mar 15, 1983	Jan CTEC
	25MG	A088004	003	Mar 15, 1983	Jan CTEC
	50MG	A088004	004	Mar 15, 1983	Jan CTEC
!	100MG	A088004	001	Nov 18, 1983	Jan CTEC
@ SUN PHARM INDUSTRIES	10MG	A089953	004	Aug 01, 1986	Jan DISC
@	25MG	A089953	003	Aug 01, 1986	Jan DISC
@	50MG	A089953	002	Aug 01, 1986	Jan DISC
@	100MG	A089953	001	Oct 07, 1988	Jan DISC

THIOTEPHA

POWDER; INTRACAVITARY, INTRAVENOUS, INTRAVESICAL  
THIOTEPHA

AP	GLAND PHARMA LTD	15MG/VIAL	A214222	001	Mar 08, 2021	Feb NEWA
----	------------------	-----------	---------	-----	--------------	----------

TIAGABINE HYDROCHLORIDE

TABLET; ORAL  
TIAGABINE HYDROCHLORIDE

@ WILSHIRE PHARMS INC	2MG	A206857	001	Oct 13, 2017	Jan DISC
@	4MG	A206857	002	Oct 13, 2017	Jan DISC
@	12MG	A206857	003	Oct 13, 2017	Jan DISC
@	16MG	A206857	004	Oct 13, 2017	Jan DISC

TICAGRELOR

TABLET; ORAL  
TICAGRELOR

AB	MYLAN	60MG	A208597	001	Jul 09, 2021	Jul NFTG
AB		90MG	A208597	002	Jul 09, 2021	Jul NEWA

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL  
TICLOPIDINE HYDROCHLORIDE

>A>	@ CHARTWELL RX	250MG	A075318	001	Aug 20, 1999	Aug CAHN
>A>	@	250MG	A075326	001	Aug 20, 1999	Aug CAHN
>D>	@ YAOPHARMA CO LTD	250MG	A075318	001	Aug 20, 1999	Aug CAHN
>D>	@	250MG	A075326	001	Aug 20, 1999	Aug CAHN

TIGECYCLINE

POWDER; INTRAVENOUS  
TIGECYCLINE

>D> AP	HONG KONG	50MG/VIAL	A214020	001	May 13, 2021	Aug CAHN
AP		50MG/VIAL	A214020	001	May 13, 2021	May NEWA
>A> AP	MEITHEAL	50MG/VIAL	A214020	001	May 13, 2021	Aug CAHN

TIMOLOL MALEATE

SOLUTION, GEL FORMING/DROPS; OPHTHALMIC  
TIMOLOL MALEATE

AB	! ALEMBIC PHARMS LTD	EQ 0.25% BASE	A212942	001	Oct 22, 2020	Apr CHRS
AB	!	EQ 0.5% BASE	A212942	002	Oct 22, 2020	Apr CHRS
	TIMOPTIC-XE					
AB	+ VALEANT PHARMS LLC	EQ 0.25% BASE	N020330	001	Nov 04, 1993	Apr CHRS
AB	+	EQ 0.5% BASE	N020330	002	Nov 04, 1993	Apr CHRS
	SOLUTION/DROPS; OPHTHALMIC					
	TIMOLOL MALEATE					
AT	MANKIND PHARMA	EQ 0.25% BASE	A078771	001	Sep 28, 2009	Apr CAHN
AT1		EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr CAHN

TIOPRONIN

TABLET; ORAL  
TIOPRONIN

AB	TEVA PHARMS USA INC	100MG	A214326	001	Apr 26, 2021	Apr NFTG
----	---------------------	-------	---------	-----	--------------	----------

TIOTROPIUM BROMIDE

SPRAY, METERED; INHALATION  
SPIRIVA RESPIMAT  
+! BOEHRINGER INGELHEIM EQ 0.00125MG BASE/INH

N021936	002	Sep 15, 2015	Mar CHRS
---------	-----	--------------	----------

TIROFIBAN HYDROCHLORIDE

SOLUTION; INTRAVENOUS

AGGRASTAT

+ MEDICURE	EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML)	N020913	002	May 17, 2002	Apr CDFR	
@	EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML)	N020913	001	May 14, 1998	Apr CDFR	
	TIROFIBAN HYDROCHLORIDE					
AP	GLAND PHARMA LTD	EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML)	A206888	001	Apr 08, 2021	Apr NFTG

TIVOZANIB HYDROCHLORIDE

CAPSULE;ORAL						
FOTIVDA						
+ AVEO PHARMS	EQ 0.89MG BASE		N212904	001	Mar 10, 2021	Mar NEWA
+!	EQ 1.34MG BASE		N212904	002	Mar 10, 2021	Mar NEWA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL						
TIZANIDINE HYDROCHLORIDE						
@ PAR PHARM INC	EQ 2MG BASE		A207199	001	Mar 14, 2017	Jun DISC
@	EQ 4MG BASE		A207199	002	Mar 14, 2017	Jun DISC

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE						
AB CADILA	EQ 2MG BASE		A208187	001	Mar 09, 2018	Feb CAHN
	EQ 4MG BASE		A208187	002	Mar 09, 2018	Feb CAHN
AB @ MYLAN	EQ 2MG BASE		A076354	001	Mar 28, 2003	Jan DISC
	EQ 4MG BASE		A076354	002	Mar 28, 2003	Feb DISC

TOBRAMYCIN

SOLUTION;INHALATION						
TOBRAMYCIN						
AN ALKEM LABS LTD	300MG/5ML		A212848	001	Apr 01, 2021	Mar NEWA
>D> @ AUROBINDO PHARMA LTD	300MG/5ML		A210871	001	Jan 22, 2021	Aug CAHN
	300MG/5ML		A210871	001	Jan 22, 2021	Jul DISC
AN >A> @ LUOXIN AUROVITAS	300MG/5ML		A210871	001	Jan 22, 2021	Jan NEWA
	300MG/5ML		A210871	001	Jan 22, 2021	Aug CAHN
SOLUTION/DROPS;OPHTHALMIC						
TOBRAMYCIN						
AT GLAND PHARMA LTD	0.3%		A212628	001	Mar 09, 2021	Feb NEWA

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION						
TOBRAMYCIN SULFATE						
AP GLAND PHARMA LTD	EQ 10MG BASE/ML		A209621	001	Feb 11, 2021	Feb NEWA
AP	EQ 40MG BASE/ML		A209621	002	Feb 11, 2021	Feb NEWA
AP	EQ 1.2GM BASE/VIAL		A211189	001	May 18, 2021	May NEWA
	TOBRAMYCIN SULFATE (PHARMACY BULK)					
AP ! FRESENIUS KABI USA	EQ 40MG BASE/ML		A065120	001	Nov 29, 2002	Jan CTEC
AP GLAND PHARMA LTD	EQ 40MG BASE/ML		A209346	001	Feb 09, 2021	Jan NEWA

TOFACITINIB CITRATE

SOLUTION;ORAL						
XELJANZ						
+! PFIZER	EQ 1MG/ML BASE		N213082	001	Sep 25, 2020	Feb CMS1
TABLET;ORAL						
TOFACITINIB CITRATE						
AB AJANTA PHARMA LTD	EQ 10MG BASE		A212943	001	Jun 01, 2021	May NFTG
TABLET, EXTENDED RELEASE;ORAL						
>A> TOFACITINIB						
>A> AB ZYDUS PHARMS	EQ 11MG BASE		A214264	001	Aug 19, 2021	Aug NFTG
>A> AB	EQ 22MG BASE		A214264	002	Aug 19, 2021	Aug NFTG

TOLAZAMIDE

TABLET;ORAL						
TOLAZAMIDE						
>A> @ CHARTWELL RX	100MG		A071633	001	Dec 09, 1987	Aug CAHN
>A> @	250MG		A070289	001	Mar 13, 1986	Aug CAHN
>A> @	500MG		A070290	001	Mar 13, 1986	Aug CAHN
>D> @ YAOPHARMA CO LTD	100MG		A071633	001	Dec 09, 1987	Aug CAHN
>D> @	250MG		A070289	001	Mar 13, 1986	Aug CAHN
>D> @	500MG		A070290	001	Mar 13, 1986	Aug CAHN

TOLBUTAMIDE

TABLET;ORAL						
TOLBUTAMIDE						
>A> @ CHARTWELL RX	500MG		A086574	001		Aug CAHN
>D> @ YAOPHARMA CO LTD	500MG		A086574	001		Aug CAHN

TOLCAPONE

TABLET;ORAL  
TOLCAPONE  
@ ALVOGEN 100MG A207729 001 Jul 29, 2020 Jan DISC

TOLMETIN SODIUM

CAPSULE;ORAL  
TOLMETIN SODIUM  
>D> AB MYLAN EQ 400MG BASE A073393 001 May 27, 1993 Aug DISC  
>A> @ EQ 400MG BASE A073393 001 May 27, 1993 Aug DISC  
>D> AB ! TEVA EQ 400MG BASE A073290 001 Nov 27, 1991 Aug DISC  
>A> @ EQ 400MG BASE A073290 001 Nov 27, 1991 Aug DISC  
TABLET;ORAL  
TOLMETIN SODIUM  
>D> ! MYLAN EQ 600MG BASE A074473 001 Aug 30, 1994 Aug DISC  
>A> @ EQ 600MG BASE A074473 001 Aug 30, 1994 Aug DISC

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL  
TOLTERODINE TARTRATE  
AB AJANTA PHARMA LTD 2MG A213397 001 May 19, 2020 Jan CMFD  
AB 4MG A213397 002 May 19, 2020 Jan CMFD  
AB AMTA 2MG A213858 001 Feb 02, 2021 Jan NEWA  
AB 4MG A213858 002 Feb 02, 2021 Jan NEWA  
@ MYLAN 2MG A201486 001 Oct 31, 2013 Jul DISC  
@ 4MG A201486 002 Oct 31, 2013 Jul DISC  
TABLET;ORAL  
TOLTERODINE TARTRATE  
AB HETERO LABS LTD V 1MG A204397 001 Aug 02, 2021 Jul NEWA  
AB 2MG A204397 002 Aug 02, 2021 Jul NEWA

TOLVAPTAN

TABLET;ORAL  
SAMSCA  
+ OTSUKA 15MG N022275 001 May 19, 2009 Feb CAHN  
AB +! 30MG N022275 002 May 19, 2009 Feb CAHN  
+ @ 60MG N022275 003 May 19, 2009 Feb CAHN  
TOLVAPTAN  
ALKEM LABS LTD 60MG A211891 002 May 19, 2020 Jul CTEC  
>D> @ APOTEX 30MG A207605 001 May 19, 2020 Aug CMFD  
>A> AB 30MG A207605 001 May 19, 2020 Aug CMFD  
AB HETERO LABS LTD V 30MG A205646 001 Jul 16, 2021 Jul NEWA

TOPIRAMATE

CAPSULE, EXTENDED RELEASE;ORAL  
TOPIRAMATE  
AB2 GLENMARK PHARMS LTD 25MG A210278 001 Feb 01, 2021 Jan NFTG  
AB2 50MG A210278 002 Feb 01, 2021 Jan NFTG  
AB2 100MG A210278 003 Feb 01, 2021 Jan NFTG  
AB2 150MG A210278 004 Feb 01, 2021 Jan NFTG  
AB2 200MG A210278 005 Feb 01, 2021 Jan NFTG  
AB1 ZYDUS PHARMS 25MG A207382 001 Nov 24, 2017 Jan CTEC  
AB1 50MG A207382 002 Nov 24, 2017 Jan CTEC  
AB1 100MG A207382 003 Nov 24, 2017 Jan CTEC  
TROKENDI XR  
AB1 + SUPERNUS PHARMS 25MG N201635 001 Aug 16, 2013 Jan CTEC  
AB1 + 50MG N201635 002 Aug 16, 2013 Jan CTEC  
AB1 + 100MG N201635 003 Aug 16, 2013 Jan CTEC  
TABLET;ORAL  
TOPIRAMATE  
>A> AB ASCENT PHARMS INC 25MG A215414 001 Aug 26, 2021 Aug NEWA  
>A> AB 50MG A215414 002 Aug 26, 2021 Aug NEWA  
>A> AB 100MG A215414 003 Aug 26, 2021 Aug NEWA  
>A> AB 200MG A215414 004 Aug 26, 2021 Aug NEWA

TOPOTECAN HYDROCHLORIDE

INJECTABLE;INJECTION  
TOPOTECAN HYDROCHLORIDE  
>D> AP MEITHEAL EQ 4MG BASE/VIAL A201166 001 Aug 08, 2012 Aug DISC  
>A> @ EQ 4MG BASE/VIAL A201166 001 Aug 08, 2012 Aug DISC

TORSEMIDE

TABLET;ORAL						
SOAANZ						
+! SARFE PHARMS	20MG		N 213218	001	Jun 14, 2021	Jul CHRS
+	20MG		N 213218	001	Jun 14, 2021	Jun NEWA
+	60MG		N 213218	002	Jun 14, 2021	Jul CHRS
+!	60MG		N 213218	002	Jun 14, 2021	Jun NEWA

TRAMADOL HYDROCHLORIDE

TABLET;ORAL						
TRAMADOL HYDROCHLORIDE						
>D>	@ GRAVITI PHARMS	50MG	A 075968	001	Jun 25, 2002	Aug CAHN
	@	50MG	A 075968	001	Jun 25, 2002	Apr CAHN
AB	POLYGEN PHARMS	50MG	A 206706	001	Jul 02, 2019	Feb CMFD
>A>	@ RISING	50MG	A 075968	001	Jun 25, 2002	Aug CAHN
TABLET, EXTENDED RELEASE;ORAL						
TRAMADOL HYDROCHLORIDE						
@ ANCHEN PHARMS	100MG		A 200491	001	Jun 27, 2012	Apr DISC
@	200MG		A 200491	002	Jun 27, 2012	Apr DISC
@	300MG		A 200491	003	Jun 27, 2012	Apr DISC

TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL						
TARKA						
>D> AB	+ ABBVIE	2MG;180MG	N 020591	001	Oct 22, 1996	Aug DISC
>A>	+ @	2MG;180MG	N 020591	001	Oct 22, 1996	Aug DISC
>D> AB	+	2MG;240MG	N 020591	004	Oct 22, 1996	Aug DISC
>A>	+ @	2MG;240MG	N 020591	004	Oct 22, 1996	Aug DISC
>D> AB	+!	4MG;240MG	N 020591	002	Oct 22, 1996	Aug DISC
>A>	+ @	4MG;240MG	N 020591	002	Oct 22, 1996	Aug DISC
	TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE					
>D> AB	GLENMARK GENERICS	2MG;180MG	A 079135	001	May 26, 2010	Aug CTEC
		2MG;180MG	A 079135	001	May 26, 2010	Aug CTEC
>D> AB		2MG;240MG	A 079135	002	May 26, 2010	Aug CTEC
>A>		2MG;240MG	A 079135	002	May 26, 2010	Aug CTEC
>D> AB		4MG;240MG	A 079135	003	May 05, 2010	Aug CTEC
>A>	!	4MG;240MG	A 079135	003	May 05, 2010	Aug CTEC

TRANEXAMIC ACID

INJECTABLE; INJECTION						
CYKLOKAPRON						
AP	+! PFIZER	100MG/ML	N 019281	001	Dec 30, 1986	Mar CAHN
	TRANEXAMIC ACID					
AP	CAPLIN	100MG/ML	A 212360	001	Jul 17, 2019	Jun CMFD
AP	PROVEPHARM SAS	100MG/ML	A 212676	001	Jul 17, 2019	Jan CAHN
	@ ZYDUS PHARMS	100MG/ML	A 205228	001	Jul 17, 2017	Apr DISC
TABLET;ORAL						
TRANEXAMIC ACID						
AB	ANI PHARMS	650MG	A 203256	001	Jul 25, 2016	Jun CMFD
	@ APOTEX INC	650MG	A 202286	001	Jan 27, 2014	Mar DISC

TRANYLCYPROMINE SULFATE

TABLET;ORAL						
TRANYLCYPROMINE SULFATE						
AB	NOVITIUM PHARMA	EQ 10MG BASE	A 206856	001	Apr 17, 2018	Apr CAHN

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC						
TRAVOPROST						
AT	MICRO LABS	0.004%	A 203767	001	Mar 19, 2021	Mar NEWA

TRAZODONE HYDROCHLORIDE

TABLET;ORAL						
TRAZODONE HYDROCHLORIDE						
@ ALVOGEN	50MG		A 071636	001	Apr 18, 1988	Jun DISC
@	100MG		A 071514	001	Apr 18, 1988	Jun DISC
AB	AUROLIFE PHARMA LLC	50MG	A 204852	001	Feb 05, 2020	Feb CMFD
AB		100MG	A 204852	002	Feb 05, 2020	Feb CMFD
AB		150MG	A 204852	003	Feb 05, 2020	Feb CMFD
AB		300MG	A 204852	004	Feb 05, 2020	Feb CMFD
	@ RISING	50MG	A 072484	001	Apr 30, 1990	Jan CAHN

TREPROSTINIL

INJECTABLE;IV (INFUSION), SUBCUTANEOUS  
REMODULIN

>A>	+!	UNITED THERAP	20MG/ML	N 021272	005	Jul 30, 2021	Aug NEWA
AP		ALEMBIC GLOBAL	1MG/ML	A 211574	001	Feb 11, 2021	Feb NEWA
AP			2.5MG/ML	A 211574	002	Feb 11, 2021	Feb NEWA
AP			5MG/ML	A 211574	003	Feb 11, 2021	Feb NEWA
AP			10MG/ML	A 211574	004	Feb 11, 2021	Feb NEWA
		SOLUTION; INTRAVENOUS, SUBCUTANEOUS REMODULIN					
	@	UNITED THERAP	20MG/20ML (1MG/ML)	N 208276	001	Jul 30, 2018	Jun DISC
	@		50MG/20ML (2.5MG/ML)	N 208276	002	Jul 30, 2018	Jun DISC
	@		100MG/20ML (5MG/ML)	N 208276	003	Jul 30, 2018	Jun DISC
	@		200MG/20ML (10MG/ML)	N 208276	004	Jul 30, 2018	Jun DISC

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL  
ARISTOCORT

>D>	@	ASTELLAS	0.5%	A 083015	002		Aug CRLD
>A>	+	@	0.5%	A 083015	002		Aug CRLD
		KENALOG					
>D>	@	DELCOR ASSET CORP	0.5%	A 083943	001		Aug CRLD
>A>	+	@	0.5%	A 083943	001		Aug CRLD
		TRIAMCINOLONE ACETONIDE					
>D> AT	!	FOUGERA PHARMS	0.025%	A 085692	001		Aug CRLD
>A> AT	+!		0.025%	A 085692	001		Aug CRLD
>D> AT	!		0.1%	A 085692	003		Aug CRLD
>A> AT	+!		0.1%	A 085692	003		Aug CRLD
>D> AT	!		0.5%	A 085692	002		Aug CRLD
>A> AT	+!		0.5%	A 085692	002		Aug CRLD
>A> AT		MICRO LABS	0.025%	A 040671	001	Jun 09, 2006	Aug CAHN
>A> AT			0.1%	A 040671	002	Jun 09, 2006	Aug CAHN
>D> AT		SAPTALIS PHARMS	0.025%	A 040671	001	Jun 09, 2006	Aug CAHN
AT			0.025%	A 040671	001	Jun 09, 2006	Jan CAHN
>D> AT			0.1%	A 040671	002	Jun 09, 2006	Aug CAHN
AT			0.1%	A 040671	002	Jun 09, 2006	Jan CAHN

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

>A> AT		MICRO LABS	0.1%	A 040672	002	Dec 13, 2006	Aug CAHN
>D> AT		SAPTALIS PHARMS	0.1%	A 040672	002	Dec 13, 2006	Aug CAHN

OINTMENT;TOPICAL

ARISTOCORT

>D>	@	ASTELLAS	0.5%	A 080745	002		Aug CRLD
>A>	+	@	0.5%	A 080745	002		Aug CRLD
		ARISTOCORT A					
>D>	@	ASTELLAS	0.5%	A 080745	003		Aug CRLD
>A>	+	@	0.5%	A 080745	003		Aug CRLD
		KENALOG					
>D>	@	DELCOR ASSET CORP	0.5%	A 083944	001		Aug CRLD
>A>	+	@	0.5%	A 083944	001		Aug CRLD
		TRIAMCINOLONE ACETONIDE					
>D> AT	!	PADAGIS US	0.025%	A 087385	002		Aug CRLD
>A> AT	+!		0.025%	A 087385	002		Aug CRLD
>D> AT	!		0.1%	A 087385	003		Aug CRLD
>A> AT	+!		0.1%	A 087385	003		Aug CRLD
>D> AT	!		0.5%	A 087385	001		Aug CRLD
>A> AT	+!		0.5%	A 087385	001		Aug CRLD

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

@ PERRIGO 0.055MG/SPRAY

A 078104 001 Jul 30, 2009 Jul CAHN

TRIAZOLAM

TABLET;ORAL  
HALCION

AB	+	PFIZER	0.125MG	N 017892	003	Apr 26, 1985	Feb CAHN
AB	+!		0.25MG	N 017892	001	Nov 15, 1982	Feb CAHN
	@		0.5MG	N 017892	002	Nov 15, 1982	Feb CAHN

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL CLOVIQUE @ CHARTWELL RX	250MG 250MG	A209731 001 Oct 21, 2019 Jun DISC A209731 001 Oct 21, 2019 Mar CAHN	
AB	TRIENTINE HYDROCHLORIDE		
>A> AB	ACCORD HLTHCARE @ CHARTWELL RX	250MG 250MG	A212929 001 Aug 30, 2021 Aug NEWA A209415 001 Sep 16, 2019 Jun DISC
AB		250MG	A209415 001 Sep 16, 2019 Mar CAHN
>A> AB	ECI PHARMS LLC	250MG	A209945 001 Aug 13, 2021 Aug NEWA

TRILACICLIB DIHYDROCHLORIDE

POWDER; INTRAVENOUS COSELA +! G1 THERAP	EQ 300MG BASE/VIAL	N214200 001 Feb 12, 2021 Feb NEWA
---	--------------------	-----------------------------------

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL TIGAN + @ KING PHARMS LLC	300MG	N017531 006 Dec 13, 2001 Apr DISC	
AB	TRIMETHOBENZAMIDE HYDROCHLORIDE ! SUN PHARM INDUSTRIES	300MG	A076570 001 Aug 28, 2003 Apr CHRS

TROPICAMIDE

SOLUTION/DROPS;OPHTHALMIC MYDRIACYL >D> AT ! ALCON LABS INC	1%	A084306 001 Aug CRLD
>A> AT +!	1%	A084306 001 Aug CRLD
>D> AT ! SANDOZ INC	0.5%	A084305 001 Aug CRLD
>A> AT +!	0.5%	A084305 001 Aug CRLD

TROSPiUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL TROSPiUM CHLORIDE AB AMTA	60MG	A214760 001 Apr 30, 2021 Apr NEWA
--	------	-----------------------------------

UMBRALISIB TOSYLATE

TABLET;ORAL UKONIQ +! TG THERAPS	EQ 200MG BASE	N213176 001 Feb 05, 2021 Feb NEWA
--	---------------	-----------------------------------

URSODIOL

CAPSULE;ORAL URSODIOL AB STRIDES PHARMA	300MG	A210344 001 Jan 22, 2021 Jan NEWA
AB VGYAAN	300MG	A214329 001 Jul 28, 2021 Jul NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL VALACYCLOVIR HYDROCHLORIDE >A> AB CADILA	EQ 500MG BASE	A079137 001 Dec 29, 2017 Aug CAHN
>A> AB	EQ 1GM BASE	A079137 002 Dec 29, 2017 Aug CAHN
>D> AB ZYDUS PHARMS	EQ 500MG BASE	A079137 001 Dec 29, 2017 Aug CAHN
>D> AB	EQ 1GM BASE	A079137 002 Dec 29, 2017 Aug CAHN

VALBENAZINE TOSYLATE

CAPSULE;ORAL INGREZZA + NEUROCRINE	EQ 60MG BASE	N209241 003 Apr 23, 2021 May NEWA
--	--------------	-----------------------------------

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL VALGANCICLOVIR HYDROCHLORIDE AB MYLAN	EQ 450MG BASE	A205151 001 Mar 03, 2021 Feb NEWA
---	---------------	-----------------------------------

VALPROIC ACID

SYRUP;ORAL

VALPROIC ACID

AA CHARTWELL RX 250MG/5ML A075782 001 Dec 22, 2000 Mar CMFD

VANCOMYCIN

SOLUTION;INTRAVENOUS, ORAL

VANCOMYCIN

&gt;A&gt; +! XELLIA PHARMS APS 5GM/100ML (50MG/ML) N213895 001 Aug 26, 2021 Aug NEWA

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

VANCOMYCIN HYDROCHLORIDE

@ HIKMA EQ 500MG BASE/VIAL A203300 001 Aug 11, 2020 Feb DISC

@ EQ 1GM BASE/VIAL A203300 002 Aug 11, 2020 Feb DISC

! HOSPIRA EQ 1.5GM BASE/VIAL A062912 003 Jul 10, 2020 May CMFD

VARDENAFIL HYDROCHLORIDE

TABLET;ORAL

LEVITRA

+ @ BAYER HLTHCARE EQ 5MG BASE N021400 001 Aug 19, 2003 Apr DISC

+ @ EQ 10MG BASE N021400 002 Aug 19, 2003 Apr DISC

VARENICLINE

TABLET;ORAL

VARENICLINE

AB PAR PHARM INC EQ 0.5MG BASE A201785 001 Aug 11, 2021 Jul NFTG

AB EQ 1MG BASE A201785 002 Aug 11, 2021 Jul NFTG

VASOPRESSIN

SOLUTION;INTRAVENOUS

VASOSTRICT

+! PAR STERILE PRODUCTS 20UNITS/100ML (0.2UNITS/ML) N204485 005 Apr 21, 2021 Apr NEWA

VENLAFAKINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAKINE HYDROCHLORIDE

&gt;A&gt; AB TORRENT EQ 37.5MG BASE A090899 001 Jun 01, 2011 Aug CAHN

&gt;A&gt; AB EQ 75MG BASE A090899 002 Jun 01, 2011 Aug CAHN

&gt;A&gt; AB EQ 150MG BASE A090899 003 Jun 01, 2011 Aug CAHN

&gt;D&gt; AB TORRENT PHARMS LLC EQ 37.5MG BASE A090899 001 Jun 01, 2011 Aug CAHN

&gt;D&gt; AB EQ 75MG BASE A090899 002 Jun 01, 2011 Aug CAHN

&gt;D&gt; AB EQ 150MG BASE A090899 003 Jun 01, 2011 Aug CAHN

AB YICHANG HUMANWELL EQ 37.5MG BASE A214654 001 Aug 06, 2021 Jul NEWA

AB EQ 75MG BASE A214654 002 Aug 06, 2021 Jul NEWA

AB EQ 150MG BASE A214654 003 Aug 06, 2021 Jul NEWA

TABLET;ORAL

VENLAFAKINE HYDROCHLORIDE

@ MYLAN EQ 25MG BASE A077166 001 Jun 13, 2008 Jan DISC

@ EQ 37.5MG BASE A077166 002 Jun 13, 2008 Jan DISC

@ EQ 50MG BASE A077166 003 Jun 13, 2008 Jan DISC

@ EQ 75MG BASE A077166 004 Jun 13, 2008 Jan DISC

@ EQ 100MG BASE A077166 005 Jun 13, 2008 Jan DISC

TABLET, EXTENDED RELEASE;ORAL

VENLAFAKINE HYDROCHLORIDE

AB ALKEM LABS LTD EQ 37.5MG BASE A214127 001 Jun 10, 2021 Jun NEWA

AB EQ 75MG BASE A214127 002 Jun 10, 2021 Jun NEWA

AB EQ 150MG BASE A214127 003 Jun 10, 2021 Jun NEWA

AB EQ 225MG BASE A214127 004 Jun 10, 2021 Jun NEWA

AB APPCO EQ 150MG BASE A214609 001 Jun 30, 2021 Jun NEWA

AB EQ 225MG BASE A214609 002 Jun 30, 2021 Jun NEWA

AB DEXCEL PHARMA EQ 75MG BASE A213927 001 Jan 21, 2021 Jan NEWA

VERICIGUAT

TABLET;ORAL

VERQUVO

+ MERCK SHARP DOHME 2.5MG N214377 001 Jan 19, 2021 Jan NEWA

+ 5MG N214377 002 Jan 19, 2021 Jan NEWA

+! 10MG N214377 003 Jan 19, 2021 Jan NEWA

VIGABATRIN

FOR SOLUTION;ORAL

VIGABATRIN

AA	ANNORA PHARMA	500MG/PACKET	A213519	001	Jan 26, 2021	Jan NEWA
AA	DEXCEL PHARMA	500MG/PACKET	A214992	001	May 13, 2021	May NEWA
AA	NAVISCI	500MG/PACKET	A213390	001	Jul 29, 2021	Jul NEWA
AA	SPECGX LLC	500MG/PACKET	A212626	001	Jul 28, 2021	Jul NEWA
	TABLET;ORAL					
	VIGABATRIN					
AB	DR REDDYS	500MG	A211539	001	Jan 29, 2021	Jan NEWA

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VILAZODONE HYDROCHLORIDE

AB	ACCORD HLTHCARE	10MG	A208209	001	Apr 27, 2021	Apr NEWA
AB		20MG	A208209	002	Apr 27, 2021	Apr NEWA
AB		40MG	A208209	003	Apr 27, 2021	Apr NEWA
AB	INVAGEN PHARMS	10MG	A208200	001	Apr 07, 2021	Mar NEWA
AB		40MG	A208200	002	Apr 07, 2021	Mar NEWA

VILOXAZINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

QELBREE

+	SUPERNUS PHARMS	EQ 100MG BASE
+		EQ 150MG BASE
+!		EQ 200MG BASE

N211964 001 Apr 02, 2021 Apr NEWA  
 N211964 002 Apr 02, 2021 Apr NEWA  
 N211964 003 Apr 02, 2021 Apr NEWA

VINBLASTINE SULFATE

INJECTABLE;INJECTION

VINBLASTINE SULFATE

!	HIKMA PHARMS	10MG/VIAL
---	--------------	-----------

A089395 001 Apr 09, 1987 Jul CAHN

VINORELBINE TARTRATE

INJECTABLE;INJECTION

VINORELBINE TARTRATE

@	FRESENIUS KABI USA	EQ 10MG BASE/ML
---	--------------------	-----------------

A076849 001 Apr 18, 2005 Jan DISC

VOCLOSPORIN

CAPSULE;ORAL

LUPKYNIS

+!	AURINIA	7.9MG
----	---------	-------

N213716 001 Jan 22, 2021 Jan NEWA

VORICONAZOLE

INJECTABLE;INTRAVENOUS

VORICONAZOLE

AP	ALMAJECT	200MG/VIAL
----	----------	------------

A206398 001 Mar 23, 2016 Feb CAHN

ZINC CHLORIDE

INJECTABLE;INJECTION

ZINC CHLORIDE

AP	EXELA PHARMA	EQ 1MG ZINC/ML
----	--------------	----------------

A212007 001 May 21, 2021 May NFTG

ZIPRASIDONE HYDROCHLORIDE

CAPSULE;ORAL

ZIPRASIDONE HYDROCHLORIDE

AB	CHARTWELL RX	EQ 20MG BASE
AB		EQ 40MG BASE
AB		EQ 60MG BASE
AB		EQ 80MG BASE

A090348 001 Sep 05, 2012 Jul CAHN  
 A090348 002 Sep 05, 2012 Jul CAHN  
 A090348 003 Sep 05, 2012 Jul CAHN  
 A090348 004 Sep 05, 2012 Jul CAHN

ZOLEDRONIC ACID

INJECTABLE;INTRAVENOUS

ZOLEDRONIC ACID

>D> AP	EMCURE PHARMS LTD	EQ 4MG BASE/5ML
>A>	@	EQ 4MG BASE/5ML

A201783 001 Mar 12, 2013 Aug DISC  
 A201783 001 Mar 12, 2013 Aug DISC

ZOLPIDEM TARTRATE

TABLET, ORALLY DISINTEGRATING;ORAL  
TOVALT ODT  
+ @ BIOVAIL LABS INTL 5MG  
+ @ 10MG

N021412 001 Apr 25, 2007 Apr CRLD  
N021412 002 Apr 25, 2007 Apr CRLD

ZONISAMIDE

CAPSULE;ORAL  
ZONEGRAN

AB	+ CONCORDIA	25MG	N020789	003	Aug 22, 2003	Mar CAHN
	+ @	50MG	N020789	002	Aug 22, 2003	Mar CAHN
AB	+!	100MG	N020789	001	Mar 27, 2000	Mar CAHN
	ZONISAMIDE					
AB	CADILA	25MG	A077625	001	Oct 16, 2006	Jul CAHN
AB		50MG	A077625	002	Oct 16, 2006	Jul CAHN
AB		100MG	A077625	003	Oct 16, 2006	Jul CAHN
AB	GRANULES	25MG	A077636	003	Jul 27, 2006	Jun CAHN
AB		50MG	A077636	002	Jul 27, 2006	Jun CAHN
AB		100MG	A077636	001	Dec 22, 2005	Jun CAHN
AB	UNICHEM	25MG	A214492	001	Jan 26, 2021	Jan NEWA
AB		50MG	A214492	002	Jan 26, 2021	Jan NEWA
AB		100MG	A214492	003	Jan 26, 2021	Jan NEWA

ACETAMINOPHEN

TABLET, EXTENDED RELEASE;ORAL  
ACETAMINOPHEN

>A> MARKSANS PHARMA 650MG A215486 001 Aug 25, 2021 Aug NEWA

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL  
ACETAMINOPHEN, ASPIRIN AND CAFFEINE  
GRANULES 250MG;250MG;65MG

A214039 001 Feb 23, 2021 Feb NEWA

ASPIRIN

CAPSULE;ORAL  
VAZALORE  
+ PLX PHARMA 81MG

N203697 002 Feb 26, 2021 Jun NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL  
ASTEPRO ALLERGY  
+! BAYER HLTHCARE 0.2055MG/SPRAY  
CHILDREN'S ASTEPRO ALLERGY  
+! BAYER HLTHCARE 0.2055MG/SPRAY

N213872 001 Jun 17, 2021 Jun NEWA

N213872 002 Jun 17, 2021 Jun NEWA

BUDESONIDE

SPRAY, METERED;NASAL  
RHINOCORT ALLERGY  
+! J AND J CONSUMER INC 0.032MG/SPRAY

N020746 003 Mar 23, 2015 Mar CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL  
CETIRIZINE HYDROCHLORIDE ALLERGY  
APOTEX 10MG  
@ 10MG

A207235 001 Aug 12, 2016 Mar CMFD

A207235 001 Aug 12, 2016 Jan DISC

TABLET;ORAL  
CETIRIZINE HYDROCHLORIDE ALLERGY  
@ CIPLA LTD 5MG  
@ 10MG

A077318 001 Jul 25, 2013 May DISC

A077318 002 Jul 25, 2013 May DISC

TABLET, CHEWABLE;ORAL  
CHILDREN'S ZYRTEC ALLERGY  
+ @ J AND J CONSUMER INC 2.5MG

N021621 007 Nov 30, 2020 Apr DISC

DEXTRMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL  
GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE  
SUN PHARM 30MG;600MG  
60MG;1.2GM

A214781 001 Jul 01, 2021 Jun NEWA

A214781 002 Jul 01, 2021 Jun NEWA

DICLOFENAC SODIUM

GEL;TOPICAL  
DICLOFENAC SODIUM  
AUROLIFE PHARMA LLC 1%  
PERRIGO 1%  
PERRIGO PHARMA INTL 1%

A204306 001 May 06, 2019 May CAHN

A211253 001 May 16, 2019 Jun CAHN

A211253 001 May 16, 2019 Jul CAHN

FEXOFENADINE HYDROCHLORIDE

SUSPENSION;ORAL  
CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY  
TARO 30MG/5ML  
CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES  
TARO 30MG/5ML

A208123 001 Nov 09, 2017 Jun CMFD

A208123 002 Nov 09, 2017 Jun CMFD

TABLET;ORAL  
FEXOFENADINE HYDROCHLORIDE

L PERRIGO CO 60MG  
180MG

A212971 001 Feb 24, 2020 Jun CMFD

A212971 002 Feb 24, 2020 Jun CMFD

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL  
FLONASE ALLERGY RELIEF  
+ GLAXOSMITHKLINE CONS 0.05MG/SPRAY  
FLUTICASONE PROPIONATE  
! HIKMA PHARMS 0.05MG/SPRAY

N205434 001 Jul 23, 2014 Apr CHRS  
A207957 001 May 26, 2016 Apr CHRS

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL  
GUAIFENESIN

>D> @ OHM LABS INC 600MG  
>A> 600MG  
>D> @ 1.2GM  
>A> 1.2GM

A209254 001 Jul 16, 2018 Aug CMFD  
A209254 001 Jul 16, 2018 Aug CMFD  
A209254 002 Jul 16, 2018 Aug CMFD  
A209254 002 Jul 16, 2018 Aug CMFD

IBUPROFEN

SUSPENSION;ORAL  
IBUPROFEN  
GUARDIAN DRUG 100MG/5ML  
STRIDES PHARMA 100MG/5ML  
@ 100MG/5ML  
100MG/5ML

>D> TABLET;ORAL  
IBUPROFEN  
@ YICHANG HUMANWELL 200MG  
A210149 001 Aug 17, 2018 Jan CMFD  
A211666 001 Feb 22, 2021 Aug DISC  
A211666 001 Feb 22, 2021 Aug DISC  
A211666 001 Feb 22, 2021 Feb NEWA

ISOPROPYL ALCOHOL

SOLUTION;TOPICAL  
ZURAGARD  
+ @ ZUREX PHARMA 70%

N210872 001 Apr 26, 2019 Jul CPOT

IVERMECTIN

LOTION;TOPICAL  
IVERMECTIN  
TARO 0.5%

A210720 001 May 06, 2020 May CMKT

KETOCONAZOLE

SHAMPOO;TOPICAL  
NIZORAL ANTI-DANDRUFF  
+! KRAMER 1%

N020310 001 Oct 10, 1997 Feb CTNA

LEVOSETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL  
LEVOSETIRIZINE DIHYDROCHLORIDE  
APOTEX 5MG

A211443 001 Apr 21, 2021 Apr NEWA

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL  
LOPERAMIDE HYDROCHLORIDE  
STRIDES PHARMA 2MG

A213070 001 Aug 11, 2021 Jul NEWA

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL  
LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE  
GUARDIAN DRUG 2MG;125MG  
HETERO LABS LTD V 2MG;125MG

A214541 001 May 27, 2021 May NEWA  
A211438 001 Jun 17, 2021 Jun NEWA

LORATADINE

SYRUP;ORAL  
LORATADINE  
HETERO LABS LTD III 1MG/ML

A210409 001 May 07, 2021 Apr NEWA

TABLET;ORAL  
LORATADINE

A214684 001 Jan 07, 2021 Jan NEWA

UNIQUE PHARM 10MG

TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

@ GLAXOSMITHKLINE 10MG

A075822 001 Feb 10, 2003 Jan DISC

TENSHI 5MG

A212795 001 Sep 18, 2020 Jun CMFD

@ 5MG

A212795 001 Sep 18, 2020 Mar DISC

10MG

A213294 001 Oct 30, 2020 Jun CMFD

## TABLET, ORALLY DISINTEGRATING;ORAL

LORATADINE

@ 10MG

A213294 001 Oct 30, 2020 Mar DISC

MICONAZOLE NITRATE

CREAM, INSERT;TOPICAL, VAGINAL

MICONAZOLE NITRATE

PERRIGO R AND D 2%,1.2GM

MONISTAT 1 COMBINATION PACK

+! MEDTECH PRODUCTS 2%,1.2GM

A079114 001 Jun 02, 2010 Jul CDFR

N021308 001 Jun 29, 2001 Jul CDFR

MINOXIDIL

AEROSOL, FOAM;TOPICAL

MINOXIDIL

PERRIGO 5%

A091344 001 Apr 28, 2011 Jul CAHN

NICOTINE POLACRILEX

TROCHE/LOZENGE;ORAL

NICORETTE

+ GLAXOSMITHKLINE EQ 2MG BASE

+! EQ 4MG BASE

NICOTINE POLACRILEX

AUROBINDO PHARMA LTD EQ 2MG BASE

EQ 4MG BASE

N022360 001 May 18, 2009 Mar CAHN

N022360 002 May 18, 2009 Mar CAHN

A213266 001 Aug 03, 2021 Jul NEWA

A213266 002 Aug 03, 2021 Jul NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AKORN EQ 0.1% BASE

A204532 001 Jan 10, 2017 Jun CMKT

EQ 0.2% BASE

A204723 001 Dec 05, 2017 Jun CMKT

ALEMBIC PHARMS LTD EQ 0.1% BASE

A209919 001 Dec 07, 2018 Feb CMKT

EQ 0.2% BASE

A209420 001 Apr 29, 2019 Jan CMKT

APOTEX INC EQ 0.2% BASE

A090918 001 Dec 05, 2017 Jan CMKT

BARR LABS INC EQ 0.2% BASE

A090848 001 Jul 13, 2015 Feb CMKT

@ BAUSCH EQ 0.1% BASE

A206046 001 Jul 26, 2017 Jun CAHN

@ CIPLA EQ 0.2% BASE

A206087 001 Dec 05, 2017 Mar CMKT

FDC LTD EQ 0.1% BASE

A209282 001 Sep 26, 2019 Feb CMKT

MYLAN EQ 0.1% BASE

A204392 001 Mar 21, 2018 Feb CMKT

EQ 0.2% BASE

A204620 001 Jun 16, 2020 Jun CAHN

USV EQ 0.1% BASE

A203152 001 Dec 07, 2015 Apr CMKT

&gt;A&gt; @ WOCKHARDT LTD EQ 0.1% BASE

A200810 001 Jun 28, 2017 Aug CMKT

OMEPRAZOLE

TABLET, DELAYED RELEASE;ORAL

OMEPRAZOLE

APOTEX 20MG

A210070 001 Feb 11, 2019 May CMFD

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

POLYETHYLENE GLYCOL 3350

ANNORA PHARMA 17GM/SCOOPFUL

A214990 001 Apr 14, 2021 Apr NEWA

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@ AUROBINDO PHARMA LTD EQ 75MG BASE

A207579 001 Nov 13, 2017 Jun DISC

@ EQ 150MG BASE

A207578 001 Nov 13, 2017 Jun DISC

@ WOCKHARDT EQ 75MG BASE

A076760 001 Feb 24, 2006 Jan DISC

ZANTAC 150

+ @ SANOFI US EQ 150MG BASE

N021698 001 Aug 31, 2004 Apr DISC

+ @ EQ 150MG BASE

N021698 002 Mar 13, 2007 Apr DISC

ZANTAC 75

+ @ SANOFI US EQ 75MG BASE

N020520 001 Dec 19, 1995 Apr DISC

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL

TRIAMCINOLONE ACETONIDE

PERRIGO 0.055MG/SPRAY

A078104 002 Nov 14, 2014 Jul CAHN

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 08 AUGUST 2021**

NO AUGUST 2021 APPROVALS

## **ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST**

The list of Orphan Designations and Approvals is available at:

<https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO AUGUST 2021 ADDITIONS

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>ABALOPARATIDE - TYMLOS</b></u>						
N 208743 001	10996208	Apr 30, 2038	DP			
<u><b>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</b></u>						
N 202450 001	11000517	Mar 13, 2029	DP U-2513			
<u><b>ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR</b></u>						
N 210595 001	11000517	Mar 13, 2029	DP U-2513			
<u><b>ALBUTEROL SULFATE - PROAIR DIGITALER</b></u>						
N 205636 002	10918816	Dec 14, 2035	DP			
	11000653	Dec 18, 2038	DP			
<u><b>ALENDRONATE SODIUM - BINOSTO</b></u>						
N 202344 001	9592195	Dec 05, 2031	DP			
<u><b>AMANTADINE HYDROCHLORIDE - GOCOVRI</b></u>						
N 208944 001	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
<u><b>AMANTADINE HYDROCHLORIDE - GOCOVRI</b></u>						
N 208944 002	11065213	Aug 23, 2038	DP			
	11077073	Aug 23, 2038	U-2106			
	11077073	Aug 23, 2038	U-2224			
	11077073	Aug 23, 2038	U-3180			
<u><b>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</b></u>						
N 209410 001	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			
<u><b>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</b></u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025	U-219			
	9072697	Nov 23, 2025	U-3054			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 003	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 004	8389578	Jan 22, 2028	U-219			
	8389578	Jan 22, 2028	U-3054			
	8796337	Nov 23, 2025	U-219			
	8796337	Nov 23, 2025	U-2497			
	8796337	Nov 23, 2025	U-3054			
	8889740	Nov 23, 2025	DP			
	8895614	Nov 23, 2025	DP			
	8895615	Nov 23, 2025	U-219			
	8895615	Nov 23, 2025	U-3054			
	8895616	Nov 23, 2025	U-219			
	8895616	Nov 23, 2025	U-3054			
	8895617	Nov 23, 2025	U-219			
	8895617	Nov 23, 2025	U-3054			
	8895618	Nov 23, 2025	DP			
	8987333	Nov 23, 2025	DP			
	9072697	Nov 23, 2025		U-219		
	9072697	Nov 23, 2025		U-3054		
<u>AMIFAMPRIDINE PHOSPHATE - FIRDAPSE</u>						
N 208078 001	11060128	Jun 29, 2032	U-2956			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	10357567	Jan 12, 2038	U-3163			
	11077192	Jan 12, 2038	U-3163			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	10894039	Oct 06, 2037	U-185			
	10894039	Oct 06, 2037	U-3			
	10952998	Oct 06, 2037	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>AMLODIPINE BENZOATE - KATERZIA</u></b>						
N 211340 001	10959991	Oct 06, 2037		U-158		
	10959991	Oct 06, 2037		U-39		
<b><u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u></b>						
N 210045 001	10925835	Jun 14, 2038		U-2410		
	10945960	Jun 14, 2038	DP			
<b><u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u></b>						
N 210045 002	10925835	Jun 14, 2038		U-2410		
	10945960	Jun 14, 2038	DP			
<b><u>AMLODIPINE BESYLATE; CELECOXIB - CONSENSI</u></b>						
N 210045 003	10925835	Jun 14, 2038		U-2410		
	10945960	Jun 14, 2038	DP			
<b><u>AMPHETAMINE SULFATE - EVEKEO ODT</u></b>						
N 209905 005	10130580	Apr 19, 2024	DP			
	10441554	Mar 10, 2037	DP			
<b><u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u></b>						
N 210875 001	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
	11077068	Feb 14, 2022	DP			
<b><u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u></b>						
N 210875 002	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
	11077068	Feb 14, 2022	DP			
<b><u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u></b>						
N 210875 003	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
	11077068	Feb 14, 2022	DP			
<b><u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u></b>						
N 210875 004	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
	11077068	Feb 14, 2022	DP			
<b><u>APOMORPHINE HYDROCHLORIDE - KYNMOBI</u></b>						
N 210875 005	10888499	Feb 14, 2022	DP			
	10959943	Apr 19, 2036		U-2825		
	11077068	Feb 14, 2022	DP			
<b><u>APREPITANT - CINVANTI</u></b>						
N 209296 001	10953018	Sep 18, 2035		U-2161		
<b><u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u></b>						
N 202971 001	10980803	Sep 24, 2033		U-1632		
	10980803	Sep 24, 2033		U-543		
<b><u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u></b>						
N 202971 002	10980803	Sep 24, 2033		U-1632		
	10980803	Sep 24, 2033		U-543		
<b><u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u></b>						
N 202971 003	10980803	Sep 24, 2033		U-1632		
	10980803	Sep 24, 2033		U-543		
<b><u>ARIPIPRAZOLE - ABILIFY MAINTENA KIT</u></b>						
N 202971 004	10980803	Sep 24, 2033		U-1632		
	10980803	Sep 24, 2033		U-543		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENNU</u>						
N 209381 001	10918723	Sep 10, 2033		U-2310		
<u>ASENAPINE MALEATE - ASENAPINE MALEATE</u>						
A 206098 002					PC	Jun 08, 2021
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 213424 001					CGT	Sep 21, 2021
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	9200002	Oct 15, 2034	DS DP U-2726	I-863	Jun 16, 2024	
	9200002	Oct 15, 2034	DS DP U-3168	I-864	Jun 16, 2024	
	9944651	Oct 15, 2034	DS DP U-2726	ODE-356	Jun 16, 2028	
	9944651	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-3168			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	9200002	Oct 15, 2034	DS DP U-2726	I-863	Jun 16, 2024	
	9200002	Oct 15, 2034	DS DP U-3168	I-864	Jun 16, 2024	
	9944651	Oct 15, 2034	DS DP U-2726	ODE-356	Jun 16, 2028	
	9944651	Oct 15, 2034	DS DP U-3168			
	9994575	Oct 15, 2034	DS DP U-2726			
	9994575	Oct 15, 2034	DS DP U-3168			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003				ODE-356	Jun 16, 2028	
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	9200002	Oct 15, 2034	DS DP U-3168	I-863	Jun 16, 2024	
	9944651	Oct 15, 2034	DS DP U-3168	I-864	Jun 16, 2024	
	9994575	Oct 15, 2034	DS DP U-3168	NCE	Jan 09, 2025	
				ODE-356	Jun 16, 2028	
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005	9200002	Oct 15, 2034	DS DP U-3168	I-863	Jun 16, 2024	
	9944651	Oct 15, 2034	DS DP U-3168	I-864	Jun 16, 2024	
	9994575	Oct 15, 2034	DS DP U-3168	NCE	Jan 09, 2025	
				ODE-356	Jun 16, 2028	
<u>AXITINIB - INLYTA</u>						
N 202324 001	10869924	Nov 05, 2036		U-3044		
<u>AXITINIB - INLYTA</u>						
N 202324 002	10869924	Nov 05, 2036		U-3044		
<u>AZACITIDINE - ONUREG</u>						
N 214120 001					ODE-320	Sep 01, 2027
<u>AZACITIDINE - ONUREG</u>						
N 214120 002					ODE-320	Sep 01, 2027
<u>AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY</u>						
N 213872 001	8071073	Jun 04, 2028	DP			
	8518919	Nov 22, 2025		U-3166		
	9919050	Nov 22, 2025	DP			
<u>AZELASTINE HYDROCHLORIDE - CHILDREN'S ASTEPRO ALLERGY</u>						
N 213872 002	>A> 8071073	Jun 04, 2028	DP			
	>A> 8518919	Nov 22, 2025		U-3166		
	>A> 9919050	Nov 22, 2025	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>BALOXAVIR MARBOXIL - XOFLUZA</u></b>						
N 210854 003	10392406	Apr 27, 2036	DS		I-811	Oct 16, 2022
	10633397	Apr 27, 2036		U-2816	NCE	Oct 24, 2023
	10633397	Apr 27, 2036		U-3000		
	10759814	Aug 09, 2037	DS DP			
	8927710	May 05, 2031	DP			
	8987441	Sep 21, 2031	DS DP			
	9815835	Jun 14, 2030	DP			
<b><u>BALOXAVIR MARBOXIL - XOFLUZA</u></b>						
N 214410 001					NCE	Oct 24, 2023
<b><u>BELINOSTAT - BELEODAO</u></b>						
N 206256 001	>A> 6888027	Aug 10, 2026	DS DP	U-1544		
<b><u>BELUMOSUDIL MESYLATE - REZUROCK</u></b>						
N 214783 001					>A> NCE	Jul 16, 2026
<b><u>BEMPEDOIC ACID - NEXLETOL</u></b>						
N 211616 001	10941095	Dec 23, 2023		U-2747		
<b><u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u></b>						
N 211617 001	10941095	Dec 23, 2023		U-2746		
<b><u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u></b>						
N 205580 001	>A> 11103483	Jan 28, 2031	DP	U-1971		
	>A> 11103483	Jan 28, 2031	DP	U-1972		
<b><u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u></b>						
N 208194 001	>A> 11103483	Jan 28, 2031	DP	U-1971		
	>A> 11103483	Jan 28, 2031	DP	U-1972		
<b><u>BENZOYL PEROXIDE; TRETINOIN - TWYNEO</u></b>						
N 214902 001	>A> 11071878	Dec 30, 2030	DP			
	>A> 9868103	Aug 08, 2028	DP	U-3194		
<b><u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u></b>						
N 214094 001	>A> 10125102	Apr 07, 2035	DS	U-3010	NCE	Dec 03, 2025
					ODE-333	Dec 03, 2027
<b><u>BEROTRALSTAT HYDROCHLORIDE - ORLADEYO</u></b>						
N 214094 002	>A> 10125102	Apr 07, 2035	DS	U-3010	NCE	Dec 03, 2025
					ODE-333	Dec 03, 2027
<b><u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u></b>						
N 210251 001					M-82	Feb 24, 2024
<b><u>BOSENTAN - TRACLEER</u></b>						
N 021290 001					>A> ODE*	Sep 05, 2024
<b><u>BOSENTAN - TRACLEER</u></b>						
N 021290 002					>A> ODE*	Sep 05, 2024
<b><u>BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR)</u></b>						
N 210557 001	6794489	Jun 28, 2025	DS DP			
<b><u>BREXANOLONE - ZULRESSO</u></b>						
N 211371 001	10940156	Mar 08, 2037		U-2552		
<b><u>BREXIPRAZOLE - REXULTI</u></b>						
N 205422 001	RE48059	Dec 23, 2028	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>BREXPIPRAZOLE - REXULTI</u></b>						
N 205422 002	RE48059	Dec 23, 2028	DS			
<b><u>BREXPIPRAZOLE - REXULTI</u></b>						
N 205422 003	RE48059	Dec 23, 2028	DS			
<b><u>BREXPIPRAZOLE - REXULTI</u></b>						
N 205422 004	RE48059	Dec 23, 2028	DS			
<b><u>BREXPIPRAZOLE - REXULTI</u></b>						
N 205422 005	RE48059	Dec 23, 2028	DS			
<b><u>BREXPIPRAZOLE - REXULTI</u></b>						
N 205422 006	RE48059	Dec 23, 2028	DS			
<b><u>BRIMONIDINE TARTRATE - LUMIFY</u></b>						
N 208144 001	9259425	Jul 14, 2030	U-2222			
<b><u>BRINCIDOFOVIR - TEMBEXA</u></b>						
N 214460 001	9303051	Aug 31, 2031	DS DP U-3165		NP ODE-354	Jun 04, 2024 Jun 04, 2028
<b><u>BRINCIDOFOVIR - TEMBEXA</u></b>						
N 214461 001	10112909	Oct 10, 2034	U-3165		NP ODE-354	Jun 04, 2024 Jun 04, 2028
	10487061	Oct 10, 2034	DP U-3165			
	8962829	Oct 10, 2034	DS DP			
	9303051	Aug 31, 2031	DS DP U-3165			
	9371344	Oct 10, 2034	DP			
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205836 001					NPP	May 10, 2021
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205836 002					NPP	May 10, 2021
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205836 003					NPP	May 10, 2021
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205836 004					NPP	May 10, 2021
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205836 005					NPP	May 10, 2021
<b><u>BRIVARACETAM - BRIVIACT</u></b>						
N 205838 001					NPP	May 10, 2021
<b><u>BROMOCRIPTINE MESYLATE - CYCLOSET</u></b>						
N 020866 001	11000522	Apr 30, 2032	U-3119			
	11000522	Apr 30, 2032	U-3120			
	11000522	Apr 30, 2032	U-3121			
	11000522	Apr 30, 2032	U-3122			
<b><u>BUPIVACAINE - EXPAREL</u></b>						
N 022496 001	11033495	Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
<b><u>BUPIVACAINE - EXPAREL</u></b>						
N 022496 002	11033495	Jan 22, 2041	DP U-3182		NPP	Mar 22, 2024
<b><u>BUPIVACAINE - POSIMIR</u></b>						
N 204803 001	8153149	Sep 15, 2025	DP		NP	Feb 01, 2024
	8153661	Sep 15, 2025	U-3074			
	8753665	Sep 15, 2025	DP U-3074			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>BUPIVACAINE - POSIMIR</u></b>						
N 204803 001	8846072	Sep 15, 2025		DP U-3074		
<b><u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u></b>						
N 211988 001	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
>A>	11083730	Apr 20, 2035	DP U-3118			
>A>	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<b><u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u></b>						
N 211988 002	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
>A>	11083730	Apr 20, 2035	DP U-3118			
>A>	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<b><u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u></b>						
N 211988 003	10098957	Apr 20, 2035	U-3118		NP	May 12, 2024
	10213510	Apr 20, 2035	DP U-3118			
	10398686	Mar 13, 2034	DP			
	10632199	Apr 20, 2035	DP U-3118			
	10898575	Apr 20, 2035	DP U-3118			
	10980886	Apr 20, 2035	DP			
>A>	11083730	Apr 20, 2035	DP U-3118			
>A>	11083797	Apr 20, 2035	DP U-3118			
	9592227	Mar 13, 2034	DP U-3118			
	9694079	Apr 20, 2035	DP U-3118			
	9744163	Mar 13, 2034	DP			
	9801945	Apr 20, 2035	DP U-3118			
	9913909	Mar 13, 2034	U-3118			
<b><u>BUPRENORPHINE - SUBLINER</u></b>						
N 209819 001	11000520	Nov 06, 2035	U-3111			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE - SUBLOCade</u>						
N 209819 002	11000520	Nov 06, 2035		U-3111		
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	10874661	Sep 18, 2032	DP			
	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	10946010	Sep 18, 2032	DP			
	11020387	Sep 18, 2032	DP U-3131			
	11020388	Sep 18, 2032	DP U-3131			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 006	10946010	Sep 18, 2032	DP			
	11020388	Sep 18, 2032	DP U-3131			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001					M-128	Dec 18, 2023
<u>CABOTEGRAVIR SODIUM - VOCABRIA</u>						
N 212887 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	8410103	Apr 28, 2026	DS DP U-3061			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 001	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT</u>						
N 212888 002	10927129	Apr 28, 2026	DS DP		NCE	Jan 21, 2026
	6838464	Feb 26, 2021	DS DP			
	7125879	Apr 21, 2025	DS DP U-3059			
	8080551	Apr 11, 2023	DS DP			
	8410103	Apr 28, 2026	DS DP U-3060			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 001	>A> 11091439	Jan 15, 2030	DS			
	>A> 11091440	Jan 15, 2030	DP			
	>A> 11098015	Jan 15, 2030	U-1617			
<u>CABOZANTINIB S-MALATE - COMETRIQ</u>						
N 203756 002	>A> 11091439	Jan 15, 2030	DS			
	>A> 11091440	Jan 15, 2030	DP			
	>A> 11098015	Jan 15, 2030	U-1617			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	>A> 11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	>A> 11091440	Jan 15, 2030	DP			
	>A> 11098015	Jan 15, 2030	U-1220			
	>A> 11098015	Jan 15, 2030	U-1480			
	>A> 11098015	Jan 15, 2030	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	>A> 11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	>A> 11091440	Jan 15, 2030	DP			
	>A> 11098015	Jan 15, 2030	U-1220			
	>A> 11098015	Jan 15, 2030	U-1480			
	>A> 11098015	Jan 15, 2030	U-2488			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	>A> 11091439	Jan 15, 2030	DS		I-854	Jan 22, 2024
	>A> 11091440	Jan 15, 2030	DP			
	>A> 11098015	Jan 15, 2030	U-1220			
	>A> 11098015	Jan 15, 2030	U-1480			
	>A> 11098015	Jan 15, 2030	U-2488			
<u>CALCITONIN SALMON - CALCITONIN-SALMON</u>						
A 212416 001					CGT	Nov 10, 2021
<u>CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV</u>						
N 212690 001	10864181	Mar 15, 2033	U-3017		>A> ODE-361	Jul 21, 2027
	>A> 8772306	Mar 15, 2033	U-1532			
	>A> 8772306	Mar 15, 2033	U-3198			
<u>CANGRELOL - KENGREAL</u>						
N 204958 001	8680052	Mar 09, 2033	U-2979			
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365 001	10918608	Oct 14, 2035	U-3071		ODE-326	Jul 31, 2027
	10918608	Oct 14, 2035	U-3072		ODE-332	Jul 31, 2027
	10918608	Oct 14, 2035	U-3073			
	10966939	Jun 17, 2035	DP U-2780			
	10966939	Jun 17, 2035	DP U-2781			
	>A> 11065209	Oct 14, 2035	U-3071			
<u>CARGLUMIC ACID - CARBAGLU</u>						
N 022562 001					ODE-345	Jan 22, 2028
<u>CASIMERSEN - AMONDYS 45</u>						
N 213026 001	10287586	Nov 12, 2030	DS DP		NCE	Feb 25, 2026
	10533174	May 04, 2021	DP		ODE-347	Feb 25, 2028
	10781450	Nov 12, 2030	U-3089			
	8524880	Apr 02, 2026	DS DP U-3087			
	8524880	Apr 02, 2026	DS DP U-3088			
	9228187	Nov 12, 2030	DS DP			
	9416361	May 04, 2021	DS			
	9447415	Jun 28, 2025	DS DP			
	9758783	Nov 12, 2030	U-3088			
	9758783	Nov 12, 2030	U-3089			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	10933053	Sep 09, 2034	U-3090			
	10933053	Sep 09, 2034	U-3091			
<u>CERITINIB - ZYKADIA</u>						
N 211225 001					ODE*	Apr 29, 2021
					ODE*	May 26, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 001					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 002					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 003					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 004					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 212144 005					CGT	Sep 20, 2021
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 214542 001					CGT	Jan 29, 2022
<u>CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE</u>						
A 214542 002					CGT	Jan 29, 2022
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	11040004	Nov 12, 2037		U-2252		
<u>CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI</u>						
N 208352 001	6706276	Mar 06, 2022		DP		
<u>CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPPIO</u>						
N 209589 001					NPP	Aug 15, 2021
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	>A> 11103490	Oct 10, 2031		DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	>A> 11103490	Oct 10, 2031		DP		
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	>A> 11103490	Oct 10, 2031		DP		
<u>COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA</u>						
N 210455 001	10786518	Jul 19, 2038		U-2978		
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001	>A> 11087354	Jun 22, 2034		U-1776		
<u>COCAINE HYDROCHLORIDE - NUMBRINO</u>						
N 209575 001					NCE	Dec 14, 2022
					NP	Jan 10, 2023
<u>COCAINE HYDROCHLORIDE - GOPRELTO</u>						
N 209963 001	10894012	Feb 07, 2037		U-3014		
	10933060	Feb 07, 2037		U-3014		
	10973811	Feb 07, 2037		U-2226		
	10987347	Feb 07, 2037		U-2225		
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					I-852	Jan 14, 2024
					ODE-328	Jan 14, 2028
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					I-852	Jan 14, 2024
					ODE-328	Jan 14, 2028

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>CRIZOTINIB - XALKORI</b></u>						
N 202570 002					I-852 ODE-328	Jan 14, 2024 Jan 14, 2028
<u><b>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS</b></u>						
N 209376 002					NCE	Apr 30, 2024
<u><b>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS</b></u>						
N 209376 003					>A> NCE	Apr 30, 2024
<u><b>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</b></u>						
N 210735 001 >A> 9662342		Jun 26, 2035		DP		
<u><b>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</b></u>						
N 210735 002 >A> 9662342		Jun 26, 2035		DP		
<u><b>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</b></u>						
N 212501 001 10993952		Feb 15, 2036		DP		
<u><b>CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE</b></u>						
N 212501 002 10993952		Feb 15, 2036		DP		
<u><b>CYCLOSPORINE - CEQUA</b></u>						
N 210913 001 10918694		Feb 28, 2037		DP		
<u><b>CYCLOSPORINE - VERKAZIA</b></u>						
N 214965 001 7973081		Jan 27, 2026	DP		ODE-358	Jun 23, 2028
8298568		Nov 03, 2027	DP			
8524779		Jan 27, 2026	DP			
9132071		Jun 02, 2029	DP			
9220694		Jan 27, 2026	DP			
9956289		Jan 27, 2026	DP			
<u><b>CYSTEAMINE BITARTRATE - PROSYSBI</b></u>						
N 203389 001 10905662		Aug 16, 2036	U-1399			
<u><b>CYSTEAMINE BITARTRATE - PROSYSBI</b></u>						
N 203389 002 10905662		Aug 16, 2036	U-1399			
<u><b>CYSTEAMINE BITARTRATE - PROSYSBI</b></u>						
N 213491 001 10905662		Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
8026284		Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
8026284*PED		Mar 22, 2028			PED	Feb 14, 2023
9173851		Jun 17, 2034	DP			
9173851*PED		Dec 17, 2034				
9192590		Jan 26, 2027	U-1399			
9192590*PED		Jul 26, 2027				
9198882		Jan 26, 2027	U-1399			
9198882*PED		Jul 26, 2027				
9233077		Jun 17, 2034	DP			
9233077*PED		Dec 17, 2034				
<u><b>CYSTEAMINE BITARTRATE - PROSYSBI</b></u>						
N 213491 002 10905662		Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
8026284		Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
8026284*PED		Mar 22, 2028			PED	Feb 14, 2023
9173851		Jun 17, 2034	DP			
9173851*PED		Dec 17, 2034				
9192590		Jan 26, 2027	U-1399			
9192590*PED		Jul 26, 2027				
9198882		Jan 26, 2027	U-1399			
9198882*PED		Jul 26, 2027				
9233077		Jun 17, 2034	DP			
9233077*PED		Dec 17, 2034				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>CYSTEAMINE BITARTRATE - PROCYSBI</u></b>						
N 213491 002	10905662	Aug 16, 2036	U-1399		ODE*	Aug 14, 2022
	8026284	Sep 22, 2027	U-1399		ODE*	Dec 22, 2024
	8026284*PED	Mar 22, 2028			PED	Feb 14, 2023
	9173851	Jun 17, 2034	DP			
	9173851*PED	Dec 17, 2034				
	9192590	Jan 26, 2027	U-1399			
	9192590*PED	Jul 26, 2027				
	9198882	Jan 26, 2027	U-1399			
	9198882*PED	Jul 26, 2027				
	9233077	Jun 17, 2034	DP			
	9233077*PED	Dec 17, 2034				
<b><u>CYSTEINE HYDROCHLORIDE - ELCYS</u></b>						
N 210660 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
<b><u>CYSTEINE HYDROCHLORIDE - NOURESS</u></b>						
N 212535 001	10905713	Jan 15, 2039	DP			
	10905714	Jan 15, 2039	DP			
	10912795	Jan 15, 2039	DP			
	10918662	Jan 15, 2039	DP			
	10933089	Jan 15, 2039	DP			
	11045438	Mar 15, 2039	DP			
<b><u>CYTARABINE; DAUNORUBICIN - VYXEOS</u></b>						
N 209401 001	10028912	Sep 29, 2034	DP U-3149		NPP	Mar 30, 2024
	10028912	Sep 29, 2034	DP U-3150		ODE-350	Mar 30, 2028
	10166184	Oct 15, 2032	DP U-3149			
	10835492	Oct 15, 2032	U-3150			
	7850990	Jan 23, 2027	DP U-3147			
	8022279	Sep 14, 2027	DP U-3147			
	8092828	Apr 01, 2029	U-3147			
	8431806	Apr 22, 2025	DP U-3147			
<b><u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u></b>						
N 022512 001	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<b><u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u></b>						
N 022512 002	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<b><u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u></b>						
N 022512 003	6087380	Dec 28, 2021	DS DP U-1931		I-862	Jun 21, 2024
	6087380*PED	Jun 28, 2022			PED	Dec 21, 2024
	7866474	Aug 31, 2027	DP	Y		
	7866474*PED	Mar 02, 2028				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9034822	Jan 20, 2031	U-1759			
	9034822*PED	Jul 20, 2031				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 001	>A> 6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	>A> 6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 002	>A> 6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	>A> 6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 003	>A> 6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	>A> 6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 004	>A> 6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	>A> 6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 005	>A> 6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	>A> 6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 214358 006	>A> 6087380	Dec 28, 2021	DS DP U-3177		NP	Jun 21, 2024
	>A> 6087380	Dec 28, 2021	DS DP U-3178		PED	Dec 21, 2024
	>A> 6087380*PED	Jun 28, 2022				
	7932273	Sep 07, 2025	DS DP			
	7932273*PED	Mar 07, 2026				
	9925174	Jun 14, 2023	DP			
	9925174*PED	Dec 14, 2023				
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	>A> 10869869	Aug 30, 2033	U-3185			
	>A> 8703781	Oct 15, 2030	DS DP U-1713			
	>A> 8703781	Oct 15, 2030	DS DP U-2032			
	>A> 8703781	Oct 15, 2030	DS DP U-2296			
	>A> 8703781	Oct 15, 2030	DS DP U-2298			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>DABRAFENIB MESYLATE - TAFINLAR</b>						
N 202806 002	>A> 10869869	Aug 30, 2033	U-3185			
	>A> 8703781	Oct 15, 2030	DS DP U-1713			
	>A> 8703781	Oct 15, 2030	DS DP U-2032			
	>A> 8703781	Oct 15, 2030	DS DP U-2296			
	>A> 8703781	Oct 15, 2030	DS DP U-2298			
	9233956	May 04, 2029	U-1811			
	9233956	May 04, 2029	U-2031			
	9233956	May 04, 2029	U-2032			
	9233956	May 04, 2029	U-2296			
<b>DALBAVANCIN HYDROCHLORIDE - DALVANCE</b>						
N 021883 001				>A> NPP		Jul 22, 2024
<b>DAPAGLIFLOZIN - FARXIGA</b>						
N 202293 001				I-857		Apr 30, 2024
<b>DAPAGLIFLOZIN - FARXIGA</b>						
N 202293 002	10973836	Mar 09, 2040	U-3127		I-857	Apr 30, 2024
<b>DAPTOMYCIN - DAPTOMYCIN</b>						
N 210282 001	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
<b>DAPTOMYCIN - DAPTOMYCIN</b>						
N 210282 002	10357535	Sep 11, 2033	DP U-3176			
	9655946	Sep 11, 2033	DP U-3175			
<b>DAROLUTAMIDE - NUBEQA</b>						
N 212099 001	11046713	Oct 27, 2030	DS			
<b>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE</b>						
N 214231 001	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<b>DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR)</b>						
N 214231 002	10442847	Feb 03, 2035	DS DP		NCE	Mar 22, 2026
<b>DEFERIPRONE - DEFERIPRONE</b>						
A 208800 001					PC	Mar 27, 2021
<b>DEFERIPRONE - FERRIPROX</b>						
N 021825 001	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
<b>DEFERIPRONE - FERRIPROX</b>						
N 021825 002	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
<b>DEFERIPRONE - FERRIPROX</b>						
N 208030 001	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			
<b>DEFERIPRONE - FERRIPROX</b>						
N 208030 002	7049328	Jun 28, 2021	U-3083		I-859	Apr 30, 2024
	8703156	Oct 26, 2029	DP U-3083			
<b>DEFERIPRONE - FERRIPROX</b>						
N 212269 001	10780055	Oct 25, 2038	DP U-3083		I-859	Apr 30, 2024
	10940115	Oct 25, 2038	DP U-3083			
	10940116	Oct 25, 2038	DP			
	7049328	Jun 28, 2021	U-3083			
<b>DEFIBROTIDE SODIUM - DEFITELIO</b>						
N 208114 001	>A> 11085043	Jun 22, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>DEGARELIX ACETATE - FIRMAGON</b></u>						
N 022201 001	10973870	Feb 10, 2029		U-1978		
<u><b>DEGARELIX ACETATE - FIRMAGON</b></u>						
N 022201 002	10973870	Feb 10, 2029		U-1978		
<u><b>DESMOPRESSIN ACETATE - NOCDURNA</b></u>						
N 022517 001	11020448	May 21, 2029		U-2327		
<u><b>DEUTETRABENAZINE - AUSTEDO</b></u>						
N 208082 001	10959996	Mar 07, 2036		U-3055	M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP	U-1995		
	9550780	Sep 18, 2033	DS DP	U-3055		
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u><b>DEUTETRABENAZINE - AUSTEDO</b></u>						
N 208082 002	10959996	Mar 07, 2036		U-3055	M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP	U-1995		
	9550780	Sep 18, 2033	DS DP	U-3055		
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u><b>DEUTETRABENAZINE - AUSTEDO</b></u>						
N 208082 003	10959996	Mar 07, 2036		U-3055	M-54	Jun 24, 2024
	10959996*PED	Sep 07, 2036			NCE	Apr 03, 2022
	8524733	Apr 03, 2031	DS DP		ODE-134	Apr 03, 2024
	8524733*PED	Oct 03, 2031			PED	Oct 03, 2022
	9233959	Sep 18, 2033	DP		PED	Oct 03, 2024
	9233959*PED	Mar 18, 2034			PED	Dec 24, 2024
	9296739	Sep 18, 2033	DP			
	9296739*PED	Mar 18, 2034				
	9550780	Sep 18, 2033	DS DP	U-1995		
	9550780	Sep 18, 2033	DS DP	U-3055		
	9550780*PED	Mar 18, 2034				
	9814708	Sep 18, 2033	DP			
	9814708*PED	Mar 18, 2034				
<u><b>DEXAMETHASONE - DEXYCU KIT</b></u>						
N 208912 001	10799642	May 11, 2032		DP		
<u><b>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</b></u>						
N 212994 001	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037		U-3094		
	10954213	Dec 09, 2037		U-3094		
	9079928	Jul 27, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</b></u>						
N 212994 002	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u><b>DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS</b></u>						
N 212994 003	10584112	Dec 09, 2037	DS DP		NCE	May 07, 2026
	10584113	Dec 09, 2037	DP			
	10759778	Dec 09, 2037	DP			
	10858341	Dec 09, 2037	U-3094			
	10954213	Dec 09, 2037	U-3094			
	9079928	Jul 27, 2032	DP			
<u><b>DICLOFENAC POTASSIUM - ZIPSOR</b></u>						
N 022202 001					NPP	May 25, 2024
<u><b>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</b></u>						
A 212317 001					CGT	Sep 26, 2021
<u><b>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</b></u>						
A 212317 002					CGT	Sep 26, 2021
<u><b>DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE</b></u>						
A 212317 003					CGT	Sep 26, 2021
<u><b>DIMETHYL FUMARATE - TECFIDERMA</b></u>						
N 204063 001	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
<u><b>DIMETHYL FUMARATE - TECFIDERMA</b></u>						
N 204063 002	10391160	Mar 13, 2035	U-3148			
	10555993	Mar 13, 2035	U-3148			
	10959972	Nov 16, 2035	U-1384			
	10994003	Mar 13, 2035	U-3148			
	11007166	Nov 16, 2035	U-1384			
	11007167	Nov 16, 2035	U-1384			
<u><b>DOCETAXEL - DOCETAXEL</b></u>						
N 205934 001	10842770	Aug 07, 2031	DP U-2998			
<u><b>DOCETAXEL - DOCETAXEL</b></u>						
N 205934 002	10842770	Aug 07, 2031	DP U-2998			
<u><b>DOCETAXEL - DOCETAXEL</b></u>						
N 205934 003	10842770	Aug 07, 2031	DP U-2998			
<u><b>DROSPIRENONE - SLYND</b></u>						
N 211367 001	>A> 10603281	Jun 28, 2031	U-2553			
	>A> 10849857	Jun 28, 2031	DP U-2553			
	10987364	Jun 28, 2031	DP			
<u><b>DROSPIRENONE; ESTETROL - NEXTSTELLIS</b></u>						
N 214154 001	7732430	Mar 02, 2025	DP U-3152		NCE	Apr 15, 2026
<u><b>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</b></u>						
N 212516 001	10959982	Apr 13, 2037	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 002	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 003	10959982	Apr 13, 2037	DP			
<u>DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE</u>						
N 212516 004	10959982	Apr 13, 2037	DP			
<u>EDARAVONE - RADICAVA</u>						
N 209176 002					ODE*	May 05, 2024
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001	7365205	Apr 18, 2027	DS			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002	7365205	Apr 18, 2027	DS			
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 003	7365205	Apr 18, 2027	DS			
<u>EFINACONAZOLE - JUBILIA</u>						
N 203567 001	10864274	Oct 02, 2034	U-2720			
	7214506	Feb 22, 2026	U-281			
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388 001	10881659	Mar 14, 2034	U-2842			
	11045470	Mar 14, 2034	U-2842			
<u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u>						
N 212273 001	10022352	Apr 09, 2027	DP U-2651		NPP	Jun 08, 2024
	10022352	Apr 09, 2027	DP U-3156		ODE-323	Dec 21, 2027
	10081621	Mar 25, 2031	DP U-2652		ODE-357	Jun 08, 2028
	10081621	Mar 25, 2031	DP U-3032			
	10081621	Mar 25, 2031	DP U-3157			
	10239867	Apr 09, 2027	DS DP U-2653			
	10239867	Apr 09, 2027	DS DP U-3033			
	10239867	Apr 09, 2027	DS DP U-3158			
	10758534	Oct 06, 2035	DS DP U-2645			
	10758534	Oct 06, 2035	DS DP U-3028			
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-2645			
	10793547	Dec 08, 2037	DS DP U-3028			
	10793547	Dec 08, 2037	DS DP U-3144			
	8324242	Aug 05, 2027	U-2645			
	8324242	Aug 05, 2027	U-3028			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-2646			
	8354427	Jul 06, 2026	U-3029			
	8354427	Jul 06, 2026	U-3145			
	8415387	Nov 12, 2027	U-2645			
	8415387	Nov 12, 2027	U-3028			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-2645			
	8598181	May 01, 2027	U-3028			
	8598181	May 01, 2027	U-3144			
	8629162	Jun 24, 2025	U-2648			
	8629162	Jun 24, 2025	U-3030			
	8629162	Jun 24, 2025	U-3146			
	9012496	Jul 15, 2033	U-2649			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-2650			
	9670163	Dec 28, 2026	DP U-3031			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-2650			
	9931334	Dec 28, 2026	DP U-3031			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u></b>						
N 212273 001	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-2645			
	9974781	Apr 09, 2027	DP U-3028			
	9974781	Apr 09, 2027	DP U-3144			
<b><u>ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED)</u></b>						
N 212273 002	10022352	Apr 09, 2027	DP U-3156		NCE	Feb 12, 2023
	10081621	Mar 25, 2031	DP U-3157		NCE	Oct 21, 2024
	10239867	Apr 09, 2027	DS DP U-3158		NPP	Jun 08, 2024
	10646481	Aug 13, 2029	DP		ODE-357	Jun 08, 2028
	10758534	Oct 06, 2035	DS DP U-3144			
	10793547	Dec 08, 2037	DS DP U-3144			
	7495103	May 20, 2027	DS DP			
	7645789	May 01, 2027	DS DP			
	7776905	Jun 03, 2027	DS DP			
	8324242	Aug 05, 2027	U-3144			
	8354427	Jul 06, 2026	U-3145			
	8410274	Dec 28, 2026	DP			
	8415387	Nov 12, 2027	U-3144			
	8598181	May 01, 2027	U-3144			
	8623905	May 01, 2027	DS DP			
	8629162	Jun 24, 2025	U-3146			
	8754224	Dec 28, 2026	DS DP			
	9012496	Jul 15, 2033	U-3154			
	9670163	Dec 28, 2026	DP U-3155			
	9931334	Dec 28, 2026	DP U-3155			
	9974781	Apr 09, 2027	DP U-3144			
<b><u>ELIGLUSTAT TARTRATE - CERDELGA</u></b>						
N 205494 001	10888544	Dec 13, 2038	U-3040			
	10888544	Dec 13, 2038	U-3041			
	10888547	Jan 31, 2031	U-3042			
	10888547	Jan 31, 2031	U-3043			
<b><u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u></b>						
N 207027 001					ODE*	Nov 16, 2025
<b><u>ELTROMBOPAG OLAMINE - PROMACTA KIT</u></b>						
N 207027 002					ODE*	Aug 26, 2021
					ODE*	Nov 16, 2025
					PED	Feb 26, 2022
<b><u>ELUXADOLINE - VIBERZI</u></b>						
N 206940 001	11007179	Mar 14, 2033	DP			
>A>	11090291	Mar 14, 2033	DP			
<b><u>ELUXADOLINE - VIBERZI</u></b>						
N 206940 002	11007179	Mar 14, 2033	DP			
>A>	11090291	Mar 14, 2033	DP			
<b><u>EMPAGLIFLOZIN - JARDIANCE</u></b>						
N 204629 001	>A> 11090323	Apr 03, 2034	U-3191			
>A>	9949997	May 17, 2034	U-2292			
>A>	9949997	May 17, 2034	U-3199			
<b><u>EMPAGLIFLOZIN - JARDIANCE</u></b>						
N 204629 002	>A> 11090323	Apr 03, 2034	U-3191			
<b><u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u></b>						
N 206073 001	11033552	May 04, 2027	DP			
>A>	11090323	Apr 03, 2034	U-3191			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</b></u>						
N 206073 002	11033552	May 04, 2027	DP			
	>A> 11090323	Apr 03, 2034		U-3191		
<u><b>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</b></u>						
N 212614 001	>A> 11090323	Apr 03, 2034		U-3192		
<u><b>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</b></u>						
N 212614 002	>A> 11090323	Apr 03, 2034		U-3192		
<u><b>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</b></u>						
N 212614 003	>A> 11090323	Apr 03, 2034		U-3192		
<u><b>EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR</b></u>						
N 212614 004	>A> 11090323	Apr 03, 2034		U-3192		
<u><b>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</b></u>						
N 206111 001	>A> 11090323	Apr 03, 2034		U-3193		
<u><b>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</b></u>						
N 206111 002	>A> 11090323	Apr 03, 2034		U-3193		
<u><b>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</b></u>						
N 206111 003	>A> 11090323	Apr 03, 2034		U-3193		
<u><b>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY</b></u>						
N 206111 004	>A> 11090323	Apr 03, 2034		U-3193		
<u><b>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</b></u>						
N 208658 001	>A> 11090323	Apr 03, 2034		U-3193		
<u><b>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</b></u>						
N 208658 002	>A> 11090323	Apr 03, 2034		U-3193		
<u><b>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</b></u>						
N 208658 003	>A> 11090323	Apr 03, 2034		U-3193		
<u><b>EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR</b></u>						
N 208658 004	>A> 11090323	Apr 03, 2034		U-3193		
<u><b>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</b></u>						
A 209721 001				PC		Mar 09, 2021
<u><b>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</b></u>						
A 209721 002				PC		Mar 09, 2021
<u><b>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE</b></u>						
A 209721 003				PC		Mar 09, 2021
<u><b>ENALAPRIL MALEATE - ENALAPRIL MALEATE</b></u>						
A 212408 001				>A> PC		Feb 13, 2022
<u><b>ENALAPRIL MALEATE - EPANED</b></u>						
N 208686 001	11040023	Mar 25, 2036	DP			
<u><b>EPHEDRINE SULFATE - EMERPHED</b></u>						
N 213407 001	>A> 11090278	May 16, 2040		U-3183		
<u><b>EPINEPHRINE - AUVI-Q</b></u>						
N 201739 001	10960155	Jun 25, 2026	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>EPINEPHRINE - AUVI-Q</u></b>						
N 201739 002	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
<b><u>EPINEPHRINE - AUVI-Q</u></b>						
N 201739 003	10842938	Dec 21, 2037	DP U-2980			
	10960155	Jun 25, 2026	DP			
<b><u>ERDAFITINIB - BALVERSA</u></b>						
N 212018 001	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
>A>	11077106	Feb 02, 2038	U-3196			
<b><u>ERDAFITINIB - BALVERSA</u></b>						
N 212018 002	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
>A>	11077106	Feb 02, 2038	U-3196			
<b><u>ERDAFITINIB - BALVERSA</u></b>						
N 212018 003	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
>A>	11077106	Feb 02, 2038	U-3196			
<b><u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u></b>						
N 211243 001	10869844	Sep 10, 2035	U-3034			
	10869844	Sep 10, 2035	U-3035			
	10869844	Sep 10, 2035	U-3036			
<b><u>ESLICARBAZEPINE ACETATE - APTIOM</u></b>						
N 022416 001	10912781	Oct 23, 2028	DP			
<b><u>ESLICARBAZEPINE ACETATE - APTIOM</u></b>						
N 022416 002	10912781	Oct 23, 2028	DP			
<b><u>ESLICARBAZEPINE ACETATE - APTIOM</u></b>						
N 022416 003	10912781	Oct 23, 2028	DP			
<b><u>ESLICARBAZEPINE ACETATE - APTIOM</u></b>						
N 022416 004	10912781	Oct 23, 2028	DP			
<b><u>ESTRADIOL - IMVEXXY</u></b>						
N 208564 001	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
<b><u>ESTRADIOL - IMVEXXY</u></b>						
N 208564 002	10888516	Jun 18, 2033	U-2316			
	10888516	Jun 18, 2033	U-2317			
	11065197	Jun 18, 2033	DP			
<b><u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u></b>						
N 214846 001	11033551	Sep 29, 2037	U-3129			
	7300935	Jan 28, 2024	DS			
	8058280	Jan 28, 2024	DS DP			
	9346822	Feb 17, 2024	U-3129			
				NCE		Dec 18, 2025
				NP		May 26, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>ESTRADIOL; PROGESTERONE - BIJUVA</u></b>						
N 210132 001	11033626	Nov 21, 2032	DP U-2439			
<b><u>ETEPLIRSEN - EXONDYS 51</u></b>						
N 206488 001	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<b><u>ETEPLIRSEN - EXONDYS 51</u></b>						
N 206488 002	RE47769	Feb 02, 2029	DP			
	RE48468	Oct 27, 2028	U-2097			
<b><u>ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME</u></b>						
N 209405 001					NDF	Mar 30, 2023
<b><u>ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN</u></b>						
A 213950 001					CGT	Aug 25, 2021
<b><u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE</u></b>						
A 212706 001					CGT	Jul 17, 2021
<b><u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u></b>						
N 209627 001	10918649	Jun 21, 2039	DP			
	10925882	Jun 21, 2039	DP			
	10940157	Jun 21, 2039	DP			
<b><u>EXENATIDE SYNTHETIC - BYDUREON</u></b>						
N 022200 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			>A> NPP	Jul 22, 2024
>A>	7456254	Jun 30, 2025	DP U-2588		PED	Aug 15, 2023
>A>	7456254	Jun 30, 2025	DP U-2589		>A> PED	Jan 22, 2025
>A>	7456254	Jun 30, 2025	DP U-2590			
>A>	7456254	Jun 30, 2025	DP U-3188			
>A>	7456254	Jun 30, 2025	DP U-3189			
>A>	7456254	Jun 30, 2025	DP U-3190			
>A>	7456254*PED	Dec 30, 2025				
>A>	7612176	Apr 13, 2025	DP U-2588			
>A>	7612176	Apr 13, 2025	DP U-2589			
>A>	7612176	Apr 13, 2025	DP U-2590			
>A>	7612176	Apr 13, 2025	DP U-3188			
>A>	7612176	Apr 13, 2025	DP U-3189			
>A>	7612176	Apr 13, 2025	DP U-3190			
>A>	7612176*PED	Oct 13, 2025				
>A>	8329648	Aug 18, 2026	U-2588			
>A>	8329648	Aug 18, 2026	U-2589			
>A>	8329648	Aug 18, 2026	U-2590			
>A>	8329648	Aug 18, 2026	U-2593			
>A>	8329648	Aug 18, 2026	U-2594			
>A>	8329648	Aug 18, 2026	U-2595			
>A>	8329648	Aug 18, 2026	U-2596			
>A>	8329648	Aug 18, 2026	U-3188			
>A>	8329648	Aug 18, 2026	U-3189			
>A>	8329648	Aug 18, 2026	U-3190			
>A>	8329648*PED	Feb 18, 2027				
	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
>A>	8431685	Apr 13, 2025	DP U-2588			
>A>	8431685	Apr 13, 2025	DP U-2589			
>A>	8431685	Apr 13, 2025	DP U-2590			
>A>	8431685	Apr 13, 2025	DP U-3188			
>A>	8431685	Apr 13, 2025	DP U-3189			
>A>	8431685	Apr 13, 2025	DP U-3190			
>A>	8431685*PED	Oct 13, 2025				
>A>	8461105	Apr 13, 2025	DP U-2588			
>A>	8461105	Apr 13, 2025	DP U-2589			
>A>	8461105	Apr 13, 2025	DP U-2590			
>A>	8461105	Apr 13, 2025	DP U-3188			
>A>	8461105	Apr 13, 2025	DP U-3189			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>EXENATIDE SYNTHETIC - BYDUREON</u></b>						
N 022200 001	>A> 8461105	Apr 13, 2025	DP U-3190			
	>A> 8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	>A> 8906851	Aug 18, 2026	U-2588			
	>A> 8906851	Aug 18, 2026	U-2589			
	>A> 8906851	Aug 18, 2026	U-2590			
	>A> 8906851	Aug 18, 2026	U-2593			
	>A> 8906851	Aug 18, 2026	U-3188			
	>A> 8906851	Aug 18, 2026	U-3189			
	>A> 8906851	Aug 18, 2026	U-3190			
	>A> 8906851*PED	Feb 18, 2027				
	>A> 9238076	Apr 15, 2024	DP U-2588			
	>A> 9238076	Apr 15, 2024	DP U-2589			
	>A> 9238076	Apr 15, 2024	DP U-2590			
	>A> 9238076	Apr 15, 2024	DP U-2599			
	>A> 9238076	Apr 15, 2024	DP U-3188			
	>A> 9238076	Apr 15, 2024	DP U-3189			
	>A> 9238076	Apr 15, 2024	DP U-3190			
	>A> 9238076*PED	Oct 15, 2024				
	>A> 9884092	Aug 18, 2026	U-2588			
	>A> 9884092	Aug 18, 2026	U-2589			
	>A> 9884092	Aug 18, 2026	U-2590			
	>A> 9884092	Aug 18, 2026	U-2593			
	>A> 9884092	Aug 18, 2026	U-2594			
	>A> 9884092	Aug 18, 2026	U-2595			
	>A> 9884092	Aug 18, 2026	U-2596			
	>A> 9884092	Aug 18, 2026	U-3188			
	>A> 9884092	Aug 18, 2026	U-3189			
	>A> 9884092	Aug 18, 2026	U-3190			
	>A> 9884092*PED	Feb 18, 2027				
<b><u>EXENATIDE SYNTHETIC - BYDUREON PEN</u></b>						
N 022200 002	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026			>A> NPP	Jul 22, 2024
	6824822	Oct 09, 2022	DP		PED	Aug 15, 2023
	6824822*PED	Apr 09, 2023			>A> PED	Jan 22, 2025
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
	>A> 7456254	Jun 30, 2025	DP U-2588			
	>A> 7456254	Jun 30, 2025	DP U-2589			
	>A> 7456254	Jun 30, 2025	DP U-2590			
	>A> 7456254	Jun 30, 2025	DP U-3188			
	>A> 7456254	Jun 30, 2025	DP U-3189			
	>A> 7456254	Jun 30, 2025	DP U-3190			
	>A> 7456254*PED	Dec 30, 2025				
	7563871	Apr 15, 2024	DP			
	7563871*PED	Oct 15, 2024				
	>A> 7612176	Apr 13, 2025	DP U-2588			
	>A> 7612176	Apr 13, 2025	DP U-2589			
	>A> 7612176	Apr 13, 2025	DP U-2590			
	>A> 7612176	Apr 13, 2025	DP U-3188			
	>A> 7612176	Apr 13, 2025	DP U-3189			
	>A> 7612176	Apr 13, 2025	DP U-3190			
	>A> 7612176*PED	Oct 13, 2025				
	8216180	Jan 12, 2028	DP			
	8216180*PED	Jul 12, 2028				
	>A> 8329648	Aug 18, 2026	U-2588			
	>A> 8329648	Aug 18, 2026	U-2589			
	>A> 8329648	Aug 18, 2026	U-2590			
	>A> 8329648	Aug 18, 2026	U-2593			
	>A> 8329648	Aug 18, 2026	U-2594			
	>A> 8329648	Aug 18, 2026	U-2595			
	>A> 8329648	Aug 18, 2026	U-2596			
	>A> 8329648	Aug 18, 2026	U-3188			
	>A> 8329648	Aug 18, 2026	U-3189			
	>A> 8329648	Aug 18, 2026	U-3190			
	>A> 8329648*PED	Feb 18, 2027				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	8361972	Mar 21, 2028	U-2588			
	8361972*PED	Sep 21, 2028				
>A>	8431685	Apr 13, 2025	DP U-2588			
>A>	8431685	Apr 13, 2025	DP U-2589			
>A>	8431685	Apr 13, 2025	DP U-2590			
>A>	8431685	Apr 13, 2025	DP U-3188			
>A>	8431685	Apr 13, 2025	DP U-3189			
>A>	8431685	Apr 13, 2025	DP U-3190			
>A>	8431685*PED	Oct 13, 2025				
	8439864	Mar 25, 2028	DP			
	8439864*PED	Sep 25, 2028				
>A>	8461105	Apr 13, 2025	DP U-2588			
>A>	8461105	Apr 13, 2025	DP U-2589			
>A>	8461105	Apr 13, 2025	DP U-2590			
>A>	8461105	Apr 13, 2025	DP U-3188			
>A>	8461105	Apr 13, 2025	DP U-3189			
>A>	8461105	Apr 13, 2025	DP U-3190			
>A>	8461105*PED	Oct 13, 2025				
	8501698	Jun 20, 2027	DP U-2588			
	8501698*PED	Dec 20, 2027				
	8690837	May 19, 2029	DP			
	8690837*PED	Nov 19, 2029				
	8721615	Jan 18, 2030	DP			
	8721615*PED	Jul 18, 2030				
	8758292	Nov 12, 2027	DP			
	8758292*PED	May 12, 2028				
	8827963	Feb 04, 2029	DP			
	8827963*PED	Aug 04, 2029				
>A>	8906851	Aug 18, 2026	U-2588			
>A>	8906851	Aug 18, 2026	U-2589			
>A>	8906851	Aug 18, 2026	U-2590			
>A>	8906851	Aug 18, 2026	U-2593			
>A>	8906851	Aug 18, 2026	U-3188			
>A>	8906851	Aug 18, 2026	U-3189			
>A>	8906851	Aug 18, 2026	U-3190			
>A>	8906851*PED	Feb 18, 2027				
	8998876	Jan 07, 2030	DP			
	8998876*PED	Jul 07, 2030				
>A>	9238076	Apr 15, 2024	DP U-2588			
>A>	9238076	Apr 15, 2024	DP U-2589			
>A>	9238076	Apr 15, 2024	DP U-2590			
>A>	9238076	Apr 15, 2024	DP U-2599			
>A>	9238076	Apr 15, 2024	DP U-3188			
>A>	9238076	Apr 15, 2024	DP U-3189			
>A>	9238076	Apr 15, 2024	DP U-3190			
>A>	9238076*PED	Oct 15, 2024				
	9320853	Mar 25, 2028	DP			
	9320853*PED	Sep 25, 2028				
>A>	9884092	Aug 18, 2026	U-2588			
>A>	9884092	Aug 18, 2026	U-2589			
>A>	9884092	Aug 18, 2026	U-2590			
>A>	9884092	Aug 18, 2026	U-2593			
>A>	9884092	Aug 18, 2026	U-2594			
>A>	9884092	Aug 18, 2026	U-2595			
>A>	9884092	Aug 18, 2026	U-2596			
>A>	9884092	Aug 18, 2026	U-3188			
>A>	9884092	Aug 18, 2026	U-3189			
>A>	9884092	Aug 18, 2026	U-3190			
>A>	9884092*PED	Feb 18, 2027				
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001	6515117	Oct 04, 2025	DS DP U-2588		M-240	Feb 15, 2022
	6515117*PED	Apr 04, 2026		>A>	NPP	Jul 22, 2024
	6824822	Oct 09, 2022	DP		PED	Aug 15, 2023
	6824822*PED	Apr 09, 2023		>A>	PED	Jan 22, 2025
	7223440	Aug 31, 2021	DP			
	7223440*PED	Mar 03, 2022				
>A>	7456254	Jun 30, 2025	DP U-2588			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001 >A> 7456254		Jun 30, 2025	DP U-2589			
>A> 7456254		Jun 30, 2025	DP U-2590			
>A> 7456254		Jun 30, 2025	DP U-3188			
>A> 7456254		Jun 30, 2025	DP U-3189			
>A> 7456254		Jun 30, 2025	DP U-3190			
>A> 7456254*PED		Dec 30, 2025	DP			
7563871		Apr 15, 2024				
7563871*PED		Oct 15, 2024				
>A> 7612176		Apr 13, 2025	DP U-2589			
>A> 7612176		Apr 13, 2025	DP U-2590			
>A> 7612176		Apr 13, 2025	DP U-3188			
>A> 7612176		Apr 13, 2025	DP U-3189			
>A> 7612176		Apr 13, 2025	DP U-3190			
>A> 7612176*PED		Oct 13, 2025	U-2588			
>A> 8329648		Aug 18, 2026	U-2589			
>A> 8329648		Aug 18, 2026	U-2590			
>A> 8329648		Aug 18, 2026	U-2593			
>A> 8329648		Aug 18, 2026	U-2594			
>A> 8329648		Aug 18, 2026	U-2595			
>A> 8329648		Aug 18, 2026	U-2596			
>A> 8329648		Aug 18, 2026	U-3188			
>A> 8329648		Aug 18, 2026	U-3189			
>A> 8329648		Aug 18, 2026	U-3190			
>A> 8329648*PED		Feb 18, 2027	U-2588			
8361972		Mar 21, 2028				
8361972*PED		Sep 21, 2028				
>A> 8431685		Apr 13, 2025	DP U-2588			
>A> 8431685		Apr 13, 2025	DP U-2589			
>A> 8431685		Apr 13, 2025	DP U-2590			
>A> 8431685		Apr 13, 2025	DP U-2597			
>A> 8431685		Apr 13, 2025	DP U-3188			
>A> 8431685		Apr 13, 2025	DP U-3189			
>A> 8431685		Apr 13, 2025	DP U-3190			
>A> 8431685*PED		Oct 13, 2025	U-2588			
>A> 8461105		Apr 13, 2025	DP U-2589			
>A> 8461105		Apr 13, 2025	DP U-2590			
>A> 8461105		Apr 13, 2025	DP U-2597			
>A> 8461105		Apr 13, 2025	DP U-3188			
>A> 8461105		Apr 13, 2025	DP U-3189			
>A> 8461105		Apr 13, 2025	DP U-3190			
>A> 8461105*PED		Oct 13, 2025	U-2588			
8501698		Jun 20, 2027				
8501698*PED		Dec 20, 2027				
>A> 8895033		Oct 04, 2030	DP U-2589			
>A> 8895033		Oct 04, 2030	DP U-2590			
>A> 8895033		Oct 04, 2030	DP U-2597			
>A> 8895033		Oct 04, 2030	DP U-2601			
>A> 8895033		Oct 04, 2030	DP U-2602			
>A> 8895033		Oct 04, 2030	DP U-3188			
>A> 8895033		Oct 04, 2030	DP U-3189			
>A> 8895033		Oct 04, 2030	DP U-3190			
>A> 8895033*PED		Apr 04, 2031	U-2588			
>A> 8906851		Aug 18, 2026	U-2589			
>A> 8906851		Aug 18, 2026	U-2590			
>A> 8906851		Aug 18, 2026	U-2593			
>A> 8906851		Aug 18, 2026	U-2597			
>A> 8906851		Aug 18, 2026	U-3188			
>A> 8906851		Aug 18, 2026	U-3189			
>A> 8906851		Aug 18, 2026	U-3190			
>A> 8906851*PED		Feb 18, 2027	U-2588			
>A> 9238076		Apr 15, 2024	DP U-2588			
>A> 9238076		Apr 15, 2024	DP U-2589			
>A> 9238076		Apr 15, 2024	DP U-2590			
>A> 9238076		Apr 15, 2024	DP U-2597			
>A> 9238076		Apr 15, 2024	DP U-2599			
>A> 9238076		Apr 15, 2024	DP U-3188			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EXENATIDE SYNTHETIC - BYDUREON BCISE</u>						
N 209210 001	>A> 9238076	Apr 15, 2024	DP U-3189			
	>A> 9238076	Apr 15, 2024	DP U-3190			
	>A> 9238076*PED	Oct 15, 2024				
	>A> 9884092	Aug 18, 2026	U-2588			
	>A> 9884092	Aug 18, 2026	U-2589			
	>A> 9884092	Aug 18, 2026	U-2590			
	>A> 9884092	Aug 18, 2026	U-2593			
	>A> 9884092	Aug 18, 2026	U-2594			
	>A> 9884092	Aug 18, 2026	U-2595			
	>A> 9884092	Aug 18, 2026	U-2596			
	>A> 9884092	Aug 18, 2026	U-2597			
	>A> 9884092	Aug 18, 2026	U-3188			
	>A> 9884092	Aug 18, 2026	U-3189			
	>A> 9884092	Aug 18, 2026	U-3190			
	>A> 9884092*PED	Feb 18, 2027				
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 001	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 002	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 003	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET</u>						
N 213072 004	10376470	May 01, 2033	DP U-3095			
	9763885	May 01, 2033	DP U-3095			
<u>FENFLURAMINE HYDROCHLORIDE - FINTEPLA</u>						
N 212102 001	10947183	Dec 20, 2036	DS DP			
	10950331	Sep 28, 2035	U-3098			
	11040018	Aug 02, 2037	U-2861			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7754702	Feb 15, 2028	U-1432			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2024	DS DP			
	7754702	Feb 15, 2028	U-2555			
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			
	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2024	DS DP		>A> NS	
	7754702	Feb 15, 2028	U-2555			Apr 28, 2024
	7754702	Feb 15, 2028	U-2556			
	7754702	Feb 15, 2028	U-2557			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>FERRIC CARBOXYMALTOSE - INJECTAFER</u></b>						
N 203565 003	8895612	Jan 08, 2027	U-1620			
	8895612	Jan 08, 2027	U-3050			
	8895612	Jan 08, 2027	U-3051			
	8895612	Jan 08, 2027	U-3115			
	8895612	Jan 08, 2027	U-3116			
	9376505	Oct 20, 2023	DS DP			
<b><u>FERRIC OXYHYDROXIDE - VELPHORO</u></b>						
N 205109 001	10624855	Nov 26, 2034	DP			
	10624855*PED	May 26, 2035				
	10682376	Nov 13, 2028	DP			
	10682376*PED	May 13, 2029				
	10695367	Nov 13, 2028	DP			
	10695367*PED	May 13, 2029				
	10925896	Nov 13, 2028	DP			
	10925896*PED	May 13, 2029				
	10925897	Nov 13, 2028	DP			
	10925897*PED	May 13, 2029				
	10933090	Nov 13, 2028	DP			
	10933090*PED	May 13, 2029				
	11013761	Nov 13, 2028	DP			
	11013761*PED	May 13, 2029				
	11013762	Nov 13, 2028	DP			
	11013762*PED	May 13, 2029				
	9561251	Jan 23, 2030	DP U-1468			
	9561251*PED	Jul 23, 2030				
<b><u>FESOTERODINE FUMARATE - TOVIAZ</u></b>						
N 022030 001	8501723	Jun 07, 2027	DP		I-861	Jun 17, 2024
	8501723*PED	Dec 07, 2027			PED	Dec 17, 2024
<b><u>FESOTERODINE FUMARATE - TOVIAZ</u></b>						
N 022030 002	8501723	Jun 07, 2027	DP		I-861	Jun 17, 2024
	8501723*PED	Dec 07, 2027			PED	Dec 17, 2024
<b><u>FEXINIDAZOLE - FEXINIDAZOLE</u></b>						
N 214429 001				>A> NCE	ODE-359	Jul 16, 2026
						Jul 16, 2028
<b><u>FINERENONE - KERENDIA</u></b>						
N 215341 001	8436180	Apr 12, 2029	DS DP		NCE	Jul 09, 2026
<b><u>FINERENONE - KERENDIA</u></b>						
N 215341 002	8436180	Apr 12, 2029	DS DP		NCE	Jul 09, 2026
<b><u>FLUCICLOVINE F-18 - AXUMIN</u></b>						
N 208054 001	10933147	Dec 30, 2035	U-2450			
	10953112	Nov 28, 2026	U-1879			
	10967077	Dec 30, 2035	U-2450			
<b><u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u></b>						
N 208798 001	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u></b>						
N 208798 001	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<b><u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u></b>						
N 208798 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<b><u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u></b>						
N 208798 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u></b>						
N 208798 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
<b><u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u></b>						
N 208798 004	10022510	May 18, 2031	DP		>A> NPP	Jul 09, 2024
	10022510*PED	Nov 18, 2031			>A> PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u></b>						
N 208798 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<b><u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u></b>						
N 208798 006	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>FLUTICASONE PROPIONATE - ARMONAIR DIGITALER</u></b>						
N 208798 006	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
<b><u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u></b>						
N 208798 007	10022510	May 18, 2031	DP		>A> NS	Jul 09, 2024
	10124131	May 18, 2031	DP		>A> PED	Jan 09, 2025
	10195375	Feb 14, 2031	DP			
	10561808	Jan 01, 2032	DP			
	10765820	May 19, 2025	DP			
	7540282	May 06, 2023	DP			
	8651103	Mar 26, 2028	DP			
	8714149	Feb 25, 2032	DP			
	8978966	Jan 13, 2032	DP			
	9216260	Jun 28, 2031	DP			
	9463288	May 19, 2025	DP			
	9616024	Sep 01, 2024	DP			
	9731087	May 18, 2031	DP			
<b><u>FLUTICASONE PROPIONATE - XHANCE</u></b>						
N 209022 001	11033696	May 20, 2033	DP			
<b><u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u></b>						
N 208799 001	10022510	May 18, 2031	DP		>A> M-61	Jul 09, 2024
	10022510*PED	Nov 18, 2031			>A> PED	Jan 09, 2025
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<b><u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u></b>						
N 208799 002	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 002	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799 003	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGITALHALER</u>						
N 208799 004	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 004	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9415008	Oct 06, 2034	DP U-645			
	9415008*PED	Apr 06, 2035				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035	DP			
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024	DP			
	9987229*PED	Mar 01, 2025				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799 005	10022510	May 18, 2031	DP			
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031	DP			
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031	DP			
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032	DP			
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036	DP			
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025	DP			
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035	DP			
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038	DP			
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023	DP			
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028	DP			
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032	DP			
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032	DP			
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034	DP U-645			
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031	DP			
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025	DP			
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024	DP			
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031	DP			
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u></b>						
N 208799 005	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035		DP		
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024		DP		
	9987229*PED	Mar 01, 2025				
<b><u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u></b>						
N 208799 006	10022510	May 18, 2031		DP		
	10022510*PED	Nov 18, 2031				
	10124131	May 18, 2031		DP		
	10124131*PED	Nov 18, 2031				
	10195375	Feb 14, 2031		DP		
	10195375*PED	Aug 14, 2031				
	10561808	Jan 01, 2032		DP		
	10561808*PED	Jul 01, 2032				
	10569034	Aug 16, 2036		DP		
	10569034*PED	Feb 16, 2037				
	10765820	May 19, 2025		DP		
	10765820*PED	Nov 19, 2025				
	10918816	Dec 14, 2035		DP		
	10918816*PED	Jun 14, 2036				
	11000653	Dec 18, 2038		DP		
	11000653*PED	Jun 18, 2039				
	7540282	May 06, 2023		DP		
	7540282*PED	Nov 06, 2023				
	8651103	Mar 26, 2028		DP		
	8651103*PED	Sep 26, 2028				
	8714149	Feb 25, 2032		DP		
	8714149*PED	Aug 25, 2032				
	8978966	Jan 13, 2032		DP		
	8978966*PED	Jul 13, 2032				
	9066957	Oct 06, 2034		DP U-645		
	9066957*PED	Apr 06, 2035				
	9216260	Jun 28, 2031		DP		
	9216260*PED	Dec 28, 2031				
	9463288	May 19, 2025		DP		
	9463288*PED	Nov 19, 2025				
	9616024	Sep 01, 2024		DP		
	9616024*PED	Mar 01, 2025				
	9731087	May 18, 2031		DP		
	9731087*PED	Nov 18, 2031				
	9782550	Aug 28, 2035		DP		
	9782550*PED	Feb 28, 2036				
	9782551	Aug 28, 2035		DP		
	9782551*PED	Feb 28, 2036				
	9987229	Sep 01, 2024		DP		
	9987229*PED	Mar 01, 2025				
<b><u>FOSCARNET SODIUM - FOSCARNET SODIUM</u></b>						
A 213001 001					CGT	Dec 28, 2021
<b><u>FOSDENOPTERIN HYDROBROMIDE - NULIBRY</u></b>						
N 214018 001	7504095	Jan 31, 2025		DP U-3092	NCE ODE-342	Feb 26, 2026 Feb 26, 2028
<b><u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u></b>						
N 212642 001					NCE W	Dec 01, 2025 Dec 01, 2025
<b><u>GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11</u></b>						
N 212643 001					NCE W	Dec 01, 2025 Dec 01, 2025
<b><u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u></b>						
N 209394 001	10028937	Jun 10, 2030		U-2141	D-175	Sep 26, 2022
	10028937	Jun 10, 2030		U-2532	M-259	Apr 10, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u></b>						
N 209394 001	10028937*PED	Dec 10, 2030			NCE	Aug 03, 2022
	10039754	Jun 10, 2030	U-2141		NPP	Apr 30, 2022
	10039754	Jun 10, 2030	U-2532		ODE-232	Apr 30, 2026
	10039754*PED	Dec 10, 2030			ODE-233	Apr 30, 2026
	10286029	Mar 14, 2034	U-2532		PED	Oct 30, 2022
	10286029*PED	Sep 14, 2034			PED	Feb 03, 2023
	8648037	Jan 19, 2032	DS DP U-2141		PED	Mar 26, 2023
	8648037	Jan 19, 2032	DS DP U-2532		PED	Oct 10, 2023
	8648037*PED	Jul 19, 2032			PED	Oct 30, 2026
	8937150	May 18, 2032	DS DP		PED	Oct 30, 2026
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS			
	9321807*PED	Dec 05, 2035				
	9586978	Jun 10, 2030	U-2141			
	9586978	Jun 10, 2030	U-2532			
	9586978*PED	Dec 10, 2030				
<b><u>GLECAPREVIR; PIBRENTASVIR - MAVYRET</u></b>						
N 215110 001	10028937	Jun 10, 2030	U-3167			
	10028937*PED	Dec 10, 2030				
	10039754	Jun 10, 2030	U-3167			
	10039754*PED	Dec 10, 2030				
	10286029	Mar 14, 2034	U-3167			
	10286029*PED	Sep 14, 2034				
	8648037	Jan 19, 2032	DS DP U-3167			
	8648037*PED	Jul 19, 2032				
	8937150	May 18, 2032	DS DP			
	8937150*PED	Nov 18, 2032				
	9321807	Jun 05, 2035	DS DP			
	9321807*PED	Dec 05, 2035				
	9586978	Jun 10, 2030	U-3167			
	9586978*PED	Dec 10, 2030				
<b><u>GLUCAGON - BAOSIMI</u></b>						
N 210134 001	10894133	Jan 03, 2038	DP			
<b><u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u></b>						
N 203284 001					NPP	Dec 21, 2021
<b><u>GLYCOPYRROLATE - LONHALA MAGNAIR KIT</u></b>						
N 208437 001	10940110	Feb 26, 2029	DP U-1773			
<b><u>GOLODIRSEN - VYONDYS 53</u></b>						
N 211970 001	10968450	Jun 28, 2025	DS DP			
	10995337	Jun 28, 2025	DP U-2675			
<b><u>HALOBETASOL PROPIONATE - LEXETTE</u></b>						
N 210566 001	10857159	Nov 30, 2036	DP			
	10857159*PED	May 30, 2037				
	11020407	Nov 30, 2036	DP U-3143			
<b><u>HYDROCORTISONE - ALKINDI SPRINKLE</u></b>						
N 213876 001	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<b><u>HYDROCORTISONE - ALKINDI SPRINKLE</u></b>						
N 213876 002	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			
<b><u>HYDROCORTISONE - ALKINDI SPRINKLE</u></b>						
N 213876 003	9649280	May 12, 2034	DP U-3075			
	9675559	Jan 10, 2033	U-3075			
	9717740	Nov 19, 2032	U-3075			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>HYDROCORTISONE - ALKINDI SPRINKLE</b></u>						
N 213876 003	9649280	May 12, 2034	DP	U-3075		
	9675559	Jan 10, 2033		U-3075		
	9717740	Nov 19, 2032		U-3075		
<u><b>HYDROCORTISONE - ALKINDI SPRINKLE</b></u>						
N 213876 004	9649280	May 12, 2034	DP	U-3075		
	9675559	Jan 10, 2033		U-3075		
	9717740	Nov 19, 2032		U-3075		
<u><b>IBREXAFUNGERP CITRATE - BREXAFEMME</b></u>						
N 214900 001	10174074	Jan 19, 2035	DS	DP		
	10370406	Jan 19, 2035		U-3159		
	10927142	Jan 19, 2035	DS			
	8188085	Aug 28, 2030	DS	DP	U-3159	
<u><b>IBRUTINIB - IMBRUVICA</b></u>						
N 205552 001	10961251	Jun 03, 2033		DP		
<u><b>IBRUTINIB - IMBRUVICA</b></u>						
N 205552 002	10961251	Jun 03, 2033		DP		
<u><b>IBRUTINIB - IMBRUVICA</b></u>						
N 210563 001	10961251	Jun 03, 2033		DP		
<u><b>IBRUTINIB - IMBRUVICA</b></u>						
N 210563 002	10961251	Jun 03, 2033		DP		
<u><b>IBRUTINIB - IMBRUVICA</b></u>						
N 210563 003	10961251	Jun 03, 2033		DP		
<u><b>IBRUTINIB - IMBRUVICA</b></u>						
N 210563 004	10961251	Jun 03, 2033		DP		
<u><b>ICOSAPENT ETHYL - VASCEPA</b></u>						
N 202057 001	10881632	Apr 29, 2030		U-3052		
	10894028	Jun 28, 2033		U-3053		
	11000499	Jun 28, 2033		U-3126		
<u><b>ICOSAPENT ETHYL - VASCEPA</b></u>						
N 202057 002	10881632	Apr 29, 2030		U-3052		
	10894028	Jun 28, 2033		U-3053		
	11000499	Jun 28, 2033		U-3126		
<u><b>IMIQUIMOD - ZYCLARA</b></u>						
N 022483 001	10918635	Apr 30, 2030		U-1455		
	10918635	Apr 30, 2030		U-172		
<u><b>INFIGRATINIB PHOSPHATE - TRUSELTIQ</b></u>						
N 214622 001	10278969	Dec 11, 2034	DP			
	8552002	Aug 25, 2029	DS	DP		
>A>	9067896	Aug 06, 2028	DS			
<u><b>INFIGRATINIB PHOSPHATE - TRUSELTIQ</b></u>						
N 214622 002	10278969	Dec 11, 2034	DP			
	8552002	Aug 25, 2029	DS	DP		
>A>	9067896	Aug 06, 2028	DS			
<u><b>IRINOTECAN HYDROCHLORIDE - ONIVYDE</b></u>						
N 207793 001	10980795	Jun 12, 2033		U-1848		
	10993914	Oct 15, 2036	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ISOPROPYL ALCOHOL - ZURAGARD</u>						
N 210872 001	10688291	Dec 20, 2034	DP U-1397		>A> M-268	Jun 24, 2024
	8226971	May 06, 2025	DP			
	8389583	Aug 09, 2029		U-1397		
	8703828	May 23, 2028	DP			
	9011897	Feb 08, 2025	DP			
	9629368	May 23, 2028		U-1397		
	9844654	Apr 24, 2036	DP	U-1397		
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 001					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 002					ODE-338	Dec 21, 2027
<u>IVACAFTOR - KALYDECO</u>						
N 207925 003					ODE-338	Dec 21, 2027
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 002	10058546	Jul 15, 2033	U-2399		ODE-335	Dec 21, 2027
	10058546	Jul 15, 2033	U-2572			
	10058546	Jul 15, 2033	U-3022			
	10058546	Jul 15, 2033	U-3023			
	10081621	Mar 25, 2031	DP U-2420			
	10081621	Mar 25, 2031	DP U-2571			
	10081621	Mar 25, 2031	DP U-3024			
	10081621	Mar 25, 2031	DP U-3025			
	10206877	Apr 14, 2035	DP U-2498			
	10206877	Apr 14, 2035	DP U-2570			
	10206877	Apr 14, 2035	DP U-3026			
	10206877	Apr 14, 2035	DP U-3027			
	8354427	Jul 06, 2026	U-3021			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	11052075	Dec 04, 2028	DP U-3181			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 002	11052075	Dec 04, 2028	DP U-3181			
<u>IVERMECTIN - IVERMECTIN</u>						
A 210720 001					PC	May 29, 2021
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	11033565	Apr 22, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVOSIDENIB - TIBSOVO</u>						
N 211192 001	10980788	Jun 07, 2039	U-3112			
	10980788	Jun 07, 2039	U-3113			
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025 001	11077055	Apr 21, 2036	DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 001	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 210861 002	10799505	Aug 15, 2036	DS DP			
<u>LAROTRECTINIB SULFATE - VITRAKVI</u>						
N 211710 001	10799505	Aug 15, 2036	DS			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 001	11053214	Dec 05, 2037	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 002	11053214	Dec 05, 2037	DS DP U-1719			
<u>LASMIDITAN SUCCINATE - REYVOW</u>						
N 211280 003	11053214	Dec 05, 2037	DS DP U-1719			
	7423050	Apr 06, 2025	DS DP U-1719			
	8748459	Mar 27, 2023	U-1719			
<u>LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN</u>						
N 208259 001	10882840	Jul 11, 2026	U-1524			
	11021456	Jul 11, 2026	U-1524			
	11028081	Jan 27, 2030	U-1524			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001				ODE*		Aug 28, 2026
				ODE*		Aug 28, 2026
				ODE*		Aug 28, 2026
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 002				ODE*		Apr 07, 2024
				ODE*		Aug 28, 2026
				ODE*		Aug 28, 2026
				ODE*		Aug 28, 2026
				PED		Oct 07, 2024
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	7253286	Oct 24, 2025	DS DP			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	7253286	Oct 24, 2025	DS DP			
<u>LEUPROLIDE MESYLATE - CAMCEVI KIT</u>						
N 211488 001	10646572	Jan 16, 2027	DP			
	9572857	Jan 16, 2027	DP			
	9744207	Jan 16, 2027	DP			
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	10987244	Apr 01, 2031	DP			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	10987244	Apr 01, 2031	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>LEVONORGESTREL - KYLEENA</b></u>						
N 208224 001	10987244	Apr 01, 2031	DP			
<u><b>LIFITEGRAST - XIIDRA</b></u>						
N 208073 001	11058677	Dec 18, 2033	DP			
<u><b>LINAGLIPITIN - TRADJENTA</b></u>						
N 201280 001	11033552	May 04, 2027	DP			
<u><b>LINAGLIPITIN; METFORMIN HYDROCHLORIDE - JENTADUETO</b></u>						
N 201281 001	10973827	Apr 02, 2029	DP			
<u><b>LINAGLIPITIN; METFORMIN HYDROCHLORIDE - JENTADUETO</b></u>						
N 201281 002	10973827	Apr 02, 2029	DP			
<u><b>LINAGLIPITIN; METFORMIN HYDROCHLORIDE - JENTADUETO</b></u>						
N 201281 003	10973827	Apr 02, 2029	DP			
<u><b>LIRAGLUTIDE RECOMBINANT - SAXENDA</b></u>						
N 206321 001					NPP	Dec 04, 2023
<u><b>LISDEXAMFETAMINE Dimesylate - VYVANSE</b></u>						
N 021977 001	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u><b>LISDEXAMFETAMINE Dimesylate - VYVANSE</b></u>						
N 021977 002	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<u><b>LISDEXAMFETAMINE Dimesylate - VYVANSE</b></u>						
N 021977 003	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>LISDEXAMFETAMINE DIMESYLYATE - VYVANSE</b>						
N 021977 003	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<b>LISDEXAMFETAMINE DIMESYLYATE - VYVANSE</b>						
N 021977 004	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<b>LISDEXAMFETAMINE DIMESYLYATE - VYVANSE</b>						
N 021977 005	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<b>LISDEXAMFETAMINE DIMESYLYATE - VYVANSE</b>						
N 021977 006	7105486	Feb 24, 2023	U-727			
	7105486	Feb 24, 2023	U-842			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-842			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-842			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-842			
	7678771*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-842			
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
<b>LISDEXAMFETAMINE DIMESYLYATE - VYVANSE</b>						
N 021977 007	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LISDEXAMFETAMINE DIMESYLYATE - VYVANSE</u>						
N 021977 007	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP	U-727		
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023		U-1034		
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023		U-727		
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP	U-727		
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023		U-727		
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP	U-842		
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023		U-842		
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP	U-842		
	7687467*PED	Aug 24, 2023				
	7700561	Feb 24, 2023	DP			
	7700561*PED	Aug 24, 2023				
	7713936	Feb 24, 2023		U-727		
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP	U-842		
	7718619*PED	Aug 24, 2023				
<u>LISDEXAMFETAMINE DIMESYLYATE - VYVANSE</u>						
N 208510 001	7105486	Feb 24, 2023		U-727		
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP	U-727		
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023		U-727		
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023		U-727		
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP	U-727		
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023		U-727		
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP	U-727		
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023		U-727		
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP	U-727		
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP	U-727		
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023		U-727		
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP	U-727		
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP	U-727		
	7723305*PED	Aug 24, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>LISDEXAMFETAMINE Dimesylate - Vyvanse</b>						
N 208510 002	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP U-727			
	7723305*PED	Aug 24, 2023				
<b>LISDEXAMFETAMINE Dimesylate - Vyvanse</b>						
N 208510 003	7105486	Feb 24, 2023	U-727			
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP U-727			
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023	U-727			
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023	U-727			
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP U-727			
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023	U-727			
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP U-727			
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023	U-727			
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP U-727			
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP U-727			
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023	U-727			
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP U-727			
	7718619*PED	Aug 24, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>LISDEXAMFETAMINE Dimesylate - Vyvanse</b>						
N 208510 003	7723305	Feb 24, 2023	DP	U-727		
	7723305*PED	Aug 24, 2023				
<b>LISDEXAMFETAMINE Dimesylate - Vyvanse</b>						
N 208510 004	7105486	Feb 24, 2023		U-727		
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP	U-727		
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023		U-727		
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023		U-727		
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP	U-727		
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023		U-727		
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP	U-727		
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023		U-727		
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP	U-727		
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP	U-727		
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023		U-727		
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP	U-727		
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP	U-727		
	7723305*PED	Aug 24, 2023				
<b>LISDEXAMFETAMINE Dimesylate - Vyvanse</b>						
N 208510 005	7105486	Feb 24, 2023		U-727		
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023	DP			
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS DP			
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS DP	U-727		
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023		U-727		
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023		U-727		
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP	U-727		
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023		U-727		
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP	U-727		
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023		U-727		
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP	U-727		
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP	U-727		
	7687467*PED	Aug 24, 2023				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>LISDEXAMFETAMINE Dimesylate - Vyvanse</b>						
N 208510 005	7713936	Feb 24, 2023		U-727		
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023		DP U-727		
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023		DP U-727		
	7723305*PED	Aug 24, 2023				
<b>LISDEXAMFETAMINE Dimesylate - Vyvanse</b>						
N 208510 006	7105486	Feb 24, 2023		U-727		
	7105486*PED	Aug 24, 2023				
	7223735	Feb 24, 2023		DP		
	7223735*PED	Aug 24, 2023				
	7655630	Feb 24, 2023	DS	DP		
	7655630*PED	Aug 24, 2023				
	7659253	Feb 24, 2023	DS	DP U-727		
	7659253*PED	Aug 24, 2023				
	7659254	Feb 24, 2023		U-727		
	7659254*PED	Aug 24, 2023				
	7662787	Feb 24, 2023	DS			
	7662787*PED	Aug 24, 2023				
	7662788	Feb 24, 2023		U-727		
	7662788*PED	Aug 24, 2023				
	7671030	Feb 24, 2023	DP	U-727		
	7671030*PED	Aug 24, 2023				
	7671031	Feb 24, 2023		U-727		
	7671031*PED	Aug 24, 2023				
	7674774	Feb 24, 2023	DP	U-727		
	7674774*PED	Aug 24, 2023				
	7678770	Feb 24, 2023		U-727		
	7678770*PED	Aug 24, 2023				
	7678771	Feb 24, 2023	DP	U-727		
	7678771*PED	Aug 24, 2023				
	7687466	Feb 24, 2023	DP			
	7687466*PED	Aug 24, 2023				
	7687467	Feb 24, 2023	DP	U-727		
	7687467*PED	Aug 24, 2023				
	7713936	Feb 24, 2023		U-727		
	7713936*PED	Aug 24, 2023				
	7718619	Feb 24, 2023	DP	U-727		
	7718619*PED	Aug 24, 2023				
	7723305	Feb 24, 2023	DP	U-727		
	7723305*PED	Aug 24, 2023				
<b>Lisinopril - Obrelis</b>						
N 208401 001	10940177	Nov 06, 2035		DP		
<b>Lonafarnib - Zokinvy</b>						
N 213969 001	7838531	Jul 26, 2024		U-3070	ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023		U-3070		
<b>Lonafarnib - Zokinvy</b>						
N 213969 002	7838531	Jul 26, 2024		U-3070	ODE-324	Nov 20, 2027
	8828356	Oct 17, 2023		U-3070		
<b>Lorlatinib - Lorbrena</b>						
N 210868 001	10420749	Jul 27, 2036	DS	DP U-2633	I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS	DP U-3096	ODE-349	Mar 03, 2028
	11020376	Jul 27, 2036	DP			
<b>Lorlatinib - Lorbrena</b>						
N 210868 002	10420749	Jul 27, 2036	DS	DP U-2633	I-847	Mar 03, 2024
	10420749	Jul 27, 2036	DS	DP U-3096	ODE-349	Mar 03, 2028
	11020376	Jul 27, 2036	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - LOTEPEPNOL ETABONATE</u>						
A 212450 001					CGT	Nov 02, 2021
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	10940108	May 03, 2033	U-2985			
	10945948	May 03, 2033	U-2985			
	10993908	May 03, 2033	U-3117			
<u>LUMASIRAN SODIUM - OXLUMO</u>						
N 214103 001 >A> 11060093		Dec 26, 2034	DS DP U-2995		ODE-339	Nov 23, 2027
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	10960009	Dec 03, 2034	U-814			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	10946015	Sep 11, 2026	DP U-1445			
<u>MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB (COPACKAGED)</u>						
N 213135 001	11033498	Aug 04, 2037	U-3164			
<u>MANNITOL - BRONCHITOL</u>						
N 202049 001					NP ODE-327	Oct 30, 2023 Oct 30, 2027
<u>MELOXICAM - ANJESQ</u>						
N 210583 001	10881663	Mar 08, 2039	U-3038			
<u>MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO</u>						
N 214383 001	10285946	Apr 25, 2032	DP		NCE ODE-348	Feb 26, 2026 Feb 26, 2028
	10322182	Apr 25, 2032	DP			
	10543274	Apr 25, 2032	U-3093			
	10869928	Apr 25, 2032	DP			
	6992207	Jun 25, 2022	DS DP U-3093			
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	10940128	Jun 14, 2030	DP U-3086			
	11020363	May 28, 2030	DP			
<u>MEROPENEM; VABORBACTAM - VABOMERE</u>						
N 209776 001	11007206	Aug 08, 2031	U-3128		NCE GAIN	Aug 29, 2022 Aug 29, 2027
	8680136	Aug 29, 2031	DS DP			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002			>A> ODE*			Apr 08, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	>A> 11103494	Aug 14, 2033	DP			
	>A> 11103495	Aug 14, 2033	DP U-2993			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	>A> 11103494	Aug 14, 2033	DP			
	>A> 11103495	Aug 14, 2033	DP U-2993			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	>A> 11103494	Aug 14, 2033	DP			
	>A> 11103495	Aug 14, 2033	DP U-2993			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	10881618	Mar 23, 2032	U-2357			
	10905652	Mar 23, 2032	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 001				>A> M-82		Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 002				>A> M-82		Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 003				>A> M-82		Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 004				>A> M-82		Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 005				>A> M-82		Jun 28, 2024
<u>METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR</u>						
N 212038 006				>A> M-82		Jun 28, 2024
<u>METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI</u>						
N 209388 001	11020361	Dec 22, 2029	U-2843			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 001	10966990	Jun 20, 2038	DP			
<u>MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE</u>						
N 211844 002	10966990	Jun 20, 2038	DP			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	10874655	May 30, 2038	U-2371			
	10874656	May 30, 2038	U-2371			
	10874657	May 30, 2038	U-2371			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>MIGALASTAT HYDROCHLORIDE - GALAFOLD</b>						
N 208623 001	10925866	Apr 28, 2028	U-2371			
	11033538	Apr 28, 2028	U-2371			
	RE48608	Feb 12, 2029	U-2371			
<b>MINOCYCLINE HYDROCHLORIDE - MINOLIRA</b>						
N 209269 001 >A>	11103517	Apr 07, 2036	DP			
<b>MINOCYCLINE HYDROCHLORIDE - MINOLIRA</b>						
N 209269 002 >A>	11103517	Apr 07, 2036	DP			
<b>MINOCYCLINE HYDROCHLORIDE - ZILXI</b>						
N 213690 001	10946101	Oct 01, 2030	U-1631			
<b>MIRABEGRON - MYRBETRIO</b>						
N 202611 001	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<b>MIRABEGRON - MYRBETRIO</b>						
N 202611 002	10842780	Sep 28, 2029	DP U-2996		I-777	Apr 27, 2021
	10842780*PED	Mar 28, 2030			I-855	Mar 25, 2024
	6346532	Mar 27, 2022	DS DP		PED	Sep 25, 2024
	6346532*PED	Sep 27, 2022				
	8772315	Oct 30, 2028	U-2300			
	8772315*PED	Apr 30, 2029				
	8835474	Nov 04, 2023	U-1527			
	8835474*PED	May 04, 2024				
	RE44872	Nov 04, 2023	U-1527			
	RE44872*PED	May 04, 2024				
<b>MIRABEGRON - MYRBETRIO GRANULES</b>						
N 213801 001	10058536	Mar 31, 2036	DP U-3108		NP	Mar 25, 2024
	10058536*PED	Oct 01, 2036			PED	Sep 25, 2024
	6346532	Mar 27, 2022	DS			
	6346532*PED	Sep 27, 2022				
	7342117	Nov 04, 2023	DS			
	7342117*PED	May 04, 2024				
	7982049	Nov 04, 2023	DP			
	7982049*PED	May 04, 2024				
<b>MONOMETHYL FUMARATE - BAFIERTAM</b>						
N 210296 001	10918615	Aug 12, 2035	DP U-1384			
	10918616	Jun 03, 2035	U-1384			
	10918617	Aug 10, 2035	DP			
	10945985	Aug 14, 2035	DP			
<b>MORPHINE SULFATE - MORPHINE SULFATE</b>						
A 212451 001					CGT	Aug 10, 2021
<b>MORPHINE SULFATE - MORPHINE SULFATE</b>						
A 212451 002					CGT	Aug 10, 2021
<b>MORPHINE SULFATE - MORPHINE SULFATE</b>						
N 022195 001					NPP	Jun 02, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - MORPHINE SULFATE</u> N 022195 002					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u> N 022207 001					NPP	Jun 02, 2024
<u>MORPHINE SULFATE - MORPHINE SULFATE</u> N 022207 002					NPP	Jun 02, 2024
<u>NALDEMEDINE TOSYLATE - SYMPROIC</u> N 208854 001 10952968		May 13, 2033	DS DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u> N 205787 001 10960155		Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR)</u> N 209862 001 10960155		Jun 25, 2026	DP			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u> N 212045 001 10722510 10973814		Aug 26, 2034 Aug 26, 2034	DP U-3110 DP U-3110			
<u>NAPROXEN SODIUM - NAPROXEN SODIUM</u> N 021920 001 >A> 11090280 >A> 11090280 >A> 11090280		Mar 03, 2026 Mar 03, 2026 Mar 03, 2026	DP U-1731 DP U-1732 DP U-3195			
<u>NERATINIB MALEATE - NERLYNX</u> N 208051 001 10035788 10035788 10035788 7982043 7982043 7982043 8518446 8518446 8518446 8669273 8790708 8790708 8790708 9139558 9139558 9139558 9211291 9211291 9265784 9630946 9630946 9630946		Oct 15, 2028 Oct 15, 2028 Oct 15, 2028 Oct 08, 2025 Oct 08, 2025 Oct 08, 2025 Nov 20, 2030 Nov 20, 2030 Nov 20, 2030 Jul 18, 2031 Nov 05, 2030 Nov 05, 2030 Nov 05, 2030 Oct 15, 2028 Oct 15, 2028 Oct 15, 2028 Mar 24, 2030 Mar 24, 2030 Aug 04, 2029 Oct 15, 2028 Oct 15, 2028 Oct 15, 2028	U-2043 U-3047 U-3097 U-2043 U-3047 U-3097 DP U-2043 DP U-3047 DP U-3097 U-3047 DP U-2043 DP U-3047 DP U-3097 U-2043 U-3047 U-3097 U-2043 U-3097 U-3047 U-2043 U-3097 U-3047 U-2043 U-3097 U-3047 U-2043			
<u>NETARSUDIL MESYLATE - RHOPRESSA</u> N 208254 001 10882840 11021456 11028081		Jul 11, 2026 Jul 11, 2026 Jan 27, 2030	U-1524 U-1524 U-1524			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u> N 205718 001 10961195		Sep 25, 2035	DS DP			
<u>NIFURTIMOX - LAMPIT</u> N 213464 001				ODE-319	Aug 06, 2027	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIFURTIMOX - LAMPIT</u>						
N 213464 002					ODE-319	Aug 06, 2027
<u>NIRAPARIB TOSYLATE - ZEJULA</u>						
N 208447 001	>A> 11091459 8071623	Mar 27, 2038 Mar 27, 2031	DP DS DP			
<u>NITAZOXANIDE - NITAZOXANIDE</u>						
A 213820 001					CGT	Jun 05, 2021
<u>NITRIC OXIDE - GENOSYL</u>						
N 202860 001	10124142 10814092 10926054 7947227 8057742 8226916 8607785 8609028 8821801 8944049 9522249 9701538 9956373	Aug 18, 2025 Oct 17, 2025 Aug 13, 2029 Oct 17, 2026 Jan 18, 2026 Aug 18, 2025 Jul 14, 2030 Aug 18, 2025 Aug 18, 2025 Aug 13, 2029 Aug 18, 2025 Jan 28, 2029 Aug 18, 2025	U-3037 U-3037 DP U-3037 U-3037 U-3037 DP U-3037 DP DP DP DP U-3037			
<u>OBETICOLIC ACID - OCALIVA</u>						
N 207999 001	RE48286	Nov 16, 2027	DS DP			
<u>OBETICOLIC ACID - OCALIVA</u>						
N 207999 002	RE48286	Nov 16, 2027	DS DP			
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11052126	Feb 03, 2036	U-2857			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 001	>A> 10011633 >A> 10093697 >A> 10487111 >A> 10487111 >A> 10975046 >A> 10981952 >A> 10981952 >A> 7132416 >A> 9694018	Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Jun 20, 2039 Nov 08, 2031 Nov 08, 2031 Sep 05, 2022 Nov 08, 2031	U-3186 U-3186 U-3186 U-3187 DS U-3186 U-3187 DS DP U-3186		>A> NCE	Jul 20, 2026
N 215498 002	>A> 10011633 >A> 10093697 >A> 10487111 >A> 10487111 >A> 10975046 >A> 10981952 >A> 10981952 >A> 7132416 >A> 9694018	Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Jun 20, 2039 Nov 08, 2031 Nov 08, 2031 Sep 05, 2022 Nov 08, 2031	U-3186 U-3186 U-3186 U-3187 DS U-3186 U-3187 DS DP U-3186		>A> NCE	Jul 20, 2026
N 215498 003	>A> 10011633 >A> 10093697 >A> 10487111 >A> 10487111 >A> 10975046 >A> 10981952 >A> 10981952 >A> 7132416 >A> 9694018	Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Jun 20, 2039 Nov 08, 2031 Nov 08, 2031 Sep 05, 2022 Nov 08, 2031	U-3186 U-3186 U-3186 U-3187 DS U-3186 U-3187 DS DP U-3186		>A> NCE	Jul 20, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 003	>A> 10011633	Nov 08, 2031	U-3186		>A> NCE	Jul 20, 2026
	>A> 10093697	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3187			
	>A> 10975046	Jun 20, 2039	DS			
	>A> 10981952	Nov 08, 2031	U-3186			
	>A> 10981952	Nov 08, 2031	U-3187			
	>A> 7132416	Sep 05, 2022	DS DP			
	>A> 9694018	Nov 08, 2031	U-3186			
<u>ODEVIXIBAT - BYLVAY</u>						
N 215498 004	>A> 10011633	Nov 08, 2031	U-3186		>A> NCE	Jul 20, 2026
	>A> 10093697	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3186			
	>A> 10487111	Nov 08, 2031	U-3187			
	>A> 10975046	Jun 20, 2039	DS			
	>A> 10981952	Nov 08, 2031	U-3186			
	>A> 10981952	Nov 08, 2031	U-3187			
	>A> 7132416	Sep 05, 2022	DS DP			
	>A> 9694018	Nov 08, 2031	U-3186			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</b></u>						
N 213378 003	9517235	Aug 23, 2031	U-3139			
<u><b>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</b></u>						
N 213378 004	10300054	Aug 23, 2031	DP U-3140		NCE	May 28, 2026
	10300054	Aug 23, 2031	DP U-3141			
	10716785	Aug 23, 2031	U-3136			
	10716785	Aug 23, 2031	U-3137			
	7262298	Nov 23, 2025	DS			
	7956187	Oct 31, 2021	DS			
	8252929	Oct 31, 2021	DS			
	8778960	Feb 13, 2032	U-3136			
	8778960	Feb 13, 2032	U-3137			
	9119848	Aug 30, 2031	DS			
	9126977	Aug 23, 2031	DP U-3136			
	9126977	Aug 23, 2031	DP U-3137			
	9517235	Aug 23, 2031	U-3138			
	9517235	Aug 23, 2031	U-3139			
<u><b>OLAPARIB - LYNPARZA</b></u>						
N 208558 001	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			
	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<u><b>OLAPARIB - LYNPARZA</b></u>						
N 208558 002	8071579	Aug 12, 2027	U-2101			
	8071579	Aug 12, 2027	U-2103			
	8071579	Aug 12, 2027	U-2480			
	8071579	Aug 12, 2027	U-2481			
	8071579	Aug 12, 2027	U-2482			
	8071579	Aug 12, 2027	U-2483			
	8071579	Aug 12, 2027	U-2716			
	8071579	Aug 12, 2027	U-2819			
	8071579	Aug 12, 2027	U-2820			
	8071579	Aug 12, 2027	U-2821			
	8071579	Aug 12, 2027	U-2822			
	8071579	Aug 12, 2027	U-2823			
	8071579	Aug 12, 2027	U-2824			
	8071579	Aug 12, 2027	U-2832			
	8071579	Aug 12, 2027	U-2833			
	8859562	Aug 04, 2031	U-2101			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>OLAPARIB - LYNPARZA</u></b>						
N 208558 002	8859562	Aug 04, 2031	U-2103			
	8859562	Aug 04, 2031	U-2480			
	8859562	Aug 04, 2031	U-2481			
	8859562	Aug 04, 2031	U-2482			
	8859562	Aug 04, 2031	U-2483			
	8859562	Aug 04, 2031	U-2716			
	8859562	Aug 04, 2031	U-2819			
	8859562	Aug 04, 2031	U-2820			
	8859562	Aug 04, 2031	U-2821			
	8859562	Aug 04, 2031	U-2822			
	8859562	Aug 04, 2031	U-2823			
	8859562	Aug 04, 2031	U-2824			
	8859562	Aug 04, 2031	U-2832			
	8859562	Aug 04, 2031	U-2833			
<b><u>OLICERIDINE - OLINVYK</u></b>						
N 210730 001 >A> 11077098		Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<b><u>OLICERIDINE - OLINVYK</u></b>						
N 210730 002 >A> 11077098		Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<b><u>OLICERIDINE - OLINVYK</u></b>						
N 210730 003 >A> 11077098		Mar 23, 2032	DS DP U-2986		NCE	Oct 30, 2025
<b><u>ORITAVANCIN DIPHOSPHATE - KIMYRSA</u></b>						
N 214155 001	8420592	Aug 29, 2029	U-3101		NCE	Aug 06, 2019
	9649352	Jul 16, 2035	DS DP		NP	Mar 12, 2024
	9682061	Apr 26, 2030	U-3101		GAIN	Aug 06, 2024
<b><u>OSIMERTINIB MESYLATE - TAGRISSO</u></b>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<b><u>OSIMERTINIB MESYLATE - TAGRISSO</u></b>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-853	Dec 18, 2023
	10183020	Jan 02, 2035	DP U-2289		ODE-337	Dec 18, 2027
	10183020	Jan 02, 2035	DP U-3016			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
<b><u>OSPEMIFENE - OSPHENA</u></b>						
N 203505 001	9566252	Nov 02, 2022	U-1370			
<b><u>OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ</u></b>						
N 212520 001	10898573	Dec 16, 2039	DP			
	10912765	Aug 26, 2031	U-2849			
	10940138	Dec 16, 2039	U-2849			
<b><u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u></b>						
N 021610 001	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027	U-3085			
	8871779	Nov 22, 2029	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 002	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 003	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 004	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 005	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 021610 006	8309112	Feb 04, 2023	DP			
	8329216	Feb 04, 2023	DP			
	8808737	Jun 21, 2027		U-3085		
	8871779	Nov 22, 2029	DS			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSTIA</u>						
N 209899 001	10239846	Nov 15, 2030		U-3132	I-860	May 27, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSTIA</u>						
N 209899 002	10239846	Nov 15, 2030		U-3132	I-860	May 27, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSTIA</u>						
N 209899 003	10239846	Nov 15, 2030		U-3132	I-860	May 27, 2024
<u>OZENOXACIN - XEPI</u>						
N 208945 001	6335447	Nov 09, 2023	DS			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	RE47739	Mar 05, 2027	DS DP			
<u>PALBOCICLIB - IBRANCE</u>						
N 212436 001	>A> 11065250 RE47739	May 24, 2036 Mar 05, 2027	DP DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>PALBOCICLIB - IBRANCE</u></b>						
N 212436 002	>A> 11065250 RE47739	May 24, 2036 Mar 05, 2027	DP DS DP			
<b><u>PALBOCICLIB - IBRANCE</u></b>						
N 212436 003	>A> 11065250 RE47739	May 24, 2036 Mar 05, 2027	DP DS DP			
<b><u>PARICALCITOL - ZEMPLAR</u></b>						
N 020819 001				>A> ODE*		Oct 18, 2023
<b><u>PARICALCITOL - ZEMPLAR</u></b>						
N 020819 002				>A> ODE*		Oct 18, 2023
<b><u>PARICALCITOL - ZEMPLAR</u></b>						
N 020819 003				>A> ODE*		Oct 18, 2023
<b><u>PATISIRAN SODIUM - ONPATTRO</u></b>						
N 210922 001	>A> 10240152 >A> 11079379	Oct 20, 2029 Aug 27, 2035	DS DP U-2378 DS DP U-2378			
<b><u>PEGCETACOPLAN - EMPAVELI</u></b>						
N 215014 001	10035822 10125171 10875893 11040107 11040107 11040107 7888323 7989589 9169307	Nov 15, 2033 Aug 02, 2033 Nov 15, 2033 Apr 09, 2038 Apr 09, 2038 Apr 09, 2038 Dec 04, 2027 Dec 04, 2027 Nov 18, 2027	DS DS DS U-3124 DP U-3172 DP U-3173 DP U-3174 DS DS DS U-3123		NCE ODE-351	May 14, 2026 May 14, 2028
<b><u>PERAMIVIR - RAPIVAB</u></b>						
N 206426 001	10391075 10391075 8778997 8778997 8778997	Feb 12, 2027 Feb 12, 2027 May 07, 2027 May 07, 2027 May 07, 2027	U-2622 U-3069 U-1627 U-2622 U-3069			
<b><u>PERAMPANEL - FYCOMPA</u></b>						
N 202834 001	6949571 6949571 6949571 6949571 6949571	Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022	DS DP U-106 DS DP U-2088 DS DP U-2089 DS DP U-2428 DS DP U-2429			
<b><u>PERAMPANEL - FYCOMPA</u></b>						
N 202834 002	6949571 6949571 6949571 6949571 6949571	Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022	DS DP U-106 DS DP U-2088 DS DP U-2089 DS DP U-2428 DS DP U-2429			
<b><u>PERAMPANEL - FYCOMPA</u></b>						
N 202834 003	6949571 6949571 6949571 6949571 6949571	Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022	DS DP U-106 DS DP U-2088 DS DP U-2089 DS DP U-2428 DS DP U-2429			
<b><u>PERAMPANEL - FYCOMPA</u></b>						
N 202834 004	6949571 6949571 6949571 6949571	Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022	DS DP U-106 DS DP U-2088 DS DP U-2089 DS DP U-2428			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2022	DS DP U-106			
	6949571	Jun 08, 2022	DS DP U-2088			
	6949571	Jun 08, 2022	DS DP U-2089			
	6949571	Jun 08, 2022	DS DP U-2428			
	6949571	Jun 08, 2022	DS DP U-2429			
<u>PEXIDARTINIB HYDROCHLORIDE - TURALIO</u>						
N 211810 001	10941142	Jul 24, 2038	DP			
	10961240	Jul 24, 2038	U-2606			
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	10947197	Jun 09, 2037	DS DP U-3130		NCE	May 26, 2026
	8487129	Nov 07, 2027	DS DP			
	8778305	Sep 21, 2030	DS DP U-3130			
	9861713	Jul 31, 2029	DS DP U-3130			
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 002	10953000	Mar 23, 2037	U-1974			
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 001				ODE-331		Oct 13, 2027
<u>PITOLISANT HYDROCHLORIDE - WAKIX</u>						
N 211150 002				ODE-331		Oct 13, 2027
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001				M-14		Nov 20, 2023
				PED		May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002				M-14		Nov 20, 2023
				PED		May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003				M-14		Nov 20, 2023
				PED		May 20, 2024
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004				M-14		Nov 20, 2023
				PED		May 20, 2024
<u>PONATINIB HYDROCHLORIDE - ICUSIG</u>						
N 203469 001			I-849			Dec 18, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003	8114874	Jan 24, 2027	DS DP		I-849	Dec 18, 2023
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004	8114874 9029533 9029533 9029533 9029533 9029533 9493470 9493470	Jan 24, 2027 Dec 22, 2026 Dec 22, 2026 Dec 22, 2026 Dec 22, 2026 Dec 22, 2026 Dec 12, 2033 Dec 12, 2033	DS DP U-1283 U-1699 U-1700 U-1701 U-836 DS DP U-1700 DS DP U-1948		I-849	Dec 18, 2023
<u>PONESIMOD - PONVORY</u>						
N 213498 001	10220023 8273779 9000018 9062014 RE43728	Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024	U-3103 U-2774 U-3102 DS DP U-2774 DS DP		NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498 002	10220023 8273779 9000018 9062014 RE43728	Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024	U-3103 U-2774 U-3102 DS DP U-2774 DS DP		NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498 003	10220023 8273779 9000018 9062014 RE43728	Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024	U-3103 U-2774 U-3102 DS DP U-2774 DS DP		NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498 004	10220023 8273779 9000018 9062014 RE43728	Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024	U-3103 U-2774 U-3102 DS DP U-2774 DS DP		NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498 005	10220023 8273779 9000018 9062014 RE43728	Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024	U-3103 U-2774 U-3102 DS DP U-2774 DS DP		NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498 006	10220023 8273779 9000018 9062014 RE43728	Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024	U-3103 U-2774 U-3102 DS DP U-2774 DS DP		NCE	Mar 18, 2026
<u>PONESIMOD - PONVORY</u>						
N 213498 007	10220023 8273779 9000018 9062014 RE43728	Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024	U-3103 U-2774 U-3102 DS DP U-2774 DS DP		NCE	Mar 18, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONESIMOD - PONVORY</u>						
N 213498 008	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	10220023	Dec 10, 2035	U-3103		NCE	Mar 18, 2026
	8273779	Dec 17, 2025	U-2774			
	9000018	Nov 16, 2024	U-3102			
	9062014	May 06, 2032	DS DP U-2774			
	RE43728	Nov 16, 2024	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205053 001					NPP	May 31, 2024
					ODE-355	Jun 17, 2028
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	9023790	Jul 04, 2031	DP U-1698		NPP	May 31, 2024
	9023790	Jul 04, 2031	DP U-3160		ODE-355	Jun 17, 2028
	9023790	Jul 04, 2031	DP U-3171			
	9358297	Jun 24, 2031	DP U-3160			
	9358297	Jun 24, 2031	DP U-3171			
<u>POSACONAZOLE - NOXAFIL POWDERMIX KIT</u>						
N 214770 001					NP	May 31, 2024
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001					ODE-340	Dec 01, 2027
					ODE-341	Dec 01, 2027
<u>RELUGOLIX - ORGOVYX</u>						
N 214621 001	10350170	Feb 25, 2036	DP		NCE	Dec 18, 2025
	10449191	Sep 29, 2037	U-3020			
	10786501	Sep 29, 2037	U-3020			
	7300935	Jan 28, 2024	DS			
	8058280	Jan 28, 2024	DS DP			
	8735401	Feb 04, 2024	U-3019			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	11007208	Sep 16, 2036	U-2984			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	11007208	Sep 16, 2036	U-2984			
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001					NCE	Oct 06, 2025
<u>REVEFENACIN - YUPELRI</u>						
N 210598 001	11008289	Jul 14, 2030	U-2440			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 002	>A> 10314828	Jul 24, 2029	U-1481			
	>A> 10335397	Jul 24, 2029	U-2579			
	>A> 10456384	Feb 26, 2029	U-2643			
	>A> 10456384	Feb 26, 2029	U-2644			
	>A> 10703763	Feb 27, 2026	U-1708			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>RIFAXIMIN - XIFAXAN</b>						
N 021361 002	>A> 10703763	Feb 27, 2026	U-2847			
	>A> 10703763	Feb 27, 2026	U-2848			
	>A> 10709694	Jul 24, 2029	U-2579			
	>A> 10765667	Feb 26, 2029	U-2643			
	>A> 10765667	Feb 26, 2029	U-2644			
	>A> 7045620	Jun 19, 2024	DS			
	>A> 7612199	Jun 19, 2024	DS DP			
	>A> 7902206	Jun 19, 2024	DS DP			
	>A> 7906542	Jun 01, 2025	DS DP			
	>A> 7915275	Feb 23, 2025	U-1707			
	>A> 7915275	Feb 23, 2025	U-1708			
	>A> 8158644	Jun 19, 2024	DP			
	>A> 8158781	Jun 19, 2024	DS			
	>A> 8193196	Sep 02, 2027	DS DP U-1707			
	>A> 8193196	Sep 02, 2027	DS DP U-1708			
	>A> 8309569	Jul 18, 2029	U-1707			
	>A> 8309569	Jul 18, 2029	U-1708			
	>A> 8518949	Feb 27, 2026	DP			
	>A> 8642573	Oct 02, 2029	U-1481			
	>A> 8741904	Feb 27, 2026	DS U-1526			
	>A> 8741904	Feb 27, 2026	DS U-1707			
	>A> 8741904	Feb 27, 2026	DS U-1708			
	>A> 8829017	Jul 24, 2029	U-1562			
	>A> 8835452	Jun 19, 2024	DS DP			
	>A> 8853231	Jun 19, 2024	DP			
	>A> 8946252	Jul 24, 2029	U-1481			
	>A> 8969398	Oct 02, 2029	U-1481			
	>A> 9271968	Feb 27, 2026	DP			
	>A> 9421195	Jul 24, 2029	U-1481			
	>A> 9629828	Jul 24, 2029	U-1994			
<b>RILPIVIRINE HYDROCHLORIDE - EDURANT</b>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3068			
<b>RIMEGEPANT SULFATE - NURTEC ODT</b>						
N 212728 001	>A> 11083724	Mar 25, 2039	DP U-2718	I-865	May 27, 2024	
	>A> 11083724	Mar 25, 2039	DP U-3142			
	8314117	Feb 22, 2031	DS DP U-2718			
	8314117	Feb 22, 2031	DS DP U-3142			
<b>RIPRETTINIB - QINLOCK</b>						
N 213973 001	10966966	Aug 12, 2040	U-3153			
<b>RISDIPLAM - EVRYSDI</b>						
N 213535 001				ODE-334	Aug 07, 2027	
<b>RISPERIDONE - PERSERIS KIT</b>						
N 210655 001	11013809	Feb 13, 2028	DP U-3135			
	>A> 11110093	Nov 05, 2026	DP U-3135			
<b>RISPERIDONE - PERSERIS KIT</b>						
N 210655 002	11013809	Feb 13, 2028	DP U-3135			
	>A> 11110093	Nov 05, 2026	DP U-3135			
<b>ROLAPITANT HYDROCHLORIDE - VARUBI</b>						
N 206500 001	7049320	Aug 19, 2028	DS DP U-1741			
<b>ROLAPITANT HYDROCHLORIDE - VARUBI</b>						
N 208399 001	7049320	Aug 19, 2028	DS DP U-1741			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988 001					PC	Nov 28, 2021
<u>RUFINAMIDE - RUFINAMIDE</u>						
A 204988 002					PC	Nov 28, 2021
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 001	11058667 9517226 9937143	May 09, 2036 Aug 22, 2033 Aug 22, 2033	U-3170 U-3084 U-3084		M-82	Feb 16, 2024
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 002	11058667 9517226 9937143	May 09, 2036 Aug 22, 2033 Aug 22, 2033	U-3170 U-3084 U-3084		M-82	Feb 16, 2024
<u>SACUBITRIL; VALSARTAN - ENTRESTO</u>						
N 207620 003	11058667 9517226 9937143	May 09, 2036 Aug 22, 2033 Aug 22, 2033	U-3170 U-3084 U-3084		M-82	Feb 16, 2024
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 001	8283380	Mar 21, 2031	U-1993			
<u>SAFINAMIDE MESYLATE - XADAGO</u>						
N 207145 002	8283380	Mar 21, 2031	U-1993			
<u>SECNIDAZOLE - SOLOSEC</u>						
N 209363 001	10849884 10849884 11000507 11000507 11000508 11000508 11020377 11020377	Sep 04, 2035 Sep 04, 2035	DP U-2583 DP U-3169 DP U-2583 DP U-3169 DP U-2583 DP U-3169 DP U-2583 DP U-3169		>A> I-866	Jun 30, 2024
<u>SELENIOUS ACID - SELENIOUS ACID</u>						
N 209379 002					NCE	Apr 30, 2024
<u>SELENIOUS ACID - SELENIOUS ACID</u>						
N 209379 003					>A> NCE	Apr 30, 2024
<u>SELEXIPAG - UPTRAVI</u>						
N 214275 001	>A> 7205302 >A> 8791122 >A> 9173881 >A> 9284280	Apr 04, 2023 Aug 01, 2030 Aug 12, 2029 Jun 25, 2030	DS DP U-1797 DS DP U-1798 U-1831			
<u>SELINEXOR - XPOVIO</u>						
N 212306 001	10519139 10519139 10519139 10544108 10544108 11034660 11034660 9079865 9079865 9079865	Aug 14, 2035 Aug 14, 2035 Aug 14, 2035 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032	DS DP U-2584 DS DP U-2855 DS DP U-3018 U-2584 U-3018 U-2584 U-3018 U-2584 U-2855 U-3018		ODE-346	Dec 18, 2027
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	10519139 10519139 10519139	Aug 14, 2035 Aug 14, 2035 Aug 14, 2035	DS DP U-2584 DS DP U-2855 DS DP U-3018		ODE-346	Dec 18, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELINEXOR - XPOVIO</u>						
N 212306 002	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 003	10519139	Aug 14, 2035	DS DP U-2584		ODE-346	Dec 18, 2027
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SELINEXOR - XPOVIO</u>						
N 212306 004	10519139	Aug 14, 2035	DS DP U-2584		ODE-346	Dec 18, 2027
	10519139	Aug 14, 2035	DS DP U-2855			
	10519139	Aug 14, 2035	DS DP U-3018			
	10544108	Jul 26, 2032	U-2584			
	10544108	Jul 26, 2032	U-3018			
	11034660	Jul 26, 2032	U-2584			
	11034660	Jul 26, 2032	U-3018			
	8999996	Sep 15, 2032	DS DP			
	9079865	Jul 26, 2032	U-2584			
	9079865	Jul 26, 2032	U-2855			
	9079865	Jul 26, 2032	U-3018			
	9714226	Jul 26, 2032	DS DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 001	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 002	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - RYBELSUS</u>						
N 213051 003	10933120	Mar 15, 2033	DP			
	10960052	Dec 16, 2031	DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024
	8536122	Mar 20, 2026	DS DP			
	9764003	Jun 21, 2033	U-3161			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003	10888605	Aug 24, 2038	DP U-3162		NCE	Dec 05, 2022
	8129343	Jan 29, 2029	DS DP		NP	Jun 04, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>SEMAGLUTIDE - WEGOVY</u></b>						
N 215256 003	8536122 9764003	Mar 20, 2026 Jun 21, 2033	DS DP  U-3161			
<b><u>SEMAGLUTIDE - WEGOVY</u></b>						
N 215256 004	10888605 8129343 8536122 9764003	Aug 24, 2038 Jan 29, 2029 Mar 20, 2026 Jun 21, 2033	DP U-3162 DS DP DS DP U-3161		NCE NP	Dec 05, 2022 Jun 04, 2024
<b><u>SEMAGLUTIDE - WEGOVY</u></b>						
N 215256 005	10888605 8129343 8536122 9764003	Aug 24, 2038 Jan 29, 2029 Mar 20, 2026 Jun 21, 2033	DP U-3162 DS DP DS DP U-3161		NCE NP	Dec 05, 2022 Jun 04, 2024
<b><u>SETMELANOTIDE ACETATE - IMCIVREE</u></b>						
N 213793 001					ODE-336	Nov 25, 2027
<b><u>SIPONIMOD FUMARIC ACID - MAYZENT</u></b>						
N 209884 003				>A> NCE		Mar 26, 2024
<b><u>SITAGLIPTIN PHOSPHATE - JANUVIA</u></b>						
N 021995 001					M-187 PED	Dec 04, 2023 Jun 04, 2024
<b><u>SITAGLIPTIN PHOSPHATE - JANUVIA</u></b>						
N 021995 002					M-187 PED	Dec 04, 2023 Jun 04, 2024
<b><u>SITAGLIPTIN PHOSPHATE - JANUVIA</u></b>						
N 021995 003					M-187 PED	Dec 04, 2023 Jun 04, 2024
<b><u>SODIUM ACETATE - SODIUM ACETATE</u></b>						
A 214805 001					CGT	Jan 03, 2022
<b><u>SODIUM OXYBATE - XYREM</u></b>						
N 021196 001	10864181	Mar 15, 2033	U-1532			
<b><u>SOFOSBUVIR - SOVALDI</u></b>						
N 204671 001					ODE*	Aug 28, 2026
<b><u>SOFOSBUVIR - SOVALDI</u></b>						
N 204671 002					ODE* ODE* PED	Apr 07, 2024 Aug 28, 2026 Oct 07, 2024
<b><u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u></b>						
N 208341 001	10086011 10086011*PED 8575135 8575135*PED 8735372 8735372*PED 8921341 8921341*PED 8940718 8940718*PED 9757406 9757406*PED	Jan 30, 2034 Jul 30, 2034 Nov 16, 2032 May 16, 2033 Mar 21, 2028 Sep 21, 2028 Nov 16, 2032 May 16, 2033 Nov 16, 2032 May 16, 2033 Jan 30, 2034 Jul 30, 2034	U-1470  DS DP U-1470  U-1470  DS DP U-1470  DS DP U-1470  DP		D-177 M-264 NPP PED PED PED PED PED PED PED DP	Nov 15, 2022 Jul 14, 2023 Mar 19, 2023 May 15, 2023 Sep 19, 2023 Jan 14, 2024

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>SOFOSBUVIR; VELPATASVIR - EPCLUSA</b></u>						
N 208341 002	10086011	Jan 30, 2034	U-1470		M-264	Jul 14, 2023
	10086011*PED	Jul 30, 2034			NS	Mar 19, 2023
	7964580	Mar 26, 2029	DS DP U-1470		PED	Sep 19, 2023
	7964580*PED	Sep 26, 2029			PED	Jan 14, 2024
	8334270	Mar 21, 2028	DS DP U-1470			
	8334270*PED	Sep 21, 2028				
	8575135	Nov 16, 2032	DS DP U-1470			
	8575135*PED	May 16, 2033				
	8580765	Mar 21, 2028	DS DP U-1470			
	8580765*PED	Sep 21, 2028				
	8618076	Dec 11, 2030	DS DP U-1470			
	8618076*PED	Jun 11, 2031				
	8633309	Mar 26, 2029	DS DP U-1470			
	8633309*PED	Sep 26, 2029				
	8735372	Mar 21, 2028	U-1470			
	8735372*PED	Sep 21, 2028				
	8889159	Mar 26, 2029	DP U-1470			
	8889159*PED	Sep 26, 2029				
	8921341	Nov 16, 2032	DS DP U-1470			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-1470			
	8940718*PED	May 16, 2033				
	9085573	Mar 21, 2028	DS DP U-1470			
	9085573*PED	Sep 21, 2028				
	9284342	Sep 13, 2030	DS DP U-1470			
	9284342*PED	Mar 13, 2031				
	9757406	Jan 30, 2034	DP			
	9757406*PED	Jul 30, 2034				
<u><b>SOFOSBUVIR; VELPATASVIR - EPCLUSA</b></u>						
N 214187 001	>A> 7964580	Mar 26, 2029	DS DP U-1470			
	>A> 7964580*PED	Sep 26, 2029				
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8334270*PED	Sep 21, 2028				
	>A> 8575135	Nov 16, 2032	DS DP U-1470			
	>A> 8575135*PED	May 16, 2033				
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8580765*PED	Sep 21, 2028				
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8618076*PED	Jun 11, 2031				
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8633309*PED	Sep 26, 2029				
	>A> 8735372	Mar 21, 2028	U-1470			
	>A> 8735372*PED	Sep 21, 2028				
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8889159*PED	Sep 26, 2029				
	>A> 8921341	Nov 16, 2032	DS DP U-1470			
	>A> 8921341*PED	May 16, 2033				
	>A> 8940718	Nov 16, 2032	DS DP U-1470			
	>A> 8940718*PED	May 16, 2033				
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9085573*PED	Sep 21, 2028				
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
	>A> 9284342*PED	Mar 13, 2031				
<u><b>SOFOSBUVIR; VELPATASVIR - EPCLUSA</b></u>						
N 214187 002	>A> 7964580	Mar 26, 2029	DS DP U-1470			
	>A> 7964580*PED	Sep 26, 2029				
	>A> 8334270	Mar 21, 2028	DS DP U-1470			
	>A> 8334270*PED	Sep 21, 2028				
	>A> 8575135	Nov 16, 2032	DS DP U-1470			
	>A> 8575135*PED	May 16, 2033				
	>A> 8580765	Mar 21, 2028	DS DP U-1470			
	>A> 8580765*PED	Sep 21, 2028				
	>A> 8618076	Dec 11, 2030	DS DP U-1470			
	>A> 8618076*PED	Jun 11, 2031				
	>A> 8633309	Mar 26, 2029	DS DP U-1470			
	>A> 8633309*PED	Sep 26, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>SOFOSBUVIR: VELPATASVIR - EPCLUSA</b></u>						
N 214187 002	>A> 8735372	Mar 21, 2028	U-1470			
	>A> 8735372*PED	Sep 21, 2028				
	>A> 8889159	Mar 26, 2029	DP U-1470			
	>A> 8889159*PED	Sep 26, 2029				
	>A> 8921341	Nov 16, 2032	DS DP U-1470			
	>A> 8921341*PED	May 16, 2033				
	>A> 8940718	Nov 16, 2032	DS DP U-1470			
	>A> 8940718*PED	May 16, 2033				
	>A> 9085573	Mar 21, 2028	DS DP U-1470			
	>A> 9085573*PED	Sep 21, 2028				
	>A> 9284342	Sep 13, 2030	DS DP U-1470			
	>A> 9284342*PED	Mar 13, 2031				
<u><b>SOFOSBUVIR: VELPATASVIR; VOXILAPREVIR - VOSEVI</b></u>						
N 209195 001	10912814	Jun 01, 2037	DP			
	8575135	Nov 16, 2032	DS DP U-2039			
	8575135	Nov 16, 2032	DS DP U-2040			
	8575135*PED	May 16, 2033				
	8735372	Mar 21, 2028	DS DP U-2039			
	8735372	Mar 21, 2028	DS DP U-2040			
	8735372*PED	Sep 21, 2028				
	8921341	Nov 16, 2032	DS DP U-2039			
	8921341	Nov 16, 2032	DS DP U-2040			
	8921341*PED	May 16, 2033				
	8940718	Nov 16, 2032	DS DP U-2039			
	8940718	Nov 16, 2032	DS DP U-2040			
	8940718*PED	May 16, 2033				
	8957046	Mar 21, 2028	U-2039			
	8957046	Mar 21, 2028	U-2040			
<u><b>SOLIFENACIN SUCCINATE - VESICARE LS</b></u>						
N 209529 001	9918970	May 18, 2031	DP			
<u><b>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</b></u>						
N 211230 001	10912754	Jun 01, 2038	U-3082			
	10940133	Mar 19, 2040	U-3099			
	10959976	Jun 01, 2038	U-3151			
<u><b>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</b></u>						
N 211230 002	10912754	Jun 01, 2038	U-3082			
	10959976	Jun 01, 2038	U-3151			
<u><b>SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE</b></u>						
N 022306 001	10799138	Apr 05, 2039	U-3125			
<u><b>SOTALOL HYDROCHLORIDE - SOTYLIZE</b></u>						
N 205108 001	11013703	Apr 01, 2034	DP			
<u><b>SOTORASIB - LUMAKRAS</b></u>						
N 214665 001				NCE	May 28, 2026	
				ODE-352	May 28, 2028	
<u><b>SPINOSAD - NATROBA</b></u>						
N 022408 001				I-858	Apr 28, 2024	
<u><b>SPIRONOLACTONE - CAROSPIR</b></u>						
N 209478 001	10888570	Oct 28, 2036	DP			
<u><b>SUFENTANIL CITRATE - DSUVIA</b></u>						
N 209128 001	10896751	Mar 16, 2030	DP			
<u><b>SUGAMMADEX SODIUM - BRIDION</b></u>						
N 022225 001				NPP	Jun 25, 2024	

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUGAMMADEX SODIUM - BRIDION</u> N 022225 002					NPP	Jun 25, 2024
<u>TACROLIMUS - PROGRAF</u> N 050708 001				>A> ODE-360	Jul 16, 2028	
<u>TACROLIMUS - PROGRAF</u> N 050708 002				>A> ODE-360	Jul 16, 2028	
<u>TACROLIMUS - PROGRAF</u> N 050708 003				>A> ODE-360	Jul 16, 2028	
<u>TACROLIMUS - PROGRAF</u> N 050709 001				>A> ODE-360	Jul 16, 2028	
<u>TACROLIMUS - ASTAGRAF XL</u> N 204096 001				ODE*	May 24, 2025	
<u>TACROLIMUS - ASTAGRAF XL</u> N 204096 002				ODE*	May 24, 2025	
<u>TACROLIMUS - ASTAGRAF XL</u> N 204096 003				ODE*	May 24, 2025	
<u>TACROLIMUS - PROGRAF</u> N 210115 001				>A> ODE-360	Jul 16, 2028	
<u>TACROLIMUS - PROGRAF</u> N 210115 002				>A> ODE-360	Jul 16, 2028	
<u>TAFENOQUINE SUCCINATE - ARAKODA</u> N 210607 001 10888558		Dec 02, 2035		U-2582		
<u>TAFLUPROST - ZIOPTAN</u> N 202514 001 10864159		May 28, 2029		DP U-778		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u> N 200533 001 11007156		Oct 22, 2022		DP U-1178		
	11007156	Oct 22, 2022		DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u> N 200533 002 11007156		Oct 22, 2022		DP U-1178		
	11007156	Oct 22, 2022		DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u> N 200533 003 11007156		Oct 22, 2022		DP U-1178		
	11007156	Oct 22, 2022		DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u> N 200533 004 11007156		Oct 22, 2022		DP U-1178		
	11007156	Oct 22, 2022		DP U-1276		
<u>TAPENTADOL HYDROCHLORIDE - NUCYNTA ER</u> N 200533 005 11007156		Oct 22, 2022		DP U-1178		
	11007156	Oct 22, 2022		DP U-1276		
<u>TASIMELTEON - HETLIOZ</u> N 205677 001 10610511		Oct 10, 2034		U-2615	I-850	Dec 01, 2023
	10610511	Oct 10, 2034		U-3007	ODE-330	Dec 01, 2027
	10945988	Jan 25, 2033		U-2149		
	10980770	Jan 25, 2033		U-3106		
	10980770	Jan 25, 2033		U-3107		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>TASIMELTEON - HETLIOZ</b>						
N 205677 001	10610511	Oct 10, 2034	U-2615	I-850	Dec 01, 2023	
	10610511	Oct 10, 2034	U-3007	ODE-330	Dec 01, 2027	
	10945988	Jan 25, 2033	U-2149			
	10980770	Jan 25, 2033	U-3106			
	10980770	Jan 25, 2033	U-3107			
<b>TASIMELTEON - HETLIOZ LO</b>						
N 214517 001	10980770	Jan 25, 2033	U-3106	NP	Dec 01, 2023	
				ODE-329	Dec 01, 2027	
<b>TAVABOROLE - TAVABOROLE</b>						
A 211963 001				PC	Apr 17, 2021	
<b>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</b>						
N 211723 001	10786511	Dec 19, 2035	DP			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-3179			
<b>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</b>						
N 202207 001				NPP	May 19, 2024	
<b>TERPOTINIB HYDROCHLORIDE - TEPMETKO</b>						
N 214096 001	8329692	Oct 30, 2029	DS DP			
	8580781	Mar 19, 2030	DS DP	NCE	Feb 03, 2026	
	8658643	Jul 04, 2028	U-3077	ODE-325	Feb 03, 2028	
	8921357	May 30, 2028	DS DP			
	8927540	Jul 21, 2028	U-3078			
	9062029	Jul 04, 2028	DP			
	9284300	Apr 29, 2028	DP			
	9403799	Jul 04, 2028	U-3077			
<b>TERIFLUNOMIDE - AUBAGIO</b>						
N 202992 001	6794410	Sep 12, 2026	U-1285	M-61	Apr 30, 2024	
	6794410*PED	Mar 12, 2027		PED	Oct 30, 2024	
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
<b>TERIFLUNOMIDE - AUBAGIO</b>						
N 202992 002	6794410	Sep 12, 2026	U-1285	M-61	Apr 30, 2024	
	6794410*PED	Mar 12, 2027		PED	Oct 30, 2024	
	8802735	Sep 14, 2030	DP			
	8802735*PED	Mar 14, 2031				
	9186346	Feb 04, 2034	U-1786			
	9186346*PED	Aug 04, 2034				
<b>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</b>						
N 209863 001	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<b>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</b>						
N 209863 002	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			
<b>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</b>						
N 209863 003	10881798	Feb 11, 2034	DP			
	10905827	Aug 21, 2031	DP			
	10912782	Feb 19, 2035	DP U-2418			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u><b>THEOPHYLLINE - THEOPHYLLINE</b></u>						
A 212184 002					CGT	Dec 08, 2021
<u><b>TICAGRELOR - BRILINTA</b></u>						
N 022433 001					I-851	May 28, 2023
<u><b>TICAGRELOR - BRILINTA</b></u>						
N 022433 002					I-851	May 28, 2023
<u><b>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</b></u>						
N 207981 001	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u><b>TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF</b></u>						
N 207981 002	10960004	Feb 03, 2037	U-2642			
	RE46284	Sep 22, 2029	U-1751			
	RE46284	Sep 22, 2029	U-2503			
<u><b>TIRBANIBULIN - KLISYRI</b></u>						
N 213189 001	10323001	Dec 28, 2027	DP		NCE	Dec 14, 2025
	10617693	Mar 12, 2038	U-3015			
	10669236	Sep 07, 2038	DS DP			
	7300931	Feb 06, 2026	DS DP			
	7851470	Feb 02, 2029	DS DP U-3015			
	8236799	Dec 28, 2025	DS DP			
	8980890	Dec 28, 2025	DS DP			
<u><b>TIVOZANIB HYDROCHLORIDE - FOTIVDA</b></u>						
N 212904 001	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u><b>TIVOZANIB HYDROCHLORIDE - FOTIVDA</b></u>						
N 212904 002	6821987	Apr 26, 2022	DS DP U-3100		NCE	Mar 10, 2026
	7166722	Nov 16, 2023	DS			
<u><b>TOLVAPTAN - SAMSCA</b></u>						
N 022275 001	10905694	Apr 07, 2030	DP			
<u><b>TOLVAPTAN - SAMSCA</b></u>						
N 022275 002	10905694	Apr 07, 2030	DP			
<u><b>TOLVAPTAN - SAMSCA</b></u>						
N 022275 003	10905694	Apr 07, 2030	DP			
<u><b>TOLVAPTAN - JYNARQUE</b></u>						
N 204441 001	10905694	Apr 07, 2030	DP			
<u><b>TOLVAPTAN - JYNARQUE</b></u>						
N 204441 002	10905694	Apr 07, 2030	DP			
<u><b>TOLVAPTAN - JYNARQUE</b></u>						
N 204441 003	10905694	Apr 07, 2030	DP			
<u><b>TOLVAPTAN - JYNARQUE</b></u>						
N 204441 004	10905694	Apr 07, 2030	DP			
<u><b>TOLVAPTAN - JYNARQUE</b></u>						
N 204441 005	10905694	Apr 07, 2030	DP			
<u><b>TORSEMIDE - SOAANZ</b></u>						
N 213218 001	>A> 10154963	Oct 06, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b>TORSEMIDE - SOAANZ</b>						
N 213218 002 >A> 10154963		Oct 06, 2033		DP		
<b>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</b>						
N 204114 001 >A> 10869869		Aug 30, 2033		U-3184		
<b>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</b>						
N 204114 002 >A> 10869869		Aug 30, 2033		U-3184		
<b>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</b>						
N 204114 003 >A> 10869869		Aug 30, 2033		U-3184		
<b>TREPROSTINIL - REMODULIN</b>						
N 021272 005 >A> 10076505		Dec 16, 2024		DP		
>A> 10695308		Dec 16, 2024		U-2845		
>A> 7999007		Mar 29, 2029		DP U-1437		
>A> 8653137		Sep 05, 2028		U-1437		
>A> 8658694		Sep 05, 2028		U-1437		
>A> 9199908		May 24, 2024		U-1771		
>A> 9593066		Dec 15, 2028	DS			
>A> 9604901		Dec 15, 2028	DS			
>A> 9713599		Dec 16, 2024		U-2036		
<b>TREPROSTINIL - TYVASO</b>						
N 022387 001					I-856	Mar 31, 2024
<b>TRIFAROTENE - AKLIEF</b>						
N 211527 001 9498465		May 30, 2033		DP U-1033		
<b>TRILACICLIB DIHYDROCHLORIDE - COSELA</b>						
N 214200 001 10085992		Mar 14, 2034		U-3081		
10189849		Oct 25, 2031	DS		NCE	Feb 12, 2026
10189850		Oct 25, 2031		DP		
10927120		Oct 25, 2031		DP		
10966984		Mar 14, 2034		U-3079		
10966984		Mar 14, 2034		U-3080		
11040042		Mar 14, 2034		DP		
8598186		Oct 25, 2031	DS DP			
8598197		Oct 25, 2031	DS DP			
9487530		Mar 14, 2034		U-3079		
9487530		Mar 14, 2034		U-3080		
9957276		Oct 25, 2031	DS			
<b>UMBRALISIB TOSYLATE - UKONIQ</b>						
N 213176 001 10072013		Jul 02, 2033		U-3063		
10072013		Jul 02, 2033		U-3064	NCE	Feb 05, 2026
10414773		May 26, 2035	DS DP	U-3063	ODE-343	Feb 05, 2028
10414773		May 26, 2035	DS DP	U-3064	ODE-344	Feb 05, 2028
10570142		Jul 02, 2033	DS DP	U-3063		
10570142		Jul 02, 2033	DS DP	U-3064		
10947244		May 26, 2035		U-3063		
10947244		May 26, 2035		U-3064		
9150579		Jul 02, 2033	DS DP			
9669033		Jul 02, 2033		U-3063		
9669033		Jul 02, 2033		U-3064		
9969740		May 26, 2035	DS DP	U-3063		
9969740		May 26, 2035	DS DP	U-3064		
<b>UPADACITINIB - RINVOQ</b>						
N 211675 001 10981923		Oct 17, 2036	DS			
10981924		Oct 17, 2036	DP			
<b>VALBENAZINE TOSYLATE - INGREZZA</b>						
N 209241 001 10874648		Oct 10, 2037		U-1995		
10874648		Oct 10, 2037		U-3046		
10906902		Dec 22, 2036	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<b><u>VALBENAZINE TOSYLATE - INGREZZA</u></b>						
N 209241 001	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037		U-1995		
	10912771	Oct 10, 2037		U-3076		
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040		U-1995		
	10952997	Oct 10, 2037		U-1995		
	10993941	Oct 10, 2037		U-1995		
	11026931	Aug 14, 2039		U-1995		
	11026939	Sep 18, 2038	DP	U-1995		
	11040029	Oct 10, 2037		U-1995		
<b><u>VALBENAZINE TOSYLATE - INGREZZA</u></b>						
N 209241 002	10874648	Oct 10, 2037		U-1995		
	10874648	Oct 10, 2037		U-3046		
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037		U-1995		
	10912771	Oct 10, 2037		U-3076		
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040		U-1995		
	10952997	Oct 10, 2037		U-1995		
	10993941	Oct 10, 2037		U-1995		
	11026931	Aug 14, 2039		U-1995		
	11026939	Sep 18, 2038	DP	U-1995		
	11040029	Oct 10, 2037		U-1995		
<b><u>VALBENAZINE TOSYLATE - INGREZZA</u></b>						
N 209241 003	10065952	Oct 28, 2036	DS DP	U-1995	NCE	Apr 11, 2022
	10844058	Oct 28, 2036	DS DP	U-1995		
	10851103	Oct 28, 2036	DS DP	U-1995		
	10851104	Oct 28, 2036	DS	U-1995		
	10857137	Oct 10, 2037		U-1995		
	10857148	Oct 10, 2037		U-1995		
	10874648	Oct 10, 2037		U-1995		
	10874648	Oct 10, 2037		U-3046		
	10906902	Dec 22, 2036	DS DP			
	10906903	Dec 22, 2036	DS DP			
	10912771	Oct 10, 2037		U-1995		
	10912771	Oct 10, 2037		U-3076		
	10919892	Dec 22, 2036	DS DP			
	10940141	Aug 10, 2040		U-1995		
	10952997	Oct 10, 2037		U-1995		
	10993941	Oct 10, 2037		U-1995		
	11026931	Aug 14, 2039		U-1995		
	11026939	Sep 18, 2038	DP	U-1995		
	11040029	Oct 10, 2037		U-1995		
	8039627	Oct 06, 2029	DS DP			
	8357697	Nov 08, 2027		U-1995		
<b><u>VALSARTAN - DIOVAN</u></b>						
N 021283 001					NPP	Apr 19, 2024
<b><u>VALSARTAN - DIOVAN</u></b>						
N 021283 002					NPP	Apr 19, 2024
<b><u>VALSARTAN - DIOVAN</u></b>						
N 021283 004					NPP	Apr 19, 2024
<b><u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u></b>						
N 208910 001	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP	U-3104		
	10959947	Mar 13, 2035	DP	U-3105		
	10959948	Mar 13, 2035	DP	U-3104		
	10959948	Mar 13, 2035	DP	U-3105		
	10959949	Mar 13, 2035	DP	U-3104		
	10959949	Mar 13, 2035	DP	U-3105		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 001	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VANCOMYCIN HYDROCHLORIDE - FIRVANO KIT</u>						
N 208910 002	10959946	Mar 13, 2035	DP			
	10959947	Mar 13, 2035	DP U-3104			
	10959947	Mar 13, 2035	DP U-3105			
	10959948	Mar 13, 2035	DP U-3104			
	10959948	Mar 13, 2035	DP U-3105			
	10959949	Mar 13, 2035	DP U-3104			
	10959949	Mar 13, 2035	DP U-3105			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	10993942	Sep 06, 2033	U-3114			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	10993942	Sep 06, 2033	U-3114			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	10993942	Sep 06, 2033	U-3114			
<u>VERICIGUAT - VERQUVO</u>						
N 214377 001	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VERQUVO</u>						
N 214377 002	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VERICIGUAT - VERQUVO</u>						
N 214377 003	10736896	May 19, 2031	DS DP		NCE	Jan 19, 2026
	8420656	May 19, 2031	DS DP			
	8921377	May 19, 2031	U-3062			
	9604948	Nov 26, 2032	DS DP U-3062			
	9993476	May 19, 2031	U-3062			
<u>VIBEGRON - GEMTESA</u>						
N 213006 001	8247415	Dec 01, 2030	DS DP U-3045		NCE	Dec 23, 2025
	8653260	Apr 02, 2029	DS			
<u>VIGABATRIN - VIGABATRIN</u>						
A 211539 001					CGT	Jul 31, 2021
<u>VILOXAZINE HYDROCHLORIDE - OELBREE</u>						
N 211964 001	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			
<u>VILOXAZINE HYDROCHLORIDE - OELBREE</u>						
N 211964 002	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033	U-727			
	9662338	Feb 07, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2021

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VILOXAZINE HYDROCHLORIDE - QELBREE</u>						
N 211964 003	9358204	Feb 07, 2033	DP		NCE	Apr 02, 2026
	9603853	Feb 07, 2033		U-727		
	9662338	Feb 07, 2033	DP			
<u>VILTOLARSEN - VILTEPSO</u>						
N 212154 001	10870676	Aug 31, 2031	DS DP	U-3039	ODE-280	Aug 12, 2027
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9790183	Sep 02, 2025		U-3109		
<u>VOCLOSPORIN - LUPKYNIS</u>						
N 213716 001	10286036	Dec 07, 2037		U-3056	NCE	Jan 22, 2026
	7332472	Oct 17, 2022	DS DP	U-3056		
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003					M-187	Jan 22, 2024
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004					M-187	Jan 22, 2024
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11020382	Dec 02, 2036		U-3133		
	11020382	Dec 02, 2036		U-3134		
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	DS DP	U-2145		
	10927117	Aug 15, 2037	DS DP			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41<sup>ST</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at  
[http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at  
[http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)